Compositions for Inhibition of Membrane Fusion-Associated Events, Including Influenza Virus Transmission

The present invention relates, first, to DP178 (SEQ ID NO:1), a peptide corresponding to amino acids 638 to 673 of the HIV-1.sub.LAI transmembrane protein (TM) gp41, and portions or analogs of DP178 (SEQ ID NO:1), which exhibit anti-membrane fusion capability, antiviral activity, such as the ability to inhibit HIV transmission to uninfected CD-4.sup.+ cells, or an ability to modulate intracellular processes involving coiled-coil peptide structures. Further, the invention relates to the use of DP178 (SEQ ID NO:1) and DP178 portions and/or analogs as antifusogenic or antiviral compounds or as inhibitors of intracellular events involving coiled-coil peptide structures. The present invention also relates to peptides analogous to DP107, a peptide corresponding to amino acids 558 to 595 of the HIV-1.sub.LAI transmembrane protein (TM) gp41, having amino acid sequences present in other viruses, such as enveloped viruses, and/or other organisms, and further relates to the uses of such peptides. These peptides exhibit anti-membrane fusion capability, antiviral activity, or the ability to modulate intracellular processes involving coiled-coil peptide structures. The present invention additionally relates to methods for identifying compounds that disrupt the interaction between DP178 and DP107, and/or between DP107-like and DP178-like peptides. Further, the invention relates to the use of the peptides of the invention as diagnostic agents. For example, a DP178 peptide may be used as an HIV subtype-specific diagnostic. The invention is demonstrated, first, by way of an Example wherein DP178 (SEQ ID:1), and a peptide whose sequence is homologous to DP178 are each shown to be potent, non-cytotoxic inhibitors of HIV-1 transfer to uninfected CD-4.sup.+ cells. The invention is further demonstrated by Examples wherein peptides having structural and/or amino acid motif similarity to DP107 and DP178 are identified in a variety of viral and nonviral organisms, and in examples wherein a number of such identified peptides derived from several different viral systems are demonstrated to exhibit antiviral activity.

Membrane fusion is a ubiquitous cell biological process (for a review, see White, J. M., 1992, Science 258:917-924). Fusion events which mediate cellular housekeeping functions, such as endocytosis, constitutive secretion, and recycling of membrane components, occur continuously in all eukaryotic cells.

Additional fusion events occur in specialized cells. Intracellularly, for example, fusion events are involved in such processes as occur in regulated exocytosis of hormones, enzymes and neurotransmitters. Intercellularly, such fusion events feature prominently in, for example, sperm-egg fusion and myoblast fusion.

Fusion events are also associated with disease states. For example, fusion events are involved in the formation of giant cells during inflammatory reactions, the entry of all enveloped viruses into cells, and, in the case of human immunodeficiency virus (HIV), for example, are responsible for the virally induced cell-cell fusion which leads to cell death.

The human immunodeficiency virus (HIV) has been implicated as the primary cause of the slowly degenerative immune system disease termed acquired immune deficiency syndrome (AIDS) (Barre-Sinoussi, F. et al., 1983, Science 220:868-870; Gallo, R. et al., 1984, Science 224:500-503). There are at least two distinct types of HIV: HIV-1 (Barre-Sinoussi, F. et al., 1983, Science 220:868-870; Gallo R. et al., 1984, Science 224:500-503) and HIV-2 (Clavel, F. et al., 1986, Science 233:343-346; Guyader, M. et al., 1987, Nature 326:662-669). Further, a large amount of genetic heterogeneity exists within populations of each of these types. Infection of human CD-4.sup.+ T-lymphocytes with an HIV virus leads to depletion of the cell type and eventually to opportunistic infections, neurological dysfunctions, neoplastic growth, and ultimately death.

HIV is a member of the lentivirus family of retroviruses (Teich, N. et al., 1984, RNA Tumor Viruses, Weiss, R. et al., eds., CSH-Press, pp. 949-956). Retroviruses are small enveloped viruses that contain a diploid, single-stranded RNA genome, and replicate via a DNA intermediate produced by a virally-encoded reverse transcriptase, an RNA-dependent DNA polymerase (Varmus, H., 1988, Science 240:1427-1439). Other retroviruses include, for example, oncogenic viruses such as human T-cell leukemia viruses (HTLV-I,-II,-III), and feline leukemia virus.

The HIV viral particle consists of a viral core, composed of capsid proteins, that contains the viral RNA genome and those enzymes required for early replicative events. Myristylated Gag protein forms an outer viral shell around the viral core, which is, in turn, surrounded by a lipid membrane enveloped derived from the infected cell membrane. The HIV enveloped surface glycoproteins are synthesized as a single 160 Kd precursor protein which is cleaved by a cellular protease during viral budding into two glycoproteins, gp41 and gp120. gp41 is a transmembrane protein and gp120 is an extracellular protein which remains noncovalently associated with gp41, possibly in a trimeric or multimeric form (Hammarskjold, M. and Rekosh, D., 1989, Biochem. Biophys. Acta 989:269-280).

HIV is targeted to CD-4.sup.+ cells because the CD-4 cell surface protein acts as the cellular receptor for the HIV-1 virus (Dalgleish, A. et al., 1984, Nature 312:763-767; Klatzmann et al., 1984, Nature 312:767-768; Maddon et al., 1986, Cell 47:333-348). Viral entry into cells is dependent upon gp120 binding the cellular CD-4.sup.+ receptor molecules (McDougal, J. S. et al., 1986, Science 231:382-385; Maddon, P. J. et al., 1986, Cell 47:333-348) and thus explains HIV's tropism for CD-4.sup.+ cells, while gp41 anchors the enveloped glycoprotein complex in the viral membrane.

HIV infection is pandemic and HIV associated diseases represent a major world health problem. Although considerable effort is being put into the successful design of effective therapeutics, currently no curative anti-retroviral drugs against AIDS exist. In attempts to develop such drugs, several stages of the HIV life cycle have been considered as targets for therapeutic intervention (Mitsuya, H. et al., 1991, FASEB J. 5:2369-2381). For example, virally encoded reverse transcriptase has been one focus of drug development. A number of reverse-transcriptase-targeted drugs, including 2',3'-dideoxynucleoside analogs such as AZT, ddI, ddC, and d4T have been developed which have been shown to been active against HIV (Mitsuya, H. et al., 1991, Science 249:1533-1544). While beneficial, these nucleoside analogs are not curative, probably due to the rapid appearance of drug resistant HIV mutants (Lander, B. et al., 1989, Science 243:1731-1734). In addition, the drugs often exhibit toxic side effects such as bone marrow suppression, vomiting, and liver function abnormalities.

Attempts are also being made to develop drugs which can inhibit viral entry into the cell, the earliest stage of HIV infection. Here, the focus has thus far been on CD4, the cell surface receptor for HIV. Recombinant soluble CD4, for example, has been shown to inhibit infection of CD-4.sup.+ T-cells by some HIV-1 strains (Smith, D. H. et al., 1987, Science 238:1704-1707). Certain primary HIV-1 isolates, however, are relatively less sensitive to inhibition by recombinant CD-4 (Daar, E. et al., 1990, Proc. Natl. Acad. Sci. U.S.A. 87:6574-6579). In addition, recombinant soluble CD-4 clinical trials have produced inconclusive results (Schooley, R. et al., 1990, Ann. Int. Med. 112:247-253; Kahn, J. O. et al., 1990, Ann. Int. Med. 112:254-261; Yarchoan, R. et al., 1989, Proc. Vth Int. Conf. on AIDS, p. 564, MCP 137).

The late stages of HIV replication, which involve crucial virus-specific secondary processing of certain viral proteins, have also been suggested as possible anti-HIV drug targets. Late stage processing is dependent on the activity of a viral protease, and drugs are being developed which inhibit this protease (Erickson, J., 1990, Science 249:527-533). The clinical outcome of these candidate drugs is still in question.

Attention is also being given to the development of vaccines for the treatment of HIV infection. The HIV-1 enveloped proteins (gp160, gp120, gp41) have been shown to be the major antigens for anti-HIV antibodies present in AIDS patients (Barin, et al., 1985, Science 228:1094-1096). Thus far, therefore, these proteins seem to be the most promising candidates to act as antigens for anti-HIV vaccine development. To this end, several groups have begun to use various portions of gp160, gp120, and/or gp41 as immunogenic targets for the host immune system. See for example, Ivanoff, L. et al., U.S. Pat. No. 5,141,867; Saith, G. et al., WO 92/22,654; Shafferman, A., WO 91/09,872; Formoso, C. et al., WO 90/07,119. Clinical results concerning these candidate vaccines, however, still remain far in the future.

Thus, although a great deal of effort is being directed to the design and testing of anti-retroviral drugs, a truly effective, non-toxic treatment is still needed.

The present invention relates, first, to DP178 (SEQ ID:1), a 36-amino acid synthetic peptide corresponding to amino acids 638 to 673 of the transmembrane protein (TM) gp41 from the HIV-1 isolate LAI (HIV-1.sub.LAI), which exhibits potent anti-HIV-1 activity. As evidenced by the Example presented below, in Section 6, the DP178 (SEQ ID:1) antiviral activity is so high that, on a weight basis, no other known anti-HIV agent is effective at concentrations as low as those at which DP178 (SEQ ID:1) exhibits its inhibitory effects.

The invention further relates to those portions and analogs of DP178 which also show such antiviral activity, and/or show anti-membrane fusion capability, or an ability to modulate intracellular processes involving coiled-coil peptide structures. The term "DP178 analog" refers to a peptide which contains an amino acid sequence corresponding to the DP178 peptide sequence present within the gp41 protein of HIV-1.sub.LAI, but found in viruses and/or organisms other than HIV-1.sub.LAI. Such DP178 analog peptides may, therefore, correspond to DP178-like amino acid sequences present in other viruses, such as, for example, enveloped viruses, such as retroviruses other than HIV-1.sub.LAI, as well as non-enveloped viruses. Further, such analogous DP178 peptides may also correspond to DP178-like amino acid sequences present in nonviral organisms.

The invention further relates to peptides DP107 analogs. DP107 is a peptide corresponding to amino acids 558-595 of the HIV-1.sub.LAI transmembrane protein (TM) gp41. The term "DP107 analog" as used herein refers to a peptide which contains an amino acid sequence corresponding to the DP107 peptide sequence present within the gp41 protein of HIV-1.sub.LAI, but found in viruses and organisms other than HIV-1.sub.LAI. Such DP107 analog peptides may, therefore, correspond to DP107-like amino acid sequences present in other viruses, such as, for example, enveloped viruses, such as retroviruses other than HIV-1.sub.LAI, as well as non-enveloped viruses. Further, such DP107 analog peptides may also correspond to DP107-like amino acid sequences present in nonviral organisms.

Further, the peptides of the invention include DP107 analog and DP178 analog peptides having amino acid sequences recognized or identified by the 107.times.178.times.4, ALLMOTI5 and/or PLZIP search motifs described herein.

The peptides of the invention may, for example, exhibit antifusogenic activity, antiviral activity, and/or may have the ability to modulate intracellular processes which involve coiled-coil peptide structures. With respect to the antiviral activity of the peptides of the invention, such an antiviral activity includes, but is not limited to the inhibition of HIV transmission to uninfected CD-4.sup.+ cells. Additionally, the antifusogenic capability, antiviral activity or intracellular modulatory activity of the peptides of the invention merely requires the presence of the peptides of the invention, and, specifically, does not require the stimulation of a host immune response directed against such peptides.

The peptides of the invention may be used, for example, as inhibitors of membrane fusion-associated events, such as, for example, the inhibition of human and non-human retroviral, especially HIV, transmission to uninfected cells. It is further contemplated that the peptides of the invention may be used as modulators of intracellular events involving coiled-coil peptide structures.

The peptides of the invention may, alternatively, be used to identify compounds which may themselves exhibit antifusogenic, antiviral, or intracellular modulatory activity. Additional uses include, for example, the use of the peptides of the invention as organism or viral type and/or subtype-specific diagnostic tools.

The terms "antifusogenic" and "anti-membrane fusion", as used herein, refer to an agent's ability to inhibit or reduce the level of membrane fusion events between two or more moieties relative to the level of membrane fusion which occurs between said moieties in the absence of the peptide. The moieties may be, for example, cell membranes or viral structures, such as viral envelopes or pili. The term "antiviral", as used herein, refers to the compound's ability to inhibit viral infection of cells, via, for example, cell-cell fusion or free virus infection. Such infection may involve membrane fusion, as occurs in the case of enveloped viruses, or some other fusion event involving a viral structure and a cellular structure (e.g., such as the fusion of a viral pilus and bacterial membrane during bacterial conjugation).

It is also contemplated that the peptides of the invention may exhibit the ability to modulate intracellular events involving coiled-coil peptide structures. "Modulate", as used herein, refers to a stimulatory or inhibitory effect on the intracellular process of interest relative to the level or activity of such a process in the absence of a peptide of the invention.

Embodiments of the invention are demonstrated below wherein an extremely low concentration of DP178 (SEQ ID:1), and very low concentrations of a DP178 homolog (SEQ ID:3) are shown to be potent inhibitors of HIV-1 mediated CD-4.sup.+ cell-cell fusion (i.e., syncytial formation) and infection of CD-4.sup.+ cells by cell-free virus. Further, it is shown that DP178 (SEQ ID:1) is not toxic to cells, even at concentrations 3 logs higher than the inhibitory DP-178 (SEQ ID:1) concentration.

The present invention is based, in part, on the surprising discovery that the DP107 and DP178 domains of the HIV gp41 protein non-covalently complex with each other, and that their interaction is required for the normal infectivity of the virus. This discovery is described in the Example presented, below, in Section 8. The invention, therefore, further relates to methods for identifying antifusogenic, including antiviral, compounds that disrupt the interaction between DP107 and DP178, and/or DP178-like peptike and DP178-like peptides.

Additional embodiments of the invention (specifically, the Examples presents in Sections 9-16 and 19-25, below) are demonstrated, below, wherein peptides, from a variety of viral and nonviral sources, having structural and/or amino acid motif similarity to DP107 and DP178 are identified, and search motifs for their identification are described. Further, Examples (in Sections 17, 18, 25-29) are presented wherein a number of the peptides of the invention are demonstrated exhibit substantial antiviral activity or activity predictive of antiviral activity.

Peptides are defined herein as organic compounds comprising two or more amino acids covalently joined by peptide bonds. Peptides may be referred to with respect to the number of constituent amino acids, i.e., a dipeptide contains two amino acid residues, a tripeptide contains three, etc. Peptides containing ten or fewer amino acids may be referred to as oligopeptides, while those with more than ten amino acid residues are polypeptides. Such peptides may also include any of the modifications and additional amino and carboxy groups as are described herein.

Peptide sequences defined herein are represented by one-letter symbols for amino acid residues as follows:

FIG. 1. Amino acid sequence of DP178 (SEQ ID:1) derived from HIV.sub.LAI ; DP178 homologs derived from HIV-1.sub.SF2 (DP-185; SEQ ID:3), HIV-1.sub.RF (SEQ ID:4), and HIV-1.sub.MN (SEQ ID:5); DP178 homologs derived from amino acid sequences of two prototypic HIV-2 isolates, namely, HIV-2.sub.rod (SEQ ID:6) and HIV-2.sub.NIHZ (SEQ ID:7); control peptides: DP-180 (SEQ ID:2), a peptide incorporating the amino acid residues of DP178 in a scrambled sequence; DP-118 (SEQ ID:10) unrelated to DP178, which inhibits HIV-1 cell free virus infection; DP-125 (SEQ ID:8), unrelated to DP178, also inhibits HIV-1 cell free virus infection; DP-116 (SEQ ID:9), unrelated to DP178, is negative for inhibition of HIV-1 infection when tested using a cell-free virus infection assay. Throughout the figures, the one letter amino acid code is used.

FIG. 2. Inhibition of HIV-1 cell-free virus infection by synthetic peptides. IC.sub.50 refers to the concentration of peptide that inhibits RT production from infected cells by 50% compared to the untreated control. Control: the level of RT produced by untreated cell cultures infected with the same level of virus as treated cultures.

FIG. 3. Inhibition of HIV-1 and HIV-2 cell-free virus infection by the synthetic peptide DP178 (SEQ ID:1). IC.sub.50 : concentration of peptide that inhibits RT production by 50% compared to the untreated control. Control: Level of RT produced by untreated cell cultures infected with the same level of virus as treated cultures.

FIGS. 4A-4B. Fusion Inhibition Assays. FIG. 4A: DP178 (SEQ ID:1) inhibition of HIV-1 prototypic isolate-mediated syncytial formation; data represents the number of virus-induced syncytial per cell. FIG. 4B: DP-180 (SEQ ID:2) represents a scrambled control peptide; DP-185 (SEQ ID:3) represents a DP178 homolog derived from HIV-1.sub.SF2 isolate; Control, refers to the number of syncytial produced in the absence of peptide.

FIG. 5. Fusion inhibition assay: HIV-1 vs. HIV-2. Data represents the number of virus-induced syncytial per well. ND: not done.

FIG. 6. Cytotoxicity study of DP178 (SEQ ID:1) and DP-116 (SEQ ID:9) on CEM cells. Cell proliferation data is shown.

FIG. 7. Schematic representation of HIV-gp41 and maltose binding protein (MBP)-gp41 fusion proteins. DP107 and DP178 are synthetic peptides based on the two putative helices of gp41. The letter P in the DP107 boxes denotes an Ile to Pro mutation at amino acid number 578. Amino acid residues are numbered according to Meyers et al., "Human Retroviruses and AIDS", 1991, Theoret. Biol. and Biophys. Group, Los Alamos Natl. Lab., Los Alamos, N. Mex. The proteins are more fully described, below, in Section 8.1.1.

FIG. 8. A point mutation alters the conformation and anti-HIV activity of M41.

FIG. 9. Abrogation of DP178 anti-HIV activity. Cell fusion assays were carried out in the presence of 10 nM DP178 and various concentrations of M41.DELTA.178 or M41P.DELTA.178.

FIG. 10. Binding of DP178 to leucine zipper of gp41 analyzed by FAb-D ELISA.

FIGS. 11A-B. Models for a structural transition in the HIV-1 TM protein. Two models are proposed which indicate a structural transition from a native oligomer to a fusogenic state following a trigger event (possibly gp120 binding to CD4). Common features of both models include (1) the native state is held together by noncovalent protein-protein interactions to form the heterodimer of gp120/41 and other interactions, principally though gp41 interactive sites, to form homo-oligomers on the virus surface of the gp120/41 complexes; (2) shielding of the hydrophobic fusogenic peptide at the N-terminus (F) in the native state; and (3) the leucine zipper domain (DP107) exists as a homo-oligomer coiled coil only in the fusogenic state. The major differences in the two models include the structural state (native or fusogenic) in which the DP107 and DP178 domains are complexed to each other. In the first model (FIG. 11A) this interaction occurs in the native state and in the second (FIG. 11B), it occurs during the fusogenic state. When triggered, the fusion complex in the model depicted in (A) is generated through formation of coiled-coil interactions in homologous DP107 domains resulting in an extended .alpha.-helix. This conformational change positions the fusion peptide for interaction with the cell membrane. In the second model (FIG. 11B), the fusogenic complex is stabilized by the association of the DP178 domain with the DP107 coiled-coil.

FIG. 12. Motif design using heptad repeat positioning of amino acids of known coiled-coils [GCN4:(SEQ ID NO:84); C-FOS:(SEQ ID NO:85); C-JUN:(SEQ ID NO:86); C-MYC:(SEQ ID NO:87); FLU LOOP 36:(SEQ ID NO:88)].

FIG. 13. Motif design using proposed heptad repeat positioning of amino acids of DP107 and DP178.

FIG. 14. Hybrid motif design crossing GCN4 and DP107 (SEQ ID NO:89).

FIG. 15. Hybrid motif design crossing GCN4 and DP178 (SEQ ID NO:1).

FIG. 16. Hybrid motif design 107.times.178.times.4, crossing DP107 and DP178. This motif was found to be the most consistent at identifying relevant DP107-like and DP178-like peptide regions.

FIG. 17. Hybrid motif design crossing GCN4, DP107, and DP178.

FIG. 18. Hybrid motif design ALLMOTI5 crossing GCN4, DP107, DP178, c-Fos c-Jun, c-Myc, and Flu Loop 36.

FIG. 19. PLZIP motifs designed to identify N-terminal proline-leucine zipper motifs.

FIG. 20. Search results for HIV-1 (BRU isolate) enveloped protein gp41 (SEQ ID NO:90). Sequence search motif designations: Spades (): 107.times.178.times.4; Hearts (.heart.) ALLMOTI5; Clubs (): PLZIP; Diamonds (.diamond-solid.): transmembrane region (the putative transmembrane domains were identified using a PC/Gene program designed to search for such peptide regions). Asterisk (*): Lupas method. The amino acid sequences identified by each motif are bracketed by the respective characters. Representative sequences chosen based on 107.times.178.times.4 searches are underlined and in bold. DP107 and DP178 sequences are marked, and additionally double-underlined and italicized.

FIG. 21. Search results for human respiratory syncytial virus (RSV) strain A2 fusion glycoprotein F1 (SEQ ID NO:91). Sequence search motif designations are as in FIG. 20.

FIG. 22. Search results for simian immunodeficiency virus (SIV) enveloped protein gp41 (AGM3 isolate) (SEQ ID NO:92). Sequence search motif designations are as in FIG. 20.

FIG. 23. Search results for canine distemper virus (strain Onderstepoort) fusion glycoprotein 1 (SEQ ID NO:93). Sequence search motif designations are as in FIG. 20.

FIG. 24. Search results for newcastle disease virus (strain Australia-Victoria/32) fusion glycoprotein F1 (SEQ ID NO:94). Sequence search motif designations are as in FIG. 20.

FIG. 25. Search results for human parainfluenza 3 virus (strain NIH 47885) fusion glycoprotein F1 (SEQ ID NO:95). Sequence search motif designations are as in FIG. 20.

FIG. 26. Search results for influenza A virus (strain A/AICHI/2/68) hemagglutinin precursor HA2 (SEQ ID NO:96). Sequence search designations are as in FIG. 20.

FIGS. 27A-F. Respiratory Syncytial Virus (RSV) peptide (SEQ ID NO:97) antiviral and circular dichroism data. FIGS. 27A-C: Peptides derived from the F2 DP178/DP107-like region [T-22:(SEQ ID NO:121); T-68:(SEQ ID NO:122); T-334:(SEQ ID NO:123); T-371:(SEQ ID NO:124); T-372:(SEQ ID NO:125); T-373:(SEQ ID NO:126); T-374:(SEQ ID NO:127); T-375:(SEQ ID NO:128); T-575:(SEQ ID NO:129)]. Antiviral and CD data. FIGS. 27D-F: Peptides derived from the F1 DP107-like region [F1-107:(SEQ ID NO:98); T-12:(SEQ ID NO:130); T-13:(SEQ ID NO:131); T-15:(SEQ ID NO:132); T-19:(SEQ ID NO:133); T-28:(SEQ ID NO:134); T-30:(SEQ ID NO:135); T-66:(SEQ ID NO:136); T-576:(SEQ ID NO:137)]. Peptide and CD data.

Antiviral activity (AV) is represented by the following qualitative symbols:

"-", negative antiviral activity;

".+-.", antiviral activity at greater than 100 .mu.g/ml;

"+", antiviral activity at between 50-100 .mu.g/ml;

"++", antiviral activity at between 20-50 .mu.g/ml;

"+++", antiviral activity at between 1-20 .mu.g/ml;

"++++", antiviral activity at <1 .mu.g/ml.

CD data, referring to the level of helicity is represented by the following qualitative symbol:

"-", no helicity;

"+", 25-50% helicity;

"++", 50-75% helicity;

"+++", 75-100% helicity.

IC.sub.50 refers to the concentration of peptide necessary to produce only 50% of the number of syncytial relative to infected control cultures containing no peptide. IC.sub.50 values were obtained using purified peptides only.

FIGS. 28A-C. Respiratory Syncytial Virus (RSV) DP178-like region (F1) peptide antiviral and CD data [F1-178:(SEQ ID NO:99); T-71:(SEQ ID NO:138); T-384:(SEQ ID NO:139); T-616:(SEQ ID NO:140); T-617:(SEQ ID NO:141); T-662:(SEQ ID NO:142); T-665:(SEQ ID NO:143); T-671:(SEQ ID NO:144); T-730:(SEQ ID NO:145)]. Antiviral symbols, CD symbols, and IC.sub.50 are as in FIGS. 27A-F. IC.sub.50 values were obtained using purified peptides only.

FIGS. 29A-E. Peptides derived from the HPIV3 F1 DP107-like region. Peptide antiviral and CD data [HPF1 107:(SEQ ID NO:100); T-42:(SEQ ID NO:146); T-39:(SEQ ID NO:147); T-40:(SEQ ID NO:148); T-45:(SEQ ID NO:149); T-46:(SEQ ID NO:150); T-582:(SEQ ID NO:151)]. Antiviral symbols, CD symbols, and IC.sub.50 are as in FIGS. 27A-F. Purified peptides were used to obtain IC.sub.50 values, except where the values are marked by an asterisk (*), in which cases, the IC.sub.50 values were obtained using a crude peptide preparation.

FIGS. 30A-C. Peptides derived from the HPIV3 F1 DP178-like region. Peptide antiviral and CD data [HPF3 178:(SEQ ID NO:101); T-269:(SEQ ID NO:152); T-626:(SEQ ID NO:153); T-383:(SEQ ID NO:154); T-577:(SEQ ID NO:155); T-578:(SEQ ID NO:156); T-579:(SEQ ID NO:157)]. Antiviral symbols, CD symbols, and IC.sub.50 are as in FIGS. 27A-F. Purified peptides were used to obtain IC.sub.50 values, except where the values are marked by an asterisk (*), in which cases, the IC.sub.50 values were obtained using a crude peptide preparation.

FIG. 31. Motif search results for simian immunodeficiency virus (SIV) isolate MM251, enveloped polyprotein gp41 (SEQ ID NO:102). Sequence search designations are as in FIG. 20.

FIG. 32. Motif search results for Epstein-Barr Virus (Strain B95-8), glycoprotein gp110 precursor (designated gp115). BALF4 (SEQ ID NO:103). Sequence search designations are as in FIG. 20.

FIG. 33. Motif search results for Epstein-Barr Virus (Strain B95-8), BZLF1 trans-activator protein (designated EB1 or Zebra) (SEQ ID NO:104). Sequence search designations are as in FIG. 20. Additionally, "@" refers to a well known DNA binding domain and "+" refers to a well known dimerization domain, as defined by Flemington and Speck (Flemington, E. and Speck, S. H., 1990, Proc. Natl. Acad. Sci. U.S.A. 87:9459-9463).

FIG. 34. Motif search results for measles virus (strain Edmonston), fusion glycoprotein F1 (SEQ ID NO:105). Sequence search designations are as in FIG. 20.

FIG. 35. Motif search results for Hepatitis B Virus (Subtype AYW), major surface antigen precursor S (SEQ ID NO:106). Sequence search designations are as in FIG. 20.

FIG. 36. Motif search results for simian Mason-Pfizer monkey virus, enveloped (TM) protein gp20 (SEQ ID NO:107). Sequence search designations are as in FIG. 20.

FIG. 37. Motif search results for Pseudomonas aerginosa, fimbrial protein (SEQ ID NO:110) (Pilin) (SEQ ID NO:108). Sequence search designations are as in FIG. 20.

FIG. 38. Motif search results for Neisseria gonorrhoeae fimbrial protein (Pilin) (SEQ ID NO:109). Sequence search designations are as in FIG. 20.

FIG. 39. Motif search results for Hemophilus influenzae fimbrial protein. Sequence search designations are as in FIG. 20.

FIG. 40. Motif search results for Staphylococcus aureus, toxic shock syndrome toxin-1(SEQ ID NO:111). Sequence search designations are as in FIG. 20.

FIG. 41. Motif search results for Staphylococcus aureus enterotoxin Type E (SEQ ID NO:112). Sequence search designations are as in FIG. 20.

FIG. 42. Motif search results for Staphylococcus aureus enterotoxin A (SEQ ID NO:113). Sequence search designations are as in FIG. 20.

FIG. 43. Motif search results for Escherichia coli, heat labile enterotoxin A (SEQ ID NO:114). Sequence search designations are as in FIG. 20.

FIG. 44. Motif search results for human c-fos proto-oncoprotein (SEQ ID NO:115). Sequence search designations are as in FIG. 20.

FIG. 45. Motif search results for human lupus KU autoantigen protein P70 (SEQ ID NO:116). Sequence search designations are as in FIG. 20.

FIG. 46. Motif search results for human zinc finger protein 10 (SEQ ID NO:117). Sequence search designations are as in FIG. 20.

FIGS. 47A-B. Measles virus (MeV) fusion protein DP178-like region antiviral and CD data [T-252AO:(SEQ ID NO:118); T-268AO:(SEQ ID NO:119)]. Antiviral symbols, CD symbols, and IC.sub.50 are as in FIGS. 27A-F. IC.sub.50 values were obtained using purified peptides.

FIGS. 48A-B. Simian immunodeficiency virus (SIV) TM (fusion) protein DP178-like region antiviral data (SEQ ID NO:120). Antiviral symbols are as in FIGS. 27A-F "NT", not tested.

FIGS. 49A-C. DP178-derived peptide antiviral data [(SEQ ID NO:158); T50:(SEQ ID NO:159); (SEQ ID NO:160); T234:(SEQ ID NO:161); T235:(SEQ ID NO:162); T570:(SEQ ID NO:163); T381:(SEQ ID NO:164); T677:(SEQ ID NO:165); T589:(SEQ ID NO:166); T590:(SEQ ID NO:167); T591:(SEQ ID NO:168); T270:(SEQ ID NO:169); T271:(SEQ ID NO:170); T273:(SEQ ID NO:171); T608:(SEQ ID NO:172); T609:(SEQ ID NO:173); T610:(SEQ ID NO:174); T611:(SEQ ID NO:175); T612:(SEQ ID NO:176); T595:(SEQ ID NO:177); T95:(SEQ ID NO:178); T96:(SEQ ID NO:179); T97:(SEQ ID NO:180); T98:(SEQ ID NO:181); T99:(SEQ ID NO:182); T103:(SEQ ID NO:183); T212:(SEQ ID NO:184); T213:(SEQ ID NO:185); T214:(SEQ ID NO:186); T215:(SEQ ID NO:187); T216:(SEQ ID NO:188); T229:(SEQ ID NO:189); T230:(SEQ ID NO:190); T231:(SEQ ID NO:191); T379:(SEQ ID NO:192); T701:(SEQ ID NO:193); T702:(SEQ ID NO:194); T703:(SEQ ID NO:195); T704:(SEQ ID NO:196); T705:(SEQ ID NO:197); T706:(SEQ ID NO:198); T156:(SEQ ID NO:199); T90:(SEQ ID NO:200)]. The peptides listed herein were derived from the region surrounding the HIV-1 BRU isolate DP178 region (e.g., gp41 amino acid residues 615-717).

In instances where peptides contained DP178 point mutations, the mutated amino acid residues are shown with a shaded background. In instances in which the test peptide has had an amino and/or carboxy-terminal group added or removed (apart from the standard amido- and acetyl-blocking groups found on such peptides), such modifications are indicated. FIGS. 49A-D: The column to the immediate right of the name of the test peptide indicates the size of the test peptide and points out whether the peptide is derived from a one amino acid peptide "walk" across the DP178 region. The next column to the right indicates whether the test peptide contains a point mutation, while the column to its right indicates whether certain amino acid residues have been added to or removed from the DP178-derived amino acid sequence. FIGS. 49E-H: The column to the immediate right of the test peptide name indicates whether the peptide represents a DP178 truncation, the next column to the right points out whether the peptide contains a point mutation, and the column to its right indicates whether the peptide contains amino acids which have been added to or removed from the DP178 sequence itself. FIGS. 49I-L: The column to the immediate right of the test peptide name indicates whether the test peptide contains a point mutation, while the column to its right indicates whether amino acid residues have been added to or removed from the DP178 sequence itself. IC.sub.50 is as defined in FIGS. 27A-F, and IC.sub.50 values were obtained using purified peptides except where marked with an asterisk (*), in which case the IC.sub.50 was obtained using a crude peptide preparation.

FIGS. 50A-B. DP107 and DP107 gp41 region truncated peptide antiviral data (SEQ ID NO:201). IC.sub.50 as defined in FIGS. 27A-F, and IC.sub.50 values were obtained using purified peptides except where marked with an asterisk (*), in which case the IC.sub.50 was obtained using a crude peptide preparation.

FIGS. 51A-C. Epstein-Barr virus Strain B95-8 BZLF1 DP178/DP107 analog region peptide walks and electrophoretic mobility shift assay results. The peptides [173-219:(SEQ ID NO:202); 185-230:(SEQ ID NO:203); T-446:(SEQ ID NO:204); 197-242:(SEQ ID NO:205); T-458:(SEQ ID NO:206); 209-246:(SEQ ID NO:207)] (T-423 to T-446, FIGS. 51A-B; T-447 to T-461, FIGS. 51B-C) represent one amino acid residue "walks" through the EBV Zebra protein region from amino acid residue 173 to 246.

The amino acid residue within this region which corresponds to the first amino acid residue of each peptide is listed to the left of each peptide, while the amino acid residue within this region which corresponds to the last amino acid residue of each peptide is listed to the right of each peptide. The length of each test peptide is listed at the far right of each line, under the heading "Res".

"ACT" refers to a test peptide's ability to inhibit Zebra binding to its response element. "+" refers to a visible, but incomplete, abrogation of the response element/Zebra homodimer complex; "+++" refers to a complete abrogation of the complex; and "-" represents a lack of complex disruption.

FIG. 52A-B. Hepatitis B virus subtype AYW major surface antigen precursor S protein DP178/DP107 analog region and peptide walks. 52A depicts Domain I (SEQ ID NO:208) (S protein amino acid residues 174-220 residues 174-219), which contains a potential DP178/DP107 analog region. In addition, peptides are listed which represent one amino acid peptide "walks" through domain I. 52B depicts Domain II (SEQ ID NO:209) (S protein amino acid residues 233-290), which contains a second potential DP178/DP107 analog region. In addition, peptides are listed which represent one amino acid peptide "walks" through domain II.

Described herein are peptides which may exhibit antifusogenic activity, antiviral capability, and/or the ability to modulate intracellular processes involving coiled-coil peptide structures. The peptides described include, first, DP178 (SEQ ID NO:1), a gp41-derived 36 amino acid peptide and fragments and analogs of DP178.

In addition, the peptides of the invention described herein include peptides which are DP107 analogs. DP107 (SEQ ID NO:99) is a 38 amino acid peptide corresponding to residues 558 to 595 of the HIV-1.sub.LAI transmembrane (TM) gp41 protein. Such DP107 analogs may exhibit antifusogenic capability, antiviral activity or an ability to modulate intracellular processes involving coiled-coil structures.

Further, peptides of the invention include DP107 and DP178 are described herein having amino acid sequences recognized by the 107.times.178.times.4, ALLMOT15, and PLZIP search motifs. Such motifs are also discussed.

Also described here are antifusogenic, antiviral, intracellular modulatory, and diagnostic uses of the peptides of the invention. Further, procedures are described for the use of the peptides of the invention for the identification of compounds exhibiting antifusogenic, antiviral or intracellular modulatory activity.

While not limited to any theory of operation, the following model is proposed to explain the potent anti-HIV activity of DP178, based, in part, on the experiments described in the Examples, infra. In the HIV protein, gp41, DP178 corresponds to a putative .alpha.-helix region located in the C-terminal end of the gp41 ectodomain, and appears to associate with a distal site on gp41 whose interactive structure is influenced by the leucine zipper motif, a coiled-coil structure, referred to as DP107. The association of these two domains may reflect a molecular linkage or "molecular clasp" intimately involved in the fusion process. It is of interest that mutations in the C-terminal .alpha.-helix motif of gp41 (i.e., the D178 domain) tend to enhance the fusion ability of gp41, whereas mutations in the leucine zipper region (i.e., the DP107 domain) decrease or abolish the fusion ability of the viral protein. It may be that the leucine zipper motif is involved in membrane fusion while the C-terminal .alpha.-helix motif serves as a molecular safety to regulate the availability of the leucine zipper during virus-induced membrane fusion.

On the basis of the foregoing, two models are proposed of gp41-mediated membrane fusion which are schematically shown in FIG. 11A-B. The reason for proposing two models is that the temporal nature of the interaction between the regions defined by DP107 and DP178 cannot, as yet, be pinpointed. Each model envisions two conformations for gp41--one in a "native" state as it might be found on a resting virion. The other in a "fusogenic" state to reflect conformational changes triggered following binding of gp120 to CD4 and just prior to fusion with the target cell membrane. The strong binding affinity between gp120 and CD4 may actually represent the trigger for the fusion process obviating the need for a pH change such as occurs for viruses that fuse within intracellular vesicles. The two major features of both models are: (1) the leucine zipper sequences (DP107) in each chain of oligomeric enveloped are held apart in the native state and are only allowed access to one another in the fusogenic state so as to form the extremely stable coiled-coils, and (2) association of the DP178 and DP107 sites as they exist in gp41 occur either in the native or fusogenic state. FIG. 11A depicts DP178/DP107 interaction in the native state as a molecular clasp. On the other hand, if one assumes that the most stable form of the enveloped occurs in the fusogenic state, the model in FIG. 11B can be considered.

When synthesized as peptides, both DP107 and DP178 are potent inhibitors of HIV infection and fusion, probably by virtue of their ability to form complexes with viral gp41 and interfere with its fusogenic process; e.g., during the structural transition of the viral protein from the native structure to the fusogenic state, the DP178 and DP107 peptides may gain access to their respective binding sites on the viral gp41, and exert a disruptive influence. DP107 peptides which demonstrate anti-HIV activity are described in Applicants' co-pending application Ser. No. 08/264,531, filed Jun. 23, 1994, which is incorporated by reference herein in its entirety.

As shown in the Examples, infra, a truncated recombinant gp41 protein corresponding to the ectodomain of gp41 containing both DP107 and DP178 domains (excluding the fusion peptide, transmembrane region and cytoplasmic domain of gp41) did not inhibit HIV-1 induced fusion. However, when a single mutation was introduced to disrupt the coiled-coil structure of the DP107 domain--a mutation which results in a total loss of biological activity of DP107 peptides--the inactive recombinant protein was transformed to an active inhibitor of HIV-1 induced fusion. This transformation may result from liberation of the potent DP178 domain from a molecular clasp with the leucine zipper, DP107 domain.

For clarity of discussion, the invention will be described primarily for DP178 peptide inhibitors of HIV. However, the principles may be analogously applied to other viruses, both enveloped and nonenveloped, and to other non-viral organisms.

The DP178 peptide (SEQ ID:1) of the invention corresponds to amino acid residues 638 to 673 of the transmembrane protein gp41 from the HIV-1.sub.LAI isolate, and has the 36 amino acid sequence (reading from amino to carboxy terminus):

NH.sub.2 -YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF-COOH (SEQ ID:1)

In addition to the full-length DP178 (SEQ ID:1) 36-mer, the peptides of the invention may include truncations of the DP178 (SEQ ID:1) peptide which exhibit antifusogenic activity, antiviral activity and/or the ability to modulate intracellular processes involving coiled-coil peptide structures. Truncations of DP178 (SEQ ID:1) peptides may comprise peptides of between 3 and 36 amino acid residues (i.e., peptides ranging in size from a tripeptide to a 36-mer polypeptide), as shown in Tables I and IA, below. Peptide sequences in these tables are listed from amino (left) to carboxy (right) terminus. "X" may represent an amino group (--NH.sub.2) and "Z" may represent a carboxyl (--COOH) group. Alternatively, "X" may represent a hydrophobic group, including but not limited to carbobenzyl, dansyl, or T-butoxycarbonyl; an acetyl group; a 9-fluorenylmethoxy-carbonyl (FMOC) group; or a covalently attached macromolecular group, including but not limited to a lipid-fatty acid conjugate, polyethylene glycol, carbohydrate or peptide group. Further, "Z" may represent an amido group; a T-butoxycarbonyl group; or a covalently attached macromolecular group, including but not limited to a lipid-fatty acid conjugate, polyethylene glycol, carbohydrate or peptide group. A preferred "X" or "Z" macromolecular group is a peptide group.

The peptides of the invention also include DP178-like peptides. "DP178-like", as used herein, refers, first, to DP178 and DP178 truncations which contain one or more amino acid substitutions, insertions and/or deletions. Second, "DP-178-like" refers to peptide sequences identified or recognized by the ALLMOTI5, 107.times.178.times.4 and PLZIP search motifs described herein, having structural and/or amino acid motif similarity to DP178. The DP178-like peptides of the invention may exhibit antifusogenic or antiviral activity, or may exhibit the ability to modulate intracellular processes involving coiled-coil peptides. Further, such DP178-like peptides may possess additional advantageous features, such as, for example, increased bioavailability, and/or stability, is or reduced host immune recognition.

HIV-1 and HIV-2 enveloped proteins are structurally distinct, but there exists a striking amino acid conservation within the DP178-corresponding regions of HIV-1 and HIV-2. The amino acid conservation is of a periodic nature, suggesting some conservation of structure and/or function. Therefore, one possible class of amino acid substitutions would include those amino acid changes which are predicted to stabilize the structure of the DP178 peptides of the invention. Utilizing the DP178 and DP178 analog sequences described herein, the skilled artisan can readily compile DP178 consensus sequences and ascertain from these, conserved amino acid residues which would represent preferred amino acid substitutions.

The amino acid substitutions may be of a conserved or non-conserved nature. Conserved amino acid substitutions consist of replacing one or more amino acids of the DP178 (SEQ ID:1) peptide sequence with amino acids of similar charge, size, and/or hydrophobicity characteristics, such as, for example, a glutamic acid (E) to aspartic acid (D) amino acid substitution. Non-conserved substitutions consist of replacing one or more amino acids of the DP178 (SEQ ID:1) peptide sequence with amino acids possessing dissimilar charge, size, and/or hydrophobicity characteristics, such as, for example, a glutamic acid (E) to valine (V) substitution.

Amino acid insertions may consist of single amino acid residues or stretches of residues. The insertions may be made at the carboxy or amino terminal end of the DP178 or DP178 truncated peptides, as well as at a position internal to the peptide. Such insertions will generally range from 2 to 15 amino acids in length. It is contemplated that insertions made at either the carboxy or amino terminus of the peptide of interest may be of a broader size range, with about 2 to about 50 amino acids being preferred. One or more such insertions may be introduced into DP178 (SEQ.ID:1) or DP178 truncations, as long as such insertions result in peptides which may still be recognized by the 107.times.178.times.4, ALLMOTI5 or PLZIP search motifs described herein, or may, alternatively, exhibit antifusogenic or antiviral activity, or exhibit the ability to modulate intracellular processes involving coiled-coil peptide structures.

Preferred amino or carboxy terminal insertions are peptides ranging from about 2 to about 50 amino acid residues in length, corresponding to gp41 protein regions either amino to or carboxy to the actual DP178 gp41 amino acid sequence, respectively. Thus, a preferred amino terminal or carboxy terminal amino acid insertion would contain gp41 amino acid sequences found immediately amino to or carboxy to the DP178 region of the gp41 protein.

Deletions of DP178 (SEQ ID:1) or DP178 truncations are also within the scope of the invention. Such deletions consist of the removal of one or more amino acids from the DP178 or DP178-like peptide sequence, with the lower limit length of the resulting peptide sequence being 4 to 6 amino acids. Such deletions may involve a single contiguous or greater than one discrete portion of the peptide sequences. One or more such deletions may be introduced into DP178 (SEQ.ID:1) or DP178 truncations, as long as such deletions result in peptides which may still be recognized by the 107.times.178.times.4, ALLMOTI5 or PLZIP search motifs described herein, or may, alternatively, exhibit antifusogenic or antiviral activity, or exhibit the ability to modulate intracellular processes involving coiled-coil peptide structures.

DP178 analogs are further described, below, in Section 5.3.

Further, the peptides of the invention include peptides having amino acid sequences corresponding to DP107 analogs. DP107 is a 38 amino acid peptide which exhibits potent antiviral activity, and corresponds to residues 558 to 595 of HIV-1.sub.LAI transmembrane (TM) gp41 protein, as shown here:

NH.sub.2 -NNLLRAIEAQQHLLQLTVWQIKQLQARILAVERYLKDQ-COOH

In addition to the full-length DP107 38-mer, the peptides of the invention may include truncations of the DP107 peptide which exhibit antifusogenic activity, antiviral activity and/or the ability to modulate intracellular processes involving coiled-coil peptide structures. Truncations of DP107 peptides may comprise peptides of between 3 and 38 amino acid residues (i.e., peptides ranging in size from a tripeptide to a 38-mer polypeptide), as shown in Tables II and IIA, below. Peptide sequences in these tables are listed from amino (left) to carboxy (right) terminus. "X" may represent an amino group (--NH.sub.2) and "Z" may represent a carboxyl (--COOH) group. Alternatively, "X" may represent a hydrophobic group, including but not limited to carbobenzyl, dansyl, or T-butoxycarbonyl; an acetyl group; a 9-fluorenylmethoxy-carbonyl (FMOC) group; or a covalently attached macromolecular group, including but not limited to a lipid-fatty acid conjugate, polyethylene glycol, carbohydrate or peptide group. Further, "Z" may represent an amido group; a T-butoxycarbonyl group; or a covalently attached macromolecular group, including but not limited to a lipid-fatty acid conjugate, polyethylene glycol, carbohydrate or peptide group. A preferred "X" or "Z" macromolecular group is a peptide group.

The peptides of the invention also include DP107-like peptides. "DP107-like", as used herein, refers, first, to DP107 and DP107 truncations which contain one or more amino acid substitutions, insertions and/or deletions. Second, "DP-107-like" refers to peptide sequences identified or recognized by the ALLMOTI5, 107.times.178.times.4 and PLZIP search motifs described herein, having structural and/or amino acid motif similarity to DP107. The DP107-like peptides of the invention may exhibit antifusogenic or antiviral activity, or may exhibit the ability to modulate intracellular processes involving coiled-coil peptides. Further, such DP107-like peptides may possess additional advantageous features, such as, for example, increased bioavailability, and/or stability, or reduced host immune recognition.

HIV-1 and HIV-2 enveloped proteins are structurally distinct, but there exists a striking amino acid conservation within the DP107-corresponding regions of HIV-1 and HIV-2. The amino acid conservation is of a periodic nature, suggesting some conservation of structure and/or function. Therefore, one possible class of amino acid substitutions would include those amino acid changes which are predicted to stabilize the structure of the DP107 peptides of the invention. Utilizing the DP107 and DP107 analog sequences described herein, the skilled artisan can readily compile DP107 consensus sequences and ascertain from these, conserved amino acid residues which would represent preferred amino acid substitutions.

The amino acid substitutions may be of a conserved or non-conserved nature. Conserved amino acid substitutions consist of replacing one or more amino acids of the DP107 peptide sequence with amino acids of similar charge, size, and/or hydrophobicity characteristics, such as, for example, a glutamic acid (E) to aspartic acid (D) amino acid substitution. Non-conserved substitutions consist of replacing one or more amino acids of the DP107 (SEQ ID:25) peptide sequence with amino acids possessing dissimilar charge, size, and/or hydrophobicity characteristics, such as, for example, a glutamic acid (E) to valine (V) substitution.

Amino acid insertions may consist of single amino acid residues or stretches of residues. The insertions may be made at the carboxy or amino terminal end of the DP107 or DP107 truncated peptides, as well as at a position internal to the peptide. Such insertions will generally range from 2 to 15 amino acids in length. It is contemplated that insertions made at either the carboxy or amino terminus of the peptide of interest may be of a broader size range, with about 2 to about 50 amino acids being preferred. One or more such insertions may be introduced into DP107 or DP107 truncations, as long as such insertions result in peptides which may still be recognized by the 107.times.178.times.4, ALLMOTI5 or PLZIP search motifs described herein, or may, alternatively, exhibit antifusogenic or antiviral activity, or exhibit the ability to modulate intracellular processes involving coiled-coil peptide structures.

Preferred amino or carboxy terminal insertions are peptides ranging from about 2 to about 50 amino acid residues in length, corresponding to gp41 protein regions either amino to or carboxy to the actual DP107 gp41 amino acid sequence, respectively. Thus, a preferred amino terminal or carboxy terminal amino acid insertion would contain gp41 amino acid sequences found immediately amino to or carboxy to the DP107 region of the gp41 protein.

Deletions of DP107 or DP178 truncations are also within the scope of the invention. Such deletions consist of the removal of one or more amino acids from the DP107 or DP107-like peptide sequence, with the lower limit length of the resulting peptide sequence being 4 to 6 amino acids. Such deletions may involve a single contiguous or greater than one discrete portion of the peptide sequences One or more such deletions may be introduced into DP107 or DP107 truncations, as long as such deletions result in peptides which may still be recognized by the 107.times.178.times.4, ALLMOTI5 or PLZIP search motifs described herein, or may, alternatively, exhibit antifusogenic or antiviral activity, or exhibit the ability to is modulate intracellular processes involving coiled-coil peptide structures.

DP107 and DP107 truncations are more fully described in Applicants' co-pending U.S. patent application Ser. No. 08/374,666, filed Jan. 27, 1995, and which is incorporated herein by reference in its entirety. DP107 analogs are further described, below, in Section 5.3.

Peptides corresponding to analogs of the DP178, DP178 truncations, DP107 and DP107 truncation sequences of the invention, described, above, in Sections 5.1 and 5.2 may be found in other viruses, including, for example, non-HIV-1.sub.LAI enveloped viruses, non-enveloped viruses and other non-viral organisms.

The term "analog", as used herein, refers to a peptide which is recognized or identified via the 107.times.178.times.4, ALLMOTI5 and/or PLZIP search strategies discussed below. Further, such peptides may exhibit antifusogenic capability, antiviral activity, or the ability to modulate intracellular processes involving coiled-coil structures.

Such DP178 and DP107 analogs may, for example, correspond to peptide sequences present in TM proteins of enveloped viruses and may, additionally correspond to peptide sequences present in non enveloped and non-viral organisms. Such peptides may exhibit antifusogenic activity, antiviral activity, most particularly antiviral activity which is specific to the virus in which their native sequences are found, or may exhibit an ability to modulate intracellular processes involving coiled-coil peptide structures.

DP178 analogs are peptides whose amino acid sequences are comprised of the amino acid sequences of peptide regions of, for example, other (i.e., other is than HIV-1.sub.LAI) viruses that correspond to the gp41 peptide region from which DP178 (SEQ ID:1) was derived. Such viruses may include, but are not limited to, other HIV-1 isolates and HIV-2 isolates. DP178 analogs derived from the corresponding gp41 peptide region of other (i.e., non HIV-1.sub.LAI) HIV-1 isolates may include, for example, peptide sequences as shown below.

NH.sub.2 -YTNTIYTLLEESQNQQEKNEQELLELDKWASLWNWF-COOH (DP-185; SEQ ID:3);

NH.sub.2 -YTGIIYNLLEESQNQQEKNEQELLELDKWANLWNWF-COOH (SEQ ID:4);

NH.sub.2 -YTSLIYSLLEKSQIQQEKNEQELLELDKWASLWNWF-COOH (SEQ ID:5).

SEQ ID:3 (DP-185), SEQ ID:4, and SEQ ID:5 are derived from HIV-1.sub.SF2, HIV-1.sub.RF, and HIV-1.sub.MN isolates, respectively. Underlined amino acid residues refer to those residues that differ from the corresponding position in the DP178 (SEQ ID:1) peptide. One such DP178 analog, DP-185 (SEQ ID:3), is described in the Example presented in Section 6, below, where it is demonstrated that DP-185 (SEQ ID:3) exhibits antiviral activity. The DP178 analogs of the invention may also include truncations, as described above. Further, the analogs of the invention modifications such those described for DP178 analogs in Section 5.1., above. It is preferred that the DP178 analogs of the invention represent peptides whose amino acid sequences correspond to the DP178 region of the gp41 protein, it is also contemplated that the peptides of the invention may, additionally, include amino sequences, ranging from about 2 to about 50 amino acid residues in length, corresponding to gp41 protein regions either amino to or carboxy to the actual DP178 is amino acid sequence.

Striking similarities, as shown in FIG. 1, exist within the regions of HIV-1 and HIV-2 isolates which correspond to the DP178 sequence. A DP178 analog derived from the HIV-2.sub.NHZ isolate has the 36 amino acid sequence (reading from amino to carboxy terminus):

NH.sub.2 -LEANISQSLEQAQIQQEKNMYELQKLNSWDVFTNWL-COOH (SEQ ID:7)

Table III and Table IV show some possible truncations of the HIV-2.sub.NHZ DP178 analog, which may comprise peptides of between 3 and 36 amino acid residues (i.e., peptides ranging in size from a tripeptide to a 36-mer polypeptide). Peptide sequences in these tables are listed from amino (left) to carboxy (right) terminus. "X" may represent an amino group (--NH.sub.2) and "Z" may represent a carboxyl (--COOH) group. Alternatively, "X" may represent a hydrophobic group, including but not limited to carbobenzyl, dansyl, or T-butoxycarbonyl; an acetyl group; a 9-fluorenylmethoxy-carbonyl (FMOC) group; or a covalently attached macromolecular group, including but not limited to a lipid-fatty acid conjugate, polyethylene glycol, carbohydrate or peptide group. Further, "Z" may represent an amido group; a T-butoxycarbonyl group; or a covalently attached macromolecular group, including but not limited to a lipid-fatty acid conjugate, polyethylene glycol, carbohydrate or peptide group. A preferred "X" or "Z" macromolecular group is a peptide group.

DP178 and DP107 analogs are recognized or identified, for example, by utilizing one or more of the 107.times.178.times.4, ALLMOTI5 or PLZIP computer-assisted search strategies described and demonstrated, below, in the Examples presented in Sections 9 through 16 and 19 through 25. The search strategy identifies additional peptide regions which are predicted to have structural and/or amino acid sequence features similar to those of DP107 and/or DP178.

The search strategies are described fully, below, in the Example presented in Section 9. While this search strategy is based, in part, on a primary amino acid motif deduced from DP107 and DP178, it is not based solely on searching for primary amino acid sequence homologies, as such protein sequence homologies exist within, but not between major groups of viruses. For example, primary amino acid sequence homology is high within the TM protein of different strains of HIV-1 or within the TM protein of different isolates of simian immunodeficiency virus (SIV). Primary amino acid sequence homology between HIV-1 and SIV, however, is low enough so as not to be useful. It is not possible, therefore, to find peptide regions similar to DP107 or DP178 within other viruses, or within non-viral organisms, whether structurally, or otherwise, based on primary sequence homology, alone.

Further, while it would be potentially useful to identify primary sequence arrangements of amino acids based on, for example, the physical chemical characteristics of different classes of amino acids rather than based on the specific amino acids themselves, such search strategies have, until now, proven inadequate. For example, a computer algorithm designed by Lupas et al. to identify coiled-coil propensities of regions within proteins (Lupas, A., et al., 1991 Science 252:1162-1164) is inadequate for identifying protein regions analogous to DP107 or DP178.

Specifically, analysis of HIV-1 gp160 (containing both gp120 and gp41) using the Lupas algorithm does not identify the coiled-coil region within DP107. It does, however, identify a region within DP178 beginning eight amino acids N-terminal to the start of DP178 and ending eight amino acids from the C-terminus. The DP107 peptide has been shown experimentally to form a stable coiled coil. A search based on the Lupas search algorithm, therefore, would not have identified the DP107 coiled-coil region. Conversely, the Lupas algorithm identified the DP178 region as a potential coiled-coil motif. However, the peptide derived from the DP178 region failed to form a coiled coil in solution.

A possible explanation for the inability of the Lupas search algorithm to accurately identify coiled-coil sequences within the HIV-1 TM, is that the Lupas algorithm is based on the structure of coiled coils from proteins that are not structurally or functionally similar to the TM proteins of viruses, antiviral peptides (e.g. DP107 and DP178) of which are an object of this invention.

The computer search strategy of the invention, as demonstrated in the Examples presented below, in Sections 9 through 16 and 19 through 25, successfully identifies regions of proteins similar to DP107 or DP178. This search strategy was designed to be used with a commercially-available sequence database package, preferably PC/Gene.

A series of search motifs, the 107.times.178.times.4, ALLMOTI5 and PLZIP motifs, were designed and engineered to range in stringency from strict to broad, as discussed in this Section and in Section 9, with 107.times.178.times.4 being preferred. The sequences identified via such search motifs, such as those listed in Tables V-XIV, below, potentially exhibit antifusogenic, such as antiviral, activity, may additionally be useful in the identification of antifusogenic, such as antiviral, compounds, and are intended to be within the scope of the invention.

Coiled-coiled sequences are thought to consist of heptad amino acid repeats. For ease of description, the amino acid positions within the heptad repeats are sometimes referred to as A through G, with the first position being A, the second B, etc. The motifs used to identify DP107-like and DP178-like sequences herein are designed to specifically search for and identify such heptad repeats. In the descriptions of each of the motifs described, below, amino acids enclosed by brackets , i.e., [ ], designate the only amino acid residues that are acceptable at the given position, while amino acids enclosed by braces, i.e., { }, designate the only amino acids which are unacceptable at the given heptad position. When a set of bracketed or braced amino acids is followed by a number in parentheses i.e., (), it refers to the number of subsequent amino acid positions for which the designated set of amino acids hold, e.g, a (2) means "for the next two heptad amino acid positions".

The ALLMOTI5 is written as follows:

{CDGHP}-{CFP} (2)-{CDGHP}-{CFP} (3)-

{CDGHP}-{CFP} (2)-{CDGHP}-{CFP} (3)-

{CDGHP}-{CFP} (2)-{CDGHP}-{CFP} (3)-

{CDGHP}-{CFP} (2)-{CDGHP}-{CFP} (3)-

{CDGHP}-{CFP} (2)-{CDGHP}-{CFP} (3)-

Translating this motif, it would read: "at the first (A) position of the heptad, any amino acid residue except C, D, G, H, or P is acceptable, at the next two (B,C) amino acid positions, any amino acid residue except C, F, or P is acceptable, at the fourth heptad position (D), any amino acid residue except C, D, G, H, or P is acceptable, at the next three (E, F, G) amino acid positions, any amino acid residue except C, F, or P is acceptable. This motif is designed to search for five consecutive heptad repeats (thus the repeat of the first line five times), meaning that it searches for 35-mer sized peptides. It may also be designed to search for 28-mers, by only repeating the initial motif four times. With respect to the ALLMOTI5 motif, a 35-mer search is preferred. Those viral (non-bacteriophage) sequences identified via such an ALLMOTI5 motif are listed in Table V, below, at the end of this Section. The viral sequences listed in Table V potentially exhibit antiviral activity, may be useful in the the identification of antiviral compounds, and are intended to be within the scope of the invention. In those instances wherein a single gene exhibits greater than one sequence recognized by the ALLMOTI5 search motif, the amino acid residue numbers of these sequences are listed under "Area 2", Area 3", etc. This convention is used for each of the Tables listed, below, at the end of this Section.

The 107.times.178.times.4 motif is written as follows:

[EFIKLNQSTVWY]-{CFMP} (2)-[EFIKLNQSTVWY]-{CFMP} (3)-

[EFIKLNQSTVWY]-{CFMP} (2)-[EFIKLNQSTVWY]-{CFMP} (3)-

[EFIKLNQSTVWY]-{CFMP} (2)-[EFIKLNQSTVWY]-{CFMP} (3)-

[EFIKLNQSTVWY]-{CFMP} (2)-[EFIKLNQSTVWY]-{CFMP} (3)-

Translating this motif, it would read: "at the first (A) position of the heptad, only amino acid residue E, F, I, K, L, N, Q, S, T, V, W, or Y is acceptable, at the next two (B,C) amino acid positions, any amino acid residue except C, F, M or P is acceptable, at the fourth position (D), only amino acid residue E, F, I, K, L, N, Q, S, T, V, W, or Y is acceptable, at the next three (E, F, G) amino acid positions, any amino acid residue except C, F, M or P is acceptable. This motif is designed to search for four consecutive heptad repeats (thus the repeat of the first line four times), meaning that it searches for 28-mer sized peptides. It may also be designed to search for 35-mers, by repeating the initial motif five times. With respect to the 107.times.178.times.4 motif, a 28-mer search is preferred.

Those viral (non-bacteriophage) sequences identified via such a 107.times.178.times.4 motif are listed in Table VI, below, at the end of this Section, with those viral (non-bacteriophage) sequences listed in Table VII, below at the end of this Section, being preferred.

The 107.times.178.times.4 search motif was also utilized to identify non-viral procaryotic protein sequences, as listed in Table VIII, below, at the end of this Section. Further, this search motif was used to reveal a number of human proteins. The results of this human protein 107.times.178.times.4 search is listed in Table IX, below, at the end of this Section. The sequences listed in Tables VIII and IX, therefore, reveal peptides which may be useful as antifusogenic compounds or in the identification of antifusogenic compounds, and are intended to be within the scope of the invention.

The PLZIP series of motifs are as listed in FIG. 19. These motifs are designed to identify leucine zipper coiled-coil like heptads wherein at least one proline residue is present at some predefined distance N-terminal to the repeat. These PLZIP motifs find regions of proteins with similarities to HIV-1 DP178 generally located just N-terminal to the transmembrane anchor. These motifs may be translated according to the same convention described above. Each line depicted in FIG. 19 represents a single, complete search motif. "X" in these motifs refers to any amino acid residue. In instances wherein a motif contains two numbers within parentheses, this refers to a variable number of amino acid residues. For example, X (1,12) is translated to "the next one to twelve amino acid residues, inclusive, may be any amino acid".

Tables X through XIV, below, at the end of this Section, list sequences identified via searches conducted with such PLZIP motifs. Specifically, Table X lists viral sequences identified via PCTLZIP, P1CTLZIP and P2CTLZIP search motifs, Table XI lists viral sequences identified via P3CTLZIP, P4CTLZIP, P5CTLZIP and P6CTLZIP search motifs, Table XII lsts viral sequences identified via P7CTLZIP, P8CTLZIP and P9CTLZIP search motifs, Table XIII lists viral sequences identified via P12LZIPC searches and Table XIV lists viral sequences identified via P23TLZIPC search motifs. The viral sequences listed in these tables represent peptides which potentially exhibit antiviral activity, may be useful in the identification of antiviral compounds, and are intended to be within the scope of the invention.

The Examples presented in Sections 17, 18, 26 and 27 below, demonstrate that viral sequences identified via the motif searches described herein identify substantial antiviral characteristics. Specifically, the Example presented in Section 17 describes peptides with anti-respiratory syncytial virus activity, the Example presented in Section 18 describes peptides with anti-parainfluenza virus activity, the Example presented in Section 26 describes peptides with anti-measles virus activity and the Example presented in Section 27 describes peptides with anti-simian immunodeficiency virus activity.

The DP107 and DP178 analogs may, further, contain any of the additional groups described for DP178, above, in Section 5.1. For example, these peptides may include any of the additional amino-terminal groups as described above for "X" groups, and may also include any of the carboxy-terminal groups as described, above, for "Z" groups.

Additionally, truncations of the identified DP107 and DP178 peptides are among the peptides of the invention. Further, such DP107 and DP178 analogs and DP107/DP178 analog truncations may exhibit one or more amino acid substitutions, insertion, and/or deletions. The DP178 analog amino acid substitutions, insertions and deletions, are as described, above, for DP178-like peptides in Section 5.1. The DP-107 analog amino acid substitutions, insertions and deletions are also as described, above, for DP107-like peptides in Section 5.2.

Tables XV through XXII, below, present representative examples of such DP107/DP178 truncations. Specifically, Table XV presents Respiratory Syncytial Virus F1 region DP107 analog carboxy truncations, Table XVI presents Respiratory Syncytial Virus F1 region DP107 analog amino truncations, Table XVII presents Respiratory Syncytial Virus F1 region DP178 analog carboxy truncations, Table XVIII presents Respiratory Syncytial Virus F1 region DP178 analog amino truncations, Table XIX presents Human Parainfluenza Virus 3 F1 region DP178 analog carboxy truncations, Table XX presents Human Parainfluenza Virus 3 F1 region DP178 analog amino truncations, Table XXI presents Human Parainfluenza Virus 3 F1 region DP107 analog carboxy truncations and Table XXII presents Human Parainfluenza Virus 3 F1 region DP107 analog amino truncations. Further, Table XXIII, below, presents DP107/DP178 analogs and analog truncations which exhibit substantial antiviral activity. These antiviral peptides are grouped according to the specific virus which they inhibit, including respiratory syncytial virus, human parainfluenza virus 3, simian immunodeficiency virus and measles virus. - ALLMOTI5 SEARCH RESULTS SUMMARY FOR ALL VIRAL (NON-BACTERIOPHAGE) PROTEINS PCGENE ALMOTIS All Viruses (no bacteriophages) FILENAME PROTEIN VIRUS AREA 1 AREA 2 AREA 3 AREA 4 AREA 5 AREA 6 AREA 7 AREA 8 P170K.sub.-- TRVPS POTENTIAL 170 KD PROTEIN TOBACCO RATTLE VIRUS (STRAIN PSG) 113-153 P194K.sub.-- TRVSY POTENTIAL 194 KD PROTEIN TOBACCO RATTLE VIRUS (STRAIN SYM 144-178 214-248 391-446 644-678 1045- 1135- 1335- 1618- 1079 1176 1376 1658 P55KD.sub.-- HSV6U 55.8 KD PROTEIN HERPES SIMPLEX VIRUS (TYPE 6/STRAIN 228-262 UGANDA-1102) PAANT.sub.-- HDVAM DELTA ANTIGEN HEPATITIS DELTA VIRUS (ISOLATE AMERICAN) 3-48 100-144 PAANT.sub .-- HDVD3 DELTA ANTIGEN HEPATITIS DELTA VIRUS (ISOLATE D380) 7-48 100-144 PAANT.sub.-- HDVIT DELTA ANTIGEN(ALPHA ANTIGEN) HEPATITIS DELTA VIRUS (ISOLATE ITALIAN) 3-48 100-144 PAANT.sub.-- HDVL1 DELTA ANTIGEN HEPATITIS DELTA VIRUS (ISOLATE LEBANON-1) 3-48 PAANT.sub.-- HDVM1 DELTA ANTIGEN HEPATITIS DELTA VIRUS (ISOLATE JAPANESE M-1) 3-48 100-144 PAANT.sub.-- HDVM2 DELTA ANTIGEN HEPATITIS DELTA VIRUS (ISOLATE JAPANESE M-2) 3-48 100-144 PAANT.sub.-- HDVNA DELTA ANTIGEN HEPATITIS DELTA VIRUS (ISOLATE NAURU) 3-48 100-144 PAANT.sub.-- HDVS1 DELTA ANTIGEN HEPATITIS DELTA VIRUS (ISOLATE JAPANESE S-1) 1-49 100-144 PAANT.sub.-- HDVS2 DELTA ANTIGEN HEPATITIS DELTA VIRUS (ISOLATE JAPANESE S-2) 1-49 100-144 PAANT.sub.-- HDVWO DELTA ANTIGEN HEPATITIS DELTA VIRUS (ISOLATE WOODCHUCK) 3-48 100-144 PAT3H.sub.-- FOWPM ANTITHROMBIN-III HOMOLOG FOWLPOX VIRUS (ISOLATE HP-438) 71-11 PATI1.sub.-- VACCV 94 KD A-TYPE INCLUSION PROTEIN VACCINIA VIRUS (STRAIN WR) 14-57 420-564 570-625 PATI1.sub.-- VARV 81 KD A-TYPE INCLUSION PROTEIN VARIOLA VIRUS 425-525 531-565 571-628 PATI2.sub.-- HSVII ALPHA TRANS-INDUCING FACTOR HERPES SIMPLEX VIRUS (TYPE 1) 304-345 PATI2.sub.-- HSVIF ALPHA TRANS-INDUCING FACTOR HERPES SIMPLEX VIRUS (TYPE 1) 102-139 304-345 PATI2.sub.-- HSVEB ALPHA TRANS-INDUCING FACTOR EQUINE HERPES VIRUS TYPE 1 (STRAIN AB4P) 101-147 268-331 PATI2.sub.-- VACCC PUTATIVE A-TYPE INCLUSION PROTEIN VACCINIA VIRUS (STRAIN COPENHAGEN) 79-124 219-263 PATI2.sub.-- VACCV PUTATIVE A-TYPE INCLUSION PROTEIN VACCINIA VIRUS 79-124 PATI2.sub.-- VZVD ALPHA TRANS-INDUCING FACTOR VARICELLA-ZOSTER VIRUS (STRAIN DUMAS) 298-361 395-429 PATI3.sub.-- VACCV PUTATIVE A-TYPE INCLUSION PROTEIN VACCINIA VIRUS 51-95 PATIN.sub.-- HSV23 ALPHA TRANS-INDUCING PROTEIN HERPES SIMPLEX VIRUS (TYPE 2) 178-219 224-381 (VMW65) PATIN.sub.-- HSV2H ALPHA TRANS-INDUCING PROTEIN HERPES SIMPLEX VIRUS (TYPE 2) 177-222 324-381 (VMW65) PATIN.sub.-- HSVBP ALPHA TRANS-INDUCING PROTEIN BOVINE HERPES VIRUS TYPE 1 195-256 PATIN.sub.-- HSVEB ALPHA TRANS-INDUCING PROTEIN EQUINE HERPES VIRUS TYPE 1 241-289 PATIN.sub.-- VZVD ALPHA TRANS-INDUCING PROTEIN( VARICELLA-ZOSTER VIRUS (STRAIN DUMAS) 206-252 PATI.sub.-- COWPX A-TYPE INCLUSION PROTEIN COWPOX VIRUS 14-57 426-526 532-566 572-629 803-959 1106- 1150 PBDL2.sub.-- EBV PROTEIN BDLF2 EPSTEIN-BARR VIRUS (STRAIN B95-8) 90-131 PBRL1.sub.-- EBV TRANSCRIPTION ACTIVATOR BRLF1 EPSTEIN-BARR VIRUS (STRAIN B95-8) 150-187 PCOA1.sub.-- POVBA COAT PROTEIN VPI POLYOMAVIRUS BK 107-144 PCOA1.sub.-- POVBK COAT PROTEIN VP1 POLYOMAVIRUS BK 107-141 PCOA1.sub.-- POVHA COAT PROTEIN VP1 HAMSTER POLYOMAVIRUS 159-195 PCOA1.sub.-- SV40 COAT PROTEIN VP1 SIMIAN VIRUS 40 109-143 PCOA2.sub.-- BFDV COAT PROTEIN VP2 BUDGERIGAR FLEDGLING DISEASE VIRUS 141-213 PCOA2.sub.-- POVBA COAT PROTEIN VP2 POLYOMAVIRUS BK (STRAIN AS) 14-64 317-315 PCOA2.sub.-- PDVBK COAT PROTEIN VP2 POLYOMAVIRUS BK 14-64 317-351 PCOA2.sub.-- POVBO COAT PROTEIN VP2 BOVINE POLYOMAVIRUS 35-76 153-216 PCOA2.sub.-- POVHA COAT PROTEIN VP2 HAMSTER POLYOMAVIRUS 7-48 174-288 PCOA2.sub.-- POVJC COAT PROTEIN VP2 POLYOMAVIRUS JC 14-64 233-267 PCOA2.sub.-- POVLY COAT PROTEIN VP2 LYMPHOTROPIC POLYOMAVIRUS 14-78 156-206 PCOA2.sub.-- POVM3 COAT PROTEIN VP2 MOUSE POLYOMAVIRUS (STRAIN 3) 5-72 137-185 PCOA2.sub.-- POVMA COAT PROTEIN VP2 MOUSE POLYOMAVIRUS 5-72 137-185 PCOA2.sub.-- POVMC COAT PROTEIN VP2 MOUSE POLYOMAVIRUS 5-72 137-185 PCOA2.sub.-- POVMK COAT PROTEIN VP2 MOUSE POLYOMAVIRUS 15-56 177-211 PCDA2.sub.-- SV40 COAT PROTEIN VP2 SIMIAN VIRUS 40 14-62 228-262 318-352 PCOAT.sub.-- ABMVW COAT PROTEIN VP2 ABUTILON MOSAIC VIRUS (ISOLATE WEST INDIA 180-214 PCOAT.sub.-- ACLSV COAT PROTEIN APPLE CHLOROTIC LEAF SPOT VIRUS 154-188 PCOAT.sub.-- AEDEV COAT PROTEIN VP1 AEDES DENSONUCLEOSIS VIRUS 243-284 PCOAT.sub.-- AMCV COAT PROTEIN ARTICHOKE MOTTLED CRINKLE VIRUS 36-70 100-134 PCOAT.sub.-- BLRV COAT PROTEIN BEAN LEAFROLL VIRUS 89-123 PCOAT.sub.-- BMV COAT PROTEIN BROME MOSAIC VIRUS 36-73 PCOAT.sub.-- BYDV1 COAT PROTEIN BARLEY YELLOW DWARF VIRUS 163-197 PCOAT.sub.-- BYDVM COAT PROTEIN BARLEY YELLOW DWARF VIRUS 163-197 PCOAT.sub.-- BYDVP COAT PROTEIN BARLEY YELLOW DWARF VIRUS 164-198 PCOAT.sub.-- BYDVR COAT PROTEIN BARLEY YELLOW DWARF VIRUS 164-198 PCOAT.sub.-- CAMVC COAT PROTEIN CAULIFLOWER MOSAIC VIRUS (STRAIN 56-90 186-223 PCOAT.sub.-- CAMVD COAT PROTEIN CAULIFLOWER MOSAIC VIRUS 53-91 187-224 PCOAT.sub.-- CAMVE COAT PROTEIN CAULIFLOWER MOSAIC VIRUS 56-90 186-223 PCOAT.sub.-- CAMVN COAT PROTEIN CAULIFLOWER MOSAIC VIRUS 56-90 185-222 PCOAT.sub.-- CAMVS COAT PROTEIN CAULIFLOWER MOSAIC VIRUS 53-91 187-224 PCOAT.sub.-- CARMV COAT PROTEIN CARNATION MOTTLE VIRUS 13-51 PCOAT.sub.-- CCMV COAT PROTEIN COWPEA CHLOROTIC MOTTLE VIRUS 141-178 PCOAT.sub.-- CERV PROBABLE COAT PROTEIN CARNATION ETCHED RING VIRUS 192-226 PCOAT.sub.-- CHVP1 MAJOR CAPSID PROTEIN PARAMECIUM BURSARIA CHLORELLA VIRUS 1 393-435 PCOAT.sub.-- CLVK COAT PROTEIN CASSAVA LATENT VIRUS 197-231 PCOAT.sub.-- CLVN COAT PROTEIN CASSAVA LATENT VIRUS 197-231 PCOAT.sub.-- CMVPC COAT PROTEIN CUCUMBER MOSAIC VIRUS 153-187 PCOAT.sub.-- CMVI COAT PROTEIN CUCUMBER MOSAIC VIRUS 153-187 PCOAT.sub.-- CMVP6 COAT PROTEIN CUCUMBER MOSAIC VIRUS 153-187 PCOAT.sub.-- CMVQ COAT PROTEIN CUCUMBER MOSAIC VIRUS 153-187 PCOAT.sub.-- CMVWL COAT PROTEIN CUCUMBER MOSAIC VIRUS 153-187 PCOAT.sub.-- CMVY COAT PROTEIN CUCUMBER MOSAIC VIRUS 153-187 PCOAT.sub.-- CNV COAT PROTEIN CUCUMBER NECROSIS VIRUS 328-365 PCOAT.sub.-- CSMV COAT PROTEIN CHLORIS STRIATE MOSAIC VIRUS 184-218 PCOAT.sub.-- CTV36 COAT PROTEIN CITRUS TRISTEZA VIRUS 79-120 PCOAT.sub.-- CYMV COAT PROTEIN CLOVER YELLOW MOSAIC VIRUS 162-204 PCOAT.sub.-- EPMV COAT PROTEIN EGGPLANT MOSAIC VIRUS 40-74 PCOAT.sub.-- FCVC6 COAT PROTEIN FELINE CALICIVIRUS 432-466 566-600 PCOAT.sub.-- FCVP4 COAT PROTEIN FELINE CALICIVIRUS 502-550 566-600 PCOAT.sub.-- FCVF9 COAT PROTEIN FELINE CALICIVIRUS 519-553 569-603 PCOAT.sub.-- FMVD PROBABLE COAT PROTEIN FIGWORT MOSAIC VIRUS 144-199 206-247 449-483 PCOAT.sub.-- FXMV COAT PROTEIN FOXTAIL MOSAIC VIRUS 168-220 PCOAT.sub.-- IRV1 CAPSID PROTEIN TIPULA IRIDESCENT VIRUS 90-124 PCOAT.sub.-- IRV22 CAPSID PROTEIN SIMULIUM IRIDESCENT VIRUS 90-124 PCOAT.sub.-- IRV6 CAPSID PROTEIN CHILO IRIDESCENT VIRUS 51-85 PCOAT.sub.-- LSV COAT PROTEIN LILY SYMPTOMLESS VIRUS 32-70 255-289 PCOAT.sub.-- MSTV COAT PROTEIN MAIZE STRIPE VIRUS 7-76 84-121 PCOAT.sub.-- MSVK COAT PROTEIN MAIZE STREAK VIRUS 187-221 PCOAT.sub.-- MSVN COAT PROTEIN MAIZE STREAK VIRUS 187-222 PCOAT.sub.-- MSVS COAT PROTEIN MAIZE STREAK VIRUS 187-221 PCOAT.sub.-- ORSV COAT PROTEIN ODONTOGLOSSUM RINGSPOT VIRUS 105-139 PCOAT.sub.-- PAVBO COAT PROTEIN VP2 BOVINE PARVOVIRUS 380-414 444-480 PCOAT.sub.-- PAVC7 COAT PROTEIN VP1 CANINE PARVOVIRUS 497-531 PCOAT.sub.-- PEBV COAT PROTEIN PEA EARLY BROWNING VIRUS 73-114 PCOAT.sub.-- POPMV COAT PROTEIN POPLAR MOSAIC VIRUS 36-81 PCOAT.sub.-- PMVS COAT PROTEIN PEPPER MILD MOTTLE VIRUS 104-138 PCOAT.sub.-- PVSP COAT PROTEIN POTATO VIRUS 39-72 251-292 PCOAT.sub.-- PYMVV COAT PROTEIN POTATO YELLOW MOSAIC VIRUS 190-224 PCOAT.sub.-- RBDV COAT PROTEIN RASPBERRY BUSHY DWARF VIRUS 10-44 140-199 PCOAT.sub.-- RCNMV COAT PROTEIN RED CLOVER NECROTIC MOSAIC VIRUS 272-306 PCOAT.sub.-- RSV COAT PROTEIN RICE STRIPE VIRUS 34-68 83-120 259-309 PCOAT.sub.-- SLCV COAT PROTEIN SQUASH LEAF CURL VIRUS 190-224 PCOAT.sub.-- SMWLM COAT PROTEIN SATELLITE MAIZE WHITE LINE MOSAIC VIRUS 66-100 PCOAT.sub.-- SOCMV COAT PROTEIN SOYBEAN CHLOROTIC MOTTLE VIRUS 128-166 PCOAT.sub.-- STNV1 COAT PROTEIN SATELLITE TOBACCO NECROSIS VIRUS 1 2-50 PCOAT.sub.-- STNV2 COAT PROTEIN SATELLITE TOBACCO NECROSIS VIRUS 2 38-72 PCOAT.sub.-- TAMV GENOME POLYPROTEIN TAMARILLO MOSAIC VIRUS 7-55 PCOAT.sub.-- TAV COAT PROTEIN TOMATO ASPERMY VIRUS 14-48 PCOAT.sub.-- TBSVB COAT PROTEIN TOMATO BUSHY STUNT VIRUS 1-37 43-77 PCOAT.sub.-- TBSVC COAT PROTEIN TOMATO BUSHY STUNT VIRUS 44-78 100-134 PCOAT.sub.-- TCV COAT PROTEIN TURNIP CRINKLE VIRUS 12-46 PCOAT.sub.-- TGMV COAT PROTEIN TOMATO GOLDEN MOSAIC VIRUS 186-220 PCOAT.sub.-- TMGMV COAT PROTEIN TOBACCO MILD GREEN MOSAIC VIRUS 103-137 PCOAT.sub.-- TMV COAT PROTEIN TOBACCO MOSAIC VIRUS 103-137 PCOAT.sub.-- TMV06 COAT PROTEIN TOBACCO MOSAIC VIRUS 103-137 PCOAT.sub.-- TMVCO COAT PROTEIN TOBACCO MOSAIC VIRUS 76-138 PCOAT.sub.-- TMVDA COAT PROTEIN TOBACCO MOSAIC VIRUS 103-137 PCOAT.sub.-- TMVER COAT PROTEIN TOBACCO MOSAIC VIRUS 103-137 PCOAT.sub.-- TMVHR COAT PROTEIN TOBACCO MOSAIC VIRUS 103-137 PCOAT.sub.-- TMVO COAT PROTEIN TOBACCO MOSAIC VIRUS 103-137 PCOAT.sub.-- TMVOM COAT PROTEIN TOBACCO MOSAIC VIRUS 103-137 PCOAT.sub.-- TMVTO COAT PROTEIN TOBACCO MOSAIC VIRUS 103-137 PCOAT.sub.-- TRVCA COAT PROTEIN TOBACCO RATTLE VIRUS 71-109 PCOAT.sub.-- TRVTC COAT PROTEIN TOBACCO RATTLE VIRUS 69-103 PCOAT.sub.-- TYDVA COAT PROTEIN TOBACCO YELLOW DWARF VIRUS 2-36 PCOAT.sub.-- TYMV COAT PROTEIN TURNIP YELLOW MOSAIC VIRUS 41-75 PCOAT.sub.-- TYMVA COAT PROTEIN TURNIP YELLOW MOSAIC VIRUS 41-75 PCOAT.sub.-- WCMVO COAT PROTEIN WHITE CLOVER MOSAIC VIRUS 163-197 PCORA.sub.-- HPBGS CORE ANTIGEN GROUND SQUIRREL HEPATITIS VIRUS 94-135 PCORA.sub.-- HPBV9 CORE ANTIGEN HEPATITIS B VIRUS 111-149 PCORA.sub.-- WHV1 CORE ANTIGEN WOODCHUCK HEPATITIS VIRUS 1 62-106 PCORA.sub.-- WHV8 CORE ANTIGEN WOODCHUCK HEPATITIS VIRUS 8 62-186 PD250.sub.-- ASFB7 PROTEIN D250R AFRICAN SWINE FEVER VIRUS 198-232 PDNB2.sub.-- ADE02 EARLY E2A DNA-BINDING PROTEIN HUMAN ADENOVIRUS TYPE 2 291-336 PDNB2.sub.-- ADE05 EARLY E2A DNA-BINDING PROTEIN HUMAN ADENOVIRUS TYPE 5 291-336 PDNBI.sub.-- EBV MAJOR DNA-BINDING PROTEIN EPSTEIN-BARR VIRUS 215-252 718-752 974- 1027- 1009 1068 PDNBI.sub.-- HCMVA MAJOR DNA-BINDING PROTEIN HUMAN CYTOMEGALOVIRUS 338-372 1013- 1070 PDNBI.sub.-- HSV11 MAJOR DNA-BINDING PROTEIN HERPES SIMPLEX VIRUS 557-595 599-640 769-803 1079- 1140 PDNBI.sub.-- HSV1F MAJOR DNA-BINDING PROTEIN HERPES SIMPLEX VIRUS 557-595 599-640 769-803 1079- 1140 PDNBI.sub.-- HSVIK MAJOR DNA-BINDING PROTEIN HERPES SIMPLEX VIRUS 557-595 599-640 769-803 1079- 1140 PDNBI.sub.-- HSVB2 MAJOR DNA-BINDING PROTEIN BOVINE HERPES VIRUS TYPE 2 552-591 599-633 1048- 1131 PDNBI.sub.-- HVE1 MAJOR DNA-BINDING PROTEIN EQUINE HERPES VIRUS TYPE 1 273-314 PDNBI.sub.-- HSVEB MAJOR DNA-BINDING PROTEIN EQUINE HERPES VIRUS TYPE 1 617-658 1107- 1148 PDNBI.sub.-- HSVSA MAJOR DNA-BINDING PROTEIN HERPES VIRUS SAIMIRI 222-259 330-367 506-557 873-907 PDNBI.sub.-- MCMVS MAJOR DNA-BINDING PROTEIN MURINE CYTOMEGALOVIRUS 584-618 987- 1125 PDNBI.sub.-- SCMVC MAJOR DNA-BINDING PROTEIN SIMIAN CYTOMEGALOVIRUS 525-562 PDNBI.sub.-- VZVD MAJOR DNA-BINDING PROTEIN VARICELLA-ZOSTER VIRUS 613-658 1043- 1077 PDNLI.sub.-- ASFM2 DNA LIGASE AFRICAN SWINE FEVER VIRUS 72-106 PDNLI.sub.-- VACCC DNA LIGASE VACCINIA VIRUS 395-436 PDNLI.sub.-- VACCV DNA LIGASE VACCINIA VIRUS 395-436 PDNLI.sub.-- VARV DNA LIGASE VARIOLA VIRUS 395-436 PDPOL.sub.-- ADE02 DNA POLYMERASE HUMAN ADENOVIRUS TYPE 2 667-743 PDPOL.sub.-- ADE05 DNA POLYMERASE HUMAN ADENOVIRUS TYPE 5 667-743 PDPOL.sub.-- ADE07 DNA POLYMERASE HUMAN ADENOVIRUS TYPE 7 733-809 PDPOL.sub.-- ADE12 DNA POLYMERASE HUMAN ADENOVIRUS TYPE 12 665-741 PDPOL.sub.-- CBEPV DNA POLYMERASE CHORISTONEURA BIENNIS ENTOMOPOXVIRUS 23-64 202-240 PDPOL.sub.-- CHVN2 DNA POLYMERASE CHLORELLA VIRUS NY-2A 247-284 PDPOL.sub.-- CHVP1 DNA POLYMERASE PARAMECIUM BURSARIA CHLORELLA VIRUS 1 247-284 PDPOL.sub.-- FOWPV DNA POLYMERASE FOWLPOX VIRUS 17-51 18-114 371-412 PDPOL.sub.-- HCMVA DNA POLYMERASE HUMAN CYTOMEGALOVIRUS(STRAIN AD169) 753-787 1033- 1074 PDPOL.sub.-- HPBDB DNA POLYMERASE DUCK HEPATITIS B VIRUS 5-39 PDPOL.sub.-- HPBDC DNA POLYMERASE DUCK HEPATITIS B VIRUS (STRAIN CHINA) 5-39 PDPOL.sub.-- HPBDW DNA POLYMERASE DUCK HEPATITIS B VIRUS (WHITE SHANGHAI DUCK 5-39 297-338 ISOLATE S3 PDPOL.sub.-- HPBGS DNA POLYMERASE GROUND SQUIRREL HEPATITIS VIRUS 291-325 PDPOL.sub.-- HPBHE DNA POLYMERASE HERON HEPATITIS B VIRUS 5-39 224-265 557-595 PDPOL.sub.-- HPBVY DNA POLYMERASE HEPATITIS B VIRUS (SUBTYPE AYW) 201-235 PDPOL.sub.-- HPBVZ DNA POLYMERASE HEPATITIS B VIRUS (SUBTYPE ADYW) 201-235 PDPOL.sub.-- HSV11 DNA POLYMERASE HERPES SIMPLEX VIRUS (TYPE 1/STRAIN 17) 511-559 PDPOL.sub.-- HSV1A DNA POLYMERASE HERPES SIMPLEX VIRUS (TYPE 1/STRAIN ANGELOTTI 511-559 PDPOL.sub.-- HSV1K DNA POLYMERASE HERPES SIMPLEX VIRUS (TYPE 1/STRAIN KOS) 511-559 PDPOL.sub.-- HSV1S DNA POLYMERASE HERPES SIMPLEX VIRUS (TYPE 1/STRAIN SC16) 511-559 PDPOL.sub.-- HSV21 DNA POLYMERASE HERPES SIMPLEX VIRUS (TYPE 2/STRAIN 186) 512-560 PDPOL.sub.-- HSVEB DNA POLYMERASE EQUINE HERPES VIRUS TYPE 1 (STRAIN AB4P) 494-528 PDPOL.sub.-- HSV11 DNA POLYMERASE ICTALURID HERPES VIRUS 1 (CHANNEL 33-67 328-366 401-435 706-749 808-858 CATFISH VIRUS) PDPOL.sub.-- NPVAC DNA POLYMERASE AUTOGRAPHA CALIFORNICA NUCLEAR 595-646 POLYHEDROSIS VIRUS PDPOL.sub.-- VACCC DNA POLYMERASE VACCINIA VIRUS (STRAIN COPENHAGEN) 627-683 770-818 828-862 PDPOL.sub.-- VACCV DNA POLYMERASE VACCINIA VIRUS (STRAIN WR) 627-683 770-818 828-862 PDPOL.sub.-- VARV DNA POLYMERASE VARIOLA VIRUS 626-682 769-817 827-861 PDPOL.sub.-- VZVD DNA POLYMERASE VARICELLA-ZOSTER VIRUS (STRAIN DUMAS) 473-533 PDPOL.sub.-- WHV1 DNA POLYMERASE WOODCHUCK HEPATITIS VIRUS 1 285-326 PDPOL.sub.-- WHVS9 DNA POLYMERASE WOODCHUCK HEPATITIS VIRUS 59 290-331 PDPOL.sub.-- WHV7 DNA POLYMERASE WOODCHUCK HEPATITIS VIRUS 7 290-331 PDPOL.sub.-- WHV8 DNA POLYMERASE WOODCHUCK HEPATITIS VIRUS 8 289-330 PDPOL.sub.-- WHV81 DNA POLYMERASE WOODCHUCK HEPATITIS VIRUS 8 290-331 (INFECTIOUS CLONE) PDPOM.sub.-- HPBVY DNA POLYMERASE HEPATITIS B VIRUS (SUBTYPE AYW) 201-235 PDUT.sub.-- HSVEB DEOXYURIDINE 5'-TRIPHOSPHATE EQUINE HERPES VIRUS TYPE 1 (STRAIN AB4PP 135-169 NUCLEOTIDOHY PDUT.sub.-- HSVSA DEOXYURIDINE 5'-TRIPHOSPHATE HERPES VIRUS SAIMIRI (STRAIN 11) 179-223 NUCLEOTIDOHY PE1A.sub.-- ADE41 EARLY E1A 27 KD PROTEIN HUMAN ADENOVIRUS TYPE 41 107-141 PE1BL.sub.-- ADE40 E1B PROTEIN, LARGE T-ANTIGEN HUMAN ADENOVIRUS TYPE 40 102-166 PE1BS.sub.-- ADE02 E1B PROTEIN, SMALL T-ANTIGEN HUMAN ADENOVIRUS TYPE 2 103-137 PE1BS.sub.-- ADE05 E1B PROTEIN, SMALL T-ANTIGEN HUMAN ADENOVIRUS TYPE 5 103-137 PE1BS.sub.-- ADE12 E1B PROTEIN, SMALL T-ANTIGEN HUMAN ADENOVIRUS TYPE 12 96-131 PE1BS.sub.-- ADE40 E1B PROTEIN, SMALL T-ANTIGEN HUMAN ADENOVIRUS TYPE 40 100-134 PE1BS.sub.-- AD841 E1B PROTEIN, SMALL T-ANTIGEN HUMAN ADENOVIRUS TYPE 41 100-134 PE1BS.sub.-- ADEM1 E1B PROTEIN, SMALL T-ANTIGEN MOUSE ADENOVIRUS TYPE 1 119-173 PE314.sub.-- ADE02 EARLY E3B 14 KD PROTEIN HUMAN ADENOVIRUS TYPE 2 2-39 PE314.sub.-- ADE03 EARLY E3 15.3 KD PROTEIN HUMAN ADENOVIRUS TYPE 3 8-49 PE314.sub.-- ADE05 EARLY E3 14.5 KD PROTEIN HUMAN ADENOVIRUS TYPE 5 2-39 PE314.sub.-- ADE07 EARLY E3 15.3 KD PROTEIN HUMAN ADENOVIRUS TYPE 7 7-48 PE320.sub.-- ADE35 EARLY E3 20.3 KD GLYCOPROTEIN HUMAN ADENOVIRUS TYPE 35 70-107 PE321.sub.-- ADE35 EARLY E3 20.6 KD GLYCOPROTEIN HUMAN ADENOVIRUS TYPE 35 125-169 PE411.sub.-- ADE02 PROBABLE EARLY E4 11 KD PROTEIN HUMAN ADENOVIRUS TYPE 2 10-44 PE411.sub.-- ADE05 PROBABLE EARLY E4 11 KD PROTEIN HUMAN ADENOVIRUS TYPE 5 10-44 PEAR.sub.-- EBV EARLY ANTIGEN PROTEIN R EPSTEIN-BARR VIRUS (STRAIN B95-8) 123-157 PEBN4.sub.-- EBV EBNA-4 NUCLEAR PROTEIN EPSTEIN-BARR VIRUS (STRAIN B95-8) 487-521 PEFT1.sub.-- VARV EARLY TRANSCRIPTION FACTOR VARIOLA VIRUS 23-71 307-34 70 KD SUBUNIT PENV1.sub.-- FRSFV ENV POLYPROTEIN PRECURSOR FRIEND SPLEEN FOCUS-FORMING VIRUS 341-375 PENV2.sub.-- FRSFV ENV POLYPROTEIN PRECURSOR FRIEND SPLEEN FOCUS-FORMING VIRUS 341-378 PENV.sub.-- AVIRE ENV POLYPROTEIN AVIAN RETICULOENDOTHELIOSIS VIRUS 420-472 PENV.sub.-- AVISN ENV POLYPROTEIN AVIAN SPLEEN NECROSIS VIRUS 426-478 PENV.sub.-- BAEVM ENV POLYPROTEIN BABOON ENDOGENOUS VIRUS (STRAIN M7) 390-456 PENV.sub.-- BIV06 ENV POLYPROTEIN PRECURSOR BOVINE IMMUNODEFICIENCY VIRUS (ISOLATE 106) 10-44 88-122 221-255 530-610 635-691 PENV.sub.-- BIV27 ENV POLYPROTEIN PRECURSOR BOVINE IMMUNODEFICIENCY VIRUS (ISOLATE 127) 10-44 88-122 159-193 250-284 559-639 664-724 PENV.sub.-- BLVAF ENV POLYPROTEIN BOVINE LEUKEMIA VIRUS (AMERICAN ISOLATE 304-379 FLK) PENV.sub.-- BLVAU ENV POLYPROTEIN BOVINE LEUKEMIA VIRUS (AUSTRALIAN ISOLATE) 304-379 FENV.sub.-- BLVAV ENV POLYPROTEIN BOVINE LEUKEMIA VIRUS (AMERICAN 304-379 ISOLATE VDM) PENV.sub.-- BLVB2 ENV POLYPROTEIN BOVINE LEUKEMIA VIRUS (BELGIUM ISOLATE 304-379 LB285) PENV.sub.-- BLVB5 ENV POLYPROTEIN BOVINE LEUKEMIA VIRUS (BELGIUM ISOLATE 304-379 LB59) PENV.sub.-- BLVJ ENV POLYPROTEIN BOVINE LEUKEMIA VIRUS (JAPANESE ISOLATE 304-379 BLV-I) PENV.sub.-- CAEVC ENV POLYPROTEIN PRECURSOR CAPRINE ARTHRITIS ENCEPHALITIS VIRUS 157-196 615-720 751-785 847-895 (STRAIN CORK) PENV.sub.-- CAEVG ENV POLYPROTEIN PRECURSOR CAPRINE ARTHRITIS ENCEPHALITIS VIRUS 154-193 613-718 749-783 845-893 (STRAIN G63) PENV.sub.-- EIAV1 ENV POLYPROTEIN PRECURSOR EQUINE INFECTIOUS ANEMIA VIRUS (CLONE P3.2-1) 39-76 436-525 559-593 668-716 PENV.sub.-- EIAV2 ENV POLYPROTEIN PRECURSOR EQUINE INFECTIOUS ANEMIA VIRUS (CLONE P3.2-2) 39-76 436-525 559-593 658-692 PENV.sub.-- EIAV3 ENV POLYPROTEIN PRECURSOR EQUINE INFECTIOUS ANEMIA VIRUS (CLONE P3.2-3) 39-76 436-525 559-593 658-716 PENV.sub.-- EIAV5 ENV POLYPROTEIN PRECURSOR EQUINE INFECTIOUS ANEMIA VIRUS (CLONE P3.2-5) 38-76 437-526 560-594 659-693 PENV.sub.-- EIAV9 ENY POLYPROTEIN PRECURSOR EQUINE INFECTIOUS ANEMIA VIRUS (CLONE 1369) 39-76 436-525 559-593 658-716 PENV.sub.-- EIAVC ENV POLYPROTEIN PRECURSOR EQUINE INFECTIOUS ANEMIA VIRUS (CLONE CL22) 39-76 436-525 559-593 658-716 PENV.sub.-- EIAVW ENV POLYPROTEIN PRECURSOR EQUINE INFECTIOUS ANEMIA VIRUS (STRAIN WSU5) 39-76 436-525 559-593 658-716 PENV.sub.-- EIAVY ENV POLYPROTEIN PRECURSOR EQUINE INFECTIOUS ANEMIA VIRUS (ISOLATE 39-76 436-525 559-593 658-716 WYOMING) PENV.sub.-- FENV1 ENV POLYPROTEIN PRECURSOR FELINE ENDOGENOUS VIRUS ECE I 503-555 567-604 PENV.sub.-- FIVPE ENVELOPE POLYPROTEIN PRECURSOR FELINE IMMUNODEFICIENCY VIRUS (ISOLATE 610-690 715-756 PETALUMA) PENV.sub.-- FIVSD ENVELOPE POLYPROTEIN PRECURSOR FELINE IMMUNODEFICIENCY VIRUS (ISOLATE 601-688 713-754 SAN DIEGO) PENV.sub.-- FIVT2 ENVELOPE POLYPROTEIN PRECURSOR FELINE IMMUNODEFICIENCY VIRUS (ISOLATE TM2) 60-122 609-689 714-755 PENV.sub.-- FLVC6 ENY POLYPROTEIN PRECURSOR FELINE LEUKEMIA PROVIRUS (CLONE CFE-6) 497-549 561-595 PENV.sub.-- FLVGL ENV POLYPROTEIN PRECURSOR FELINE LEUKEMIA VIRUS (STRAIN A/GLASGOW-1) 478-530 542-576 PENV.sub.-- FLVLB ENV POLYPROTEIN PRECURSOR FELINE LEUKEMIA VIRUS (STRAIN LAMBDA-BI) 498-550 562-596 PENV.sub.-- FLVSA ENV POLYPROTEIN PRECURSOR FELINE LEUKEMIA VIRUS (STRAIN SARMA) 475-527 539-573 PENV.sub.-- FOAMV ENV POLYPROTEIN HUMAN SPUMARETROVIRUS 1-41 154-205 321-355 563-693 866-903 PENV.sub.-- FSVGA ENV POLYPROTEIN PRECURSOR FELINE SARCOMA VIRUS (STRAIN 498-550 562-596 GARDNER-ARNSTEIN) PENV.sub.-- FSVGB ENV POLYPROTEIN PRECURSOR FELINE SARCOMA VIRUS (STRAIN GA) 478-530 542-576 PENV.sub.-- FSVSM ENV POLYPROTEIN PRECURSOR FELINE SARCOMA VIRUS (STRAIN SM) 481-524 545-579 PENY.sub.-- FSVST ENV POLYPROTEIN PRECURSOR FELINE SARCOMA VIRUS (STRAIN SNYDER-THEILEN) 498-532 PENV.sub.-- GALV ENV POLYPROTEIN PRECURSOR GIBBON APE LEUKEMIA VIRUS 523-575 587-621 PENV.sub.-- HTL1A ENV POLYPROTEIN HUMAN T CELL LEUKEMIA VIRUS TYPE I 321-383 (STRAIN ATK) PENV.sub.-- HTLIC ENV POLYPROTEIN HUMAN T CELL LEUKEMIA VIRUS TYPE I 316-383 (CARIBBEAN ISOLATE) PENV.sub.-- HTLIM ENV POLYPROTEIN HUMAN T CELL LEUKEMIA VIRUS TYPE I 321-383 (ISOLATE MT-2) PENV.sub.-- HTLV2 ENV POLYPROTEIN PRECURSOR HUMAN T CELL LEUKEMIA VIRUS TYPE II 317-377 PENV.sub.-- HV1A2 ENVELOPE POLYPROTEIN GP160 HUMAN IMMUNODEFICIENCY VIRUS TYPE I 497-593 612-711 766-845 PRECURSOR (ARV2/SF2 ISOLATE PENV.sub.-- HV1B1 ENVELOPE POLYPROTEIN GP160 HUMAN IMMUNODEFICIENCY VIRUS TYPE I 505-594 610-712 767-843 PRECURSOR (BH10 ISOLATE) PENV.sub.-- HV1B8 ENVELOPE POLYPROTEIN GP160 HUMAN IMMUNODEFICIENCY VIRUS TYPE I 500-589 605-703 762-838 PRECURSOR (BH8 ISOLATE) PENV.sub.-- HV1BN ENVELOPE POLYPROTEIN GP160 HUMAN IMMUNODEFICIENCY VIRUS TYPE I 331-365 501-590 609-708 763-831 PRECURSOR(CONT (BRAIN ISOLATE) PENV.sub.-- HV1BR ENVELOPE POLYPROTEIN GP160 HUMAN IMMUNODEFICIENCY VIRUS TYPE I 510-599 615-717 772-841 PRECURSOR (BRU ISOLATE) PENV.sub.-- HVIC4 ENVELOPE POLYPROTEIN GP160 HUMAN IMMUNODEFICIENCY VIRUS TYPE I 342-376 510-606 626-724 779-855 PRECURSOR (CDC-451 ISOLATE) PENV.sub.-- HV1EL ENVELOPE POLYPROTEIN GP160 HUMAN IMMUNODEFICIENCY VIRUS TYPE I 255-296 502-591 607-709 768-829 PRECURSOR (ELI ISOLATE) PENV.sub.-- HV1H2 ENVELOPE POLYPROTEIN GP160 HUMAN IMMUNODEFICIENCY VIRUS TYPE I 505-594 610-712 767-836 PRECURSOR (HXB2 ISOLATE) PENV.sub.-- HV1H3 ENVELOPE POLYPROTEIN GP160 HUMAN IMMUNODEFICIENCY VIRUS TYPE I 505-594 610-712 767-843 PRECURSOR (HXB3 ISOLATE) PENV.sub.-- HV1J3 ENVELOPE POLYPROTEIN GP160 HUMAN IMMUNODEFICIENCY VIRUS TYPE I 343-377 517-605 622-723 778-843 PRECURSOR (JH3 ISOLATE) PENV.sub.-- HV1JR ENVELOPE POLYPROTEIN GP160 HUMAN IMMUNODEFICIENCY VIRUS TYPE I 329-363 497-586 603-704 759-835 PRECURSOR (JRCSF ISOLATE) PENV.sub.-- HV1KB ENVELOPE POLYPROTEIN GP160 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 88-122 338-372 511-545 555-599 618-677 681-718 772-848 PRECURSOR (STRAIN KB-1-GP32) PENV.sub.-- HV1MA ENVELOPE POLYPROTEIN GP160 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 259-300 507-596 617-714 770-825 PRECURSOR (MAL ISOLATE) PENV.sub.-- HV1MF ENVELOPE POLYPROTEIN GP160 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 503-592 622-710 765-841 PRECURSOR (MFA ISOLATE) PENV.sub.-- HV1MN ENVELOPE POLYPROTEIN GP160 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 336-370 506-595 617-713 774-841 PRECURSOR (MN ISOLATE) FENV.sub.-- HV1N5 ENVELOPE POLYPROTEIN GP160 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 326-360 PRECURSOR (NEW YORK-5 ISOL PENV.sub.-- HV1ND ENVELOPE POLYPROTEIN GP160 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 249-290 495-584 601-702 757-825 PRECURSOR (NDK ISOLATE) PENV.sub.-- HV1OY ENVELOPE POLYPROTEIN GP160 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 336-370 497-593 610-711 766-842 PRECURSOR (OYI ISOLATE) PENV.sub.-- HV1PV ENVELOPE POLYPROTEIN GP160 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 505-594 610-712 767-843 PRECURSOR (PV22 ISOLATE) PENV.sub.-- HV1RH ENVELOPE POLYPROTEIN GP160 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 344-378 507-603 619-721 776-852 PRECURSOR (RF/HAT ISOLATE) PENV.sub.-- HV1S1 ENVELOPE POLYPROTEIN GP160 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 496-585 602-703 758-835 PRECURSOR (SF162 ISOLATE) PENV.sub.-- HV1S3 ENVELOPE POLYPROTEIN GP160 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 332-366 494-590 607-708 763-837 PRECURSOR (SF33 ISOLATE) PENV.sub.-- HV1SC ENVELOPE POLYPROTEIN GP160 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 331-365 498-594 611-712 767-834 PRECURSOR (SC ISOLATE) PENV.sub.-- HV1W1 ENVELOPE POLYPROTEIN GP160 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 331-365 498-594 611-712 767-836 PRECURSOR (WMJ1 ISOLATE) PENV.sub.-- HV1W2 ENVELOPE POLYPROTEIN GP160 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 327-361 489-584 602-703 758-827 PRECURSOR (WMJ2 ISOLATE) PENV.sub.-- HV1Z2 ENVELOPE POLYPROTEIN GP160 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 255-296 502-591 610-709 764-831 PRECURSOR (Z2/CDC-Z34 ISOLAT PENV.sub.-- HV1Z3 ENVELOPE POLYPROTEIN GP160 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 251-292 PRECURSOR (ZAIRE 3 ISOLATE) PENV.sub.-- HV1Z6 ENVELOPE POLYPROTEIN GP160 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 256-297 504-593 609-711 766-840 PRECURSOR (ZAIRE 6 ISOLATE) PENV.sub.-- HV1Z8 ENVELOPE POLYPROTEIN GP160 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 266-307 512-601 617-675 682-719 774-831 PRECURSOR (Z-84 ISOLATE) PENV.sub.-- HV1ZH ENVELOPE POLYPROTEIN GP160 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 522-594 612-671 675-712 777-839 PRECURSOR (ZAIRE HZ321 ISOLA PENV.sub.-- HV2BE ENVELOPE POLYPROTEIN GP160 HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 447-481 510-595 617-680 PRECURSOR (ISOLATE BEN) PENV.sub.-- HV2CA ENVELOPE POLYPROTEIN GP160 HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 512-597 619-709 PRECURSOR (ISOLATE CAM2) PENV.sub.-- HV2D1 ENVELOPE POLYPROTEIN GP160 HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 501-586 608-698 PRECURSOR (ISOLATE D194) PENV.sub.-- HV2G1 ENVELOPE POLYPROTEIN GP160 HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 439-473 502-587 609-699 PRECURSOR (ISOLATE GHANA-1) PENV.sub.-- HV2NZ ENVELOPE POLYPROTEIN GP160 HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 488-587 609-699 PRECURSOR (ISOLATE NIH-Z) PENV.sub.-- HV2RO ENVELOPE POLYPROTEIN GP160 HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 511-596 618-708 PRECURSOR (ISOLATE ROD) PENV.sub.-- HV2S2 ENVELOPE POLYPROTEIN GP160 HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 442-476 505-590 612-702 PRECURSOR (ISOLATE ST/24.1C# PENV.sub.-- HV2SB ENVELOPE POLYPROTEIN GP160 HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 526-588 614-700 PRECURSOR (ISOLATE SBLISY) PENV.sub.-- HV2ST ENVELOPE POLYPROTEIN GP160 HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 442-476 505-590 612-702 PRECURSOR (ISOLATE ST) PENV.sub.-- IPMAE ENV POLYPROTEIN PRECURSOR MOUSE INTRACISTERNAL A-PARTICLE 367-422 465-527 PENV.sub.-- JSRV ENV POLYPROTEIN PRECURSOR SHEEP PULMONARY ADENOMATOSIS VIRUS 403-455 571-605 PENV.sub.-- MCFF ENV POLYPROTEIN PRECURSOR MINK CELL FOCUS-FORMING MURINE LEUKEMIA 473-525 537-571 VIRUS PENV.sub.-- MCFF3 ENV POLYPROTEIN PRECURSOR MINK CELL FOCUS-FORMING MURINE LEUKEMIA 474-526 538-572 (COAT POLYPROTE VIRUS (ISOLA PENV.sub.-- MLVAV ENV POLYPROTEIN PRECURSOR AKV MURINE LEUKEMIA VIRUS 503-555 567-601 PENV.sub.-- MLVCB ENV POLYPROTEIN PRECURSOR CAS-BR-E MURINE LEUKEMIA VIRUS 498-550 562-596 PENV.sub.-- MLVF5 ENV POLYPROTEIN PRECURSOR FRIEND MURINE LEUKEMIA VIRUS (ISOLATE 57) 520-564 576-610 PENV.sub.-- MLVFF ENV POLYPROTEIN PRECURSOR FRIEND MURINE LEUKEMIA VIRUS (ISOLATE FB29) 520-564 576-610 PENV.sub.-- MLVFP ENV POLYPROTEIN PRECURSOR FRIEND MURINE LEUKEMIA VIRUS 520-564 576-610 (ISOLATE PVC-211) PENV.sub.-- MLVHO ENV POLYPROTEIN PRECURSOR HOMULV MURINE LEUKEMIA VIRUS 504-551 563-597 PENV.sub.-- MLVKI ENV POLYPROTEIN KIRSTEN MURINE LEUKEMIA VIRUS 40-92 104-138 PENV.sub.-- MLVMO ENV POLYPROTEIN PRECURSOR MOLONEY MURINE LEUKEMIA VIRUS 502-554 566-600 PENV.sub.-- MLVRD ENV POLYPROTEIN PRECURSOR RADIATION MURINE LEUKEMIA VIRUS 497-549 561-595 PENV.sub.-- MLVRK ENV POLYPROTEIN PRECURSOR RADIATION MURINE LEUKEMIA VIRUS 497-549 561-595 (STRAIN KAPLAN) PENV.sub.-- MMTVB ENV POLYPROTEIN MOUSE MAMMARY TUMOR VIRUS (STRAIN BR6) 477-539 556-612 PENV.sub.-- MMTVG ENV POLYPROTEIN MOUSE MAMMARY TUMOR VIRUS (STRAIN GR) 477-539 556-612 PENV.sub.-- MPMV ENV POLYPROTEIN SIMIAN MASON-PFIZER VIRUS 408-474 PENV.sub.-- MSVFB ENV POLYPROTEIN FBJ MURINE OSTEOSARCOMA VIRUS 43-95 107-141 PENV.sub.-- OMVVS ENV POLYPROTEIN PRECURSOR OVINE LENTIVIRUS (STRAIN SA-OMVV) 22-64 185-223 664-746 780-816 PENV.sub.-- RMCFV ENV POLYPROTEIN PRECURSOR RAUSCHER MINK CELL FOCUS-INDUCING VIRUS 484-528 540-574 PENV.sub.-- RSFFV ENV POLYPROTEIN PRECURSOR RAUSCHER SPLEEN FOCUS-FORMING VIRUS 342-376 PENV.sub.-- SFV1 ENV POLYPROTEIN SIMIAN FOAMY VIRUS (TYPE 1) 1-41 101-140 154-205 321-355 563-651 658-693 866-904 PENV.sub.-- SFV3L ENV POLYPROTEIN SIMIAN FOAMY VIRUS (TYPE 3/STRAIN LK3) 5-46 158-209 319-357 560-706 863-901 PENV.sub.-- SIVA ENVELOPE POLYPROTEIN GP160 SIMIAN IMMUNODEFICIENCY VIRUS (AGM155 269-310 551-623 643-693 PRECURSOR ISOLATE) PENV.sub.-- SIVAG ENVELOPE POLYPROTEIN GP160 SIMIAN IMMUNODEFICIENCY VIRUS (AGM3 556-628 651-699 808-852 PRECURSOR ISOLATE) PENV.sub.-- SIVAI ENVELOPE POLYPROTEIN GP160 SIMIAN IMMUNODEFICIENCY VIRUS (ISOLATE 257-291 336-370 535-607 627-684 792-840 PRECURSOR AGM/CLONE GR1 PENV.sub.-- SIVAT ENVELOPE POLYPROTEIN GP160 SIMIAN IMMUNODEFICIENCY VIRUS (TYO-1 264-298 549-621 644-692 796-833 PRECURSOR ISOLATE) PENV.sub.-- SIVCZ ENVELOPE POLYPROTEIN GP160 CHIMPANZEE IMMUNODEFICIENCY VIRUS (SIV(CPZ)) 253-291 330-365 512-584 669-703 803-837 PRECURSOR PENV.sub.-- SIVGB ENVELOPE POLYPROTEIN GP160 SIMIAN IMMUNODEFICIENCY VIRUS (ISOLATE GB1) 566-654 677-725 PRECURSOR PENV.sub.-- SIVM1 ENVELOPE POLYPROTEIN GP160 SIMIAN IMMUNODEFICIENCY VIRUS (MM142-83 114-151 465-506 528-613 635-725 809-864 PRECURSOR ISOLATE) PENV.sub.-- SIVM2 ENVELOPE POLYPROTEIN GP160 SIMIAN IMMUNODEFICIENCY VIRUS (MM251 71-109 161-219 245-286 PRECURSOR ISOLATE) PENV.sub.-- SIVMK ENVELOPE POLYPROTEIN GP160 SIMIAN IMMUNODEFICIENCY VIRUS (K6W ISOLATE) 464-505 540.612 638-724 PRECURSOR PENV.sub.-- SIVML ENVELOPE POLYPROTEIN GP160 SIMIAN IMMUNODEFICIENCY VIRUS (K78 ISOLATE) 464-505 540-612 638-724 PRECURSOR PENV.sub.-- SIVS4 ENVELOPE POLYPROTEIN GP160 SIMIAN IMMUNODEFICIENCY VIRUS (F236/SMH4 466-509 517-606 638-728 812-853 PRECURSOR ISOLATE) PENV.sub.-- SIVSP ENVELOPE POLYPROTEIN GP160 SIMIAN IMMUNODEFICIENCY VIRUS (PBJ/BC13 470-513 521-620 642-732 811-848 PRECURSOR ISOLATE) PENV.sub.-- SMRVH ENV POLYPROTEIN PRECURSOR SQUIRREL MONKEY RETROVIRUS (SMRV-H) 400-466 PENV.sub.-- SRV1 ENV POLYPROTEIN SIMIAN RETROVIRUS SRV-1 409-475 PENV.sub.-- VILV ENV POLYPROTEIN PRECURSOR VISNA LENTIVIRUS (STRAIN 1514) 21-62 184-222 637-740 773-809 PENV.sub.-- VILV1 ENV POLYPROTEIN PRECURSOR VISNA LENTIVIRUS (STRAIN 1514/CLONE LV1-1KS1) 21-62 184-222 643-746 780-816 PENV.sub.-- VILV2 ENV POLYPROTEIN PRECURSOR VISNA LENTIVIRUS (STRAIN 1414/CLONE LV1-1KS2) 21-62 184-222 645-748 782-818 PERBA.sub.-- AVTER ERBA ONCOGENE PROTEIN AVIAN ERYTHROBLASTOSIS VIRUS (STRAIN E54) 106-140 PETF1.sub.-- FOWP1 EARLY TRANSCRIPTION FACTOR 70 FOWLPOX VIRUS (STRAIN FP-1) 190-224 553-587 KD SUBUNIT PETF1.sub.-- SFVKA EARLY TRANSCRIPTION FACTOR 70 SHOPE FIBROMA VIRUS (STRAIN KASZA) 37-71 267-340 550-587 KD SUBUNIT PETF1.sub.-- VACCC EARLY TRANSCRIPTION FACTOR 70 VACCINIA VIRUS (STRAIN COPENHAGEN) 23-71 307-341 KD SUBUNIT PETF1.sub.-- VACCV EARLY TRANSCRIPTION FACTOR 70 VACCINIA VIRUS (STRAIN WR) 23-71 307-341 KD SUBUNIT PETF2.sub.-- VACCC EARLY TRANSCRIPTION FACTOR 70 VACCINIA VIRUS (STRAIN COPENHAGEN) 52-97 174-208 KD SUBUNIT PETF2.sub.-- VARV EARLY TRANSCRIPTION FACTOR 70 VARIOLA VIRUS 52-97 174-208 KD SUBUNIT PEXON.sub.-- HCMVA ALKALINE EXONUCLEASE HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 80-114 PEXON.sub.-- HSVEB ALKALINE EXONUCLEASE EQUINE HERPESVIRUS TYPE 1 (STRAIN AB4P) 89-141 PEXON.sub.-- PRVN3 ALKALINE EXONUCLEASE PSEUDORABIES VIRUS (STRAIN NIA-3) 82-120 PEXON.sub.-- VZVD ALKALINE EXONUCLEASE VARICELLA-ZOSTER VIRUS (STRAIN DUMAS) 109-157 342-383 PFIB2.sub.-- ADE40 41.4 KD FIBER PROTEIN HUMAN ADENOVIRUS TYPE 40 182-237 PFIB2.sub.-- ADE41 41.4 KD FIBER PROTEIN HUMAN ADENOVIRUS TYPE 41 182-223 PFIBP.sub.-- ADE03 FIBER PROTEIN HUMAN ADENOVIRUS TYPE 3 156-194 PFIBP.sub.-- ADE07 FIBER PROTEIN HUMAN ADENOVIRUS TYPE 7 176-210 PFIBP.sub.-- ADE40 FIBER PROTEIN HUMAN ADENOVIRUS TYPE 40 303-352 PFIBP.sub.-- ADE41 FIBER PROTEIN HUMAN ADENOVIRUS TYPE 41 320-366 PFIBP.sub.-- ADEB3 FIBER PROTEIN BOVINE ADENOVIRUS TYPE 3 181-215 585-626 PFOSX.sub.-- MSVFR V-FOX/FOX TRANSFORMING PROTEIN FBR MURINE OSTEOSARCOMA VIRUS 131-169 PFOS.sub.-- AVINK P55-V-POS TRANSFORMING PROTEIN AVIAN RETROVIRUS NK24 109-152 PFOS.sub.-- MSVFB P55-V-FOS TRANSFORMING PROTEIN FBJ MURINE OSTEOSARCOMA VIRUS 155-193 PGAGC.sub.-- AVISC P47(GAG-CRK) PROTEIN AVIAN SARCOMA VIRUS (STRAIN CT10) 57-101 PGAG.sub.-- AVEV1 GAG POLYPROTEIN AVIAN ENDOGENOUS VIRUS EV-1 57-94 PGAG.sub.-- AVEV2 GAG POLYPROTEIN AVIAN ENDOGENOUS ROUS-ASSOCIATED VIRUS-0 6-43 PGAG.sub. -- AVIMC GAG POLYPROTEIN AVIAN MYELOCYTOMATOSIS VIRUS MC29 57-94 PGAG.sub.-- AVIMD GAG POLYPROTEIN AVAIN MYELOCYTOMATOSIS VIRUS HBI 57-94 PGAG.sub.-- AVISU CORE PROTEIN P19 AVIAN SARCOMA VIRUS (STRAIN UR2) 57-94 PGAG.sub.-- AVISY GAG POLYPROTEIN (P53) AVAIN SARCOMA VIRUS (STRAIN Y73) 57-94 PGAG.sub.-- BIV06 GAG POLYPROTEIN BOVINE IMMUNODEFICIENCY VIRUS (ISOLATE 106) 1-41 PGAG.sub.-- EIAVY GAG POLYPROTEIN EQUINE INFECTIOUS ANEMIA VIRUS (CLONE CL22) 61-118 PGAG.sub.-- FTVPE GAG POLYPROTEIN FELINE IMMUNODEFICIENCY VIRUS 76-110 (ISOLATE PETALUMA) PGAG.sub.-- FTVSD GAG POLYPROTEIN FELINE IMMUNODEFICIENCY VIRUS 76-110 (ISOLATE SAN DIEGO) PGAG.sub.-- FIVT2 GAG POLYPROTEIN FELINE IMMUNODEFICIENCY VIRUS (ISOLATE TM2) 76-110 PGAG.sub.-- FLV GAG POLYPROTEIN FELINE LEUKEMIA VIRUS 496-537 PGAG.sub.-- FOAMV GAG POLYPROTEIN HUMAN SPUMARETROVIRUS 130-186 391-425 439-480 607-655 PGAG.sub.-- FSVMD GAG POLYPROTEIN FELINE SARCOMA VIRUS (STRAIN MCDONOUGH) 499-534 PGAG.sub.-- FUJSV GAG POLYPROTEIN FUJINAMI SARCOMA VIRUS 57-94 PGAG.sub.-- GALVI GAG POLYPROTEIN GIBBON APE LEUKEMIA VIRUS 393-444 PGAG.sub.-- HV1A2 GAG POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 87-133 294-328 (ARV2/SF2 ISOLATE PGAG.sub.-- HV1B1 GAG POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 90-131 292-326 (BH10 ISOLATE) PGAG.sub.-- HHV1B5 GAG POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 90-131 292-326 (BH5 ISOLATE) PGAG.sub.-- HV1BR GAG POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 99-131 292-326 (BRU ISOLATE) PGAG.sub.-- HV1C4 GAG POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 90-131 292-326 (CDC-451 ISOLATE) PGAG.sub.-- HV1EL GAG POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 93-131 292-326 (ELI ISOLATE) PGAG.sub.-- HV1H2 GAG POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 90-131 292-326 (HXB2 ISOLATE) PGAG.sub.-- HV1J3 GAG POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 87-131 292-326 (JH3 ISOLATE) PGAG.sub.-- HVIJR GAG POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 87-131 292-326 (JRCSF ISOLATE) PGAG.sub.-- HV1MA GAG POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 93-137 (MAL ISOLATE) PGAG.sub.-- HV1MN GAG POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 87-134 295-329 (MN ISOLATE) PGAG.sub.-- HV1N5 GAG POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 90-131 292-326 (NEW YORK-5 ISOL PGAG.sub.-- HV1ND GAG POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 87-128 289-323 (NDK ISOLATE) PGAG.sub.-- HV1OY GAG POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 90-131 292-326 (OYI ISOLATE) PGAG.sub.-- HV1PV GAG POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 90-131 292-326 (PV22 ISOLATE) PGAG.sub.-- HV1RH GAG POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 90-131 292-326 (RF/HAT ISOLATE) PGAG.sub.-- HV1U4 GAG POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 87-127 (STRAIN UGANDAN PGAG.sub.-- HV1W2 GAG POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 292-326 (WMJ2 ISOLATE) PGAG.sub.-- HV1Z2 GAG POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 87-132 293-327 (Z2/CDC-Z34 ISOLAT PGAG.sub.-- HV2SB GAG POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 292-326 (ISOLATE SBLISY) PGAG.sub.-- IPHA RETROVIRUS-RELATED GAG HAMSTER INTRACISTERNAL A-PARTICLE 93-127 320-357 POLYPROTE IN PGAG.sub.-- IPMA RETROVIRUS-RELATED GAG MOUSE INTRACISTERNAL A-PARTICLE 67-103 POLYPROTEIN PGAG.sub.-- IPMAE RETROVIRUS-RELATED GAG MOUSE INTRACISTERNAL A-PARTICLE 89-133 138-172 POLYPROTEIN PGAG.sub.-- JSRV GAG POLYPROTEIN SHEEP PULMONARY ADENOMATOSIS VIRUS 470-504 PGAG.sub.-- MMTVB GAG POLYPROTEIN MOUSE MAMMARY TUMOR VIRUS (STRAIN BR6) 83-151 156-190 PGAG.sub.-- MMTVG GAG POLYPROTEIN MOUSE MAMMARY TUMOR VIRUS (STRAIN GR) 83-151 156-190 PGAG.sub.-- MPMV GAG POLYPROTEIN SIMIAN MASON-PFIZER VIRUS 222-260 PGAG.sub.-- RSVP GAG POLYPROTEIN ROUS SARCOMA VIRUS (STRAIN PRAGUE C) 57-94 PGAG.sub.-- SCVLA MAJOR COAT PROTEIN SACCHAROMYCES CEREVISIAE VIRUS L-A (SCV-L-A) 102-139 490-531 PGAG.sub.-- SPV1 GAG POLYPROTEIN SIMIAN FOAMY VIRUS (TYPE 1) 128-177 378-416 583-634 PGAG.sub.-- SFV3L GAG POLYPROTEIN SIMIAN FOAMY VIRUS (TYPE 3/STRAIN LK3) 373-407 435-522 591-632 PGAG.sub.-- SIVA1 GAG POLYPROTEIN SIMIAN IMMUNODEFICIENCY VIRUS (AGM155 302-336 ISOLATE) PGAG.sub.-- SIVAG GAG POLYPROTEIN SIMIAN IMMUNODEFICIENCY VIRUS (AGM3 306-340 ISOLATE) PGAG.sub.-- SIVAI GAG POLYPROTEIN SIMIAN IMMUNODEFICIENCY VIRUS (ISOLATE 183-217 473-507 AGM/CLONE GR PGAG.sub.-- SIVAT GAG POLYPROTEIN SIMIAN IMMUNODEFICIENCY VIRUS (TYO-1 302-336 ISOLATE) PGAG.sub.-- SIVCZ GAG POLYPROTEIN CHIMPANZEE IMMUNODEFICIENCY VIRUS (SIV(CPZ)) 301-335 PGAG.sub.-- SIVGB GAG POLYPROTEIN SIMIAN IMMUNODEFICIENCY VIRUS (ISOLATE GB1) 163-204 223-267 283-317 PGAG.sub.-- SMSAV GAG POLYPROTEIN SIMIAN SARCOMA VIRUS 394-431 PHELI.sub.-- HSV11 PROBABLE HELICASE HERPES SIMPLEX VIRUS (TYPE 1/STRAIN 17) 172-206 769-820 PHELI.sub.-- HSV2H PROBABLE HELICASE HERPES SIMPLEX VIRUS (TYPE 2/STRAIN HG52) 468-502 670-721 PHELI.sub.-- HSVSA PROBABLE HELICASE HERPES VIRUS SAIMIRI (STRAIN 11) 158-203 413-449 599-633 PHELI.sub.-- VZVD PROBABLE HELICASE VARICELLA-ZOSTER VIRUS (STRAIN DUMAS) 445-517 782-821 PHEMA.sub.-- CVBF HEMAGGLUTITIN-ESTERASE BOVINE CORONAVIRUS (STRAIN F15) 208-242 PRECURSOR PHEMA.sub.-- CVBLY HEMAGGLUTININ-ESTERASE BOVINE CORONAVIRUS (STRAIN LY-138) 208-242 PRECURSOR PHEMA.sub.-- CVBM HEMAGGLUTININ-ESTERASE BOVINE CORONAVIRUS (STRAIN MEBUS) 208-242 PRECURSOR PHEMA.sub.-- CVBQ HEMAGGLUTININ-ESTERASE BOVINE CORONAVIRUS (STRAIN QUEBEC), 208-242 PRECURSOR PHEMA.sub.-- CVHOC HEMAGGLUTININ-ESTERASE HUMAN CORONAVIRUS (STRAIN OC43) 208-242 PRECURSOR PHEMA.sub.-- IAAIC HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/A1CH1/2/68) 380-456 PHEMA.sub.-- IABAN HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/BANGKOK/1/79) 364-440 PHEMA.sub.-- IABUD HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/BUDGERIGAR/ 378-454 HOKKAIDO/1/77) PHEMA.sub.-- IACKA HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/CHICKEN/ 378-454 ALABAMA/1/175) PHEMA.sub.-- IACKG HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/CHICKEN/ 108-142 375-475 494-528 GERMANY/N/49) PHEMA.sub.-- IACKP HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/CHICKEN/ 360-452 487-532 PENNSYLVANIA/1/83) PHEMA.sub.-- IACKQ HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/CHICKEN/ 360-452 487-532 PENNSYLVANIA/1370/ PHEMA.sub.-- IACKS HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/CHICKEN/ 377-469 504-549 SCOTLAND/59) PHEMA.sub.-- IACKV HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/CHICKEN/ 112-146 377-469 VICTORIA/1/185) PHEMA.sub.-- IADA1 HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/DUCK/ 378-454 ALBERTA/28/76) PHEMA.sub.-- IADA2 HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/DUCK/ 377-476 495-547 ALBERTA/60/76) PHEMA.sub.-- IADA3 HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/DUCK/ 380-453 ALBERTA/78/76) PHEMA.sub.-- IADA4 HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/DUCK/ 379-478 506-548 ALBERTA/35/76) PHEMA.sub.-- IADCZ HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/(DUCK/ 378-454 CZECHOSLOVAKIA/56) PHEMA.sub.-- IADEI HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/DUCK/ 21-55 377-472 ENGLAND/1/56) PHEMA.sub.-- IADH1 HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/DUCK/ 364-440 HOKKAIDO/5/77) PHEMA.sub.-- IADH2 HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/DUCK/ 364-440 HOKKAIDO/8/80) PHEMA.sub.-- IADH3 HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/DUCK/ 364-440 HOKKAIDO/33/80) PHEMA.sub.-- IADH4 HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/DUCK/ 364-440 HOKKAIDO/7/82) PHEMA.sub.-- IADH5 HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/DUCK/ 364-440 HOKKAIDO/21/82) PHEMA.sub.-- IADH6 HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/DUCK/ 364-440 HOKKAIDO/9/85) PHEMA.sub.-- IADH7 HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/DUCK/ 364-440 HOKKAIDO/10/85) PHEMA.sub.-- IADIR HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/DUCK/ 379-471 506-551 IRELAND/113/83) PHEMA.sub.-- IADM1 HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/DUCK/ 21-55 MEMPHIS/546/76 PHEMA.sub.-- IADM2 HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/DUCK/ 380-456 MEMPHIS/928/74) PHEMA.sub.-- IADNY HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/DUCK/ 21-55 NEW YORK/12/78) PHEMA.sub.-- IADNZ HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/DUCK/ 378-454 NEW ZEALAND/31/76) PHEMA.sub.-- IADU1 HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/DUCK/ 21-55 UKRAINE/1/60) PHEMA.sub.-- IADU3 HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/DUCK/ 380-456 UKRAINE/1/63) PHEMA.sub.-- IAEN7 HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/ENGLAND/321/77 380-456 PHEMA.sub.-- IAFPR HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/FOWL PLAGUE 377-477 VIRUS/ROSTOCK PHEMA.sub.-- IAGRE HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/GREY TEAL/ 378-454 AUSTRALIA/2/79 PHEMA.sub.-- IAGU2 HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/GULL/ 378-473 MARYLAND/704/77) PHEMA.sub.-- IAGUA HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/GULL/ASTRAKHAN/ 377-476 227/84) PHEMA.sub.-- IAHAL HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/EQUINE/ALGIERS/72) 379-455 PHEMA.sub.-- IAHC6 HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/EQUINE/ 112-146 360-484 503-537 CAMBRIDGE/1/63) PHEMA.sub.-- IAHC7 HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/EQUINE/ 112-146 360-484 503-537 CAMBRIDGE/1/73) PHEMA.sub.-- IAHCD HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/EQUINE/ 360-484 503-537 C. DETROIT/1/64) PHEMA.sub.-- IANDE HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/EQUINE/DETROIT/ 360-484 503-537 1/64) PHEMA.sub.-- IAHFO HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/EQUINE/ 379-455 FONTAINEBLEAU/76) PHEMA.sub.-- IAHK6 HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/EQUINE/ 379-455 KENTUCKY/2/86) PHEMA.sub.-- IAHK7 HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/EQUINE/KENTUCKY/ 379-455 1/87) PHEMA.sub.-- IAHLE HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/EQUINE/ 112-146 360-484 503-537 LEXINGTON/1/66) PHEMA.sub.-- IAHLO HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/EQUINE/LONDON/ 112-146 360-484 503-537 1416/73) PHEMA.sub.-- IAHMI HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/EQUINE/MIAMI/ 379-455 1/63 PHEMA.sub.-- IAHNM HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/EQUINE/NEW 379-455 MARKET/76) PHEMA.sub.-- IAHNN HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/EQUINE/NEW 112-146 360-484 503-537 MARKET/1/77) PHEMA.sub.-- IAHPR HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/EQUINE/ 112-146 360-484 503-537 PRAGUE/1/56) PHEMA.sub.-- IAHRO HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/EQUINE/ 379-455 ROMANIA/80) PHEMA.sub.-- IAHSA HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/EQUINE/ 379-455 SANTIAGO/1/85) PHEMA.sub.-- IAHSP HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/EQUINE/ 112-146 360-484 503-537 SAO PAULO/1/76) PHEMA.sub.-- IAHSW HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/EQUINE/ 112-146 360-484 503-537 SWITZERLAND/137/72) PHEMA.sub.-- IAHTE HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/EQUINE/ 379-455 TENNESSEE/5/86) PHEMA.sub.-- IAHTO HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/EQUINE/ 379-455 TOKYO/71) PHEMA.sub.-- IAHUR HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/EQUINE/ 379-455 URUGUAY/1/63) PHEMA.sub.-- IAJAP HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/JAPAN/305/57 375-467 502-547 PHEMA.sub.-- IAKIE HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/KIEV/59/79) 376-478 506-541 PHEMA.sub.-- IALEN HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/LENINGRAD/54/1) 376-478 506-548 PHEMA.sub.-- IAMAA HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/MALLARD/ 377-453 ASTRAKHAN/244/82) PHEMA.sub.-- IAMAB HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/MALLARD/ 382-458 ASTRAKHAN/263/82) PHEMA.sub.-- IAMAO HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/MALLARD/ 380-456 NEW YORK/6874/78) PHEMA.sub.-- IAME1 HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/MEMPHIS/1/71) 380-456 PHEMA.sub.-- IAME2 HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/MEMPHIS/102/72) 380-456 PHEMA.sub.-- IAME6 HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/MEMPHIS/6/86) 364-440 PHEMA.sub.-- IAMTN HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/MINK/SWEDEN/84) 108-142 375-475 PHEMA.sub.-- IANT6 HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/NT/60/68) 389-456 PHEMA.sub.-- IAPIL HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/PILOT WHALE/ 378-477 496-534 MAINE/328/84) PHEMA.sub.-- IAPUE HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/PUERTO RICO/8/34) 376-478 506-548 PHEMA.sub.-- IARUD HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/RUDDY 376-454 TURNSTONE/NEW JERSE PHEMA.sub.-- IASE2 HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/SEAL/ 378-454 MASSACHUSETTS/133/82) PHEMA.sub.-- IASH2 HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/SHEARWATER/ 379-474 506-552 AUSTRALIA/72) PHEMA.sub.-- IASTA HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/STARLING/ 112-146 377-469 VICTORIA/5156/85) PHEMA.sub.-- IATKI HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/TURKEY/IRELAND/ 379-471 506-551 1378/83) PHEMA.sub.-- IATKM HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/TURKEY/ 378-454 MINNESOTA/833/60 PHEMA.sub.-- IATKO HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/TURKEY/ONTARIO/ 392-470 504-548 7732/66) PHEMA.sub.-- IATKP HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/TURKEY/ONTARIO/ 378-454 493-540 6118/68) PHEMA.sub.-- IATKR HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/TURKEY/OREGON/ 30-64 374-474 71) PHEMA.sub.-- IATKW HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/TURKEY/ 373-472 487-539 WISCONSIN/1/66) PHEMA.sub.-- IATRA HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/TERN/AUSTRALIA/ 21-55 G70C/75) PHEMA.sub.-- IAUDO HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/UDORN/ 387-456 307/72) PHEMA.sub.-- IAUSS HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/USSR/ 376-478 506-548 90/77 PHEMA.sub.-- IAVI7 HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/VICTORIA/3/75) 381-457 PHEMA.sub.-- IAWIL HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/WILSON-SMITH/33) 375-477 555-547 PHEMA.sub.-- IAZCO HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/SWINE/ 380-456 COLORADO/1/77) PHEMA.sub.-- IAZH2 HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/SWINE/HONG 364-440 KONG/81/78) PHEMA.sub.-- IAZH3 HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/SWINE/HONG 364-440 KONG/126/82) PHEMA.sub.-- IAZIN HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/SWINE/ 379-478 506-548 INDIANA/1726/88) PHEMA.sub.-- IAZNJ HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/SWINE/ 379-478 506-547 NEW JERSEY/11/76) PHEMA.sub.-- IAZUK HEMAGGLUTININ PRECURSOR INFLUENZA A VIRUS (STRAIN A/SWINE/ 380-456 UKKEL/1/84 PHEMA.sub.-- INBBE HEMAGGLUTININ PRECURSOR INFLUENZA B VIRUS (STRAIN B/BEIJING/1/87 388-473 PHEMA.sub.-- INBBO HEMAGGLUTININ PRECURSOR INFLUENZA B VIRUS (STRAIN B/BONN/43) 378-463 PHEMA.sub.-- INBEN HEMAGGLUTININ PRECURSOR INFLUENZA B VIRUS (STRAIN B/ENGLAND/222/82) 396-471 PHEMA.sub.-- INBHK HEMAGGLUTININ PRECURSOR INFLUENZA B VIRUS (STRAIN B/HONG KONG/8/73) 381-463 PHEMA.sub.-- INBLE HEMAGGLUTININ PRECURSOR INFLUENZA B VIRUS (STRAIN B/LEE/40) 387-472 PHEMA.sub.-- INBMD HEMAGGLUTITIN PRECURSOR INFLUENZA B VIRUS (STRAIN B/MARYLAND/59) 377-462 PHEMA.sub.-- INBME HEMAGGLUTININ PRECURSOR INFLUENZA B VIRUS (STRAIN B/MEMPHIS/6/86) 381-468 PHEMA.sub.-- INBOR HEMAGGLUTITIN PRECURSOR INFLUENZA B VIRUS (STRAIN B/OREGON/5/80) 386-471 PHEMA.sub.-- INBSI HEMAGGLUTININ PRECURSOR INFLUENZA B VIRUS (STRAIN B/SINGAPORE/222/79) 386-471 PHEMA.sub.-- INBUS HEMAGGLUTININ PRECURSOR INFLUENZA B VIRUS (STRAIN B/USSR/100/83) 379-464 PHEMA.sub.-- INBVI HEMAGGLUTININ PRECURSOR INFLUENZA B VIRUS (STRAIN B/VICTORIA/3/85) 381-466 PHEMA.sub.-- INBVK HEMAGGLUTININ PRECURSOR INFLUENZA B VIRUS (STRAIN B/VICTORIA/2/87) 388-473 PHEMA.sub.-- INCCA HEMAGGLUTININ PRECURSOR INFLUENZA C VIRUS (STRAIN C/CALIFORNIA/78) 483-571 PHEMA.sub.-- INCEN HEMAGGLUTININ PRECURSOR INFLUENZA C VIRUS (STRAIN C/ENGLAND/892/63) 471-559 PHEMA.sub.-- INCGL HEMAGGLUTININ PRECURSOR INFLUENZA C VIRUS (STRAIN C/GREAT 471-559 LAKES/1167/54) PHEMA.sub.-- INCHY HEMAGGLUTININ INFLUENZA C VIRUS (STRAIN C/HYOGO/1/83) 470-558 PHEMA.sub.-- INCJH HEMAGGLUTININ PRECURSOR INFLUENZA C VIRUS (STRAIN C/ 484-572 JOHANNESBURG/1/166) PHEMA.sub.-- INCKY HEMAGGLUTININ INFLUENZA C VIRUS (STRAIN C/KYOTO/41/82) 470-558 PHEMA.sub.-- INCMI HEMAGGLUTININ PRECURSOR INFLUENZA C VIRUS (STRAIN C/MISSISSIPPI/80) 470-558 PHEMA.sub.-- INCNA HEMAGGLUTININ INFLUENZA C VIRUS (STRAIN C/NARA/82) 470-558 PHEMA.sub.-- INCP1 HEMAGGLUTININ PRECURSOR INFLUENZA C VIRUS (STRAIN C/PIG/BEIJING/10/81) 471-559 PHEMA.sub.-- INCP2 HEMAGGLUTININ PRECURSOR INFLUENZA C VIRUS (STRAIN C/PIG/BEIJING/115/81) 471-559 PHEMA.sub.-- INCP3 MEASLES VIRUS (STRAIN HALLE) INFLUENZA C VIRUS (STRAIN C/PIG/BEIJING/439/82) 471-559 PHEMA.sub.-- INCTA HEMAGGLUTININ PRECURSOR INFLUENZA C VIRUS (STRAIN C/TAYLOR/1233/147 471-559 PHEMA.sub.-- INCYA HEMAGGLUTININ PRECURSOR INFLUENZA C VIRUS (STRAIN C/YAMAGATA/10/81) 471-559 PHEMA.sub.-- MEASE HEMAGGLUTININ-NEURAMINIDASE MEASLES VIRUS (STRAIN EDMONSTON) 46-90 PHEMA.sub.-- MEASH HEMAGGLUTININ-NEURAMINIDASE MEASLES VIRUS (STRAIN HALLE) 46-90 PHEMA.sub.-- MEASI HEMAGGLUTININ-NEURAMINIDASE MEASLES VIRUS (STRAIN IP-3-CA) 46-87 PHEMA.sub.-- MEASY HEMAGGLUTININ-NEURAMINIDASE MEASLES VIRUS (STRAIN YAMAGATA-1) 46-87 PHEMA.sub.-- MUMPI HEMAGGLUTININ-NEURAMINIDASE MUMPS VIRUS (STRAIN SBL-1 34-99 PHEMA.sub.-- MUMPM HEMAGGLUTININ-NEURAMINIDASE MUMPS VIRUS (STRAIN MIYAHARA VACCINE) 34-99 PHEMA.sub.-- MUMPR HEMAGGLUTININ-NEURAMINIDASE MUMPS VIRUS (STRAIN RW) 34-99 PHEMA.sub.-- MUMPS HEMAGGLUTININ-NEURAMINIDASE MUMPS VIRUS (STRAIN SBL) 34-99 PHEMA.sub.-- NDVA HEMAGGLUTININ-NEURAMINIDASE NEWCASTLE DISEASE VIRUS (STRAIN AUSTRALIA- 8-52 477-529 VICTORIA/32) PHEMA.sub.-- NDVB HEMAGGLUTININ-NEURAMINIDASE NEWCASTLE DISEASE VIRUS (STRAIN BEAUDETTE 1-49 C/45) PHEMA.sub.-- NDVD HEMAGGLUTININ-NEURAMINIDASE NEWCASTLE DISEASE VIRUS (STRAIN D26/76) 1-52 PHEMA.sub.-- NDVM HEMAGGLUTININ-NEURAMINIDASE NEWCASTLE DISEASE VIRUS (STRAIN MIYADERA/51) 1-52 PHEMA.sub.-- NDVQ HEMAGGLUTININ-NEURAMINIDASE NEWCASTLE DISEASE VIRUS (STRAIN 1-52 QUEENSLAND/66) PHEMA.sub.-- NDVTG HEMAGGLUTININ-NEURAMINIDASE NEWCASTLE DISEASE VIRUS (STRAIN TEXAS G.B./48) 1-49 PHEMA.sub.-- NDVU HEMAGGLUTININ-NEURAMINIDASE NEWCASTLE DISEASE VIRUS (STRAIN ULSTER/67) 1-52 PHEMA.sub.-- PHODV HEMAGGLUTININ-NEURAMINIDASE PHOCINE DISTEMPER VIRUS 39-73 PHEMA.sub.-- PI1HW HEMAGGLUTININ-NEURAMINIDASE HUMAN PARAINFLUENZA 1 VIRUS (STRAIN 66-110 WASHINGTON/ 1957) PHEMA.sub.-- PI2H HEMAGGLUTININ-NEURAMINIDASE HUMAN PARAINFLUENZA 2 VIRUS 247-281 PHEMA.sub.-- PI2HT HEMAGGLUTININ-NEURAMINIDASE HUMAN PARAINFLUENZA 2 VIRUS (STRAIN 247-281 TOSHIBA) PHEMA.sub.-- PI3B HEMAGGLUTININ-NEURAMINIDASE BOVINE PARAINFLUENZA 3 VIRUS 38-93 PHEMA.sub.-- PI3H4 HEMAGGLUTININ-NEURAMINIDASE HUMAN PARAINFLUENZA 3 VIRUS (STRAIN NIH 13-110 394-428 47585) PHEMA.sub.-- PI3HA HEMAGGLUTININ-NEURAMINIDASE HUMAN PARAINFLUENZA 3 VIRUS (STRAIN 20-110 394-428 AUS/124854/74) PHEMA.sub.-- PI3HT HEMAGGLUTININ-NEURAMINIDASE HUMAN PARAINFLUENZA 3 VIRUS (STRAIN 13-110 394-425 TEX/545/80) PHEMA.sub.-- PI3HU HEMAGGLUTININ-NEURAMINIDASE HUMAN PARAINFLUENZA 3 VIRUS (STRAIN 13-110 394-428 TEX/9305/82 ) PHEMA.sub.-- PI3HV HEMAGGLUTININ-NEURAMINIDASE HUMAN PARAINFLUENZA 3 VIRUS (STRAIN 13-110 394-428 TEX/12677/8 3) PHEMA.sub.-- PI3HW HEMAGGLUTININ-NEURAMINIDASE HUMAN PARAINFLUENZA 3 VIRUS (STRAIN 13-110 394-428 WASH/641/79 ) PHEMA.sub.-- PI3HX HEMAGGLUTININ-NEURAMINIDASE HUMAN PARAINFLUENZA 3 VIRUS (STRAIN WASH/ 13-110 394-428 1511/73) PHEMA.sub.-- PI4HA HEMAGGLUTININ-NEURAMINIDASE HUMAN PARAINFLUENZA 4A VIRUS (STRAIN 54-85 TOSHIBA) PHEMA.sub.-- RACVI HEMAGGLUTININ PRECURSOR RACCOON POXVIRUS 166-214 256-290 PHEMA.sub.-- RINDK HEMAGGLUTININ-NEURAMINIDASE RINDERPEST VIRUS (STRAIN KABETE O) 46-87 PHEMA.sub.-- RINDL HEMAGGLUTININ-NEURAMINIDASE RINDERPEST VIRUS (STRAIN L) 46-87 191-225 PHEMA.sub.-- SEND5 HEMAGGLUTININ-NEURAMINIDASE SENDAI VIRUS (STRAIN Z/HOST MUTANTS) 57-110 PHEMA.sub.-- SENDF HEMAGGLUTININ-NEURAMINIDASE SENDAI VIRUS (STRAIN FUSHIMI) 57-110 PHEMA.sub.-- SENDH HEMAGGLUTININ-NEURAMINIDASE SENDAI VIRUS (STRAIN HARRIS) 57-110 PHEMA.sub.-- SENDJ HEMAGGLUTININ-NEURAMINIDASE SENDAI VIRUS (STRAIN HVJ) 57-110 PHEMA.sub.-- SENDZ HEMAGGLUTININ-NEURAMINIDASE SENDAI VIRUS (STRAIN Z) 57-110 PHI(MA.sub.-- SV41 HEMAGGLUTININ-NEURAMINIDASE SIMIAN VIRUS 41 18-52 387-421 PHEMA.sub.-- SV5 HEMAGGLUTININ-NEURAMINIDASE SIMIAN VIRUS 5 (STRAIN W3) 27-82 PHEMA.sub.-- SV5LN HEMAGGLUTININ-NEURAMINIDASE SIMIAN VIRUS 5 (ISOLATE HUMAN/LN) 27-82 PHEMA.sub.-- VARV HEMAGGLUTININ PRECURSOR VARIOLA VIRUS 177-211 PEMX3.sub.-- ADE02 PERIPENTONAL HEXON-ASSOCIATED HUMAN ADENOVIRUS TYPE 2 90-134 PROTEIN PEMX3.sub.-- ADE05 PERIPENTONAL HEXON-ASSOCIATED HUMAN ADENOVIRUS TYPE 5 90-134 PROTEIN PHEX9.sub.-- ADE02 HEXON-ASSOCIATED PROTEIN HUMAN ADENOVIRUS TYPE 2 85-134 PHEX9.sub.-- ADE05 HEXON-ASSOCIATED PROTEIN HUMAN ADENOVIRUS TYPE 5 85-134 PHEX9.sub.-- ADE07 HEXON-ASSOCIATED PROTEIN HUMAN ADENOVIRUS TYPE 7, AND HUMAN 93-138 ADENOVIRUS TYPE PHEX9.sub.-- ADE12 HEXON-ASSOCIATED PROTEIN HUMAN ADENOVIRUS TYPE 12 88-137 PHEX9.sub.-- ADE41 HEXON-ASSOCIATED PROTEIN HUMAN ADENOVIRUS TYPE 41 67-126 PHEX9.sub.-- ADEC2 HEXON-ASSOCIATED PROTEIN CANINE ADENOVIRUS TYPE 2 53-103 PHEX9.sub.-- .sub.-- ADENT HEXON-ASSOCIATED PROTEIN TUPAIA ADENOVIRUS 61-109 PHEX.sub.-- ADE02 HEXON PROTEIN HUMAN ADENOVIRUS TYPE 2 341-386 433-467 583-624 PHEX.sub.-- ADE05 HEXON PROTEIN HUMAN ADENOVIRUS TYPE 5 330-379 PHEX.sub.-- ADE40 HEXON PROTEIN HUMAN ADENOVIRUS TYPE 40 303-352 408-449 553-587 PHEX.sub.-- ADE41 HEXON PROTEIN HUMAN ADENOVIRUS TYPE 41 306-355 555-589 PHEX.sub.-- ADEB3 HEXON PROTEIN BOVINE ADENOVIRUS TYPE 3 301-346 385-419 544-578 705-739 PHRG.sub.-- COWPX HOST RANGE PROTEIN COWPOX VIRUS 320-395 455-469 PI226.sub.-- ASFB7 LATE PROTEIN 1226R AFRICAN SWINE FEVER VIRUS (STRAIN BA71V) 110-151 PIBMP.sub.-- CAMV4 INCLUSION BODY MATRIX PROTEIN CAULIFLOWER MOSAIC VIRUS (STRAIN D4) 3-44 371-419 PIBMP.sub.-- CAMVB INCLUSION BODY MATRIX PROTEIN CAULIFLOWER MOSAIC VIRUS (STRAIN BARI 1) 379-420 PIBMP.sub.-- CAMVC INCLUSION BODY MATRIX PROTEIN CAULIFLOWER MOSAIC VIRUS (STRAIN CM-1841) 3-37 378-419 PIBMP.sub.-- CAMVD INCLUSION BODY MATRIX PROTEIN CAULIFLOWER MOSAIC VIRUS (STRAIN D/H) 3-44 379-419 PIBMP.sub.-- CAMVE INCLUSION BODY MATRIX PROTEIN CAULIFLOWER MOSAIC VIRUS (STRAIN BBC) 3-37 371-419 PIBMP.sub.-- CAMVJ INCLUSION BODY MATRIX PROTEIN CAULIFLOWER MOSAIC VIRUS (STRAIN S-JAPAN) 3-37 378-419 PIBMP.sub.-- CAMVN INCLUSION BODY MATRIX PROTEIN CAULIFLOWER MOSAIC VIRUS (STRAIN NY8153) 3-37 378-419 PIBMP.sub.-- CAMVP INCLUSION BODY MATRIX PROTEIN CAULIFLOWER MOSAIC VIRUS (STRAIN PV147) 3-37 374-419 PIBMP.sub.-- CAMVS INCLUSION BODY MATRIX PROTEIN CAULIFLOWER MOSAIC VIRUS (STRAIN 3-37 378-419 STRASBOURG) PIBMP.sub.-- CERV INCLUSION BODY MATRIX PROTEIN CARNATION ETCHED RING VIRUS 3-37 PIBMP.sub.-- FMVD INCLUSION BODY MATRIX PROTEIN FIGWORT MOSAIC VIRUS (STRAIN DXS) 1-51 372-406 PIBMP.sub.-- SOCMV INCLUSION BODY MATRIX PROTEIN 1-48 132-179 PIC18-HCMVA PROBABLE PROCESSING AND HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 53-98 290-324 498-532 TRANSPORT PROTEIN PIC18.sub.-- HSV11 PROCESSING AND TRANSPORT HERPES SIMPLEX VIRUS (TYPE 1/STRAIN 17) 331-365 PROTEIN PIC18.sub.-- HSV1A PROCESSING AND TRANSPORT HERPES SIMPLEX VIRUS (TYPE 1/STRAIN 331-365 PROTEIN ANGELOTTI) PIC18.sub.-- HSV1F PROCESSING AND TRANSPORT HERPES SIMPLEX VIRUS (TYPE 1/STRAIN F) 324-362 PROTEIN PIC18.sub.-- HSVE2 PROBABLE PROCESSING AND BOVINE HERPES VIRUS TYPE 2 (STRAIN BMV) 466-500 TRANSPORT PROTEIN PIC18.sub.-- HSVEB PROBABLE PROCESSING AND HERPES VIRUS TYPE 1 (ISOLATE HVS25A) 341-375 TRANSPORT PROTEIN PIC18.sub.-- HSVSA PROBABLE PROCESSING AND HERPES VIRUS SAIMIRI (STRAIN 11) 58-99 361-395 TRANSPORT PROTEIN PIC18.sub.-- MCMVS PROBABLE PROCESSING AND MURINE CYTOMEGALOVIRUS (STRAIN SMITH) 60-112 290-340 647-691 TRANSPORT PROTEIN PIC18.sub.-- PRVIF PROBABLE PROCESSING AND PSEUDORABIES VIRUS (STRAIN INDIANA- 299-333 303-337 TRANSPORT PROTEIN FUNCKHAUSER/BECKE PIC18.sub.-- HSVBJ TRANS-ACTING TRANSCRIPTIONAL BOVINE HERPES VIRUS TYPE 1 (STRAIN JURA) 190-224 PROTEIN ICP0 P8CP0.sub.-- HSVBK TRANS-ACTING TRANSCRIPTIONAL BOVINE HERPES VIRUS TYPE 1 (STRAIN K22) 190-224 PROTEIN ICP0 PICP4.sub.-- HSVMG TRANS-ACTING TRANSCRIPTIONAL MAREK'S DISEASE HERPES VIRUS (STRAIN GA) 1022- ACTIVATOR PR 1056 PICP4.sub.-- VZVD TRANS-ACTING TRANSCRIPTIONAL VARICELLA-ZOSTER VIRUS (STRAIN DUMAS) 920-954 PROTEIN ICP4 PIE63.sub.-- HCMVA TRANSCRIPTIONAL REGULATOR HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 207-241 IE63 HOMOLOG PIE63.sub.-- HSV11 TRANSCRIPTIONAL REGULATOR IE63 HERPES SIMPLEX VIRUS (TYPE 1/STRAIN 17) 241-275 PIE63.sub.-- HSVEB TRANSCRIPTIONAL REGULATOR IE63 EQUINE HERPES VIRUS TYPE 1 (STRAIN AB4P) 282-316 HOMOLOG PIE63.sub.-- VZVD TRANSCRIPTIONAL REGULATOR IE63 VARICELLA-ZOSTER VIRUS (STRAIN DUMAS) 195-229 258-306 HOMOLOG PIE68.sub.-- HSVE4 IMMEDIATE-EARLY PROTEIN IE68 EQUINE HERPES VIRUS TYPE 4 (STRAIN 1942) 87-121 PIE68-HSVEB IMMEDIATE-EARLY PROTEIN IE68 EQUINE HERPES VIRUS TYPE 1 (STRAIN AB4P) 99-133 PIE68.sub.-- HSVSA IMMEDIATE-EARLY PROTEIN HERPES VIRUS SAIMIRI (STRAIN 11) 48-85 PIR05.sub.-- HCMVA HYPOTHETICAL PROTEIN IRL5 HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 13-47 PIR12.sub.-- HCMVA HYPOTHETICAL PROTEIN IRL12 HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 74-162 PKABL.sub.-- FSVHY TYROSINE-PROTEIN KINASE FELINE SARCOMA VIRUS (STRAIN HARDY- 280-314 TRANSFORMING PROT ZUCKERMAN 2) PKABL.sub.-- MLVAB TYROSINE-PROTEIN KINASE ABELSON MURINE LEUKEMIA VIRUS 217-251 TRANSFORMING PROT PKAKT.sub.-- MLVAT AKT KINASE TRANSFORMING ART8 MURINE LEUKEMIA VIRUS 172-227 263-384 PROTEIN PKFES.sub.-- FSVGA TYROSINE-PROTEIN KINASE FELINE SARCOMA VIRUS (STRAIN 23-64 104-178 TRANSFORMING PROT GARDNER-ARNSTEIN) PKFOR.sub.-- FSVGR TYROSINE-PROTEIN KINASE FELINE SARCOMA VIRUS (STRAIN 218-252 TRANSFORMING PROT GARDNER-RASHEED) PKFMS.sub.-- FSVMD FMS TYROSINE KINASE FELINE SARCOMA VIRUS (STRAIN MCDONOUGH) 313-362 638-679 812-849 TRANSFORMING PROTEIN PKFPS.sub.-- AVISP TYROSINE-PROTEIN KINASE AVIAN SARCOMA VIRUS (STRAIN PRCII) 65-99 TRANSFORMING PROT PKFPS.sub.-- FUJSV TYROSINE-PROTEIN KINASE FUJINAMI SARCOMA VIRUS 65-99 152-251 348-398 TRANSFORMING PROT PKITH.sub.-- AMEPV THYMIDINE KINASE AMSACTA MOOREI ENTOMOPOXVIRUS 47-81 PKITH.sub.-- CAPVK THYMIDINE KINASE CAPRIPOXVIRUS (STRAIN KS-1 38-82 PKITH.sub.-- EBV THYMIDINE KINASE EPSTEIN-BARR VIRUS (STRAIN B95.8) 228-262 431-472 PKITH.sub.-- HSV11 THYMIDINE KINASE HERPES SIMPLEX VIRUS (TYPE 1/STRAIN 17) 90-124 PKITH.sub.-- HSV1C THYMIDINE KINASE HERPES SIMPLEX VIRUS (TYPE 1/STRAIN CL101) 90-124 PKITH.sub.-- HSV1E THYMIDINE KINASE HERPES SIMPLEX VIRUS (TYPE 1/STRAIN HFEM) 90-124 PKITH.sub.-- HSV1K THYMIDINE KINASE HERPES SIMPLEX VIRUS (TYPE 1/STRAIN KOS) 90-124 PKITH.sub.-- HSV1S THYMIDINE KINASE HERPES SIMPLEX VIRUS (TYPE 1/STRAIN SC16) 90-124 PKITH.sub.-- HSV23 THYMIDINE KINASE HERPES SIMPLEX VIRUS (TYPE 2/STRAIN 333) 91-125 PKITH.sub.-- HSVBM THYMIDINE KINASE BOVINE HERPES VIRUS TYPE 3 (STRAIN WC11) 616-665 PKITH.sub.-- HSVE4 THYMIDINE KINASE EQUINE HERPES VIRUS-TYPE 4 (STRAIN 1942) 19-53 178-219 PKITH.sub.-- HSVEB THYMIDINE KINASE EQUINE HERPES VIRUS TYPE 1 (STRAIN AB4P) 19-53 178-230 PKITH.sub.-- HSVF THYMIDINE KINASE FELINE HERPES VIRUS (FELID HERPES VIRUS 1) 180-214 PKITH.sub.-- HSVMR THYMIDINE KINASE MARMOSET HERPES VIRUS 52-86 PKITH.sub.-- HSVSA THYMIDINE KINASE HERPES VIRUS SAIMIRI (STRAIN 11) 337-389 PKITH.sub.-- PRVN3 THYMIDINE KINASE PSEUDORABIES VIRUS (STRAIN NIA-3) 161-202 PKMIL.sub.-- AVIMH MIL SERINE/THREONINE-PROTEIN AVIAN RETROVIRUS MH2 69-103 KINASE TRANSF PKR15.sub.-- HSV11 GENE 15 PROTEIN KINASE ICTALURID HERPES VIRUS 1 190-224 PKR2.sub.-- HSV11 PROBABLE SERINE/THREONINE- HERPES SIMPLEX VIRUS (TYPE 1/STRAIN 17) 57-91 281-315 PROTEIN KINASE PKR74.sub.-- HSV11 GENE 74 PROTEIN KINASE ICTALURID HERPES VIRUS 1 487-528 597-631 PKRAF.sub.-- MSV36 RAP SERINE/THREONINE-PROTEIN MURINE SARCOMA VIRUS 3611 11-45 KINASE TRANSF PKRBI.sub.-- VACCC 30 KD PROTEIN KINASE HOMOLOG VACCINIA VIRUS (STRAIN COPENHAGEN) 127-168 PKRBI.sub.-- VACCV 30 KD PROTEIN KINASE HOMOLOG VACCINIA VIRUS (STRAIN WR) 127-168 PKRB1.sub.-- VARV 30 KD PROTEIN KINASE HOMOLOG VARIOLA VIRUS 123-171 PKRB2.sub.-- VACCC POSSIBLE PROTEIN KINASE B12 VACCINIA VIRUS (STRAIN COPENHAGEN) 147-181 PKRB2.sub.-- VACCV POSSIBLE PROTEIN KINASE B12 VACCINIA VIRUS (STRAIN WR) 147-181 PKRF1.sub.-- VACCC POSSIBLE PROTEIN KINASE F10 VACCINIA VIRUS (STRAIN COPENHAGEN) 169-203 PKRF1.sub.-- VACCP POSSIBLE PROTEIN KINASE F10 VACCINIA VIRUS (STRAIN L-IVP) 136-170 PKRF1.sub.-- VARV POSSIBLE PROTEIN KINASE F10 VARIOLA VIRUS 169-203 PKROS.sub.-- AVISU ROS TYROSINE KINASE AVIAN SARCOMA VIRUS (STRAIN UR2) 111-145 TRANSFORMING PROTEIN PKRYK.sub.-- AVIR3 TYROSINE-PROTEIN KINASE AVIAN RETROVIRUS RPL30 15-66 TRANSFORMING PROT PKTHY.sub.-- VACCV THYMIDYLATE KINASE VACCINIA VIRUS (STRAIN WR), 135-169 (STRAIN COPENHAGEN) PKYES.sub.-- AVISY TYROSINE-PROTEIN KINASE AVIAN SARCOMA VIRUS (STRAIN Y73) 174-233 TRANSFORMING PROT PL100.sub.-- ADE02 LATE 100 KD PROTEIN HUMAN ADENOVIRUS TYPE 2 441-475 PL100.sub.-- ADE05 LATE 100 KD PROTEIN HUMAN ADENOVIRUS TYPE 5 223-264 PL100.sub.-- ADE40 LATE 100 KD PROTEIN HUMAN ADENOVIRUS TYPE 40 191-232 408-442 PL100.sub.-- ADE41 LATE 100 KD PROTEIN HUMAN ADENOVIRUS TYPE 41 199-233 PL52.sub.-- ADE02 LATE L1 52 KD PROTEIN HUMAN ADENOVIRUS TYPE 2 238-284 301-349 PL52.sub.-- ADE05 LATE L2 52 KD PROTEIN HUMAN ADENOVIRUS TYPE 5 238-284 301-349 PLMP2.sub.-- EBV GENE TERMINAL PROTEIN EPSTEIN-BARR VIRUS (STRAIN B95-8) 144-179 294-338 PMCEL.sub.-- SFVKA MRNA CAPPING ENZYME SHOPE FIBROMA VIRUS (STRAIN KASZA) 54-152 622-656 PMCEL.sub.-- VACCC MRNA CAPPING ENZYME VACCINIA VIRUS (STRAIN COPENHAGEN) 1-41 623-657 PMCEL.sub.-- VACCV MRNA CAPPING ENZYME VACCINIA VIRUS (STRAIN WR) 1-41 623-657 PMCEL.sub.-- VARV MRNA CAPPING ENZYME VARIOLA VIRUS 1-39 623-657 PMCES.sub.-- VACCC MRNA CAPPING ENZYME VACCINIA VIRUS (STRAIN COPENHAGEN) 72-137 245-286 PMCES.sub.- - VACCV MRNA CAPPING ENZYME VACCINIA VIRUS (STRAIN WR) 72-137 245-286 PMCES.sub.-- VARV MRNA CAPPING ENZYME VARIOLA VIRUS 72-137 245-286 PMCE.sub.-- ASFB7 MRNA CAPPING ENZYME AFRICAN SWINE FEVER VIRUS (STRAIN BA71V) 116-157 279-313 738-772 PMOVP.sub.-- ORSV MOVEMENT PROTEIN ODONTOGLOSSUM RINGSPOT VIRUS 53-90 PMOVP.sub.-- PPMVS MOVEMENT PROTEIN PEPPER MILD MOTTLE VIRUS (STRAIN 26-66 SPAIN) PMOVP.sub.-- TMGMV MOVEMENT PROTEIN TOBACCO MILD GREEN MOSAIC VIRUS 29-66 (TMV STRAIN U2) PMOVP.sub.-- TMVTO MOVEMENT PROTEIN TOBACCO MOSAIC VIRUS (STRAIN TOMATO/L) 32-66 PMOVP.sub.-- TOMVA MOVEMENT PROTEIN TOMATO MOSAIC VIRUS (STRAIN LIIA) 32-80 PMOVP.sub.-- TOMVL MOVEMENT PROTEIN TOMATO MOSAIC VIRUS (STRAIN LII) 32-80 PMTC1.sub.-- CHVN1 MODIFICATION METHYLASE CVIBI CHLORELLA VIRUS NC-1A 222-256 PMTC2.sub.-- CHVP1 MODIFICATION METHYLASE CVIAII PARAMECIUM BURSARIA CHLORELLA VIRUS 1 116-164 PMYC.sub.-- AVIM2 MYC TRANSFORMING PROTEIN AVIAN MYELOCYTOMATOSIS VIRUS CM11 229-266 375-419 PMYC.sub.-- AVIMC MYC TRANSFORMING PROTEIN AVIAN MYELOCYTOMATOSIS VIRUS MC29 230-267 376-420 PMYC.sub.-- AVIMD MYC TRANSFORMING PROTEIN AVIAN MYELOCYTOMATOSIS VIRUS HB1 230-267 376-420 PMYC.sub.-- AVIME MYC TRANSFORMING PROTEIN AVIAN RETROVIRUS MH2E21 377-421 PMYC.sub.-- AVIOK MYC TRANSFORMING PROTEIN AVIAN RETROVIRUS OK10 224-261 370-414 PMYC.sub.-- FLV MYC TRANSFORMING PROTEIN FELINE LEUKEMIA VIRUS 393-437 PMYC.sub.-- FLVTT MYC TRANSFORMING PROTEIN FELINE LEUKEMIA PROVIRUS FTT 393-437 PNCA2.sub.-- CVMAS NUCLEOCAPSID PROTEIN MURINE CORONAVIRUS MHV (STRAIN A59) 12-46 PNCAP.sub.-- AINOV NUCLEOCAPSID PROTEIN AINO VIRUS 177-211 PNCAP.sub.-- BEV NUCLEOCAPSID PROTEIN BERNE VIRUS 46-83 122-156 PNCAP.sub.-- BRSVA NUCLEOCAPSID PROTEIN BOVINE RESPIRATORY SYNCYTIAL VIRUS 62-108 163-200 248-303 343-383 (STRAIN A51908) PNCAP.sub.-- BUNGE NUCLEOCAPSID PROTEIN BUNYAVIRUS GERMISTON 176-226 PNCAP.sub.-- BUNLC NUCLEOCAPSID PROTEIN BUNYAVIRUS LA CROSSE 176-229 PNCAP.sub.-- BUNSH NUCLEOCAPSID PROTEIN BUNYAVIRUS SNOWSHOE HARE 176-229 PNCAP.sub.-- BUNYW NUCLEOCAPSID PROTEIN BUNYAMWERA VIRUS 175-228 PNCAP.sub.-- CCHFV NUCLEOCAPSID PROTEIN CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS 223-306 427-461 (ISOLATE C6803 PNCAP.sub.-- CDVO NUCLEOCAPSID PROTEIN CANINE DISTEMPER VIRUS (STRAIN 137-174 179-217 354-402 ONDERSTEPOORT) PNCAP.sub.-- CHAV NUCLEOCAPSID PROTEIN CHANDIPURA VIRUS (STRAIN 1653514) 40-84 321-369 PNCAP.sub.-- CVBF NUCLEOCAPSID PROTEIN BOVINE CORONAVIRUS (STRAIN F15) 349-383 PNCAP.sub.-- CVBM NUCLEOCAPSID PROTEIN BOVINE CORONAVIRUS (STRAIN MEBUS) 349-383 PNCAP.sub.-- CVCAE NUCLEOCAPSID PROTEIN CANINE ENTERIC CORONAVIRUS (STRAIN K378) 165-227 PNCAP.sub.-- CVHOC NUCLEOCAPSID PROTEIN HUMAN CORONAVIRUS (STRAIN OC43) 349-383 PNCAP.sub.-- CVMJH NUCLEOCAPSID PROTEIN MURINE CORONAVIRUS MHV (STRAIN JHM) 12-46 PNCAP.sub.-- CVPFS NUCLEOCAPSID PROTEIN PORCINE TRANSMISSIBLE GASTROENTERITIS 149-206 CORONAVIRUS (S PNCAP.sub.-- CVPPU NUCLEOCAPSID PROTEIN PORCINE TRANSMISSIBLE GASTROENTERITIS 165-227 CORONAVIRUS (S PNCAP.sub.-- CVPR8 NUCLEOCAPSID PROTEIN PORCINE RESPIRATORY CORONAVIRUS (STRAIN 86/ 149-228 137004/BRIT PNCAP.sub.-- CVPRM NUCLEOCAPSID PROTEIN PORCINE RESPIRATORY CORONAVIRUS (STRAIN 149-228 RM4) PNCAP.sub.-- CVRSD NUCLEOCAPSID PROTEIN RAT CORONAVIRUS (STRAIN 681) 12-46 PNCAP.sub.-- CVTKE NUCLEOCAPSID PROTEIN TURKEY ENTERIC CORONAVIRUS 349-383 PNCAP.sub.-- DUGBV NUCLEOCAPSID PROTEIN DUGBE VIRUS 230-306 PNCAP.sub.-- FIPV NUCLEOCAPSID PROTEIN FELINE INFECTIOUS PERITONITIS VIRUS (STRAIN 151-286 79-1146) PNCAP.sub.-- HANTV NUCLEOCAPSID PROTEIN HANTAAN VIRUS (STRAIN 76-118) 1-35 40-74 333-381 PNCAP.sub.-- HAZVJ NUCLEOCAPSID PROTEIN HAZARA VIRUS (ISOLATE JC280) 233-237 PNCAP.sub.-- HRSV1 NUCLEOCAPSID PROTEIN HUMAN RESPIRATORY SYNCYTIAL VIRUS 62-145 163-200 248-303 343-380 (SUBGROUP B/STRAI PNCAP.sub.-- HRSVA NUCLEOCAPSID PROTEIN HUMAN RESPIRATORY SYNCYTIAL VIRUS 62-145 163-200 248-303 343-380 (STRAIN A2) PNCAP.sub.-- IBVG NUCLEOCAPSID PROTEIN AVIAN INFECTIOUS BRONCHITIS VIRUS 186-227 (STRAIN GRAY) PNCAP.sub.-- IBVK NUCLEOCAPSID PROTEIN AVIAN INFECTIOUS BRONCHITIS VIRUS 186-220 (STRAIN KB8523) PNCAP.sub.-- JUNIN NUCLEOCAPSID PROTEIN JUNIN ARENA VIRUS 96-151 PNCAP.sub.-- LASSG NUCLEOCAPSID PROTEIN LASSA VIRUS (STRAIN GA391) 65-113 126-174 PNCAP.sub.-- LASSJ NUCLEOCAPSID PROTEIN LASSA VIRUS (STRAIN JOSIAH) 65-113 122-174 467-504 PNCAP.sub.-- LDV NUCLEOCAPSID PROTEIN LACTATE DEHYDROGENASE-ELEVATING VIRUS( 3-40 PNCAP.sub.-- LYCVA NUCLEOCAPSID PROTEIN LYMPHOCYTIC CHORIOMENINGITIS VIRUS (STRAIN 45-117 460-497 ARMSTRON PNCAP.sub.-- LYCVW NUCLEOCAPSID PROTEIN LYMPHOCYTIC CHORIOMENINGITIS VIRUS (STRAIN 45-79 83-117 460-497 WE) PNCAP.sub.-- MAGV NUCLEOCAPSID PROTEIN MAGUARI VIRUS 175-228 PNCAP.sub.-- MEASE NUCLEOCAPSID PROTEIN MEASLES VIRUS (STRAIN EDMONSTON) 188-226 363-411 PNCAP.sub.-- MEASH NUCLEOCAPSID PROTEIN MEASLES VIRUS (STRAIN HALLE) 188-226 363-411 PNCAP.sub.-- MEAS1 NUCLEOCAPSID PROTEIN MEASLES VIRUS (STRAIN IP-3-CA) 188-226 363-411 PNCAP.sub.-- MEASY NUCLEOCAPSID PROTEIN MEASLES VIRUS (STRAIN YAMAGATA-1) 188-226 363-411 PNCAP.sub.-- MOPEI NUCLEOCAPSID PROTEIN MOPEIA VIRUS 65-106 471-505 PNCAP.sub.-- MUMP1 NUCLEOCAPSID PROTEIN MUMPS VIRUS (STRAIN SBL-1) 214-255 500-534 PNCAP.sub.-- MUMPM NUCLEOCAPSID PROTEIN MUMPS VIRUS (STRAIN MIYAHARA VACCINE) 214-255 PNCAP.sub.-- PHV NUCLEOCAPSID PROTEIN PROSPECT HILL VIRUS 1-35 40-74 337-392 PNCAP.sub.-- PI1HC NUCLEOCAPSID PROTEIN HUMAN PARAINFLUENZA 1 VIRUS (STRAIN C39) 212-272 441-510 PNCAP.sub.-- PI1HW NUCLEOCAPSID PROTEIN HUMAN PARAINFLUENZA 1 VIRUS (STRAIN 212-272 441-510 WASHINGTON/1957) PNCAP.sub.-- PI2HT NUCLEOCAPSID PROTEIN HUMAN PARAINFLUENZA 2 VIRUS (STRAIN 214-266 344-378 TOSHIBA) PNCAP.sub.-- PI3B NUCLEOCAPSID PROTEIN BOVINE PARAINFLUENZA 3 VIRUS 200-403 446-490 PNCAP.sub.-- PI3H4 NUCLEOCAPSID PROTEIN HUMAN PARAINFLUENZA 3 VIRUS (STRAIN 87-135 208-266 344-403 440-491 NIH 47885) PNCAP.sub.-- PI4HA NUCLEOCAPSID PROTEIN HUMAN PARAINFLUENZA 4A VIRUS (STRAIN 58-94 191-267 TOSHIBA) PNCAP.sub.-- PI4HB NUCLEOCAPSID PROTEIN HUMAN PARAINFLUENZA 4B VIRUS (STRAIN 68-33) 58-94 191-267 PNCAP.sub.-- PIARV NUCLEOCAPSID PROTEIN PICHINDE ARENAVIRUS 65-112 PNCAP.sub.-- PIRYV NUCLEOCAPSID PROTEIN PIRY VIRUS 71-116 325-359 PNCAP.sub.-- PUUMH NUCLEOCAPSID PROTEIN PUUMALA VIRUS (STRAIN HALLNAS B1) 1-35 40-75 337-392 PNCAP.sub.-- PUMMS NUCLEOCAPSID PROTEIN PUUMALA VIRUS (STRAIN SOTAKAMO) 1-35 40-75 337-385 PNCAP.sub.-- PVM NUCLEOCAPSID PROTEIN PNEUMONIA VIRUS OF MICE 93-141 248-303 344-388 PNCAP.sub.-- RABVA NUCLEOCAPSID PROTEIN RABIES VIRUS (STRAIN AVO1) 133-167 PNCAP.sub.-- SEND5 NUCLEOCAPSID PROTEIN SENDAI VIRUS (STRAIN Z/HOST MUTANTS) 212-272 345-404 PNCAP.sub.-- SENDE NUCLEOCAPSID PROTEIN SENDAI VIRUS (STRAIN ENDERS) 212-272 345-404 PNCAP.sub.-- SENDZ NUCLEOCAPSID PROTEIN SENDAI VIRUS (STRAIN Z) 212-272 345-408 PNCAP.sub.-- SEOUS NUCLEOCAPSID PROTEIN SEOUL VIRUS (STRAIN SR-11) 1-35 40-74 333-381 PNCAP.sub.-- SV41 NUCLEOCAPSID PROTEIN SIMIAN VIRUS 41 215-267 372-406 418-466 PNCAP.sub.-- SYNV NUCLEOCAPSID PROTEIN SONCHUS YELLOW NET VIRUS 332-366 PNCAP.sub.-- TACV NUCLEOCAPSID PROTEIN TACARIBE VIRUS 50-84 230-264 PNCAP.sub.-- TOSV NUCLEOCAPSID PROTEIN TOSCANA VIRUS 215-249 PNCAP.sub.-- TSWVB NUCLEOCAPSID PROTEIN TOMATO SPOTTED WILT VIRUS (BRAZILIAN 79-120 ISOLATE CHPNH1/BR- PNCAP.sub.-- TSWVH NUCLEOCAPSID PROTEIN TOMATO SPOTTED WILT VIRUS (HAWAIIAN 79-120 ISOLATE) PNCAP.sub.-- TSWVL NUCLEOCAPSID PROTEIN TOMATO SPOTTED WILT VIRUS (STRAIN L3) 79-120 PNCAP.sub.- - UUK NUCLEOCAPSID PROTEIN UUKUNIEMI VIRUS 51-102 PNCAP.sub.-- VHSV0 NUCLEOCAPSID PROTEIN VIRAL HEMORRHAGIC SEPTICEMIA VIRUS (STRAIN 249-325 07-71) PNCAP.sub.-- VHSVM NUCLEOCAPSID PROTEIN VIRAL HEMORRHAGIC SEPTICEMIA VIRUS 142-180 249-325 (STRAIN MAKAH) PNCAP.sub.-- VSVIG NUCLEOCAPSID PROTEIN VESICULAR STOMATITIS VIRUS (SEROTYPE 42-108 INDIANA/STRAIN G PNCAP.sub.-- VSVJO NUCLEOCAPSID PROTEIN VESICULAR STOMATITIS VIRUS (SEROTYPE 67-115 NEW JERSEY/STRA PNCAP.sub.-- VSVSJ NUCLEOCAPSID PROTEIN VESICULAR STOMATITIS VIRUS (STRAIN SAN JUAN) 42-115 PNEF.sub.-- HV2BE NEGATIVE FACTOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 7-48 (ISOLATE BEN) PNEF.sub.-- HV2D1 NEGATIVE FACTOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 7-41 (ISOLATE D194) PNEF.sub.-- HV2RO NEGATIVE FACTOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 112-160 (ISOLATE ROD) PNEF.sub.-- HV2SB NEGATIVE FACTOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 109-150 (ISOLATE SBLISY) PNEF.sub.-- HV2ST NEGATIVE FACTOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 108-149 (ISOLATE ST) PNEF.sub.-- SIVAI NEGATIVE FACTOR SIMIAN IMMUNODEFICIENCY VIRUS 96-140 (ISOLATE AGM/CLONE GR1 PNEF.sub.-- SIVS4 NEGATIVE FACTOR SIMIAN IMMUNODEFICIENCY VIRUS 9-43 233-267 (F236/SMH4 ISOLATE) PNRAM.sub.-- IABDA NEURAMINIDASE INFLUENZA A VIRUS (STRAIN A/BLACK DUCK/ 47-81 AUSTRALIA/702/78 PNRAM.sub.-- IACAO NEURAMINIDASE INFLUENZA A VIRUS (STRAIN A/CAMEL/MONGOLIA/ 33-74 82) PNRAM.sub.-- IACHI NEURAMINIDASE INFLUENZA A VIRUS (STRAIN A/CHILE/83) 50-91 PNRAM.sub.-- IACKQ NEURAMINIDASE INFLUENZA A VIRUS (STRAIN A/CHICKEN/ 349-383 PENNSYLVANIA/1370/ PNRAM.sub.-- IACKR NEURAMINIDASE INFLUENZA A VIRUS (STRAIN A/CHICKEN/ 349-383 PENNSYLVANIA/1370/ PNRAM.sub.-- IADGE NEURAMINIDASE INFLUENZA A VIRUS (STRAIN A/DUCK/GERMANY/49) 14-48 PNRAM.sub.-- IAFPW NEURAMINIDASE INFLUENZA A VIRUS (STRAIN A/FOWL PLAGUE 14-48 194-229 VIRUS/WEYBRID PNRAM.sub.-- IAHCO NEURAMINIDASE INFLUENZA A VIRUS (STRAIN A/EQUINE/COR/16/74 10-47 193-227 PNRAM.sub.-- IAHKI NEURAMINIDASE INFLUENZA A VIRUS (STRAIN A/EQUINE/KENTUCKY/ 5-44 361-402 1/81) PNRAM.sub.-- IAKIE NEURAMINIDASE INFLUENZA A VIRUS (STRAIN A/KIEV/59/79) 50-91 PNRAM.sub.-- IALEN NEURAMINIDASE INFLUENZA A VIRUS (STRAIN A/ 50-91 LENINGRAD/54/1) PNRAM.sub.-- IAME1 NEURAMINIDASE INFLUENZA A VIRUS (STRAIN A/ 50-88 MEMPHIS/1/71H-A/BELLAMY/42N PNRAM.sub.-- IARUE NEURAMINIDASE INFLUENZA A VIRUS (STRAIN A/RUDDY 49-91 TURNSTONE/NEW JERSE PNRAM.sub.-- IASH2 NEURAMINIDASE INFLUENZA A VIRUS (STRAIN A/SHEARWATER/ 10-44 AUSTRALIA/72) PNRAM.sub.-- IATKR NEURAMINIDASE INFLUENZA A VIRUS (STRAIN A/TURKEY/OREGON/ 7-41 71) PNRAM.sub.-- IATRA NEURAMINIDASE INFLUENZA A VIRUS (STRAIN A/TERN/AUSTRALIA/ 49-83 G70C/75) PNRAM.sub.-- IAUSS NEURAMINIDASE INFLUENZA A VIRUS (STRAIN A/USSR/90/77) 49-91 PNRAM.sub.-- IAWHM NEURAMINIDASE INFLUENZA A VIRUS (STRAIN A/WHALE/MAINE/1/84) 49-91 PNRAM.sub.-- INBBE NEURAMINIDASE INFLUENZA B VIRUS (STRAIN B/BEIJING/1/87) 5-46 348-382 PNRAM.sub.-- INBHK NEURAMINIDASE INFLUENZA B VIRUS (STRAIN B/HONG KONG/8/73) 5-46 349-383 PNRAM.sub. -- INBLE NEURAMINIDASE INFLUENZA B VIRUS (STRAIN B/LEE/40) 5-46 349-383 PNRAM.sub.-- INBLN NEURAMINIDASE INFLUENZA B VIRUS (STRAIN B/LENINGRAD/179/86), 5-39 348-382 (STRAIN B/M PNRAM.sub.-- INBMD NEURAMINIDASE INFLUENZA B VIRUS (STRAIN B/MARYLAND/59) 5-39 349-383 PNRAM.sub.-- INBMF NEURAMINIDASE INFLUENZA B VIRUS (STRAIN B/MEMPHIS/3/89) 5-46 348-282 PNRAM.sub.-- INBOR NEURAMINIDASE INFLUENZA B VIRUS (STRAIN B/OREGON/5/80) 5-46 349-383 PNRAM.sub.-- INBSI NEURAMINIDASE INFLUENZA B VIRUS (STRAIN B/SINGAPORE/222/79) 5-39 349-383 PNRAM.sub.-- INBUS NEURAMINIDASE INFLUENZA B VIRUS (STRAIN B/USSR/100/83) 5-39 349-383 PNRAM.sub.-- INBVI NEURAMINIDASE INFLUENZA B VIRUS (STRAIN B/VICTORIA/3/85 5-39 348-382 PNS2.sub.-- SIDEV PROBABLE STRUCTURAL PROTEIN BOMBYX DENSONUCLEGSIS VIRUS 790-828 PRECURSOR PNSS.sub.-- INSVN NON-STRUCTURAL PROTEIN IMPATIENS NECROTIC SPOT VIRUS (STRAIN NL-07) 95-129 204-238 PNSS.sub.-- TSWVB NON-STRUCTURAL PROTEIN TOMATO SPOTTED WILT VIRUS (BRAZILIAN 3-37 ISOLATE CPNH1/BR3 PNSS.sub.-- TSWVL NON-STRUCTURAL PROTEIN TOMATO SPOTTED WILT VIRUS (STRAIN L3) 3-37 PNTP1.sub.- - AMEPV NUCLEOSIDE TRIPHOSPHATASE I AMSACTA MOOREI ENTOMOPOXVIRUS 28-69 110-144 PNTP1.sub.-- CBEPV NUCLEOSIDE TRIPHOSPHATASE I CHORISTONEURA BIENNIS ENTOSIOPOXVIRUS 122-169 415-449 514-555 PNTP1.sub.-- VACCC NUCLEOSIDE TRIPHOSPHATASE I VACCINIA VIRUS (STRAIN COPENHAGEN) 56-83 248-289 549-599 PNTP1.sub.-- VACCV NUCLEOSIDE TRIPHOSPHATASE I VACCINIA VIRUS (STRAIN WR) 56-90 248-289 549-599 PNTP1.sub.-- VARV NUCLEOSIDE TRIPHOSPHATASE I VARIOLA VIRUS 154-195 455-505 PP100.sub.-- HSV6U MAJOR ANTIGENIC STRUCTURAL HERPES SIMPLEX VIRUS (TYPE 6/STRAIN 189-223 689-735 PROTEIN UGANDA-1102) PPAP1.sub.-- VACCC POLY(A)POLYMERASE CATALYTIC VACCINIA VIRUS (STRAIN COPENHAGEN) 121-180 SUBUNIT PPAP1.sub.-- VACCV POLY(A)POLYMERASE CATALYTIC VACCINIA VIRUS (STRAIN WR) 121-180 SUBUNIT PPAP1.sub.-- VARV POLY(A)POLYMERASE CATALYTIC VARIOLA VIRUS 121-180 SUBUNIT PPAP2.sub.-- CAPVK POLY(A)POLYMERASE REGULATORY CAPRIPOXVIRUS (STRAIN KS-1) 112-146 SUBUNIT PPAP2.sub.-- FOWPV POLY(A)POLYMERASE REGULATORY FOWLPOX VIRUS 95-154 SUBUNIT PPAP2.sub.-- VACCC POLY(A)POLYMERASE REGULATORY VACCINIA VIRUS (STRAIN COPENHAGEN) 203-249 SUBUNIT PPAP2.sub.-- VACCV POLY(A)POLYMERASE REGULATORY VACCINIA VIRUS (STRAIN WR) 203-249 SUBUNIT PPAP2.sub.-- VARV POLY(A)POLYMERASE REGULATORY VARIOLA VIRUS 203-249 SUBUNIT PPE12.sub.-- NPVAC 12.1 KD PROTEIN IN PE 5'REGION AUTOGRAPHA CALIFORNICA NUCLEAR 15-56 60-105 POLYHEDROSIS VIRUS PPE12.sub.-- NPVOP 11.5 KD PROTEIN IN P26 5'REGION ORGYIA PSEUDOTSUGATA MULTICAPSID 11-98 POLYHEDROSIS VIRUS PPE38.sub.-- NPVAC MAJOR IMMEDIATE EARLY PROTEIN AUTOGRAPHA CALIFORNICA NUCLEAR 19-77 197-249 POLYHEDROSIS VIRUS PPE38.sub.-- NPVOP MAJOR IMMEDIATE EARLY PROTEIN ORGYIA PSEUDOTSUGATA MULTICAPSID 190-240 POLYHEDROSIS VIRUS PPE48.sub.-- NPVAC 48.3 KD PROTEIN IN PE-P26 AUTOGRAPHA CALIFORNICA NUCLEAR 4-42 46-89 97-131 INTERGENIC REGION POLYHEDROSIS VIRUS PPE48.sub.-- NPVOP 47.3 KD PROTEIN IN PE-P26 ORGYIA PSEUDOTSUGATA MULTICAPSID 47-82 165-199 INTERGENIC REGION POLYHEDROSIS VIRUS PPIV2.sub.-- ADE07 MATURATION PROTEIN HUMAN ADENOVIRUS TYPE 7 414-448 PPIV6.sub.-- ADE02 PROTEIN VI PRECURSOR HUMAN ADENOVIRUS TYPE 2 37-71 PPIV6.sub.-- ADE05 PROTEIN VI PRECURSOR HUMAN ADENOVIRUS TYPE 5 37-71 PPOL1.sub.-- BAYMG GENOME POLYPROTEIN 1 BARLEY YELLOW MOSAIC VIRUS (GERMAN 329-363 743-777 957-991 1265- 2229- 2309- 2368- ISOLATE) 1299 2266 2352 2404 PPOL1.sub.-- BAYMJ GENOME POLYPROTEIN 1 BARLEY YELLOW MOSAIC VIRUS (JAPANESE 329-363 671-705 743-777 957-994 1265- 2227- 2307- 2366- STRAIN II-1) 1299 2264 2350 2402 PPOL1.sub.-- GCMV RNA1 POLYPROTEIN HUNGARIAN GRAPEVINE CHROME MOSAIC VIRUS 120-161 165-216 230-273 377-415 PPOL1.sub.-- GFLV RNA1 POLYPROTEIN GRAPEVINE FANLEAF VIRUS 170-212 488-519 636-677 691-725 1157- 1378- 1906- 1196 1412 1943 PPOL1.sub.-- TBRVS RNA1 POLYPROTEIN TOMATO BLACK RING VIRUS (STRAIN S) 223-278 929-977 PPOL2.sub.-- TRSVR RNA1 POLYPROTEIN TOMATO RINGSPOT VIRUS (ISOLATE RASPBERRY) 161-206 PPOL2.sub.-- BAYMG GENOME POLYPROTEIN 2 BARLEY YELLOW MOSAIC VIRUS (GERMAN 240-281 669-732 739-773 787-628 ISOLATE) PPOL2.sub.-- BAYMJ GENOME POLYPROTEIN 2 BARLEY YELLOW MOSAIC VIRUS (JAPANESE 669-732 739-773 787-828 STRAIN II-I) PPOL2.sub.-- GFLV RNA2 POLYPROTEIN GRAPEVINE FANLEAF VIRUS 365-406 542-602 PPOL2.sub.-- TBRVS RNA2 POLYPROTEIN TOMATO BLACK RING VIRUS (STRAIN S) 4-38 PPOL2.sub.-- TRSVR RNA2 POLYPROTEIN TOMATO RINGSPOT VIRUS (ISOLATE RASPBERRY) 158-206 334-368 PPOLG.sub.-- BOVEV GENOME POLYPROTEIN BOVINE ENTEROVIRUS (STRAIN VG-5-27) 849-886 1008- 1382- 1459- 1576- 1064 1416 1507 1617 PPOLG.sub.-- BVDVN GENOME POLYPROTEIN BOVINE VIRAL DIARRHEA VIRUS (ISOLATE NADL) 244-289 446-491 629-663 1033- 1303- 1392- 1869- 2226- 1074 1344 1443 1910 2260 PPOLG.sub.-- BVDVS GENOME POLYPROTEIN BOVINE VIRAL DIARRHEA VIRUS (STRAIN SD-1) 245-289 446-491 629-663 1033- 1303- 1392- 1779- 2136- 1074 1344 1443 1829 2170 PPOLG.sub.-- BYMV GENOME POLYPROTEIN BEAN YELLOW MOSAIC VIRUS 96-130 PPOLG.sub.-- COXA2 GENOME POLYPROTEIN COXSACKIE VIRUS A21 (STRAIN COE) 9-43 562-596 664-698 1045- 1498- 1607- 1805- 1901- 1100 1546 1648 1839 1946 PPOLG.sub.-- COXA9 GENOME POLYPROTEIN COXSACKIE VIRUS A9 (STRAIN GRIGGS) 15-49 1040- 1895- 1086 1940 PPOLG.sub.-- COXB1 GENOME POLYPROTEIN COXSACKIE VIRUS B1 15-49 1021- 1876- 1067 1921 PPOLG.sub.-- COXB3 GENOME POLYPROTEIN COXSACKIE VIRUS B3 15-49 1024- 1879- 1970 1924 PPOLG.sub.-- COXB4 GENOME POLYPROTEIN COXSACKIE VIRUS B4 15-49 642-681 1022- 1877- 1068 1922 PPOLG.sub.-- COXB5 GENOME POLYPROTEIN COXSACKIE VIRUS B5 15-49 1024- 1879- 1070 1924 PPOLG.sub.-- CYVV GENOME POLYPROTEIN CLOVER YELLOW VEIN VIRUS 120-154 PPOLG.sub.-- DEN18 GENOME POLYPROTEIN DENGUE VIRUS TYPE 1 (STRAIN 836-1) 74-108 PPOLG.sub.-- DEN1A GENOME POLYPROTEIN DENGUE VIRUS TYPE 1 (STRAIN AHF 82-80) 74-108 PPOLG.sub.-- DEN1C GENOME POLYPROTEIN DENGUE VIRUS TYPE 1 (STRAIN CV1636/77) 74-108 PPOLG.sub. -- DEN1S GENOME POLYPROTEIN DENGUE VIRUS TYPE 1 (STRAIN SINGAPORE S275/90) 74-108 832-873 960-994 1142- 1386- 1614- 2518- 2946- 1179 1420 1648 2554 3016 PPOLG.sub.-- DEN1W GENOME POLYPROTEIN DENGUE VIRUS TYPE 1 (STRAIN WESTERN PACIFIC) 74-108 833-874 961-995 1143- 1180 PPOLG.sub.-- DEN21 GENOME POLYPROTEIN DENGUE VIRUS TYPE 2 (ISOLATE MALAYSIA M1) 448-492 PPOLG.sub.-- DEN22 GENOME POLYPROTEIN DENGUE VIRUS TYPE 2 (ISOLATE MALAYSIA M2) 448-495 PPOLG.sub.-- DEN26 GENOME POLYPROTEIN DENGUE VIRUS TYPE 2 (STRAIN 16681) 74-108 728-777 961-995 1146-1180 1246-1280 1418-1452 1615-1649 2517-2551 PPOLG.sub.-- DEN27 GENOME POLYPROTEIN DENGUE VIRUS TYPE 2 (STRAIN 16681-PDK53) 74-108 728-777 961-995 1146-1180 1246-1280 1418-1452 1615-1649 2485-2551 PPOLQ.sub.-- DEN2D GENOME POLYPROTEIN DENGUE VIRUS TYPE 2 (STRAIN D2-04) 728-777 PPOLG.sub.-- DEN2H GENOME POLYPROTEIN DENGUE VIRUS TYPE 2 (STRAIN TH-36) 497-546 PPOLG.sub.-- DEN2J GENOME POLYPROTEIN DENGUE VIRUS TYPE 2 (STRAIN JAMAICA) 74-108 728-777 961-995 1146-1180 1246-1280 1418-1452 1615-1649 2517-2551 PPOLG.sub.-- DEN2N GENOME POLYPROTEIN DENGUE VIRUS TYPE 2 (STRAIN NEW GUINEA C) 213-247 398-432 PPOLG.sub.-- DEN2P GENOME POLYPROTEIN DENGUE VIRUS TYPE 2 (STRAIN PR159/S1) 74-108 728-777 832-875 961-995 1146-1180 1246-1280 1418-1452 1615-1649 PPOLG.sub.-- DEN2T GENOME POLYPROTEIN DENGUE VIRUS TYPE 2 (STRAIN TONGA 1974) 448-497 552-595 681-715 866-900 966-1000 1205-1239 PPOLG.sub.-- DEN2U GENOME POLYPROTEIN DENGUE VIRUS TYPE 2 (STRAIN PUO-218) 614-663 PPOLG.sub.-- DEN3 GENOME POLYPROTEIN DENGUE VIRUS TYPE 3 830-872 959-993 1385-1419 2224-2258 2480-2521 2704-2738 2940-2978 2980-3014 PPOLG.sub.-- DEN4 GENOME POLYPROTEIN DENGUE VIRUS TYPE 4 957-993 1380-1414 2514-2555 2701-2735 2941-2975 2977-3011 PPOLG.sub.-- EC11G GENOME POLYPROTEIN ECHOVIRUS 11 (STRAIN GREGORY) 213-259 1079-1113 PPOLG.sub.-- EMCV GENOME POLYPROTEIN ENCEPHALOMYOCARDITIS VIRUS 1074-1115 1472-1518 1522-1570 1665-1706 1789-1823 PPOLG.sub.-- EMCVB GENOME POLYPROTEIN ENCEPHALOMYOCARDITIS VIRUS (STRAIN EMC-B 145-179 1076-1117 1474-1520 1524-1572 1667-1708 NONDIABETO PPOLG.sub.-- EMCVD GENOME POLYPROTEIN ENCEPHALOMYOCARDITIS VIRUS (STRAIN EMC-D 145-179 1076-1117 1474-1520 1524-1572 1667-1708 DIABETOGEN PPOLG.sub.-- ENMG3 GENOME POLYPROTEIN MENGO ENCEPHALOMYOCARDITIS VIRUS (STRAIN 145-179 37A) PPOLQ.sub.-- ENMGO GENOME POLYPROTEIN MENGO ENCEPHALOMYOCARDITIS VIRUS 78-112 PPOLG.sub.-- FMDV1 GENOME POLYPROTEIN FOOT-AND-MOUTH DISEASE VIRUS (STRAIN A10-61) 221-255 294-328 578-612 1103-1153 1493-1528 2165-2200 PPOLG.sub.-- FMDVA GENOME POLYPROTEIN FOOT-AND-MOUTH DISEASE VIRUS (STRAIN A12) 220-254 293-327 577-611 1103-1164 1493-1528 2164-2199 PPOLG.sub.-- FMDVO GENOME POLYPROTEIN FOOT-AND-MOUTH DISEASE VIRUS (STRAINS O1K 221-255 1103-1153 1493-1528 2164-2199 AND O1BFS) PPOLG.sub.-- FMDVS GENOME POLYPROTEIN FOOT-AND-MOUTH DISEASE VIRUS (STRAIN 87-128 693-728 C1-SANTA PAU [C--S PPOLG.sub.-- FMDVT GENOME POLYPROTEIN FOOT-AND-MOUTH DISEASE VIRUS (STRAIN C1) 221-255 283-317 577-611 PPOLG.sub.-- HCV1 GENOME POLYPROTEIN HEPATITIS C VIRUS (ISOLATE 1) 364-398 PPOLG.sub.-- HCVA GENOME POLYPROTEIN HOG CHOLERA VIRUS (STRAIN ALFORT) 440-493 626-660 695-729 1033-1070 1190-1235 1307-1343 1779-1820 2136-2170 2466-2500 2525-2559 2667-2708 3057-3098 3152-3193 3406-3440 PPOLG.sub.-- HCVB GENOME POLYPROTEIN HOG CHOLERA VIRUS (STRAIN BRESCIA) 440-493 626-660 695-729 1033-1070 1173-1235 1779-1820 2136-2170 2388-2436 PPOLG.sub.-- HCVBK 2466-2500 2525-2559 2667-2708 3057-3098 3152-3195 3406-3440 3521-3562 PPOLG.sub.-- HCVE0 GENOME POLYPROTEIN HEPATITIS C VIRUS (ISOLATE BK) 357-398 2328-2365 PPOLG.sub.-- HCVH GENOME POLYPROTEIN HEPATITIS C VIRUS (ISOLATE EC10) 65-99 PPOLG.sub.-- HCVH4 GENOME POLYPROTEIN HEPATITIS C VIRUS (ISOLATE H) 364-398 PPOLG.sub.-- HCVH7 GENOME POLYPROTEIN HEPATITIS C VIRUS (ISOLATE HCV-476) 364-398 PPOLG.sub.-- HCVH8 GENOME POLYPROTEIN HEPATITIS C VIRUS (ISOLATE HCT27) 236-270 PPOLG.sub.-- HCVHK GENOME POLYPROTEIN HEPATITIS C VIRUS (ISOLATE HCT18) 248-282 PPOLG.sub.-- HCVJ2 GENOME POLYPROTEIN HEPATITIS C VIRUS (ISOLATE HCV-KF) 357-398 PPOLG.sub.-- HCVJ5 GENOME POLYPROTEIN HEPATITIS C VIRUS (ISOLATE HC-J2) 357-388 PPOLG.sub.-- HCVJ6 GENOME POLYPROTEIN HEPATITIS C VIRUS (ISOLATE HC-J5) 364-398 PPOLG.sub.-- HCVJ7 GENOME POLYPROTEIN HEPATITIS C VIRUS (ISOLATE HC-J6) 364-401 1716-1750 2082-2116 PPOLG.sub.-- HCVJ8 GENOME POLYPROTEIN HEPATITIS C VIRUS (ISOLATE HC-J7) 364-398 PPOLG.sub.-- HCVJA GENOME POLYPROTEIN HEPATITIS C VIRUS (ISOLATE HC-J8) 364-398 1716-1750 2082-2116 2468-2502 2538-2572 PPOLG.sub.-- HCVJT GENOME POLYPROTEIN HEPATITIS C VIRUS (ISOLATE JAPANESE) 357-405 2331-2365 PPOLG.sub.-- HCVTW GENOME POLYPROTEIN HEPATITIS C VIRUS (ISOLATE HC-JT) 357-391 2331-2365 PPOLG.sub.-- HPAV2 GENOME POLYPROTEIN HEPATITIS C VIRUS (ISOLATE TAIWAN) 357-398 2328-2365 2444-2503 PPOLG.sub.-- HPAV4 GENOME POLYPROTEIN HEPATITIS A VIRUS (STRAIN 24A) 2-43 101-135 203-237 870-904 1021-1055 1117-1151 PPOLG.sub.-- HPAV8 GENOME POLYPROTEIN HEPATITIS A VIRUS (STRAIN 43C) 2-43 101-135 203-237 870-904 1021-1055 1117-1151 PPOLG.sub.-- HPAVC GENOME POLYPROTEIN HEPATITIS A VIRUS (STRAIN 18F) 2-43 101-135 203-237 870-904 1021-1055 1117-1151 PPOLG.sub.-- HPAVG GENOME POLYPROTEIN HEPATITIS A VIRUS (STRAIN CR326) 2-43 101-135 203-237 PPOLG.sub.-- HPAVH GENOME POLYPROTEIN HEPATITIS A VIRUS (STRAIN GA76) 80-114 182-216 PPOLG.sub.-- HPAVL GENOME POLYPROTEIN HEPATITIS A VIRUS (STRAIN HM-175) 2-43 101-135 203-237 870-904 1021-1055 1103-1151 PPOLG.sub.-- HPAVM GENOME POLYPROTEIN HEPATITIS A VIRUS (STRAIN LA) 2-43 101-135 203-237 870-904 1021-1055 1103-1151 PPOLG.sub.-- HPAVS GENOME POLYPROTEIN HEPATITIS A VIRUS (STRAIN MBB) 2-43 101-135 203-237 870-984 1021-1055 1103-1158 PPOLG.sub.-- HPAVT GENOME POLYPROTEIN SIMIAN HEPATITIS A VIRUS (STRAIN AGM-27) 6-47 105-139 207-241 849-908 1025-1059 1115-1155 1158-1198 PPOLG.sub.-- HRV14 GENOME POLYPROTEIN SIMIAN HEPATITIS A VIRUS (STRAIN CY-145) 2-43 101-135 203-237 PPOLG.sub.-- HRV1A GENOME POLYPROTEIN HUMAN RHINOVIRUS 14 (HRV-14) 1020-1054 1393-1427 1479-1513 1877-1920 PPOLG.sub.-- HRV1B GENOME POLYPROTEIN HUMAN RHINOVIRUS 1A (HRV-1A) 362-396 PPOLG.sub.-- HRV2 GENOME POLYPROTEIN HUMAN RHINOVIRUS 1B (HRV-1B) 387-421 863-904 1133-1168 PPOLG.sub.-- HRV89 GENOME POLYPROTEIN HUMAN RHINOVIRUS 2 (HRV-2) 856-897 1126-1169 1552-1593 PPOLG.sub.-- HUEV7 GENOME POLYPROTEIN HUMAN RHINOVIRUS 89 (HRV-89) 1566-1607 PPOLG.sub.-- IBDVO GENOME POLYPROTEIN HUMAN ENTEROVIRUS 70 (STRAIN J670/71) 359-397 876-917 1032-1088 1403-1441 1896-1934 PPOLG.sub.-- JAEV1 STRUCTURAL POLYPROTEIN AVIAN INFECTIOUS BURSAL DISEASE VIRUS 134-168 250-291 475-524 (STRAIN OH) PPOLG.sub.-- JAEV5 GENOME POLYPROTEIN JAPANESE ENCEPHALITIS VIRUS (STRAIN SA-14) 74-122 211-256 539-576 980-1014 1409-1450 2463-2497 2739-2777 2782-2823 3322-3359 3387-3428 PPOLG.sub.-- JAEVJ GENOME POLYPROTEIN JAPANESE ENCEPHALITIS VIRUS (STRAIN SA(V)) 74-122 211-256 539-576 980-1014 1409-1450 2463-2497 2739-2777 2782-2823 3322-3359 3387-3428 PPOLG.sub.-- JAEVN GENOME POLYPROTEIN JAPANESE ENCEPHALITIS VIRUS (STAIN JAOARS982) 74-128 211-256 539-576 980-1014 1409-1450 2463-2497 2739-2777 2782-2823 3322-3359 3387-3428 PPOLG.sub.-- KUNJM GENOME POLYPROTEIN JAPANESE ENCEPHALITIS VIRUS (STRAIN 7-48 138-183 467-504 908-942 1337-1378 NAKAYAMA) PPOLG.sub.-- LANVT GENOME POLYPROTEIN KUNJIN VIRUS (STRAIN MRM61C) 74-108 207-251 851-885 2464-2498 2528-2579 2740-2778 3325-3359 3389-3423 PPOLG.sub.-- LANVY GENOME POLYPROTEIN LANGAT VIRUS (STRAIN TP21) 68-102 431-465 962-996 1431-1472 1932-1966 2536-2591 2967-3001 3003-3037 3102-3145 PPOLG.sub.-- LIV GENOME POLYPROTEIN LANGAT VIRUS (STRAIN YELANTSEV) 68-102 431-465 PPOLG.sub.-- LIVSB GENOME POLYPROTEIN LOUPING ILL VIRUS (LI) 68-123 231-272 431-465 PPOLG.sub.-- MCFA GENOME POLYPROTEIN LOUPING ILL VIRUS (STRAIN SB 526) 151-185 PPOLG.sub.-- MVEV GENOME POLYPROTEIN MOSQUITO CELL FUSING AGENT (CFA FLAVIVIRUS) 80-114 908-942 2049-2087 2630-2689 3036-3095 3290-3341 PPOLG.sub.-- OMV GENOME POLYPROTEIN MURRAY VALLEY ENCEPHALITIS VIRUS 67-115 209-253 853-887 979-1013 1408-1449 PPOLG.sub.-- PEMVC GENOME POLYPROTEIN ORNITHOGALUM MOSAIC VIRUS 481-515 946-984 1072-1106 PPOLG.sub.-- POLIM GENOME POLYPROTEIN PEPPER MOTTLE VIRUS (CALIFORNIA ISOLATE) 55-100 207-248 377-411 704-738 827-862 877-947 1021-1055 1167-1201 1488-1529 1787-1821 1948-1982 2202-2236 2258-2310 2805-2839 3003-3037 PPOLG.sub.-- POL1S GENOME POLYPROTEIN POLIOVIRUS TYPE 1 (STRAIN MAHONEY) 1046-1101 1414-1448 1500-1548 1806-1840 1902-1947 PPOLG.sub.-- POL2L GENOME POLYPROTEIN POLIOVIRUS TYPE 1 (STRAIN SABIN) 9-43 899-933 1047-1102 1415-1449 1501-1549 1610-1651 1808-1842 1904-1949 PPOLG.sub.-- POL2W GENOME POLYPROTEIN POLIOVIRUS TYPE 2 (STRAIN LANSING) 9-43 897-831 1045-1100 1413-1447 1502-1547 1608-1649 1806-1840 1902-1947 PPOLG.sub.-- POL32 GENOME POLYPROTEIN POLIOVIRUS TYPE 2 (STRAIN-2) 9-43 897-831 1045-1100 1413-1447 1502-1547 1608-1649 1806-1840 1902-1947 PPOLG.sub.-- POL3L GENOME POLYPROTEIN POLIOVIRUS TYPE 3 (STRAIN 23127) 9-43 896-930 1044-1098 1412-1446 1498-1546 1607-1648 1805-1839 1901-1946 PPOLG.sub.-- PPVD GENOME POLYPROTEIN POLIOVIRUS TYPE 3 (STRAINS P3/LEON/37 AND 9-43 896-930 1044-1099 1412-1446 1498-1546 1607-1648 1805-1839 1901-1946 P3/LEON 12A[1]B) PPOLG.sub.-- PPVEA GENOME POLYPROTEIN PLUM POX POTYVIRUS (STRAIN D) 164-208 441-503 728-769 815-867 921-955 1741-1782 PPOLG.sub.-- PPVNA GENOME POLYPROTEIN PLUM POX POTYVIRUS (STRAIN EL AMAR) 116-157 784-818 1146-1197 PPOLG.sub.-- PPVRA GENOME POLYPROTEIN PLUM POX POTYVIRUS (ISOLATE NAT) 164-208 403-437 440-502 727-768 814-873 920-954 1740-1781 PPOLG.sub.-- PRSVH GENOME POLYPROTEIN PLUM POX POTYVIRUS (STRAIN RANKOVIC) 164-208 403-437 440-502 727-768 814-866 920-954 1740-1781 PPOLG.sub.-- PRSVP GENOME POLYPROTEIN PAPAYA RINGSPOT VIRUS (STRAIN P/MUTANT HA) 68-102 434-468 PPOLG.sub.-- PRSVW GENOME POLYPROTEIN PAPAYA RINGSPOT VIRUS (STRAIN P/MUTANT 325-359 HA 5-1) PPOLG.sub.-- PSBMV GENOME POLYPROTEIN PAPAYA RINGSPOT VIRUS (STRAIN W) 325-359 PPOLG.sub.-- PVYC GENOME POLYPROTEIN PEA SEED-BORNE MOSAIC VIRUS (STRAIN DPD1) 253-315 355-389 529-589 935-976 984-1018 1080-1177 1588-1627 1808-1860 1971-2015 2379-2413 2712-2746 2870-2907 PPOLG.sub.-- PVYHU GENOME POLYPROTEIN POTATO VIRUS Y (STRAIN C) 131-196 701-735 802-856 PPOLG.sub.-- PVYN GENOME POLYPROTEIN POTATO VIRUS Y (STRAIN HUNGARIAN) 144-181 701-735 802-863 901-949 1401-1441 1492-1526 1728-1772 1777-1818 2272-2306 PPOLG.sub.-- PVYO GENOME POLYPROTEIN POTATO VIRUS Y (STRAIN N) 140-196 211-245 701-735 802-863 1401-1441 1492-1526 1728-1772 1777-1818 1929-1970 PPOLG.sub.-- PWVSE GENOME POLYPROTEIN POTATO VIRUS Y (STRAIN O) 140-196 211-245 701-735 802-856 PPOLG.sub.-- PWVTB GENOME POLYPROTEIN PASSIONFRUIT WOODINESS VIRUS (STRAIN SEVERE) 203-237 PPOLG.sub.-- PYFVI GENOME POLYPROTEIN PASSIONFRUIT WOODINESS VIRUS (STRAIN TIP 203-237 BRIGHT) PPOLG.sub.-- STEVM GENOME POLYPROTEIN PARSNIP YELLOW FLECK VIRUS (ISOLATE P-121) 194-228 1111-1172 1379-1413 1858-1899 1950-1991 2703-2737 PPOLG.sub.-- SVDVH GENOME POLYPROTEIN ST. LOUIS ENCEPHALITIS VIRUS (STRAIN MS1-7) 106-143 673-707 739-773 975-1009 1404-1438 PPOLG.sub.-- SVDVU GENOME POLYPROTEIN SWINE VESICULAR DISEASE VIRUS (STRAIN H/3 '76) 15-49 1024-1070 1779-1813 1890-1924 PPOLG.sub.-- TBEVS GENOME POLYPROTEIN SWINE VESICULAR DISEASE VIRUS (STRAIN UKG/27/72) 15-49 1024-1070 1890-1924 PPOLG.sub.-- TBEVW GENOME POLYPROTEIN TICK-BORNE ENCEPHALITIS VIRUS (STRAIN SOFJIN) 68-140 231-272 431-465 1158-1192 1431-1472 1929-1966 2182-2216 2535-2590 2965-2999 3051-3092 3100-3143 PPOLG.sub.-- TEV GENOME POLYPROTEIN TICK-BORNE ENCEPHALITIS VIRUS (WESTERN 68-140 231-272 431-465 1158-1192 1431-1472 1932-1966 2536-2591 2967-3001 SUBTYPE) 3003-3037 3053-3094 3102-3145 PPOLG.sub.-- TMEVB THEILER'S MURINE TOBACCO ETCH VIRUS 73-124 166-222 540-584 720-782 828-925 1148-1192 1416-1460 1494-1535 ENCEPHALOMYELITIS VIRUS (S 1668-1702 1747-1781 1792-1826 2395-2434 2787-2821 PPOLG.sub.-- TMEVD GENOME POLYPROTEIN THEILER'S MURINE ENCEPHALOMYELITIS VIRUS 1306-1340 1483-1518 1601-1635 (STRAIN BEAN PPOLG.sub.-- TMEVG GENOME POLYPROTEIN THEILER'S MURINE ENCEPHALOMYELITIS VIRUS 1304-1338 1481-1516 1599-1663 (STRAIN DA) PPOLG.sub.-- TUMV GENOME POLYPROTEIN THEILER'S MURINE ENCEPHALOMYELITIS VIRUS 1306-1340 1483-1518 1601-1635 - (STRAIN GDVII) PPOLG.sub.-- TVMV GENOME POLYPROTEIN TURNIP MOSAIC VIRUS 216-259 314-362 494-528 768-839 1443-1477 PPOLG.sub.-- WMV2 GENOME POLYPROTEIN TOBACCO VEIN MOTTLING VIRUS 34-68 408-449 667-704 761-813 851-885 969-1017 1031-1072 1643-1677 1686-1725 2316-2374 2701-2749 2814-2848 PPOLG.sub.-- WNV GENOME POLYPROTEIN WATERMELON MOSAIC VIRUS II 68-105 202-236 PPOLG.sub.-- YEFVI GENOME POLYPROTEIN WEST NILE VIRUS 74-108 207-251 847-881 973-1007 1413-1447 2461-2495 2525-2576 2737-2775 3320-3357 3385-3426 PPOLG.sub.-- YEFV2 GENOME POLYPROTEIN YELLOW FEVER VIRUS (STRAIN 17D) 418-452 525-563 728-768 1388-1444 2231-2276 2477-2565 2958-2996 3097-3143 PPOLG.sub.-- YEFV8 GENOME POLYPROTEIN YELLOW FEVER VIRUS (STRAIN PASTEUR 17D-204) 418-452 525-563 728-768 1388-1444 2231-2276 2477-2565 2958-2996 3097-3143 PPOLH.sub.-- POLIM GENOME POLYPROTEIN YELLOW FEVER VIRUS (STRAIN 1899/81) 75-116 418-452 525-563 728-768 PPOLN.sub.-- EEVVT GENOME POLYPROTEIN POLIOVIRUS TYPE 1 (STRAIN MAHONEY) 9-43 1047-1102 1415-1449 1501-1549 1610-1651 1808-1842 1904-1949 PPOLN.sub.-- FCVC6 NONSTRUCTURAL POLYPROTEIN VENEZUELAN EQUINE ENCEPHALITIS VIRUS 345-382 898-932 1945-1979 (STRAIN TRINIDAD PPOLN.sub.-- FCVF9 NON-STRUCTURAL POLYPROTEIN FELINE CALICIVIRUS (STRAIN CFI/68 FIV) 510-544 PPOLN.sub.-- HEVBU NON-STRUCTURAL POLYPROTEIN FELINE CALICIVIRUS (STRAIN F9) 4-45 369-410 `986-1020 1023-1061 PPOLN.sub.- - HEVME NON-STRUCTURAL POLYPROTEIN HEPATITIS E VIRUS (STRAIN BURMA) 338-379 1139-1177 PPOLN.sub.-- HEVMY NON-STRUCTURAL POLYPROTEIN HEPATITIS E VIRUS (STRAIN MEXICO) 338-379 PPOLN.sub.-- HEVPA NON-STRUCTURAL POLYPROTEIN HEPATITIS E VIRUS (STRAIN MYANMAR) 338-379 1139-1184 PPOLN.sub.-- MIDDV NON-STRUCTURAL POLYPROTEIN HEPATITIS E VIRUS (STRAIN PAKISTAN) 337-378 1138-1176 PPOLN.sub.-- ONNVG NONSTRUCTURAL POLYPROTEIN MIDDELBURG VIRUS 922-977 PPOLN.sub.-- RHDV NONSTRUCTURAL POLYPROTEIN O'NYONG-NYONG VIRUS (STRAIN GULU) 899-933 1942-1986 2444-2502 PPOLN.sub.-- RRVN NONSTRUCTURAL POLYPROTEIN RABBIT HEMORRHAGIC DISEASE VIRUS 188-234 306-347 409-457 1657-1716 PPOLN.sub.-- RRVT NONSTRUCTURAL POLYPROTEIN ROSS RIVER VIRUS (STRAIN NB5092) 895-929 1928-1962 2414-2467 PPOLN.sub.-- RUBVT NONSTRUCTURAL POLYPROTEIN ROSS RIVER VIRUS (STRAIN T48) 597-631 1083-1136 PPOLN.sub.-- SFV NONSTRUCTURAL POLYPROTEIN RUBELLA VIRUS (STRAIN THERIEN) 1506-1540 1551-1585 1730-1767 1862-1896 PPOLN.sub.-- SINDO NONSTRUCTURAL POLYPROTEIN SEMLIKI FOREST VIRUS 1094-1128 2358-2392 PPOLN.sub.-- SINDV NONSTRUCTURAL POLYPROTEIN SINDBIS VIRUS (SUBTYPE OCKELBO/STRAIN 919-971 1491-1525 1961-1996 2444-2478 EDSBYN 82-5) PPOLR.sub.-- EPMV NONSTRUCTURAL POLYPROTEIN SINDBIS VIRUS (STRAIN HRSP) 1491-1525 1959-1994 2442-2476 PPOLS.sub.-- EEEV RNA REPLICASE POLYPROTEIN EGGPLANT MOSAIC VIRUS 899-933 1127-1161 PPOLS.sub.-- EEEV3 STRUCTURAL POLYPROTEIN EASTERN EQUINE ENCEPHALITIS VIRUS 372-406 914-952 PPOLS.sub.-- EEVV8 STRUCTURAL POLYPROTEIN EASTERN EQUINE ENCEPHALITIS VIRUS (STRAIN 373-407 915-952 VA33[TEN BRO PPOLS.sub.-- EEVVT STRUCTURAL POLYPROTEIN VENEZUELAN EQUINE ENCEPHALITIS VIRUS 1216-1250 (STRAIN TC-83) PPOLS.sub.-- IBDV5 STRUCTURAL POLYPROTEIN VENEZUELAN EQUINE ENCEPHALITIS VIRUS 1216-1250 (STRAIN TRINIDAD PPOLS.sub.-- IBDVA STRUCTURAL POLYPROTEIN AVIAN INFECTIOUS BURSAL DISEASE VIRUS 134-168 231-286 470-523 (STRAIN 52/70) PPOLS.sub.-- IBDVC STRUCTURAL POLYPROTEIN AVIAN INFECTIOUS BURSAL DISEASE VIRUS 134-168 231-286 470-523 (STRAIN AUSTURALI PPOLS.sub.-- IBDVE STRUCTURAL POLYPROTEIN AVIAN INFECTIOUS BURSAL DISEASE VIRUS 134-168 231-286 470-523 (STRAIN CU-1) PPOLS.sub.-- IBDVP NONSTRUCTURAL PROTEIN VP4 AVIAN INFECTIOUS BURSAL DISEASE VIRUS 134-168 231-286 304-340 (STRAIN E) PPOLS.sub.-- IBDVS STRUCTURAL POLYPROTEIN AVIAN INFECTIOUS EURSAL DISEASE VIRUS 115-149 212-267 451-504 (STRAIN PBG-98) PPOLS.sub.-- IPNVJ STRUCTURAL POLYPROTEIN AVIAN INFECTIOUS BURSAL DISEASE VIRUS 134-168 249-283 470-523 (STRAIN STC) PPOLS.sub.-- IPNVN STRUCTURAL POLYPROTEIN INFECTIOUS PANCREATIC NECROSIS VIRUS 69-103 723-785 (SEROTYPE JASPER) PPOLS.sub.-- ONNVG STRUCTURAL POLYPROTEIN INFECTIOUS PANCREATIC NECROSIS VIRUS 716-786 (STRAIN N1) PPOLS.sub.-- RRV2 STRUCTURAL POLYPROTEIN O'NYONG-NYONG VIRUS (STRAIN GULU) 1204-1238 PPOLS.sub.-- RRVN STRUCTURAL POLYPROTEIN ROSS RIVER VIRUS (STRAIN 213970) 35-69 PPOLS.sub.-- RRVT STRUCTURAL POLYPROTEIN ROSS RIVER VIRUS (STRAIN NB5092) 369-403 939-973 PPOLS.sub.-- RUBVH STRUCTURAL POLYPROTEIN ROSS RIVER VIRUS (STRAIN T48) 939-973 PPOLS.sub.-- RUBVR STRUCTURAL POLYPROTEIN RUBELLA VIRUS (VACCINE STRAIN HPV77) 999-1036 PPOLS.sub.-- RUBVT STRUCTURAL POLYPROTEIN RUBELLA VIRUS (VACCINE STRAIN RA27/3) 999-1036 PPOLS.sub.-- SINDO STRUCTURAL POLYPROTEIN RUBELLA VIRUS (STRAIN THERIEN) 999-1036 PPOLS.sub.-- SINDV STRUCTURAL POLYPROTEIN SINDBIS VIRUS (SUBTYPE OCKELBO/STRAIN EDSBYN 362-396 82-5) PPOLS.sub.-- SINDW STRUCTURAL POLYPROTEIN SINDBIS VIRUS (STRAINS HRSP AND HRLP) 362-396 PPOLS.sub.-- WEEV STRUCTURAL POLYPROTEIN SINDBIS VIRUS WILD TYPE SB DERIVED FROM 34-68 STRAIN AR339) PPOL.sub.-- BAEVM STRUCTURAL POLYPROTEIN WESTERN EQUINE ENCEPHALITIS VIRUS 913-947 PPOL.sub.-- BLVAU POL POLYPROTEIN BABOON ENDOGENOUS VIRUS (STRAIN M7) 42-80 676-743 794-832 1001-1042 PPOL.sub.-- BLVJ POL POLYPROTEIN BOVINE LEUKEMIA VIRUS (AUSTRALIAN ISOLATE) 625-673 PPOL.sub.-- CAEVC POL POLYPROTEIN BOVINE LEUKEMIA VIRUS (JAPANESE ISOLATE BLV-1) 625-673 PPOL.sub.-- CAMVD POL POLYPROTEIN CAPRINE ARTHRITIS ENCEPHALITIS VIRUS (STRAIN 879-934 CORK) PPOL.sub.-- COYMV ENZYMATIC POLYPROTEIN CAULIFLOWER MOSAIC VIRUS (STRAIN D/H) 177-211 PPOL.sub.-- EIAV9 PUTATIVE POLYPROTEIN COMMELINA YELLOW MOTTLE VIRUS 87-121 333-367 447-498 838-876 896-930 1310-1351 PPOL.sub.-- EIAVC POL POLYPROTEIN EQUINE INFECTIOUS ANEMIA VIRUS (CLONE 1369) 513-566 1022- 1056 PPOL.sub.-- EIAVY POL POLYPROTEIN EQUINE INFECTIOUS ANEMIA VIRUS (CLONE CL22) 513-566 1022- 1056 PPOL.sub.-- FENVI POL POLYPROTEIN EQUINE INFECTIOUS ANEMIA VIRUS (ISOLATE 512-565 1021- WYOMING) 1055 PPOL.sub.-- FIVPE POL POLYPROTEIN FELINE ENDOGENOUS VIRUS ECE1 533-600 623-659 858-899 PPOL.sub.-- FIVSD POL POLYPROTEIN FELINE IMMUNODEFICIENCY VIRUS (ISOLATE 429-473 606-663 PETALUMA) PPOL.sub.-- FIVT2 POL POLYPROTEIN FELINE IMMUNODEFICIENCY VIRUS (ISOLATE 428-473 606-642 SAN DIEGO) PPOL.sub.-- FMVD POL POLYPROTEIN FELINE IMMUNODEFICIENCY VIRUS (ISOLATE TM2) 428-472 595-662 PPOL.sub.-- FOAMV ENZYMATIC POLYPROTEIN FIGWORT MOSAIC VIRUS (STRAIN DXS) 403-437 PPOL.sub.-- GALV POL POLYPROTEIN HUMAN SPUMARETROVIRUS (FOAMY VIRUS) 140-174 217-256 285-326 PPOL.sub.-- HTL1A POL POLYPROTEIN GIBBON APE LEUKEMIA VIRUS 528-562 673-740 PPOL.sub.-- HTL1C POL POLYPROTEIN HUMAN T-CELL LEUKEMIA VIRUS TYPE I (STRAIN 670-711 ATK) PPOL.sub.-- HV1A2 POL POLYPROTEIN HUMAN T-CELL LEUKEMIA VIRUS TYPE I 670-711 (CARIBBEAN ISOLATE) PPOL.sub.-- HV1B1 POL POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 501-537 606-664 (ARV2/SF2 ISOLATE) PPOL.sub.-- HV1B5 POL POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 513-549 639-676 (BH10 ISOLATE) PPOL.sub.-- HVIBR POL POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 513-549 618-676 (BH5 ISOLATE) PPOL.sub.-- HVIEL POL POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 513-549 618-676 (BRU ISOLATE) PPOL.sub.-- HV1H2 POL POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 500-536 626-663 (ELI ISOLATE) PPOL.sub.-- HV1JR POL POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 501-537 606-664 (HXB2 ISOLATE) PPOL.sub.-- HV1MA POL POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 505-541 610-668 (JRCSF ISOLATE) PPOL.sub.-- HVIMN POL POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 476-536 601-663 (MAL ISOLATE) PPOL.sub.-- HV1N5 POL POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 504-540 609-667 (MN ISOLATE) PPOL.sub.-- HV1ND POL POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 501-537 627-664 (NEW YORK-5 ISOL PPOL.sub.-- HV1OY POL POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 500-536 626-663 (NDK ISOLATE) PPOL.sub.-- HV1PV POL POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 501-537 606-664 (OYI ISOLATE) PPOL.sub.-- HV1RH POL POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 513-549 693-676 (PV22 ISOLATE) PPOL.sub.-- HV1U4 POL POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 500-536 605-663 (RF/HAT ISOLATE) PPOL.sub.-- HV122 POL POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 500-536 601-663 (STRAIN UGANDAN PPOL.sub.-- HV2BE POL POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 500-536 626-663 (Z2/CDC-Z34 ISOLA PPOL.sub.-- HV2CA POL POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 49-83 484-582 653-687 817-851 (ISOLATE BEN) PPOL.sub.-- HV2D1 POL POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 356-390 464-562 632-666 (ISOLATE CAM2) PPOL.sub.-- HV2D2 POL POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 502-600 671-705 (ISOLATE D194) PPOL.sub.-- HV2G1 POL POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 376-410 484-526 529-577 653-687 (ISOLATE D205.7) PPOL.sub.-- HV2NZ POL POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 464-562 633-667 (ISOLATE GHANA-1 PPOL.sub.-- HV2RO POL POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 44-78 356-390 464-529 633-667 (ISOLATE NIH-Z) PPOL.sub.-- HV2SB POL POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 357-391 465-563 634-668 (ISOLATE ROD) PPOL.sub.-- HV2ST POL POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 46-80 473-562 633-667 (ISOLATE SBLISY) PPOL.sub.-- IPHA POL POLYPROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 484-518 522-577 653-687 (ISOLATE ST) PPOL.sub.-- JSRV PUTATIVE POL POLYPROTEIN HAMSTER INTRACISTERNAL A-PARTICLE 462-503 PPOL.sub.-- MLVAK POL POLYPROTEIN SHEEP PULMONARY ADENOMATOSIS VIRUS 190-231 PPOL.sub.-- MLVAV POL POLYPROTEIN AKR MURINE LEUKEMIA VIRUS 325-392 PPOL.sub.-- MLVF5 POL POLYPROTEIN AKV MURINE LEUKEMIA VIRUS 677-744 PPOL.sub.-- MLVFF POL POLYPROTEIN FRIEND MURINE LEUKEMIA VIRUS (ISOLATE 57) 682-749 PPOL.sub.-- MLVFP POL POLYPROTEIN FRIEND MURINE LEUKEMIA VIRUS (ISOLATE FB29) 682-749 PPOL.sub.-- MLVMO POL POLYPROTEIN FRIEND MURINE LEUKEMIA VIRUS (ISOLATE 682-749 PVC-211) PPOL.sub.-- MLVRD POL POLYPROTEIN MOLONEY MURINE LEUKEMIA VIRUS 677-744 PPOL.sub.-- MLVRK POL POLYPROTEIN RADIATION MURINE LEUKEMIA VIRUS 677-744 PPOL.sub.-- MPMV POL POLYPROTEIN RADIATION MURINE LEUKEMIA VIRUS (STRAIN 62-129 KAPLAN) PPOL.sub.-- OMVVS POL POLYPROTEIN SIMIAN MASON-PFIZER VIRUS 470-504 578-613 PPOL.sub.-- RSVP POL POLYPROTEIN OVINE LENTIVIRUS (STRAIN SA-OMVV) 470-505 855-910 PPOL.sub.-- RTBV POL POLYPROTEIN ROUS SARCOMA VIRUS (STRAIN PRAGUE C) 646-684 PPOL.sub.-- RTBVP POLYPROTEIN RICE TUNGRO BACILLIFORM VIRUS 7-44 59-96 101-135 176-236 325-362 433-474 1005- 1405- 1039 1439 PPOL.sub.-- SFV1 POLYPROTEIN RICE TUNGRO BACILLIFORM VIRUS (ISOLATE 7-44 59-96 101-135 176-236 325-362 433-474 1005- 1405- PHILIPPINES) 1039 1439 PPOL.sub.-- SFV3L POL POLYPROTEIN SIMIAN FOAMY VIRUS (TYPE 1) 349-383 427-464 494-535 PPOL.sub.-- SIVA1 POL POLYPROTEIN SIMIAN FOAMY VIRUS (TYPE 3/STRAIN LK3) 124-165 429-467 496-530 PPOL.sub.-- SIVA2 POL POLYPROTEIN SIMIAN IMMUNODEFICIENCY VIRUS (AGM155 351-385 637-678 737-771 938-979 ISOLATE) PPOL.sub.-- SIVAG POL POLYPROTEIN SIMIAN IMMUNODEFICIENCY VIRUS (AGM266 45-86 ISOLATE) PPOL.sub.-- SIVAI POL POLYPROTEIN SIMIAN IMMUNODEFICIENCY VIRUS (AGM3 477-516 642-683 742-783 ISOLATE) PPOL.sub.-- SIVAT POL POLYPROTEIN SIMIAN IMMUNODEFICIENCY VIRUS (ISOLATE 175-209 476-515 641-700 942-983 1020- AGM/CLONE GRI 1054 PPOL.sub.-- SIVCZ POL POLYPROTEIN SIMIAN IMMUNODEFICIENCY VIRUS (TYO-1 657-698 757-798 ISOLATE) PPOL.sub.-- SIVGB POL POLYPROTEIN CHIMPANZEE IMMUNODEFICIENCY VIRUS 527-561 626-688 (SIV(CPZ)) PPOL.sub.-- SIVMI POL POLYPROTEIN SIMIAN IMMUNODEFICIENCY VIRUS (ISOLATE GB1) 9-57 446-483 629-673 793-827 912-946 PPOL.sub.-- SIVMK POL POLYPROTEIN SIMIAN IMMUNODEFICIENCY VIRUS (MM142-83 485-519 654-688 ISOLATE) PPOL.sub.-- SIVS4 POL POLYPROTEIN SIMIAN IMMUNODEFICIENCY VIRUS (K6W ISOLATE) 485-519 654-688 PPOL.sub.-- SIVSP POL POLYPROTEIN SIMIAN IMMUNODEFICIENCY VIRUS (F236/SMH4 446-482 617-651 ISOLATE) PPOL.sub.-- SOCMV POL POLYPROTEIN SIMIAN IMMUNODEFICIENCY VIRUS (PBJ/BC13 451-485 620-654 ISOLATE) PPOL.sub.-- SRV1 ENZYMATIC POLYPROTEIN SOYBEAN CHLOROTIC MOTTLE VIRUS 247-295 372-416 PPOL.sub.-- VILV POL POLYPROTEIN SIMIAN RETROVIRUS SRV-1 470-504 578-63 PPOL.sub.-- VILV1 POL POLYPROTEIN VISNA LENTIVIRUS (STRAIN 1514) 489-524 874-929 PPOL.sub.-- VILV1 POL POLYPROTEIN VISNA LENTIVIRUS (SIMIAN 1514/CLONE LVI-1KS1) 489-524 874-929 PPP15.sub.-- HCMVA POL POLYPROTEIN VISNA LENTIVIRUS (STRAIN 1514/CLONE LVI-1KS2) 489-524 874-929 PPR73.sub.-- MMVB LARGE STRUCTURAL HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 116-150 187-221 PHOSPHOPROTEIN PP150 PPR73.sub.-- MMTVC PROTEIN PR73 MOUSE MAMMARY TUMOR VIRUS (STRAIN BR6) 152-200 PPR73.sub.-- MMTVG PROTEIN PR73 MOUSE MAMMARY TUMOR VIRUS (STRAIN C3H) 20-79 PPR7L.sub.-- MMTVG PROTEIN PR73 MOUSE MAMMARY TUMOR VIRUS (STRAIN GR) 61-95 142-201 PPR7R.sub.-- MMTVG PROTEIN PR73 MOUSE MAMMARY TUMOR VIRUS (STRAIN GR) 145-204 270-311 PPYHD.sub.-- CPVBM PROTEIN PR73 MOUSE MAMMARY TUMOR VIRUS (STRAIN GR) 141-200 266-307 PPYHD.sub.-- NPVAC POLYHEDRIN PRECURSOR BOMBYX MORI CYTOPLASMIC POLYHEDROSIS VIRUS 13-85 PPYHD.sub.-- NPVAS POLYHEDRIN AUTOGRAPRA CALIFORNICA NUCLEAR 13-47 POLYHEDROSIS VIRUS PPYHD.sub.-- NPVBM POLYHEDRIN AGROTIS SEGETUM NUCLEAR 14-48 POLYHEDROSI S VIRUS PPYHD.sub.-- NPVBS POLYHEDRIN BOMBYX MORI NUCLEAR POLYHEDROSIS VIRUS 12-54 PPYHD.sub.-- NPVLD POLYHEDRIN BUZURA SUPRESSARIA NUCLEAR POLYHEDROSIS 14-48 VIRUS PPYHD.sub.-- NPVMB POLYHEDRIN LYMANTRIA DISPAR MULTICAPSID NUCLEAR 14-48 POLYHEDROSIS V PPYHD.sub.-- NPVOP POLYHEDRIN MAMESTRA BRASSICAE NUCLEAR POLYHEDROSIS 14-48 VIRUS PPYHD.sub.-- NPVOS POLYHEDRIN ORGYIA PSEUDOTSUGATA MULTICAPSID 13-47 POLYHEDROSIS VIRUS PPYHD.sub.-- NPVPF POLYHEDRIN ORGYIA PSEUDOTSUGATA SINGLE CAPSID NUCLEAR 14-48 POLYHED PPYHD.sub.-- NPVSE POLYHEDRIN PANOLIS FLAMMEA MULTIPLE NUCLEOCAPSID 14-48 POLYHEDROSIS PPYHD.sub.-- NPVSF POLYHEDRIN SPODOPTHRA EXIGUA NUCLEAR POLYHEDROSIS 14-48 VIRUS (STRAIN PPYHD.sub.-- NPVSL POLYHEDRIN SPODOPTHRA FRUGIPERDA NUCLEAR 14-48 POLYHEDROSIS VIRUS PRASK.sub.-- MSVKI POLYHEDRIN SPODOGTHRA LITTGRALIS NUCLEAR 17-51 POLYHEDROSIS VIRUS PREV.sub.-- BIV27 TRANSFORMING PROTEIN 21 KIRSTEN MURINE SARCOMA VIRUS 142-176 PREV.sub.-- EIAV9 REV PROTEIN BOVINE IMMUNODEFICIENCY VIRUS (ISOLATE 127) 77-115 PREV.sub.-- EIAVC REV PROTEIN EQUINE INFECTIOUS ANEMIA VIRUS (CLONE 1369) 51-89 PREV.sub.-- EIAVY REV PROTEIN EQUINE INFECTIOUS ANEMIA VIRUS (CLONE CL22) 51-89 PREV.sub.-- HV112 REV PROTEIN EQUINE INFECTIOUS ANEMIA VIRUS (ISOLATE 81-119 WYOMING) PREV.sub.-- HV1A2 REV PROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 35-69 (CLONE 12) PREV.sub.-- HV1B1 REV PROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 32-69 (ARV2/SF2 ISOLATE PREV.sub.-- HV1B8 REV PROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 35-69 (BH10 ISOLATE) PREV.sub.-- HV1BN REV PROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 25-59 (B8 ISOLATE) PREV.sub.-- HV1BR REV PROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 22-59 (BRAIN ISOLATE) PREV.sub.-- HV1EL REV PROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 35-69 (BRU ISOLATE) PREV.sub.-- HV1H2 REV PROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 32-66 (ELI ISOLATE) PREV.sub.-- HV1J3 REV PROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 35-69 (HXB2 ISOLATE) PREV.sub.-- HV1JR REV PROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 29-63 (JH3 ISOLATE) PREV.sub.-- HV1MA REV PROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 31-66 (JRCSF ISOLATE) PREV.sub.-- HV1MN REV PROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 31-66 (MAL ISOLATE) PREV.sub.-- HV1OY REV PROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 31-66 (MN ISOLATE) PREV.sub.-- HV1PV REV PROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 32-69 (OY1 ISOLATE) PREV.sub.-- HV1S3 REV PROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 35-69 (PV22 ISOLATE) AN PREV.sub.-- HV1SC REV PROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 35-69 (SF33 ISOLATE) PREV.sub.-- SIVA1 REV PROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 32-69 (SC ISOLATE) PREV.sub.-- SIVAG REV PROTEIN SIMIAN IMMUNODEFICIENCY VIRUS 26-77 (AGM155 ISOLATE) PREV.sub.-- SIVA1 REV PROTEIN SIMIAN IMMUNODEFICIENCY VIRUS (AGM3 26-77 ISOLATE) PREV.sub.-- SIVAT REV PROTEIN SIMIAN IMMUNODEFICIENCY VIRUS (ISOLATE 29-77 AGM/CLONE GR PREV.sub.-- SIVCZ REV PROTEIN SIMIAN IMMUNODEFICIENCY VIRUS (TYO-1 28-75 ISOLATE) PREV.sub.-- VILV REV PROTEIN CHIMPANZEE IMMUNODEFICIENCY VIRUS 33-67 PRIRI.sub.-- ASFM2 REV PROTEIN VISNA LENTIVIRUS (STRAIN 1514) 21-62 PRIRI.sub.-- EBV RIBONUCLEOSIDE-DIPHOSPHATE AFRICAN SWINE FEVER VIRUS (ISOLATES MALAWI 7-41 88-133 635-683 REDUCTASE LAR LIL 20/1) PRIRI.sub.-- HCMVA RIBONUCLEOSIDE-DIPHOSPHATE EPSTEIN-BARR VIRUS (STRAIN B95-8) 213-247 689-723 REDUCTASE LAR PRIR1.sub.-- HSVEB RIBONUCLEOSIDE-DIPHOSPHATE HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 632-668 REDUCTASE LAR PRIR1.sub.-- HSVSA RIBONUCLEOSIDE-DIPHOSPHATE EQUINE HERPES VIRUS TYPE 1 (STRAIN AB4P) 76-110 REDUCTASE LAR PRIR1.sub.-- VACCC RIBONUCLEOSIDE-DIPHOSPHATE HERPESVIRUS SAIMIRI (STRAIN 11) 324-365 REDUCTASE LAR PRIR1.sub.-- VACCV RIBONUCLEOSIDE-DIPHOSPHATE VACCINIA VIRUS (STRAIN COPENHAGEN) 367-402 REDUCTASE LAR PRIR1.sub.-- VARV RIBONUCLEOSIDE-DIPHOSPHATE VACCINIA VIRUS (STRAIN WR) 367-402 REDUCTASE LAR PRIR1.sub.-- VZVD RIBONUCLEOSIDE-DIPHOSPHATE VARIOLA VIRUS 367-402 REDUCTASE LAR PRIR2.sub.-- EBV RIBONUCLEOSIDE-DIPHOSPHATE VARICELLA-ZOSTER VIRUS (STRAIN DUMAS) 223-257 REDUCTASE LAR PRIR2.sub.-- HSVB3 RIBONUCLEOSIDE-DIPHOSPHATE EPSTEIN-BARR VIRUS (STRAIN B95-8) 89-137 REDUCTASE SMA PRIR2.sub.-- HSVEB RIBONUCLEOSIDE-DIPHOSPHATE BOVINE HERPESVIRUS TYPE 1 (STRAIN 34) 101-135 REDUCTASE SMA PRIR2.sub.-- HSVSA RIBONUCLEOSIDE-DIPHOSPHATE EQUINE HERPESVIRUS TYPE 1 (STRAIN AB4P) 106-140 REDUCTASE SMA PRIR2.sub.-- SFVKA RIBONUCLEOSIDE-DIPHOSPHATE HERPESVIRUS SAIMIRI (STRAIN 11) 125-159 REDUCTASE SMA PRIR2.sub.-- VACCC RIBONUCLEOSIDE-DIPHOSPHATE SHOPE FIBROMA VIRUS (STRAIN KASZA) 98-132 REDUCTASE SMA PRIR2.sub.-- VACCP RIBONUCLEOSIDE-DIPHOSPHATE VACCINIA VIRUS (STRAIN COPENHAGEN) 98-132 REDUCTASE SMA PRIR2.sub.-- VACCV RIBONUCLEOSIDE-DIPHOSPHATE VACCINIA VIRUS (STRAIN L-IVP) 98-132 REDUCTASE SMA PRIR2.sub.-- VARV RIBONUCLEOSIDE-DIPHOSPHATE VACCINIA VIRUS (STRAIN WR) 98-132 REDUCTASE SMA PRL1.sub.-- HSV2H RIBONUCLEOSIDE-DIPHOSPHATE VARIOLA VIRUS 98-132 REDUCTASE SMA PRP94.sub.-- VACCV NEUROVIRULENCE FACTOR HERPES SIMPLEX VIRUS (TYPE 2/STRAIN HG52) 171-212 PRP94.sub.-- VARV RNA-POLYMERASE-ASSOCIATED VACCINIA VIRUS (STRAIN WR), AND (STRAIN 116-150 465-540 757-791 TRANSCRIPTION S COPENHAGEN PRPO1.sub.-- VACCC RNA-POLYMERASE-ASSOCIATED VARIOLA VIRUS 41-75 116-150 465-540 757-791 TRANSCRIPTION S PRPO1.sub.-- VACCV DNA-DIRECTED RNA POLYMERASE VACCINIA VIRUS (STRAIN COPENHAGEN) 243-291 622-656 754-791 954-988 1006- 147 KD POLYPE 1057 PRPO1.sub.-- VARV DNA-DIRECTED RNA POLYMERASE VACCINIA VIRUS (STRAIN WR) 243-291 622-656 754-791 954-988 1024- 147 KD POLYPE 1058 PRPO2.sub.-- CAPVK DNA-DIRECTED RNA POLYMERASE VARIOLA VIRUS 243-291 622-656 754-791 954-988 1006- 147 KD POLYPE 1057 PRPO2.sub.-- COWPX DNA-DIRECTED RNA POLYMERASE CAPRIPOXVIRUS (STRAIN KS-1) 19-60 114-155 589-630 132 KD POLYPE PRPO2.sub.-- VACCV DNA-DIRECTED RNA POLYMERASE COWPOX VIRUS 211-245 359-400 833-874 132 KD POLYPE PRPO2.sub.-- VARV DNA-DIRECTED RNA POLYMERASE VACCINIA VIRUS (STRAIN WR), AND 211-245 359-400 833-874 132 KD POLYPE (STRAIN COPENHAGEN) PRPO4.sub.-- VACCC DNA-DIRECTED RNA POLYMERASE VARIOLA VIRUS 211-245 359-400 833-874 132 KD POLYPE PRPO4.sub.-- VACCV DNA-DIRECTED RNA POLYMERASE VACCINIA VIRUS (STRAIN COPENHAGEN) 62-116 35 KD POLYPEP PRPO4.sub.-- VARV DNA-DIRECTED RNA POLYMERASE VACCINIA VIRUS (STRAIN WR) 62-116 35 KD POLYPEP PRPO5.sub.-- VACCC DNA-DIRECTED RNA POLYMERASE VARIOLA VIRUS 62-116 35 KD POLYPEP PRPO5.sub.-- VACCV DNA-DIRECTED RNA POLYMERASE VACCINIA VIRUS (STRAIN COPEHAGEN) 1-71 30 KD POLYPEP PRPO5.sub.-- VARV DNA-DIRECTED RNA POLYMERASE VACCINIA VIRUS (STRAIN WR) 1-71 30 KD POLYPEP PRPO6.sub.-- VACCV DNA-DIRECTED RNA POLYMERASE VARIOLA VIRUS 1-71 30 KD POLYPEP PRPO6.sub.-- VARV DNA-DIRECTED RNA POLYMERASE VACCINIA VIRUS (STRAIN WR), AND 25-59 22 KD POLYPEP STRAIN COPEHAGEN) PRPO7.sub.-- VACCV DNA-DIRECTED RNA POLYMERASE VARIOLA VIRUS 25-59 22 KD POLYPEP PRPO7.sub.-- VARV DNA-DIRECTED RNA POLYMERASE VACCINIA VIRUS (STRAIN WR), AND 43-93 19 KD POLYPEP STRAIN COPEHAGEN) PRPOA.sub.-- LELV DNA-DIRECTED RNA POLYMERASE VARIOLA VIRUS 43-93 19 KD POLYPEP PRPOL.sub.-- EAV RNA-DIRECTED RNA POLYMERASE LELYSTAND VIRUS 1533- 1721- 1958- 2109- 1567 1758 1992 2157 PRRP1.sub.-- IAANN RNA-DIRECTED RNA POLYMERASE EQUINE ARTERITIS VIRUS 1083- 1477- 1633- 1117 1518 1673 PRRP1.sub.-- IABEI RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/ANN ARBOR/6/60) 171-242 279-313 SUBUNIT P1 PRRP1.sub.-- IADUN RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/BEIJING/11/56) 171-242 279-313 350-391 SUBUNIT P1 PRRP1.sub.-- IAGU2 RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/DUNEDIN/4/73) 171-242 279-313 SUBUNIT P1 PRRP1.sub.-- IAHLO RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/GULL/MARYLAND/ 171-242 279-313 SUBUNIT P1 704/77) PRRP1.sub.-- IAHTE RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/QUINE/LONDON/ 168-242 279-313 SUBUNIT P1 1416/73) PRRP1.sub.-- IAKIE RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/EQUINE/ 168-242 279-313 SUBUNIT P1 TENNESSEE/5/86) PRRP1.sub.-- IAKOR RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/KIEV/59/79) 171-242 279-313 SUBUNIT P1 PRRP1.sub.-- IALE1 RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/KOREA/426/68) 171-242 279-313 SUBUNIT P1 PRRP1.sub.-- IALE2 RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/LENINGRAD/134/57) 171-242 279-313 SUBUNIT P1 PRRP1.sub.-- IALE3 RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/LENINGRAD/134/ 171-242 279-313 SUBUNIT P1 17/57) PRRP1.sub.-- IAMAN RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/LENINGRAD/134/ 171-242 279-313 SUBUNIT P1 47/57) PRRP1.sub.-- IAME8 RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/MALLARD/NEW 171-242 279-313 SUBUNIT P1 YORK/6750/78 PRRP1.sub.-- IANT6 RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/MEMPHIS/8/88) 171-242 279-313 SUBUNIT P1 PRRP1.sub.-- IAPUE RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/NT/60/68) 171-242 279-313 SUBUNIT P1 PRRP1.sub.-- IASIN RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/PUERTO RICO/8/34) 168-242 279-313 SUBUNIT P1 PRRP1.sub.-- IATKM RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/SINGAPORE/1/57) 171-242 279-313 SUBUNIT P1 PRRP1.sub.-- IAV17 RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/TURKEY/ 171-242 279-313 SUBUNIT P1 MINNESOTA/833/80 PRRP1.sub.-- IAWIL RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/VICTORIA/3/75) 171-242 279-313 SUBUNIT P1 PRRP1.sub.-- IAWIS RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/WILSON-SMITH/33) 168-242 279-313 SUBUNIT P1 PRRP1.sub.-- IAZH3 RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/WISCONSIN/3523/88) 168-242 279-313 SUBUNIT P1 PRRP1.sub.-- IAZON RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/SWINE/HONG 187-242 279-313 SUBUNIT P1 KONG/126/82) PRRP1.sub.-- IAZTF RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/SWINE/ONTARIO/ 171-242 279-313 SUBUNIT P1 2/81) PRRP1.sub.-- INBAC RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/SWINE/TENNESSE/ 171-242 279-313 SUBUNIT P1 26/77) PRRP1.sub.-- INBAD RNA-DIRECTED RNA POLYMERASE INFLUENZA B VIRUS (STRAIN B/ANN ARBOR/1/66) 208-249 SUBUNIT P1 PRRP1.sub.-- INBLE RNA-DIRECTED RNA POLYMERASE INFLUENZA B VIRUS (STRAIN B/ANN ARBOR/1/66 208-249 SUBUNIT P1 [WILD-TYPE] PRRP1.sub.-- INCJI RNA-DIRECTED RNA POLYMERASE INFLUENZA B VIRUS (STRAIN B/LEE/40) 208-249 SUBUNIT P1 PRRP2.sub.-- IAANN RNA-DIRECTED RNA POLYMERASE INFLUENZA C VIRUS (STRAIN C/JJ/50) 350-384 648-686 707-752 SUBUNIT P1 PRRP2.sub.-- IADH2 RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/ANN 110-144 177-218 SUBUNIT P2 ARBOR/6/60) PRRP2.sub.-- IAFPR RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/DUCK/ 110-144 177-218 SUBUNIT P2 HOKKAIDO/8/80) PRRP2.sub.-- IAGU2 RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/FOWL PLAGUE 110-144 177-218 SUBUNIT P2 VIRUS/ROSTOCK PRRP2.sub.-- IAHLO RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/GULL/MARYLAND/ 110-144 177-218 SUBUNIT P2 704/77) PRRP2.sub.-- IAHTE RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/EQUINE/LONDON/ 110-144 177-218 SUBUNIT P2 1416/73) PRRP2.sub.-- IAKOR RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/EQUINE/ 110-144 177-218 TENNESSEE/5/86) PRRP2.sub.-- IALE1 RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/KOREA/426/68) 110-144 177-218 SUBUNIT P2 PRRP2.sub.-- IALE2 RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/LENINGRAD/134/57) 110-144 177-218 SUBUNIT P2 PRRP2.sub.-- IAMAN RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/LENINGRAD/134/ 110-144 177-218 SUBUNIT P2 17/157) PRRP2.sub.-- IANT6 RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/MALLARD/NEW 110-144 177-218 SUBUNIT P2 YORK/6750/78) PRRP2.sub.-- IAP10 RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/NT/60/68) 110-144 177-218 SUBUNIT P2 PRRP2.sub.-- IAPUE RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/PINTAIL/ 110-144 177-218 SUBUNIT P2 ALBERTA/119/79) PRRP2.sub.-- IARUD RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/PUERTO RICO/8/34) 110-144 177-218 SUBUNIT P2 PRRP2.sub.-- IASIN RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/RUDDY 110-144 177-218 SUBUNIT P2 TURNSTONE/NEW JERS PRRP2.sub.-- IATKM RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/SINGAPORE/1/57) 110-144 177-218 SUBUNIT P2 PRRP2.sub.-- IAV17 RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/TURKEY/ 110-144 177-218 SUBUNIT P2 MINNESOTA/833/80) PRRP2.sub.-- IAWIL RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/VICTORIA/3/75) 110-144 177-218 SUBUNIT P2 PPRP2.sub.-- IAZH2 RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/WILSON-SMITH/33) 110-144 177-218 SUBUNIT P2 PRRP2.sub.-- IAZH3 RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/SWINE/HONG 110-144 177-218 SUBUNIT P2 KONG/81/78 PRRP2.sub.-- IAZI1 RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/SWINE/HONG 110-144 177-218 SUBUNIT P2 KONG/126/82) PRRP2.sub.-- IAZTF RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/SWINE/IOWA/15/30 110-141 177-218 SUBUNIT P2 PRRP2.sub.-- INBAC RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/SWINE/TENNESSE/ 110-144 177-218 SUBUNIT P2 26/77) PRRP2.sub.-- INBAD RNA-DIRECTED RNA POLYMERASE INFLUENZA B VIRUS (STRAIN B/ANN ARBOR/ 111-196 349-393 SUBUNIT P2 1/66 [COLD-ADAPTE PRRP2.sub.-- INBSI RNA-DIRECTED RNA POLYMERASE INFLUENZA B VIRUS (STRAIN B/ANN ARBOR/ 111-196 349-390 SUBUNIT P2 1/66 [WILD-TYPE]) PRRP3.sub.-- IAANN RNA-DIRECTED RNA POLYMERASE INFLUENZA B VIRUS (STRAIN B/SINGAPORE/222/79) 111-196 349-383 SUBUNIT P2 PRRP3.sub.-- IABAD RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/ANN ARBOR/6/60) 1-42 363-402 473-514 707-755 SUBUNIT P3 PRRP3.sub.-- IACHI RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN BUDGERIGAR/ 1-42 363-402 473-514 518-567 707-755 SUBUNIT P3 HOKKAIDO/1/77) PRRP3.sub.-- IAFPR RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/CHILE/1/83) 1-42 363-402 473-514 707-755 SUBUNIT P3 PRRP3.sub.-- IAFPW RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/FOWL PLAGUE 1-42 363-402 473-514 707-755 SUBUNIT P3 VIRUS/ROS TOCK PRRP3.sub.-- IAGU2 RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/FOWL PLAGUE 1-42 363-402 473-514 707-755 SUBUNIT P3 VIRUS/WEY BRID PRRP3.sub.-- IAGUA RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/GULL/ 1-42 363-402 473-514 707-755 SUBUNIT P3 MARYLAND/704/77 PRRP3.sub.-- IAHK6 RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/GULL/ 7-41 363-402 473-514 707-755 SUBUNIT P3 ASTRAKHAN/227/84) PRRP3.sub.-- IAHLO RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/EQUINE/ 1-42 363-402 473-514 707-755 SUBUNIT P3 KENTUCKY/1416/73) PRRP3.sub.-- IAHPR RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/EQUINE/ 1-42 363-402 473-514 707-755 SUBUNIT P3 LONDON/1416/73) PRRP3.sub.-- IAKIE RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/EQUINE/ 1-42 363-402 473-514 721-755 SUBUNIT P3 PRAGUE/1/56) PRRP3.sub.-- IAKOR RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/KIEV/59/79) 1-42 363-402 473-514 707-755 SUBUNIT P3 PRRP3.sub.-- IALE1 RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/KOREA/ 1-42 363-402 473-514 707-755 SUBUNIT P3 426/68) PRRP3.sub.-- IALE2 RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/LENINGRAD/ 1-42 363-402 473-514 707-755 SUBUNIT P3 134/57) PRRP3.sub.-- IALE3 RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/LENINGRAD/ 1-42 363-402 473-514 707-755 SUBUNIT P3 134/17/57) PRRP3.sub.-- IAMAN RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/LENINGRAD/ 1-42 363-482 473-514 707-755 SUBUNIT P3 134/47/57) PRRP3.sub.-- IAME8 RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/MALLARD/NEW 363-402 473-514 707-755 SUBUNIT P3 YORK/6750/78) PRRP3.sub.-- IANT6 RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/MEMPIS/8/88) 7-41 363-402 473-514 707-755 SUBUNIT P3 PRRP3.sub.-- IAPUE RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/NT/60/68) 1-42 363-402 473-514 707-755 SUBUNIT P3 PRRP3.sub.-- IARUD RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/PUERTO RICO/8(34) 1-42 363-402 473-514 707-755 SUBUNIT P3 PRRP3.sub.-- IASE2 RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/RUDDY 1-42 363-402 473-514 707-755 SUBUNIT P3 TURNSTONE/NEW JERSE PRRP3.sub.-- IASIN RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/SEAL/ 1-42 363-402 473-514 707-755 SUBUNIT P3 MASSACHUSETTS/133/82) PRRP3.sub.-- IATKM RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/SINGAPORE/1/57) 1-42 363-402 473-514 707-755 SUBUNIT P3 PRRP3.sub.-- IAV17 RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/TURKEY/ 1-42 363-402 473-514 707-755 SUBUNIT P3 MINNESOTA/833/80) PRRP3.sub.-- IAWIL RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/VICTORIA/3/75) 1-42 363-402 473-514 707-755 SUBUNIT P3 PRRP3.sub.-- IAZI1 RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/WILSON-SMITH/33 1-2 363-402 473-514 707-755 SUBUNIT P3 PRRP3.sub.-- IAZTE RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/SWINE/IOWA/15/30) 1-42 363-402 473-514 707-755 SUBUNIT P3 PRRP3.sub.-- INBAC RNA-DIRECTED RNA POLYMERASE INFLUENZA A VIRUS (STRAIN A/SWINE/TENNESSEE/ 7-41 363-402 473-514 707-755 SUBUNIT P3 24/77 PRRP3.sub.-- INBAD RNA-DIRECTED RNA POLYMERASE INFLUENZA B VIRUS (STRAIN B/ANN ARBOR/1/66 458-533 SUBUNIT P3 [COLD-ADAPTE PRRP3.sub.-- INCBE RNA-DIRECTED RNA POLYMERASE INFLUENZA B VIRUS (STRAIN B/ANN ARBOR/1/66 458-533 SUBUNIT P3 [WILD-TYPE]) PRRP3.sub.-- INCJJ RNA-DIRECTED RNA POLYMERASE INFLUENZA C VIRUS (STRAIN C/BERLIN/1/85) 235-269 275-309 SUBUNIT P3 PRRP3.sub.-- THOGV RNA-DIRECTED RNA POLYMERASE INFLUENZA C VIRUS (STRAIN C/JJ/50) 235-269 275-316 SUBUNIT P3 PRRPA.sub.-- CVH22 RNA-DIRECTED RNA POLYMERASE THOGOTO VIRUS 343-401 SUBUNIT P3 PRRPA.sub.-- CVMJH RNA-DIRECTED RNA POLYMERASE HUMAN CORONAVIRUS (STRAIN 229E) 358-392 495-571 1742- 1971- 3664- 3912- 1776 2008 3724 3946 PRRPB.sub.-- BEV RNA-DIRECTED RNA POLYMERASE MURINE CORONAVIRUS MHV (STRAIN JHM) 617-651 1364- 2769- 3586- 3821- 4075- 4319- 1398 2803 3620 3855 4121 4353 PRRPB.sub.-- CVMA5 RNA-DIRECTED RNA POLYMERASE BERNE VIRUS 20-64 617-651 943- 1009 PRRPB.sub.-- CVMJH RNA-DIRECTED RNA POLYMERASE MURINE CORONAVIRUS MHV (STRAIN A59) 1129- 1303- 1453- 1692- 2629- 1170 1337 1494 1726 2670 PRRPB.sub.-- IBVB RNA-DIRECTED RNA POLYMERASE MURINE CORONAVIRUS MV (STRAIN JHM) 1129- 1303- 1453- 1690- 2627- 1170 1337 1494 1724 2668 PRRPB.sub.-- IBVK RNA-DIRECTED RNA POLYMERASE AVIAN INFECTIOUS BRONCHITIS VIRUS 499-550 650-695 1460- 1509- 2246- (STRAIN BEAUDETTE) 1494 1548 2287 PRRPL.sub.-- BTV10 RNA-DIRECTED RNA POLYMERASE AVIAN INFECTIOUS BRONCHITIS VIRUS 115-156 (STRAIN KB8523) PRRPL.sub.-- BUNYW RNA-DIRECTED RNA POLYMERASE BLUETONGUE VIRUS (SEROTYPE 10/ISOLATE USA) 308-342 705-748 825-903 1021- 1114- 1076 1201 PRRPL.sub.-- CDVO RNA POLYMERASE BUNYAMWERA VIRUS 2-36 80-114 308-363 371-412 1704- 1802- 1889- 1741 1861 1935 PRRPL.sub.-- HANTV RNA POLYMERASE BETA SUBUNIT CANINE DISTEMPER VIRUS (STRAIN 20-54 ONDERSTEPOORT) PRRPL.sub.-- HRSVA RNA POLYMERASE HANTAAN VIRUS (STRAIN 76-118) 98-139 174-208 372-431 557-591 655-696 731-783 905-949 1276- 1419- 1742- 1993- 1310 1453 1776 2027 PRRPL.sub.-- MABVM RNA POLYMERASE BETA SUBUNIT HUMAN RESPIRATORY SYNCYTIAL VIRUS 87-188 827-861 1131- 1185- 1465- (STRAIN A2 1179 1220 1517 PRRPL.sub.-- MASVP RNA-DIRECTED RNA POLYMERASE MARBURG VIRUS (STRAIN MUSOKE) 597-631 1046- 1490- 1804- 2029- 2194- 1092 1552 1838 2063 2266 PRRPL.sub.-- MEASE RNA-DIRECTED RNA POLYMERASE MARBURG VIRUS (STRAIN POPP) 597-631 1046- 1490- 1092 1552 PRRPL.sub.-- MUMPM RNA POLYMERASE BETA SUBUNIT MEASLES VIRUS (STRAIN EDMONSTON) 197-231 790-824 869-903 1064- 1283- 2121- 1109 1317 2155 PRRPL.sub.-- NDVB RNA POLYMERASE BETA SUBUNIT MUMPS VIRUS (STRAIN MIYAHARA VACCINE) 164-214 220-254 267-304 576-627 752-807 1231- 1447- 1487- 1566- 2191- 1286 1481 1531 1600 2225 PRRPL.sub.-- PI2HT RNA POLYMERASE BETA SUBUNIT NEWCASTLE DISEASE VIRUS (STRAIN BEAUDETTE 167-208 230-295 1969- 2043- 2108- C/45) 2013 2077 2142 PRRPL.sub.-- PI3H4 RNA POLYMERASE BETA SUBUNIT HUMAN PARAINFLUENZA 2 VIRUS (STRAIN 136-170 575-628 750-785 1226- 1316- 1417- 1564- 1687- TOSHIBA) 1901- 1284 1357 1479 1630 1721 1955 PRRPL.sub.-- PUUMH RNA POLYMERASE BETA SUBUNIT HUMAN PARAINFLUENZA 3 VIRUS (STRAIN 48-91 107-163 540-574 747-781 1064- 1293- 1499- 1994- NIH 47885) 1129 1356 1536 2036 PRRPL.sub.-- RABVP RNA-DIRECTED RNA POLYMERASE PUUMALA VIRUS (STRAIN HALLNAS B1) 98-132 381-415 444-488 557-591 655-696 731-783 922-976 1119- 1742- 1940- 1993- 1153 1776 1975 2032 PRRPL.sub.-- RABVS RNA POLYMERASE BETA SUBUNIT RABIES VIRUS (STRAIN PV) 73-114 197-231 696-730 1174- 1522- 1584- 2068- 1222 1580 1618 2123 PRRPL.sub.-- RDV RNA POLYMERASE BETA SUBUNIT RABIES VIRUS (STRAIN SAD B19) 73-114 197-231 696-730 749-783 1174- 1522- 1584- 1222 1580 2123 PRRPL.sub.-- RVFVZ RNA-DIRECTED RNA POLYMERASE RICE DWARF VIRUS 17-61 534-575 844-878 918-985 1037- 1071 PRRPL.sub.-- SEND5 RNA-DIRECTED RNA POLYMERASE RIFT VALLEY FEVER VIRUS (STRAIN ZH-548 M12) 398-439 641-678 832-887 1081- 1653- 1819- 1115 1687 1870 PRRPL.sub.-- SENDE RNA POLYMERASE BETA SUBUNIT SENDAI VIRUS (STRAIN Z/HOST MUTANTS) 398-343 540-600 612-656 747-781 1064- 1239- 1499- 2000- 2146- 1119 1280 1536 2034 2216 PRRPL.sub.-- SENDZ RNA POLYMERASE BETA SUBUNIT SENDAI VIRUS (STRAIN ENDERS) 129-163 360-420 432-476 567-601 884-939 1059- 1319- 1820- 1966- 1100 1356 1854 2036 PRRPL.sub.-- SEOU8 RNA POLYMERASE BETA SUBUNIT SENDAI VIRUS (STRAIN Z) 309-343 540-600 612-656 747-781 1064- 1239- 1499- 2000- 2146- 1119 1280 1536 2034 2216 PRRPL.sub.-- SV5WR RNA-DIRECTED RNA POLYMERASE SEOUL VIRUS (STRAIN 80-39) 98-139 174-208 557-591 655-696 731-765 1742- 1947- 1993- 1776 1981 2027 PRRPL.sub.-- SYNV RNA POLYMERASE BETA SUBUNIT SIMIAN VIRUS 5 (STRAIN 21004-WR) 547-627 747-781 1225- 1319- 1592- 1676- 2024- 1280 1353 1626 1715 2058 PRRPL.sub.-- TSWVB RNA POLYMERASE RNA BETA SONCHUS YELLOW NET VIRUS 760-794 825-859 977- 1089- 1978- 2059- SUBUNIT 1014 1137 2032 2107 PRRPL.sub.-- UUK RNA-DIRECTED RNA POLYMERASE TOMATO SPOTTED WILT VIRUS (BRAZILIAN 46-101 399-433 539-573 589-634 1119- 1195- 1321- 1538- ISOLATE CPNH1/BR- 1153 1236 1379 1572 1684- 1857- 2073- 2156- 2206- 2315- 2378- 2809- 1725 1898 2127 2200 2247 2368 2419 2843 PRRPL.sub.-- VSVJH RNA POLYMERASE UUKUNIEMI VIRUS 127-183 282-323 836-874 1030- 1481- 2015- 2061- 1071 1515 2049 2098 PRRPL.sub.-- VSVJO RNA POLYMERASE BETA SUBUNIT VESICULAR STOMATITIS VIRUS (SEROTYPE NEW 319-358 674-715 720-763 1522- 1802- JERSEY/STRA 1567 1836 PRRPL.sub.-- VSVSJ RNA POLYMERASE BETA SUBUNIT VESICULAR STOMATITIS VIRUS (SEROTYPE NEW 319-358 674-715 720-763 1802- JERSEY/STRA 1836 PRRPO.sub.-- ACLSV RNA POLYMERASE BETA SUBUNIT VESICULAR STOMATITIS VIRUS (STRAIN SAN JUAN) 674-715 720-763 1019- 1742- 2066- 1074 1799 2107 PRRPO.sub.-- BWYVF RNA-DIRECTED RNA POLYMERASE APPLE CHLOROTIC LEAF SPOT VIRUS 228-262 557-596 916-950 1235- 1269 PRRPO.sub.-- BYDV1 PUTATIVE RNA-DIRECTED RNA BEET WESTERN YELLOWS VIRUS (ISOLATE FL-1) 304-341 POLYMERASE PRRPO.sub.-- BYDVP PUTATIVE RNA-DIRECTED RNA BARLEY YELLOW DWARF VIRUS (ISOLATE MAV-PS1) 234-285 POLYMERASE PRRPO.sub.-- BYDVR PUTATIVE RNA-DIRECTED RNA BARLEY YELLOW DWARF VIRUS (ISOLATE PAV) 234-285 POLYMERASE PRRPO.sub.-- CARMV PUTATIVE RNA-DIRECTED RNA BARLEY YELLOW DWARF VIRUS (ISOLATE P-PAV) 234-285 POLYMERASE PRRPO.sub.-- CGMVS PROBABLE RNA-DIRECTED RNA CARNATION MOTTLE VIRUS 93-131 POLYMERASE PRRPO.sub.-- IBDV5 PUTATIVE RNA-DIRECTED RNA CUCUMBER GREEN MOTTLE MOSAIC VIRUS 7-41 387-428 446-480 726-767 1445- POLYMERASE (WATERMELON STR 1479 PRRPO.sub.-- IBDVA PUTATIVE RNA-DIRECTED RNA AVIAN INFECTIOUS BURSAL DISEASE VIRUS 384-432 446-484 POLYMERASE (STRAIN 52170) PRRPO.sub.-- IPNVJ PUTATIVE RNA-DIRECTED RNA AVIAN INFECTIOUS BURSAL DISEASE VIRUS 144-185 266-307 709-757 771-809 POLYMERASE (STRAIN AUSTURALI PRRPO.sub.-- IPNVS PUTATIVE RNA-DIRECTED RNA INFECTIOUS PANCREATIC NECROSIS VIRUS 147-181 268-407 501-535 750-802 POLYMERASE (SEROTYPE JASPER) PRRPO.sub.-- LYCVA PUTATIVE RNA-DIRECTED RNA INFECTIOUS PANCREATIC NECROSIS VIRUS 147-181 366-407 501-535 753-802 POLYMERASE (SEROTYPE SP) PRRPO.sub.-- LYCVW RNA POLYMERASE LYMPHOCYTIC CHORIOMENINGITIS VIRUS (STRAIN 301-346 805-886 926-960 1509- 2090- ARMSTRON 1543 2124 PRRPO.sub.-- MCMV RNA POLYMERASE LYMPHOCYTIC CHORIOMENINGITIS VIRUS (STRAIN 301-345 WE) PRRPO.sub.-- PEAMV PROBABLE RNA-DIRECTED RNA MAIZE CHLOROTIC MOTTLE VIRUS 181-215 697-731 POLYMERASE PRRPO.sub.-- PLRV1 RNA-DIRECTED RNA POLYMERASE PEA ENATION MOSAIC VIRUS 321-358 PRLPO.sub.-- PLRVW PUTATIVE RNA-DIRECTED RNA POTATO LEAFROLL VIRUS (STRAIN 1) 336-373 423-457 POLYMERASE PRRPO.sub.-- PPMVS PUTATIVE RNA-DIRECTED RNA POTATO LEAFROLL VIRUS (STRAIN WAGENINGEN) 336-373 423-457 POLYMERASE PRRPP.sub.-- RCNMV PUTATIVE RNA-DIRECTED RNA PEPPER MILD MOTTLE VIRUS (STRAIN SPAIN 321-362 402-454 627-661 862-896 POLYMERASE PRRPO.sub.-- REOVD PUTATIVE RNA-DIRECTED RNA RED CLOVER NECROTIC MOSAIC VIRUS 666-700 POLYMERASE PRLPO.sub.-- REOVJ RNA-DIRECTED RNA POLYMERASE REOVIRUS (TYPE 3/STRAIN DEARING) 310-361 PRRPO.sub.-- REOVL RNA-DIRECTED RNA POLYMERASE REOVIRUS (TYPE 2/STRAIN D5/JONES) 310-344 PRRPO.sub.-- ROTBR RNA-DIRECTED RNA POLYMERASE REOVIRUS (TYPE 1/STRAIN LANG) 310-361 PRRPO.sub.-- ROTBU RNA-DIRECTED RNA POLYMERASE BOVINE ROTAVIRUS (STRAIN RF) 60-96 133-167 204-245 535-569 579-631 639-686 690-724 771-805 SUBUNIT VP1 PRRPO.sub.-- ROTPC RNA-DIRECTED RNA POLYMERASE BOVINE ROTAVIRUS (STRAIN UK) 60-96 133-167 204-245 535-569 579-631 639-686 690-724 771-805 SUBUNIT VP1 PRRPO.sub.-- ROTPG RNA-DIRECTED RNA POLYMERASE PORCINE ROTAVIRUS (GROUP C/STRAIN COWDEN) 3-44 255-299 335-397 476-510 518-620 966-1007 SUBUNIT VP1 PRRPO.sub.-- ROTS1 RNA-DIRECTED RNA POLYMERASE PORCINE ROTAVIRUS (STRAIN GOTTFRIED) 62-96 133-167 336-377 581-631 636-686 690-724 771-842 SUBUNIT VP1 PRRPO.sub.-- SBMV RNA-DIRECTED RNA POLYMERASE SIMIAN 11 ROTAVIRUS (STRAIN SA11) 60-96 133-167 535-569 579-631 639-686 690-724 771-805 SUBUNIT VP1 PRRPO.sub.-- SCVLA PROBABLE RNA-DIRECTED RNA SOUTHERN BEAN MOSAIC VIRUS 628-665 POLYMERASE PRRPO.sub.-- TACV RNA-DIRECTED RNA POLYMERASE SACCHAROMYCES CEREVISIAE VIRUS L-A 100-134 147-191 PRRPO.sub.-- TMGMV RNA POLYMERASE TACARIBE VIRUS 155-204 220-278 375-416 484-518 891-925 1030- 1285- 1981- 1081 1319 2015 PRRPO.sub.-- TMV PUTATIVE RNA-DIRECTED RNA TOBACCO MILD GREEN MOSAIC VIRUS (TMV 401-449 682-720 765-818 POLYMERASE STRAIN U2) PRRPO.sub.-- TMVKR PUTATIVE RNA-DIRECTED RNA TOBACCO MOSAIC VIRUS (VULGARE) 3-37 401-453 665-699 POLYMERASE PRRPO.sub.-- TMVTO PUTATIVE RNA-DIRECTED RNA TOBACCO MOSAIC VIRUS (STRAIN KOREAN) 3-37 401-453 665-699 POLYMERASE PRRPO.sub.-- TNVD PUTATIVE RNA-DIRECTED RNA TOBACCO MOSAIC VIRUS (STRAIN TOMATO/L) 3-37 401-453 860-894 POLYMERASE PRRPP.sub.-- BRSVA RNA-DIRECTED RNA POLYMERASE TOBACCO NECROSIS VIRUS (STRAIN D) 102-144 PRRPP.sub.-- CDVO RNA POLYMERASE ALPHA SUBUNIT BOVINE RESPIRATORY SYNCYTIAL VIRUS (STRAIN 99-158 160-216 A51908) PRRPP.sub.-- HRSV RNA POLYMERASE ALPHA SUBUNIT CANINE DISTEMPER VIRUS (STRAIN 312-373 ONDERSTEPOORT) PRRPP.sub.-- HRSV1 RNA POLYMERASE ALPHA SUBUNIT HUMAN RESPIRATORY SYNCYTIAL VIRUS 99-158 160-216 PRRPP.sub.-- HRSVA RNA POLYMERASE ALPHA SUBUNIT HUMAN RESPIRATORY SYNCYTIAL VIRUS 99-158 160-216 (SUBGROUP B/STRA1 PRRPP.sub.-- HRSVL RNA POLYMERASE ALPHA SUBUNIT HUMAN RESPIRATORY SYNCYTIAL VIRUS (STRAIN 99-158 160-216 A2) PRRPP.sub.-- MEASE RNA POLYMERASE ALPHA SUBUNIT HUMAN RESPIRATORY SYNCYTIAL VIRUS 99-158 160-216 (SUBGROUP A/STRAI PRRPP.sub.-- MEASI RNA POLYMERASE ALPHA SUBUNIT MEASLES VIRUS (STRAIN EDMONSTON) 315-374 460-495 PRRPP.sub.-- MEASY RNA POLYMERASE ALPHA SUBUNIT MEASLES VIRUS (STRAIN IP-3-CA) 315-374 460-495 PRRPP.sub.-- MUMP1 RNA POLYMERASE ALPHA SUBUNIT MEASLES VIRUS (STRAIN YAMAGATA-1) 315-374 460-495 PRRPP MUMPE RNA POLYMERASE ALPHA SUBUNIT MUMPS VIRUS (STRAIN SBL-1) 149-183 213-275 PRRPP.sub.-- MUMPM RNA POLYMERASE ALPHA SUBUNIT MUMPS VIRUS (STRAIN ENDERS) 214-276 PRRPP.sub.-- NDVA RNA POLYMERASE ALPHA SUBUNIT MUMPS VIRUS (STRAIN MIYAHARA VACCINE) 214-276 PRRPP.sub.-- NDVB RNA POLYMERASE ALPHA SUBUNIT NEWCASTLE DISEASE VIRUS (STRAIN AUSTRALIA- 100-134 VICTORIA/32) PRRPP.sub.-- PI1HB RNA POLYMERASE ALPHA SUBUNIT NEWCASTLE DISEASE VIRUS (STRAIN BEAUDETTE 100-138 C/45) PRRPP.sub.-- PI1HC RNA POLYMERASE ALPHA SUBUNIT HUMAN PARAINFLUENZA 1 VIRUS (STRAIN C35) 80-114 313-364 375-437 PRRPP.sub.-- PI1HD RNA POLYMERASE ALPHA SUBUNIT HUMAN PARAINFLUENZA 1 VIRUS (STRAIN C39) 80-114 313-364 375-437 PRRPP.sub.-- PI1HE RNA POLYMERASE ALPHA SUBUNIT HUMAN PARAINFLUENZA 1 VIRUS (STRAIN CI-5/73) 80-114 313-364 375-437 PRRPP.sub.-- PI2H RNA POLYMERASE ALPHA SUBUNIT HUMAN PARAINFLUENZA 1 VIRUS (STRAIN CI-14/830) 66-114 237-271 313-364 375-437 PRPPP.sub.-- PI2HT RNA POLYMERASE ALPHA SUBUNIT HUMAN PARAINFLUENZA 2 VIRUS 218-281 PRRPP.sub.-- PI3B RNA POLYMERASE ALPHA SUBUNIT HUMAN PARAINFLUENZA 2 VIRUS (STRAIN 218-281 TOSHIBA) PRRPP.sub.-- PIHH4 RNA POLYMERASE ALPHA SUBUNIT BOVINE PARAINFLUENZA 3 VIRUS 31-130 414-470 PRRPP.sub.-- PI4HA RNA POLYMERASE ALPHA SUBUNIT HUMAN PARAINFLUENZA 3 VIRUS (STRAIN NIH 410-499 47885) PRRPP.sub.-- PI4HB RNA POLYMERASE ALPHA SUBUNIT HUMAN PARAINFLUENZA 4A VIRUS (STRAIN 4-38 222-285 TOSHIBA) PRRPP.sub.-- PIRYV RNA POLYMERASE ALPHA SUBUNIT HUMAN PARAINFLUENZA 4B VIRUS (STRAIN 222-285 68-333) PRRPP.sub.-- RABVA RNA POLYMERASE ALPHA SUBUNIT PIRY VIRUS 137-174 PRRPP.sub.-- RABVC RNA POLYMERASE ALPHA SUBUNIT RABIES VIRUS (STRAIN AVO1) 93-127 PRRPP.sub.-- RABVE RNA POLYMERASE ALPHA SUBUNIT RABIES VIRUS (STRAIN CVS-11) 93-127 PRRPP.sub.-- RABVP RNA POLYMERASE ALPHA SUBUNIT RABIES VIRUS (STRAIN ERA), AND (STRAIN PM) 93-127 PRRPP.sub.-- RABVS RNA POLYMERASE ALPHA SUBUNIT RABIES VIRUS (STRAIN PV) 93-127 PRRPP.sub.-- SEND5 RNA POLYMERASE ALPHA SUBUNIT RABIES VIRUS (STRAIN SAD B19 93-127 PRRPP.sub.-- SEND6 RNA POLYMERASE ALPHA SUBUNIT SENDAI VIRUS (STRAIN Z/HOST MUTANTS) 313-364 375-447 PRRPP.sub.-- SENDF RNA POLYMERASE ALPHA SUBUNIT SENDAI VIRUS (STRAIN 6/94) 323-364 375-447 PRRPP.sub.-- SENDH RNA POLYMERASE ALPHA SUBUNIT SENDAI VIRUS (STRAIN FUSHIMI) 313-364 375-447 PRRPP.sub.-- SENDZ RNA POLYMERASE ALPHA SUBUNIT SENDAI VIRUS (STRAIN HARRIS) 313-364 375-447 PRRPP.sub.-- SV5 RNA POLYMERASE ALPHA SUBUNIT SENDAI VIRUS (STRAIN Z) 313-364 375-447 PRRPP.sub.-- SYNV RNA POLYMERASE ALPHA SUBUNIT SIMIAN VIRUS 5 (STRAIN W3) 205-278 PRRPP.sub.-- VSVIG RNA POLYMERASE ALPHA SUBUNIT SONCHUS YELLOW NET VIRUS 138-173 233-281 PRRPP.sub.-- VSVIM RNA POLYMERASE ALPHA SUBUNIT VESICULAR STOMATITIS VIRUS (SEROTYPE 3-43 INDIANA/STRAI N G PRRPP.sub.-- VSVJM RNA POLYMERASE ALPHA SUBUNIT VESICULAR STOMATITIS VIRUS (SEROTYPE 3-43 INDIANA/STRAI N M PRRPP.sub.-- VSVJO RNA POLYMERASE ALPHA SUBUNIT VESICULAR STOMATITIS VIRUS (SEROTYPE 3-37 NEW JERSEY/ST RAI PRRPP.sub.-- VSVSJ RNA POLYMERASE ALPHA SUBUNIT VESICULAR STOMATITIS VIRUS (SEROTYPE 3-37 NEW JERSEY/ST RAI PSPHR.sub.-- AMEPV RNA POLYMERASE ALPHA SUBUNIT VESICULAR STOMATITIS VIRUS (STRAIN SAN JUAN) 3-43 PSPI2.sub.-- VACCV SPHEROIDIN AMSACTA MOOREI ENTOMOPOXVIRUS 223-264 361-395 PSPI2.sub.-- VARV SERINE PROTEINASE INHIBITOR VACCINIA VIRUS (STRAIN WR) 21-86 PSPI3.sub.-- VACCC SERINE PROTEINASE INHIBITOR 2 VARIOLA VIRUS 21-86 PSPI3.sub.-- VACCV SERINE PROTEINASE INHIBITOR 3 VACCINIA VIRUS (STRAIN COPENHAGEN) 118-167 225-266 PSPI3.sub.-- VARV SERINE PROTEINASE INHIBITOR 3 VACCINIA VIRUS (STRAIN WR) 118-167 225-266 PSPIA.sub.-- VACCC SERINE PROTEINASE INHIBITOR 3 VARIOLA VIRUS 122-171 229-270 PT2C2.sub.-- CHVP1 SERINE PROTEINASE INHIBITOR 2 VACCINIA VIRUS (STRAIN COPENHAGEN) 11-65 HOMOLOG FIRST PTAA2.sub.-- VACCV TYPE II RESTRICTION ENZYME CVIAI1 PARAMECIUM BURSARIA CHLORELLA VIRUS 45-85 PTAG8.sub.-- FOWPV TRANS-ACTIVATOR PROTEIN A2 VACCINIA VIRUS (STRAIN WR, COPENHAGEN, AND 95-133 173-207 VARIOLA VI PTAG8.sub.-- VACCV TRANS-ACTIVATOR PROTEIN FP0 FOWLPOX VIRUS 3-51 PTAG8.sub.-- VARV TRANS-ACTIVATOR PROTEIN GK1 VACCINIA VIRUS (STRAIN WR), (STRAIN 3-51 COPENHAGEN ) PTALA.sub.-- BFDV TRANS-ACTIVATOR PROTEIN GK1 VARIOLA VIRUS 3-51 PTALA.sub.-- POVBO LARGE T ANTIGEN BUDGERIGAR FLEDGLLNG DISEASE VIRUS 291-325 464-498 PTALA.sub.-- POVHA LARGE T ANTIGEN BOVINE POLYOMAVIRUS 303-337 495-537 PTALA.sub.-- POVJC LARGE T ANTIGEN HAMSTER POLYOMAVIRUS 464-501 587-621 PTALA.sub.-- POVLY LARGE T ANTIGEN POLYOMAVIRUS JC 153-187 589-623 PTALA.sub.-- POVM3 LARGE T ANTIGEN LYMPHOTROPIC POLYOMAVIRUS 3-41 206-258 437-478 PTALA.sub.-- POVMA LARGE T ANTIGEN MOUSE POLYOMAVIRUS (STRAIN 3) 509-544 PTALA.sub.-- POVMC LARGE T ANTIGEN MOUSE POLYOMAVIRUS (STRAIN A2) 507-542 PTAMI.sub.-- POVHA LARGE T ANTIGEN MOUSE POLYOMAVIRUS (STRAIN CRAWFORD 504-539 SMALL-PLAQUE) PTAMI.sub.-- POVM3 MIDDLE T ANTIGEN HAMSTER POLYOMAVIRUS 339-378 PTAMI.sub.-- POVMA MIDDLE T ANTIGEN MOUSE POLYOMAVIRUS (STRAIN 3) 211-245 388-422 PTAMI.sub.-- POVMC MIDDLE T ANTIGEN MOUSE POLYOMAVIRUS (STRAIN A2) 192-226 369-403 PTASM.sub.-- POVBO MIDDLE T ANTIGEN MOUSE POLYOMAVIRUS (STRAIN CRAWFORD 192-226 369-403 SMALL-PLAQUE) PTASM.sub.-- POVLY SMALL T ANTIGEN BOVINE POLYOMAVIRUS 41-85 PTATR.sub.-- NPVAC SMALL T ANTIGEN LYMPHOTROPIC POLYOMAVIRUS 3-41 PTATR.sub.-- NPVBM TRANS-ACTIVATING AUTOGRAPHA CALIFORNICA NUCLEAR 408-442 46-480 489-523 TRANSCRIPTIONAL REGULAT POLYHEDROSIS VIRUS PTATR.sub.-- NPVOP TRANS-ACTIVATING BOMBYX MORI NUCLEAR POLYHEDROSIS VIRUS 413-447 451-485 494-528 TRANSCRIPTIONAL REGULAT PTAT.sub.-- SIVA1 TRANS-ACTIVATING ORGYIA PSEUDOTSUGATA MULTICAPSID 391-455 511-554 TRANSCRIPTIONAL REGULAT POLYHEDROSIS VIRUS PTAT.sub.-- SIVAI TAT PROTEIN SIMIAN IMMUNODEFICIENCY VIRUS 73-109 (AGM155 ISOLATE) PTAT.sub.-- VILV TAT PROTEIN SIMIAN IMMUNODEFICIENCY VIRUS 137-185 (ISOLATE AGM/CLONE GRI PTAT.sub.-- VILV1 TRANS-ACTIVATING VISNA LENTIVIRUS (STRAIN 1514) 28-74 TRANSCRIPTIONAL REGULAT PTAT.sub.-- VILV2 TRANS-ACTIVATING VISNA LENTIVIRUS (STRAIN 1514/CLONE LV1-1kS1) 40-74 TRANSCRIPTIONAL REGULAT PTCB.sub.-- FLV TRANS-ACTIVATING VISNA LENTIVIRUS (STRAIN 1514/CLONE LV1-1KS2) 40-74 TRANSCRIPTIONAL REGULAT PTEGP.sub.-- HSVII T-CELL RECEPTOR BETA CHAIN FELINE LEUKEMIA VIRUS 279-321 PRECURSOR PTEGP.sub.-- HSVEA TEGUMENT PHOSPHOPROTEIN US9 HERPES SIMPLEX VIRUS (TYPE 1/STRAIN 17) 27-61 PTEGP.sub.-- HSVEB NONSENSE PTEGP.sub.-- HSVEK NONSENSE PTEGP.sub.-- HSVSB NONSENSE PTEGU.sub.-- EBV NONSENSE PTEGU.sub.-- HCMVA LARGE TEGUMENT PROTEIN EPSTEIN-BARR VIRUS (STRAIN B95-8) 768-802 821-855 938-972 1101- 1208- 1479- 1700- 1809- 1138 1242 1516 1753 1867 1870- 1920- 3108- 1916 1954 3149 PTEGU.sub.-- HSV11 PROBABLE LARGE TEGUMENT HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 34-71 215-249 543-581 700-738 868-909 936-977 1004- 1163- PROTEIN 1038 1200 1237- 2200- 1296 2235 PTEGU.sub.-- HSV6G LARGE TEGUMENT PROTEIN HERPES SIMPLEX VIRUS (TYPE 1/STRAIN 17) 731-765 801-842 1022- 1223- 1275- 1315- 1520- 1609- 1059 1269 1309 1370 1531 1669 1673- 1749- 1820- 2670- 1714 1783 1854 2704 PTEGU.sub.-- HSVEB LARGE TEGUMENT PROTEIN HERPES SIMPLEX VIRUS (TYPE 6/STRAIN GS) 30-71 224-262 567-608 712-757 951- 1091- 1192- 1357- 1000 1181 1233 1400 PTEGU.sub.-- HSVSA LARGE TEGUMENT PROTEIN EQUINE HERPESVIRUS TYPE 1 (STRAIN AB4P) 560-597 635-683 794-848 908-956 1108- 1155- 1399- 1487- 1151 1246 1458 1549 1619- 1661- 1702- 1806- 1947- 1657 1695 1736 1843 1981 PTEGU.sub.-- VZVD PROBABLE LARGE TEGUMENT HERPESVIRUS SAIMIRI (STRAIN 11) 520-558 560-598 615-652 672-710 777-822 846-898 948-986 1287- PROTEIN 1332 1434- 1502 PTERM.sub.-- ADE02 LARGE TEGUMENT PROTEIN VARICELLA-ZOSTER VIRUS (STRAIN DUMAS) 657-696 713-747 804-841 933-972 1117- 1415- 1528- 1572- 1158 1471 1562 1620 1633- 1719- 1945- 2727- 1705 1756 1986 2761 PTERM.sub.-- ADE05 DNA TERMINAL PROTEIN HUMAN ADENOVIRUS TYPE 2 490-572 PTERM.sub.-- ADE07 DNA TERMINAL PROTEIN HUMAN ADENOVIRUS TYPE 5 490-592 PTERM.sub.-- ADE12 DNA TERMINAL PROTEIN HUMAN ADENOVIRUS TYPE 7 491-559 PTJUN.sub.-- AVIS1 DNA TERMINAL PROTEIN HUMAN ADENOVIRUS TYPE 12 443-491 497-538 PTMAF.sub.-- AVIS4 TRANSFORMING PROTEIN JUN AVIAN SARCOMA VIRUS (STRAIN 17) 210-284 PTOP1.sub.-- SFVKA TRANSFORMING PROTEIN MAF AVIAN MUSCULOAPONEUROTIC FIBROSARCOMA 247-288 295-340 VIRUS AS42 PTOP2.sub.-- ASFB7 DNA TOPOISOMERASE SHOPE FIBROMA VIRUS (STRAIN KASZA) 127-183 269-310 PTOP2.sub.-- ASFM2 DNA TOPOISOMERASE II AFRICAN SWINE FEVER VIRUS (STRAIN BA71V) 146-180 481-515 601-642 945-979 1038- 1123- 1093 1162 PTSIS.sub.-- SMSAV DNA TOPOISOMERASE II AFRICAN SWINE FEVER VIRUS (ISOLATE MALAWI 146-180 480-514 600-641 902-936 944-978 1038- 1122- LIL 20/1) 1091 1161 PTYSY.sub.-- VZVD PDGF-RELATED TRANSFORMING SIMIAN SARCOMA VIRUS 16-71 PROTEIN P28-SIS PUBIL.sub.-- NPVOP THYMIDYLATE SYNTHASE VARICELLA-ZOSTER VIRUS (STRAIN DUMAS) 215-260 PUL01.sub.-- HCMVA UBIQUITIN-LIKE PROTEIN ORGYIA PSEUDOTSUGATA MULTICAPSID 43-80 POLYHEDROSIS VIRUS PUL03.sub.-- HSV11 HYPOTHETICAL PROTEIN UL1 HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 169-203 PUL03.sub.-- HSV2H PROTEIN UL3 HERPES SIMPLEX VIRUS (TYPE 1/STRAIN 17) 94-128 PUL03.sub.-- HSVEB PROTEIN UL3 HERPES SIMPLEX VIRUS (TYPE 2/STRAIN HG52) 92-126 PUL04.sub.-- HSV11 GENE 60 PROTEIN EQUINE HERPESVIRUS TYPE 1 (STRAIN AB4P) 70-104 PUL06.sub.-- EBV PROTEIN UL4 HERPES SIMPLEX VIRUS (TYPE 1/STRAIN 17) 102-136 PUL06.sub.-- HCMVA VIRION PROTEIN BBRF1 EPSTEIN-BARR VIRUS (STRAIN B95-8) 104-145 313-347 376-410 PUL06.sub.-- HSV11 HYPOTHETICAL PROTEIN UL6 HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 216-250 PUL06.sub.-- HSVEB VIRION PROTEIN UL6 HERPES SIMPLEX VIRUS (TYPE 1/STRAIN 17) 36-94 103-141 294-329 337-371 416-479 PUL06.sub.-- HSVSA VIRION GENE 56 PROTEIN EQUINE HERPESVIRUS TYPE 1 (STRAIN AB4P) 62-170 357-413 448-503 PUL06.sub.-- VZVD VIRION GENE 43 PROTEIN HERPES VIRUS SAIMIRI (STRAIN 11) 90-140 151-194 302-336 364-405 PUL08.sub.-- HCMVA VIRION GENE 54 PROTEIN VARICELLA-ZOSTER VIRUS (STRAIN DUMAS) 87-131 350-409 704-738 PUL09.sub.-- HSVEB HYPOTHETICAL PROTEIN UL8 HUMAN CYTOMEGALOVIRUS (STRAIN AD 169) 6-50 PUL09.sub.-- VZVD ORIGIN OF REPLICATION BINDING EQUINE HERPESVIRUS TYPE 1 (STRAIN AB4P) 174-208 PROTEIN PUL11.sub.-- HCMVA ORIGIN OF REPLICATION BINDING VARICELLA-ZOSTER VIRUS (STRAIN DUMAS) 122-163 PROTEIN PUL13.sub.-- HCMVA NONSENSE PUL14.sub.-- HCMVA HYPOTHETICAL PROTEIN UL13 HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 47-81 185-227 PUL14.sub.-- HSVEB HYPOTHETICAL PROTEIN UL14 HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 305-343 PUL14.sub.-- PRVN3 HYPOTHETICAL GENE 45 PROTEIN EQUINE HERPESVIRUS TYPE 1 (STRAIN AB4P) 52-96 246-283 PUL14.sub.-- VZVD UL14 PROTEIN HOMOLOG PSEUDORABIES VIRUS (STRAIN NIA-3) 43-95 PUL16.sub.-- HSVEB HYPOTHETICAL GENE 46 PROTEIN VARICELLA-ZOSTER VIRUS (STRAIN DUMAS) 61-103 PUL17.sub.-- HSV6U GENE 45 PROTEIN EQUINE HERPESVIRUS TYPE 1 (STRAIN AB4P) 266-300 PUL21.sub.-- HSVEB PROTEIN 10R HERPES SIMPLEX VIRUS (TYPE 6/STRAIN 239-280 UGANDA-1102 PUL23.sub.-- HCMVA GENE 40 PROTEIN EQUINE HERPESVIRUS TYPE 1 (STRAIN AB4P) 44-75 421-474 PUL24.sub.-- HCMVA HYPOTHETICAL PROTEIN UL23 HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 213-253 PUL24.sub.-- ILTVT HYPOTHETICAL PROTEIN UL14 HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 5-39 PUL25.sub.-- HCMVA PROTEIN UL24 HOMOLOG INFECTIOUS LARYNGOTRACHEITIS VIRUS (STRAIN 161-195 THORNE V88 PUL25.sub.-- HSV11 HYPOTHETICAL PROTEIN UL25 HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 255-341 351-399 PUL25.sub.-- HSVEB VIRION PROTEIN UL25 HERPES SIMPLEX VIRUS (TYPE 1/STRAIN 17) 370-411 PUL25.sub.-- HSVSA VIRION PROTEIN UL25 EQUINE HERPESVIRUS TYPE 1 (STRAIN AB4P) 364-413 PUL25.sub.-- ILTVT VIRION GENE 19 PROTEIN HERPESVIRUS SAIMIRI (STRAIN 11) 29-92 183-231 365-406 PUL25.sub.-- VZVD 64.1 KD VIRION PROTEIN INFECTIOUS LARYNGOTRACHEITIS VIRUS (STRAIN 38-84 165-206 THORNE V88 PUL31.sub.-- HCMVA VIRION GENE 34 PROTEIN VARICELLA-ZOSTER VIRUS (STRAIN DUMAS) 340-388 PUL31.sub.-- HSVEB HYPOTHETICAL PROTEIN UL31 HUN CYTOMEGALOVIRUS (STRAIN AD169) 244-285 PUL31.sub.-- VZVD GENE 29 PROTEIN EQUINE HERPESVIRUS TYPE 1 (STRAIN AB4P) 153-157 PUL32.sub.-- HSVEB GENE 27 PROTEIN VARICELLA-ZOSTER VIRUS (STRAIN DUMAS) 163-197 PUL32.sub.-- VZVD MAJOR ENVELOPE GLYCOPROTEIN EQUINE HERPESVIRUS TYPE 1 (STRAIN AB4P) 342-376 300 (STRAIN ABI) PUL33.sub.-- HCMVA PROBABLE MAJOR ENVELOPE VARICELLA-ZOSTER VIRUS (STRAIN DUMAS) 72-106 296-344 GLYCOPROTEIN 26 PUL33.sub.-- VZVD PROTEIN COUPLED RECEPTOR HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 94-135 309-352 HOMOLOG UL33 PUL34.sub.-- EBV GENE 25 PROTEIN VARICELLA-ZOSTER VIRUS (STRAIN DUMAS) 29-63 PUL34.sub.-- HCMVA BFRF1 PROTEIN EPSTEIN-BARR VIRUS (STRAIN B95.8) 159-200 PUL34.sub.-- HSV11 HYPOTHETICAL PROTEIN UL34 HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 113-147 PUL35.sub.-- HCMVA VIRION PROTEIN UL34 HERPES SIMPLEX VIRUS (TYPE 1/STRAIN 17) 187-221 PUL37.sub.-- EBV HYPOTHETICAL PROTEIN UL35 HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 231-268 PUL37.sub.-- HSV11 PROTEIN BOLF1 EPSTEIN-BARR VIRUS (STRAIN B95-8) 708-742 PUL37.sub.-- HSVEB PROTEIN UL37 HERPES SIMPLEX VIRUS (TYPE 1/STRAIN 17) 853-891 PUL37.sub.-- HSVSA GENE 23 PROTEIN EQUINE HERPESVIRUS TYPE 1 (STRAIN AB4P) 82-137 311-345 614-648 715-750 781-822 PUL37.sub.-- VZVD GENE 63 PROTEIN HERPESVIRUS SAIMIRI (STRAIN 11) 6-65 682-741 PUL38.sub.-- HCMVA GENE 21 PROTEIN VARICELLA-ZOSTER VIRUS (STRAIN DUMAS) 719-753 786-827 PUL41.sub.-- VZVD HYPOTHETICAL PROTEIN UL38 HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 10-51 PUL42.sub.-- HSV11 HOST SHUTOFF VIRION PROTEIN VARICELLA-ZOSTER VIRUS (STRAIN DUMAS) 330-366 PUL42.sub.-- HSVEB DNA-BINDING PROTEIN UL42 HERPES SIMPLEX VIRUS (TYPE 1/STRAIN 17) 134-168 221-263 PUL43.sub.-- HCMVA DNA-BINDING GENE 18 PROTEIN EQUINE HERPESVIRUS TYPE 1 (STRAIN AB4P) 138-172 PUL43.sub.-- HSVE4 HYPOTHETICAL PROTEIN UL43 HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 72-109 PUL43.sub.-- VZVD MEMBRANE PROTEIN UL43 HOMOLOG EQUINE HERPESVIRUS TYPE 4 (STRAIN 1942) 27-68 PUL45.sub.-- HSVIK GENE 15 MEMBRANE PROTEIN VARICELLA-ZOSTER VIRUS (STRAIN DUMAS) 312-363 PUL45.sub.-- HSV1M PROTEIN UL45 HERPES SIMPLEX VIRUS (TYPE 1/STRAIN KOS) 96-137 PUL47.sub.-- HCMVA PROTEIN UL45 HERPES SIMPLEX VIRUS (TYPE 1/STRAIN MP) 96-137 PUL47.sub.-- HSV11 PROTEIN UL47 HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 114-165 448-485 745-856 PUL47.sub.-- HSV1F VIRION PROTEIN UL47 HERPES SIMPLEX VIRUS (TYPE 1/STRAIN 17) 473-518 PUL47.sub.-- HSVBP VIRION PROTEIN UL47 HERPES SIMPLEX VIRUS (TYPE 1/STRAIN F 473-518 PUL47.sub.-- HSVE4 80.7 KD ALPHA TRANS-INDUCING BOVINE HERPESVIRUS TYPE 1 (STRAIN P8-2) 561-612 PROTEIN PUL47.sub.-- HSVEB 97 KD ALPHA TRANS-INDUCING EQUINE HERPESVIRUS TYPE 4 (STRAIN 1942) 183-246 582-620 825-866 PROTEIN PUL47.sub.-- VZVD 97 KD ALPHA TRANS-INDUCING EQUINE HERPESVIRUS TYPE 1 (STRAIN AB4P) 219-253 371-412 817-866 PROTEIN PUL50.sub.-- HCMVA ALPHA TRANS-INDUCING FACTOR VARICELLA-ZOSTER VIRUS (STRAIN DUMAS) 84-135 156-209 664-701 91.8 KD PROTEIN PUL51.sub.-- HSV11 PROTEIN UL50 HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 155-189 PUL51.sub.-- HSVE4 PROTEIN UL51 HERPES SIMPLEX VIRUS (TYPE 1/STRAIN 17) 118-169 PUL51.sub.-- HSVEB GENE 8 PROTEIN EQUINE HERPES VIRUS TYPE 4 (STRAIN 1942) 121-162 PUL51.sub.-- VZVD GENE 8 PROTEIN EQUINE HERPESVIRUS TYPE 1 (STRAIN AB4P) 120-161 PUL52.sub.-- EBV GENE 7 PROTEIN VARICELLA-ZOSTER VIRUS (STRAIN DUMAS) 122-163 PUL52.sub.-- HSV11 PROBABLE DNA REPLICATION EPSTEIN-BARR VIRUS (STRAIN B95-8) 188-255 PROTEIN BSLF 1 PUL52.sub.-- HSVEB DNA REPLICATION PROTEIN HERPES SIMPLEX VIRUS (TYPE 1/STRAIN 17) 189-223 UL52 PUL52.sub.-- HSVSA DNA REPLICATION PROTEIN EQUINE HERPESVIRUS TYPE 1 (STRAIN AB4P) 141-182 929-970 UL52 PUL52.sub.-- VZVD PROBABLE DNA REPLICATION GENE HERPESVIRUS SAIMIRI (STRAIN 11) 445-483 56 PROTEIN PUL53.sub.-- HCMVA PROBABLE DNA REPLICATION GENE VARICELLA-ZOSTER VIRUS (STRAIN DUMAS) 301-342 6 PROTEIN PUL55.sub.-- HSV2H PROTEIN UL53 HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 12-48 PUL64.sub.-- HCMVA PROTEIN UL55 HERPES SIMPLEX VIRUS (TYPE 2/STRAIN HG52) 151-185 PUL70.sub.-- HCMVA HYPOTHETICAL PROTEIN UL64 HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 32-73 PUL74.sub.-- HCMVA PROBABLE DNA REPLICATION HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 39-99 PROTEIN UL70 PUL87.sub.-- HSV6U HYPOTHETICAL PROTEIN UL74 HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 43-79 PUL87.sub.-- HSVSA HYPOTHETICAL PROTEIN SR HERPES SIMPLEX VIRUS (TYPE 6/STRAIN 729-770 UGANDA-1102) PUL88.sub.-- HCMVA HYPOTHETICAL GENE 24 PROTEIN HERPES VIRUS SAIMIRI (STRAIN 11) 366-400 582-616 PUL91.sub.-- HSVSA HYPOTHETICAL PROTEIN UL88 HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 357-391 PUL92.sub.-- EBV HYPOTHETICAL GENE 30 PROTEIN HERPESVIRUS SAIMIRI (STRAIN 11) 24-58 PUL92.sub.-- HCMVA HYPOTHETICAL PROTEIN BDLF4 EPSTEIN-BARR VIRUS (STRAIN B95-8) 107-144 188-222 PUL92.sub.-- HSV6U HYPOTHETICAL PROTEIN UL92 HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 79-116 PUL92.sub.-- HSVSA HYPOTHETICAL PROTEIN 9R HERPES SIMPLEX VIRUS (TYPE 6/STRAIN 101-145 174-216 UGANDA-1102) PUL93.sub.-- HCMVA HYPOTHETICAL GENE 31 PROTEIN HERPESVIRUS SAIMIRI (STRAIN 11) 88-122 PUL95.sub.- - HCMVA PROTEIN UL93 HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 23-57 299-384 PUL95.sub.-- HSV6U HYPOTHETICAL PROTEIN UL95 HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 34-71 259-293 PUL96.sub.-- HCMVA HYPOTHETICAL PROTEIN 13R HERPES SIMPLEX VIRUS (TYPE 6/STRAIN 73-151 233-270 UGANDA-1102) PUL96.sub.-- HSV6U HYPOTHETICAL PROTEIN UL96 HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 51-103 PUL96.sub.-- HSVSA HYPOTHETICAL PROTEIN 14R HERPES SIMPLEX VIRUS (TYPE 6/STRAIN 53-113 UGANDA-1102) PULA2.sub.-- HCMVA HYPOTHETICAL GENE 35 PROTEIN HERPESVIRUS SAIMIRI (STRAIN 11) 45-100 PULA4.sub.- - HCMVA HYPOTHETICAL PROTEIN UL102 HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 6-40 758-792 PULD0.sub.-- HCMVA VIRION PROTEIN UL104 HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 1-56 130-171 330-764 439-492 541-575 PUNG.sub.-- HSV11 HYPOTHETICAL PROTEIN UL130 HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 84-125 PUNG.sub.-- HSV23 URACIL-DNA GLYCOSYLASE HERPES SIMPLEX VIRUS (TYPE 1/STRAIN 17) 227-268 PUNG.sub.-- HSV2H URACIL-DNA GLYCOSYLASE HERPES SIMPLEX VIRUS (TYPE 2/STRAIN 333) 188-229 PUNG.sub.-- HSVSA URACIL-DNA GLYCOSYLASE HERPES SIMPLEX VIRUS (TYPE 2/STRAIN HG52 148-189 PUNG.sub.-- SFVKA URACIL-DNA GLYCOSYLASE HERPESVIRUS SAIMIRI (STRAIN 11) 135-176 PUS02.sub.-- HSVEB URACIL-DNA GLYCOSYLASE SHOPE FIBROMA VIRUS (STRAIN KASZA) 81-115 PUS02.sub.-- HSVER GENE 68 PROTEIN EQUINE HERPESVIRUS TYPE 1 (STRAIN AB4P) 79-120 PUS07.sub.-- HCMVA US1 PROTEIN EQUINE HERPESVIRUS TYPE 1 (STRAIN 86-120 KENTUCKY A) PUS11.sub.-- HCMVA HYPOTHETICAL PROTEIN HXLF5 2-36 PUS14.sub.-- HCMVA HYPOTHETICAL PROTEIN HXLF1 HUMAN CYTOMEGALOVIRUS (STRAIN AD169) PUS18.sub.-- HCMVA HYPOTHETICAL PROTEIN HVLF4 HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 3-51 PUS23.sub.-- HCMVA MEMBRANE PROTEIN HWLF5 HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 187-225 PUS24.sub.-- HCMVA HYPOTHETICAL PROTEIN HHLF7 HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 294-335 535-578 PUS26.sub.-- HCMVA HYPOTHETICAL PROTEIN HHLF6 HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 135-172 PUS27.sub.-- HCMVA HYPOTHETICAL PROTEIN HHLF5 HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 535-584 PUS30.sub.-- HCMVA G-PROTEIN COUPLED RECEPTOR HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 6-40 HOMOLOG US27 PV125.sub.-- AMVLE HYPOTHETICAL PROTEIN HHRF5 HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 135-169 274-312 PV143.sub.-- NPVAC 125 KD PROTEIN ALFALFA MOSAIC VIRUS (STRAIN 425/ 18-52 326-367 591-649 ISOLATE LEIDEN PV16K.sub.-- TRVPS HELICASE AUTOGRAPHA CALIFORNICA NUCLEAR 313-350 1114- 1179- POLYHEDROSIS VIRUS 1150 1213 PV16K.sub.-- TRVSY 16 KD PROTEIN TOBACCO RATTLE VIRUS (STRAIN PSG) 75-117 PV1A.sub.-- BBMV 16 KD PROTEIN TOBACCO RATTLE VIRUS (STRAIN SYM) 75-117 PV1A.sub.-- BMV 1A PROTEIN BROAD BEAN MOTTLE VIRUS 21-55 349-405 492-526 710-751 837-884 890-924 PV1A.sub.-- CCMV 1A PROTEIN BROME MOSAIC VIRUS 4-66 348-411 PV1A.sub.-- CMVFN 1A PROTEIN COWPEA CHLOROTIC MOTTLE VIRUS 4-53 242-276 348-389 487-526 PV1A.sub.-- CMVO 1A PROTEIN CUCUMBER MOSAIC VIRUS (STRAIN FNY) 11-66 393-434 584-619 868-916 PV1A.sub.-- CMVQ 1A PROTEIN CUCUMBER MOSAIC VIRUS (STRAIN O) 11-66 393-434 584-619 868-916 PV1A.sub.-- PSVJ 1A PROTEIN CUCUMBER MOSAIC VIRUS (STRAIN Q) 11-66 393-434 PV1A.sub.-- TAV 1A PROTEIN PEANUT STUNT VIRUS (STRAIN J) 4-66 PVS3K.sub.-- HSVTH 1A PROTEIN TOMATO ASPERMY VIRUS 11-59 392-433 857-923 PV24K.sub.-- BDV 23.5 KD PROTEIN TURKEY HERPESVIRUS (STRAIN H2) 177-211 PV25K.sub.-- NPVAC 24 KD ANTIGEN BORNA DISEASE VIRUS 63-121 130-171 PV28K.sub.-- PLRV1 25 KD PROTEIN AUTOGRAPHA CALIFORNICA NUCLEAR 4-50 POLYHEDROSIS VIRUS PV28K.sub.-- PLRVW 28 KD PROTEIN POTATO LEAFROLL VIRUS (STRAIN 1) 116-150 PV290.sub.-- ASFL5 28 KD PROTEIN POTATO LEAFROLL VIRUS (STRAIN WAGENINGEN) 116-150 PV29K.sub.-- PEBV LIS 290 PROTEIN AFRICAN SWINE FEVER VIRUS (STRAIN LIS57) 138-183 PV29K.sub.-- TRVSY 29.6 KD PROTEIN EARLY BROWNING VIRUS 115-192 PVS9K.sub.-- TRVTC 29 KD PROTEIN TOBACCO RATTLE VIRUS (STRAIN SYM), AND 167-201 (STRAIN PSG) PV2A.sub.-- CCMV 29 KD PROTEIN TOBACCO RATTLE VIRUS (STRAIN TCM) 45-79 PV2A.sub.-- CMVFN 2A PROTEIN COWPEA CHLOROTIC MOTTLE VIRUS 768-806 PV2A.sub.-- PSVJ 2A PROTEIN CUCUMBER MOSAIC VIRUS (STRAIN FNY) 386-420 PV2A.sub.-- TAV 2A PROTEIN PEANUT STUNT VIRUS (STRAIN J) 717-751 PV30K.sub.-- TRVTC 2A PROTEIN TOMATO ASPERMY VIRUS 722-756 PV360.sub.-- ASFB7 29.1 KD PROTEIN TOBACCO RATTLE VIRUS (STRAIN TCM) 105-218 PV362.sub.-- ASFB7 K'360 PROTEIN AFRICAN SWINE FEVER VIRUS (STRAIN BA71V) 53-87 151-192 PV363.sub.-- ASFB7 K'362 PROTEIN AFRICAN SWINE FEVER VIRUS (STRAIN BA71V) 54-102 161-212 290-324 PV3A.sub.-- BMV D'363 PROTEIN AFRICAN SWINE FEVER VIRUS (STRAIN BA71V) 153-199 PV3A.sub.-- CMVFN 3A PROTEIN BROME MOSAIC VIRUS 11-45 PV3A.sub.-- CMVM 3A PROTEIN CUCUMBER MOSAIC VIRUS (STRAIN FNY) 215-255 PV3A.sub.-- CMVO 3A PROTEIN CUCUMBER MOSAIC VIRUS (STRAIN M) 215-255 PV3A.sub.-- CMVY 3A PROTEIN CUCUMBER MOSAIC VIRUS (STRAIN O) 215-255 PV51K.sub.-- ACLSV 3A PROTEIN CUCUMBER MOSAIC VIRUS (STRAIN Y) 215-255 PV51K.sub.-- BWYVF 50.8 KD PROTEIN APPLE CHLOROTIC LEAF SPOTVIRUS 72-106 PV51K.sub.-- BWYVG 51 KD PROTEIN BEET WESTERN YELLOWS VIRUS (ISOLATE FL-1) 113-147 196-233 404-451 PV56K.sub.-- PLRV1 51 KD PROTEIN BEET WESTERN YELLOWS VIRUS (ISOLATE GBI) 113-147 196-233 407-451 PV56K.sub.-- PLRVW 56 KD PROTEIN POTATO LEAFROLL VIRUS (STRAIN 1) 47-81 438-472 PV58K.sub.-- BSMV 56 KD PROTEIN POTATO LEAFROLL VIRUS (STRAIN WAGENINGEN) 47-81 438-475 PV66K.sub.-- BWYVF 58 KD PROTEIN BARLEY STRIPE MOSAIC VIRUS 128-162 323-371 PV70K.sub.-- PLRV1 66.2 KD PROTEIN BEET WESTERN YELLOWS VIRUS (ISOLATE FL-1) 480-521 PV70K.sub.-- PLRVW 69.7 KD PROTEIN POTATO LEAFROLL VIRUS (STRAIN 1) 98-144 514-548 PV90K.sub.-- AMVLE 69.7 KD PROTEIN POTATO LEAFROLL VIRUS (STRAIN WAGENINGEN) 98-144 409-443 514-548 PVA04.sub.- - VACCC 90 KD PROTEIN ALFALFA MOSAIC VIRUS (STRAIN 425/ISOLATE 107-141 LEIDEN) PVA04.sub.-- VACCV PROTEIN A4 VACCINIA VIRUS (STRAIN COPENHAGEN) 32-66 231-275 PVA04--VARV PROTEIN A4 VACCINIA VIRUS (STRAIN WR) 32-66 231-275 PVA06.sub.-- VACCC PROTEIN A4 VARIOLA VIRUS 22-66 210-265 PVA06.sub.-- VACCV PROTEIN A6 VACCINIA VIRUS (STRAIN COPENHAGEN) 97-213 314-355 PVA06.sub.-- VARV PROTEIN A6 VACCINIA VIRUS (STRAIN WR) 96-212 313-354 PVA08.sub.-- VACCC PROTEIN A6 VARIOLA VIRUS 97-213 313-358 PVA08.sub.-- VARV PROTEIN A8 VACCINIA VIRUS (STRAIN COPENHAGEN) 176-236 PVA09.sub.-- VACCC PROTEIN A8 VARIOLA VIRUS 176-236 PVA09.sub.-- VARV PROTEIN A9 VACCINIA VIRUS (STRAIN COPENHAGEN) 46-81 PVA11.sub.-- VACCC PROTEIN A9 VARIOLA VIRUS 46-95 PVA11.sub.-- VARV PROTEIN A11 VACCINIA VIRUS (STRAIN COPENHAGEN) 97-134 141-175 219-283 PVA12.sub.-- VACCC PROTEIN A11 VARIOLA VIRUS 98-176 220-284 PVA12.sub.-- VARV PROTEIN A12 VACCINIA VIRUS (STRAIN COPENHAGEN) 114-148 PVA18.sub.-- VACCC PROTEIN A12 VARIOLA VIRUS 111-152 PVA18.sub.-- VACCV 56 KD ABORTIVE LATE PROTEIN VACCINIA VIRUS (STRAIN COPENHAGEN) 433-467 PVA18.sub.-- VARV 56 KD ABORTIVE LATE PROTEIN VACCINIA VIRUS (STRAIN WR) 307-341 433-467 PVA20.sub.-- VACCC 56 KD ABORTIVE LATE PROTEIN VARIOLA VIRUS 307-341 433-467 PVA20.sub.-- VARV PROTEIN A20 VACCINIA VIRUS (STRAIN COPENHAGEN) 1-67 PVA22.sub.-- VACCC PROTEIN A20 VARIOLA VIRUS 1-67 PVA22.sub.-- VARV PROTEIN A22 VACCINIA VIRUS (STRAIN COPENHAGEN) 28-69 PVA23.sub.-- VACCC PROTEIN A22 VARIOLA VIRUS 39-80 PVA23.sub.-- VARV PROTEIN A23 VACCINIA VIRUS (STRAIN COPENHAGEN) 95-143 173-207 255-289 344-382 PVA31.sub.-- VARV PROTEIN A23 VARIOLA VIRUS 95-143 173-207 255-289 344-382 PVA32.sub.-- VACCV PROTEIN A31 VARIOLA VIRUS 88-126 PVA32.sub.-- VARV PROTEIN A32 VACCINIA VIRUS (STRAIN WR), AND (STRAIN COPENHAGEN PVA33.sub.-- VARV PROTEIN A32 VARIOLA VIRUS 217-251 PVA36.sub.-- VACCV PROTEIN A33 VARIOLA VIRUS 63-97 PVA36.sub.-- VARV PROTEIN A36 PRECURSOR VACCINIA VIRUS (STRAIN WR), AND (STRAIN 26-67 109-155 COPENHAGEN) PVA37.sub.-- VACCC PROTEIN A36 PRECURSOR VARIOLA VIRUS 26-67 PVA37.sub.-- VACCV PROTEIN A37 VACCINIA VIRUS (STRAIN COPENHAGEN) 24-65 PVA38.sub.-- VACCC PROTEIN A37 VACCINIA VIRUS (STRAIN WR) 24-65 PVA38.sub.-- VACCV PROTEIN A38 VACCINIA VIRUS (STRAIN COPENHAGEN) 44-91 PVA38.sub.-- VARV PROTEIN A38 VACCINIA VIRUS (STRAIN WR) 44-91 PVA39.sub.-- VACCC PROTEIN A38 VARIOLA VIRUS 44-91 PVA39.sub.-- VACCV PROTEIN A39 VACCINIA VIRUS (STRAIN COPENHAGEN) 37-71 PVA46.sub.-- VACCC PROTEIN A39 VACCINIA VIRUS (STRAIN WR) 75-109 PVA46.sub.-- VACCV PROTEIN A46 VACCINIA VIRUS (STRAIN COPENHAGEN) 81-126 PVA46.sub.-- VARV PROTEIN A46 VACCINIA VIRUS (STRAIN WR) 81-126 PVA46.sub.-- VACCC PROTEIN A46 VARIOLA VIRUS 81-126 PVA47.sub.-- VACCV PROTEIN A47 VACCINIA VIRUS (STRAIN COPENHAGEN) 62-96 143-184 PVA47.sub.-- VARV PROTEIN A47 VACCINIA VIRUS (STRAIN WR) 62-96 143-184 PVA49.sub.-- VACCC PROTEIN A47 VARIOLA VIRUS 62-96 143-184 PVA49.sub.-- VACCV PROTEIN A49 VACCINIA VIRUS (STRAIN COPENHAGEN) 3-40 126-160 PVA49.sub.-- VARV PROTEIN A49 VACCINIA VIRUS (STRAIN WR) 3-40 126-160 PVA52.sub.-- VACCC PROTEIN A49 VARIOLA VIRUS 3-40 126-160 PVA52.sub.-- VACCV PROTEIN A52 VACCINIA VIRUS (STRAIN COPENHAGEN) 91-132 PVA57.sub.-- VACCC PROTEIN A52 VACCINIA VIRUS (STRAIN WR) 91-132 PVA57.sub.-- VACCV GUANYLATE KINASE HOMOLOG VACCINIA VIRUS (STRAIN COPENHAGEN) 134-168 PVAL1.sub.-- MSVK GUANYLATE KINASE HOMOLOG VACCINIA VIRUS (STRAIN WR) 134-168 PVAL1.sub.-- MSVN AL1 PROTEIN MAIZE STREAK VIRUS (KENYAN ISOLATE) 230-269 PVAL1.sub.-- MSVS AL1 PROTEIN MAIZE STREAK VIRUS (NIGERIAN ISOLATE) 228-262 PVAL1.sub.-- SLCV AL1 PROTEIN MAIZE STREAK VIRUS (SOUTH-AFRICAN 228-262 ISOLATE) PVAL1.sub.-- TYDVA AL1 PROTEIN SQUASH LEAF CURL VIRUS 117-151 PVAL3.sub.-- ABMVW AL1 PROTEIN TOBACCO YELLOW DWARF VIRUS (STRAIN 191-225 AUSTRALIA) PVAL3.sub.-- BGMV AL3 PROTEIN ABUTILON MOSAIC VIRUS (ISOLATE WEST INDIA) 44-78 83-124 PVAL3.sub.-- PYMVV AL3 PROTEIN BEAN GOLDEN MOSAIC VIRUS 44-78 83-124 PVAL3.sub.-- SLCV AL3 PROTEIN POTATO YELLOW MOSAIC VIRUS (ISOLATE 30-78 87-121 VENEZUELA) PVAL3.sub.-- TGMV AL3 PROTEIN SQUASH LEAF CURL VIRUS 46-80 91-125 PVAT.sub.-- CAMVC AL3 PROTEIN TOMATO GOLDEN MOSAIC VIRUS 44-78 PVAT.sub.-- CAMVD APHID TRANSMISSION PROTEIN CAULIFLOWER MOSAIC VIRUS (STRAIN CM-1841) 22-70 84-127 PVAT.sub.-- CAMVE APHID TRANSMISSION PROTEIN CAULIFLOWER MOSAIC VIRUS (STRAIN DIH) 22-70 PVAT.sub.-- CAMVN APHID TRANSMISSION PROTEIN CAULIFLOWER MOSAIC VIRUS (STRAIN BBC) 22-70 93-127 PVAT.sub.-- CAMVP APHID TRANSMISSION PROTEIN CAULIFLOWER MOSAIC VIRUS (STRAIN NY8153) 22-70 93-127 PVAT.sub.-- CAMVS APHID TRANSMISSION PROTEIN CAULIFLOWER MOSAIC VIRUS (STRAIN PV147) 22-70 93-127 PVAT.sub.-- CAMVW APHID TRANSMISSION PROTEIN CAULIFLOWER MOSAIC VIRUS (STRAIN 22-70 93-130 STRASBOURG) PVAT.sub.-- CERV APHID TRANSMISSION PROTEIN CAULIFLOWER MOSAIC VIRUS (STRAIN W260) 36-70 PVB03.sub.-- VACCV APHID TRANSMISSION PROTEIN CARNATION ETCHED RING VIRUS 99-138 PVB04.sub.-- VACCC PROTEIN B3 VACCINIA VIRUS (STRAIN WR) 108-142 PVB04.sub.-- VACCV PROTEIN B4 VACCINIA VIRUS (STRAIN COPENHAGEN) 89-123 321-372 496-530 PVB04.sub.-- VARV PROTEIN B4 VACCINIA VIRUS (STRAIN WR) 89-123 321-372 PVB05.sub.-- VACC0 PROTEIN B4 VARIOLA VIRUS 89-134 324-372 492-530 PVB05.sub.-- VACCC PLAQUE-SIZE/HOST RANGE PROTEIN VACCINIA VIRUS (STRAIN LC16MO) 254-298 PRECURSOR PVB05.sub.-- VACCL PLAQUE-SIZE/HOST RANGE PROTEIN VACCINIA VIRUS (STRAIN COPENHAGEN) 254-298 PRECURSOR PVB05.sub.-- VACCV PLAQUE-SIZE/HOST RANGE PROTEIN VACCINIA VIRUS (STRAIN LISTER) 254-298 PRECURSOR PVB07.sub.-- VACCV PLAQUE-SIZE/HOST RANGE PROTEIN VACCINIA VIRUS (STRAIN WR) 254-298 PRECURSOR PVB08.sub.-- VACCC PROTEIN B7 PRECURSOR VACCINIA VIRUS (STRAIN WR), AND (STRAIN 28-62 COPENHAGEN) PVB08.sub.-- VACCV PROTEIN B8 PRECURSOR VACCINIA VIRUS (STRAIN COPENHAGEN) 26-60 PVB18.sub.-- VACCC PROTEIN B8 PRECURSOR VACCINIA VIRUS (STRAIN WR) 26-60 PVB18.sub.-- VACCV PROTEIN B18 VACCINIA VIRUS (STRAIN COPENHAGEN) 337-375 491-532 PVB18.sub.-- VARV PROTEIN B18 VACCINIA VIRUS (STRAIN WR) 337-375 491-532 PVB19.sub.-- VACCC PROTEIN B18 VARIOLA VIRUS 337-378 491-532 PVB19.sub.-- VACCD SURFACE ANTIGEN S PRECURSOR VACCINIA VIRUS (STRAIN COPENHAGEN) 87-121 PVB19.sub.-- VACCV SURFACE ANTIGEN S PRECURSOR VACCINIA VIRUS (STRAIN DAIREN 1) 85-119 PVB20.sub .-- VACCC SURFACE ANTIGEN S PRECURSOR VACCINIA VIRUS (STRAIN WR) 85-119 PVB21.sub.-- VACCV PROTEIN B20 VACCINIA VIRUS (STRAIN COPENHAGEN) 48-85 PVBL1.sub.-- BMGV PROTEIN B21 VACCINIA VIRUS (STRAIN WR) 61-95 PVBL1.sub.-- SLCV BL1 PROTEIN BEAN GOLDEN MOSAIC VIRUS 159-193 PVBL1.sub.-- TGMV BL1 PROTEIN SQUASH LEAF CURL VIRUS 159-193 PVBR1.sub.-- BGMV BL1 PROTEIN TOMATO GOLDEN MOSAIC VIRUS 159-193 PVBR1.sub.-- SLCV BR1 PROTEIN BEAN GOLDEN MOSAIC VIRUS 172-206 PVBR1.sub.-- TGMV BR1 PROTEIN SQUASH LEAF CURL VIRUS 20-61 PVC02.sub.-- VACCC BR1 PROTEIN TOMATO GOLDEN MOSAIC VIRUS 25-59 PVC02.sub.-- VACCV PROTEIN C2 VACCINIA VIRUS (STRAIN COPENHAGEN) 37-82 262-302 391-442 PCC04.sub.-- SFVKA PROTEIN C2 VACCINIA VIRUS (STRAIN WR) 37-82 262-302 391-442 PVC04.sub.-- VACCC PROTEIN C4 SHOPE FIBROMA VIRUS (STRAIN KASZA) 175-223 374-408 PVC04.sub.-- VACCV PROTEIN C4 VACCINIA VIRUS (STRAIN COPENHAGEN) 12-46 PVC04.sub.-- VARV PROTEIN C4 VACCINIA VIRUS (STRAIN WR) 12-46 PVC05.sub.-- SFVKA PROTEIN C4 VARIOLA VIRUS 12-46 PVC05.sub.-- VACCC HYPOTHETICAL PROTEIN C5 SHOPE FIBROMA VIRUS (STRAIN KASZA) 82-125 PVC05.sub.-- VACCV PROTEIN C5 VACCINIA VIRUS (STRAIN COPENHAGEN) 31-68 PVC05.sub.-- VARV PROTEIN C5 VACCINIA VIRUS (STRAIN WR) 31-68 PVC08.sub.-- SFVKA PROTEIN C5 VARIOLA VIRUS 32-70 73-121 PVC09.sub.-- SFVKA HYPOTHETICAL PROTEIN C8 SHOPE FIBROMA VIRUS (STRAIN KASZA) 45-86 PVC09.sub.-- VACCC HYPOTHETICAL PROTEIN C9 SHOPE FIBROMA VIRUS (STRAIN KASZA) 63-106 PVC09.sub.-- VACCV PROTEIN C9 VACCINIA VIRUS (STRAIN COPENHAGEN) 82-116 168-226 289-325 575-612 PVC10.sub.-- VACCC PROTEIN C9 VACCINIA VIRUS (STRAIN WR) 82-116 168-226 289-323 575-612 PVC10.sub.-- VACCV PROTEIN C10 VACCINIA VIRUS (STRAIN COPENHAGEN) 136-180 PVC10.sub.-- VARV PROTEIN C10 VACCINIA VIRUS (STRAIN WR) 136-176 PVC12.sub.-- SFVKA PROTEIN C10 VARIOLA VIRUS 136-170 PVC13.sub.-- SFVKA HYPOTHETICAL PROTEIN C12 SHOPE FIBROMA VIRUS (STRAIN KASZA) 2-36 PVC16.sub.-- VACCC PROTEIN C13 SHOPE FIBROMA VIRUS (STRAIN KASZA) 3-66 137-182 189-240 PVC17.sub.-- VACCC PROTEIN C16/B22 VACCINIA VIRUS (STRAIN COPENHAGEN) 142-176 PVC18.sub.-- VACCC PROTEIN C17/B23 VACCINIA VIRUS (STRAIN COPENHAGEN) 100-155 325-359 PVC19.sub.-- SFVKA PROTEIN C18/B24 VACCINIA VIRUS (STRAIN COPENHAGEN) 40-98 PVC19.sub.-- VACCC PROTEIN C19 SHOPE FIBROMA VIRUS (STRAIN KASZA) 56-97 PVCAP.sub.-- EBV PROTEIN C19/B25 VACCINIA VIRUS (STRAIN COPENHAGEN) 218-252 PVCAP.sub.-- HCMVA MAJOR CAPSID PROTEIN EPSTEIN-BARR VIRUS (STRAIN B95-8) 150-184 670-709 PVCAP.sub.-- HSV11 MAJOR CAPSID PROTEIN HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 136-174 191-225 260-294 PVCAP.sub.-- HSV6U MAJOR CAPSID PROTEIN HERPES SIMPLEX VIRUS (TYPE 1/STRAIN 17) 116-175 308-356 PVCAP.sub.-- HSVEB MAJOR CAPSID PROTEIN HERPES SIMPLEX VIRUS 136-174 230-266 311-382 PVCAP.sub.-- HSVSA MAJOR CAPSID PROTEIN EQUINE HERPESVIRUS TYPE 1 (STRAIN AB4P) 150-184 304-352 PVCAP.sub.-- PRVIS MAJOR CAPSID PROTEIN HERPESVIRUS SAIMIRI (STRAIN 11) 479-520 673-714 755-799 PVCAP.sub.-- VZVD MAJOR CAPSID PROTEIN PSEUDORABIES VIRUS (STRAIN INDIANA S) 105-160 292-326 PVCG3.sub.-- NPVAC MAJOR CAPSID PROTEIN VARICELLA-ZOSTER VIRUS (STRAIN DUMAS) 128-198 316-350 PVD05.sub.-- FOWP1 DNA-BINDING PROTEIN AUTOGRAPHA CALIFORNICA NUCLEAR 110-248 POLYHEDROSIS VIRUS PVD05.sub.-- VACCC 92.6 KD PROTEIN FOWLPOX VIRUS (STRAIN FP-1) 145-181 PVD05.sub.-- VACCV PROTEIN D5 VACCINIA VIRUS (STRAIN COPENHAGEN) 123-157 PVD05.sub.-- VARV PROTEIN D5 VACCINIA VIRUS (STRAIN WR) 123-157 PVD09.sub.-- VACCC PROTEIN D5 VARIOLA VIRUS 123-157 PVD09.sub.-- VACCV PROTEIN D9 VACCINIA VIRUS (STRAIN COPENHAGEN) 126-160 PVD09.sub.-- VARV PROTEIN D9 VACCINIA VIRUS (STRAIN WR) 126-160 PVD10.sub.-- FOWP1 PROTEIN D9 VARIOLA VIRUS 126-160 PVD10.sub.-- SFVKA PROTEIN D10 FOWLPOX VIRUS (STRAIN FP-1) 65-99 188-222 PVD10.sub.-- VARV PROTEIN D10 SHOPE FIBROMA VIRUS (STRAIN KASZA) 4-52 PVDBP.sub.-- CAMVC PROTEIN D10 VARIOLA VIRUS 67-105 PVDBP.sub.-- CAMVD DNA-BINDING PROTEIN CAULIFLOWER MOSAIC VIRUS (STRAIN CM-1841) 1-35 PVDBP.sub.-- CAMVE DNA-BINDING PROTEIN CAULIFLOWER MOSAIC VIRUS (STRAIN D/H) 1-35 PVDBP.sub.-- CAMVN DNA-BINDING PROTEIN CAULIFLOWER MOSAIC VIRUS (STRAIN BBC) 1-35 PVDBP.sub.-- CAMVS DNA-BINDING PROTEIN CAULIFLOWER MOSAIC VIRUS (STRAIN NY8153) 1-35 PVE02.sub.-- VACCC DNA-BINDING PROTEIN CAULIFLOWER MOSAIC VIRUS (STRAIN 1-35 STRASBOURG) PVE02.sub.-- VACCV PROTEIN E2 VACCINIA VIRUS (STRAIN COPENHAGEN) 282-336 PVE02.sub.-- VARV PROTEIN E2 VACCINIA VIRUS (STRAIN WR) 282-336 PVE03.sub.-- VACCC PROTEIN E2 VARIOLA VIRUS 282-336 PVE03.sub.-- VACCV PROTEIN E3 VACCINIA VIRUS (STRAIN COPENHAGEN) 17-61 PVE03.sub.-- VARV PROTEIN E3 VACCINIA VIRUS (STRAIN WR) 17-61 PVE05.sub.-- VACCC PROTEIN E3 VARIOLA VIRUS 17-61 PVE05.sub.-- VACCD PROTEIN E5 VACCINIA VIRUS (STRAIN COPENHAGEN) 28-93 PVE05.sub.-- VACCV PROTEIN E5 VACCINIA VIRUS (STRAIN DAIREN I) 38-103 PVE05.sub.-- VARV PROTEIN ES VACCINIA VIRUS (STRAIN WR) 38-103 PVE06.sub.-- VACCC PROTEIN E5 VARIOLA VIRUS 38-103 PVE06.sub.-- VACCV PROTEIN E6 VACCINIA VIRUS (STRAIN COPENHAGEN) 105-139 232-266 PVE06.sub.-- VARV PROTEIN E6 VACCINIA VIRUS (STRAIN WR) 105-139 232-266 PVE18.sub.-- NPVAC PROTEIN E6 VARIOLA VIRUS 105-139 367-401 PVE1.sub.-- HPV1A EARLY 18.5 KD PROTEIN AUTOGRAPHA CALIFORNICA NUCLEAR 112-163 POLYHEDROSIS VIRUS PVE1.sub.-- HPV31 E1 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 1A 137-171 PVE1.sub.-- HPV33 E1 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 31 56-90 PVE1.sub.-- HPV35 E1 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 33 33-67 133-167 PVE1.sub.-- HPV39 E1 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 35 56-90 PVE1.sub.-- HPV41 E1 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 39 59-96 PVE1.sub.-- HPV42 E1 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 41 55-89 312-346 PVE1.sub.-- MPV58 E1 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 42 25-87 PVE1.sub.-- HPV6B E1 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 58 33-67 119-174 PVE1.sub.-- PAPVE E1 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 6B 265-299 PVE26.sub.-- NPVAC E1 PROTEIN EUROPEAN ELK PAPILLOMAVIRUS 176-210 PVE2.sub.-- CRPVK EARLY 25.9 KD PROTEIN AUTOGRAPHA CALIFORNICA NUCLEAR 72-117 POLYHEDROSIS VIRUS PVE2.sub.-- HPV05 PROBABLE E2 PROTEIN COTTONTAIL RABBIT (SHOPE) PAPILLOMAVIRUS 3-44 (STRAIN KANS PVE2.sub.-- HPV08 PROBABLE E2 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 5 5-57 276-310 342-383 437-471 PVE2.sub.-- HPV16 PROBABLE E2 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 8 5-55 148-182 PVE2.sub.-- HPV18 E2 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 16 61-105 315-349 PVE2.sub.-- HPV1A E2 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 18 65-100 PVE2.sub.-- HPV2A E2 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 1A 3-37 159-193 PVE2.sub.-- HPV31 E2 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 2A 13-47 159-193 PVE2.sub.-- HPV33 E2 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 31 61-105 PVE2.sub.-- HPV35 E2 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 33 63-101 297-331 PVE2.sub.-- HPV39 E2 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 35 62-106 158-192 PVE2.sub.-- HPV41 E2 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 39 74-110 323-357 PVE2.sub.-- HPV47 E2 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 41 6-54 PVE2.sub.-- HPV51 E2 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 47 5-55 148-182 PVE2.sub.-- HPV57 E2 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 51 154-191 PVE2.sub.-- HPV58 E2 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 57 13-47 179-213 PVE2.sub.-- HPV5B E2 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 58 2-36 PVE2.sub.-- PAPVD PROBABLE E2 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 5B 5-57 PVE2.sub.-- PAPVE PROBABLE E2 PROTEIN DEER PAPILLOMAVIRUS 107-141 PVE2.sub.-- PCPV1 PROBABLE E2 PROTEIN EUROPEAN ELK PAPILLOMAVIRUS 113-150 PVE2.sub.-- RHPV1 E2 PROTEIN PYGMY CHIMPANZEE PAPILLOMAVIRUS TYPE 1 318-361 PVE39.sub.-- NPVAC E2 PROTEIN RHESUS PAPILLOMAVIRUS TYPE 1 62-106 307-341 PVE39.sub.-- NPVOP EARLY 39 KD PROTEIN AUTOGRAPHA CALIFORNICA NUCLEAR 20-57 POLYHEDROSIS VIRUS PVE4.sub.-- HPV18 EARLY 39 KD PROTEIN ORGYIA PSEUDOTSUGATA MULTICAPSID 119-156 POLYHEDROSIS VIRUS PVE4.sub.-- HPV41 PROBABLE E4 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 18 42-86 PVE5.sub.-- HPV5B PROBABLE E4 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 41 63-97 PVEF.sub.-- GVTN PROBABLE E5 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 5B 3-40 96-130 PVENV.sub.-- BEV VIRAL ENHANCING FACTOR TRICHOPLUSIA NI GRANULOSIS VIRUS (TNGV) 681-719 (VEF) (104 KD GLYCOP PVENV.sub.-- DHVI1 ENVELOPE PROTEIN BERNE VIRUS (BEV) 195-229 PVENV.sub.-- MCV1 ENVELOPE GLYCOPROTEIN DHORI VIRUS (STRAIN INDIAN/1313/61) (DHO) 318-366 PRECURSOR PVENV.sub.-- MCV2 MAJOR ENVELOPE PROTEIN (43 KD MOLLUSCUM CONTAGIOSUM VIRUS SUBTYPE 252-286 PROTEIN P43K) 1 (MCVI) PVENV.sub.-- THOGV MAJOR ENVELOPE PROTEIN (43 KD MOLLUSCUM CONTAGIOSUM V IRUS SUBTYPE 252-286 PROTEIN P43K) 2 (MCVII) PVENV.sub.-- VACCC ENVELOPE GLYCOPROTEIN THOGOTO VIRUS (THO) 313-354 PRECURSOR (SURFACE PVENV.sub.-- VACC1 MAJOR ENVELOPE PROTEIN (37 KD VACCINIA VIRUS (STRAIN COPENHAGEN) 257-295 PROTEIN) (P37K) PVENV.sub.-- VACCP MAJOR ENVELOPE PROTEIN (37 KD VACCINIA VIRUS (STRAIN IHD-J) 257-295 PROTEIN) (P37K) PVENV.sub.-- VACCV MAJOR ENVELOPE PROTEIN (37 KD VACCINIA VIRUS (STRAIN L-IVP) 257-295 PROTEIN) (P37K) PVENV.sub.-- VARV MAJOR ENVELOPE PROTEIN (37 KD VACCINIA VIRUS (STRAIN WR) 257-295 PROTEIN) (P37K) PVETS.sub.-- NPVAC MAJOR ENVELOPE PROTEIN (37 KD VARIOLA VIRUS 257-295 PROTEIN) (P37K) PVF01.sub.-- VACCC ECORI-T SITE PROTEIN ETS AUTOGRAPHA CALIFORNICA NUCLEAR 1-53 POLYHEDROSIS VIRUS ( PVF01.sub.-- VACCV PROTEIN F1 VACCINIA VIRUS (STRAIN COPENHAGEN), AND 46-80 124-158 VACCINIA VIRUS PVF03.sub.-- VACCC PROTEIN F1 (FRAGMENT) VACCINIA VIRUS (STRAIN WR) 46-80 124-158 PVF03.sub.-- VACCV PROTEIN F3 VACCINIA VIRUS (STRAIN COPENHAGEN) 71-110 PVF05.sub.-- VACCC PROTEIN F3 VACCINIA VIRUS (STRAIN WR) 71-110 PVF05.sub.-- VACCP 36 KD MAJOR MEMBRANE PROTEIN VACCINIA VIRUS (STRAIN COPENHAGEN) 81-129 282-320 PRECURSOR PVF05.sub.-- VACCV 36 KD MAJOR MEMBRANE PROTEIN VACCINIA VIRUS (STRAIN L-1VP) 81-129 282-320 PRECURSOR PVF05.sub.-- VARV 36 KD MAJOR MEMBRANE PROTEIN VACCINIA VIRUS (STRAIN WR) 81-129 283-321 PRECURSOR PVF06.sub.-- VARV 36 KD MAJOR MEMBRANE PROTEIN VARIOLA VIRUS 81-122 281-322 PRECURSOR PVF11.sub.-- VACCC PROTEIN F6 VARIOLA VIRUS 8-44 PVF11.sub.-- VACCP PROTEIN F11 VACCINIA VIRUS (STRAIN COPENHAGEN) 217-258 269-315 PVF11.sub.-- VARV PROTEIN F11 VACCINIA VIRUS (STRAIN L-1VP) 213-254 265-311 PVF12.sub.-- VACCC PROTEIN F11 VARIOLA VIRUS 41-75 269-311 PVF12.sub.-- VACCP PROTEIN F12 VACCINIA VIRUS (STRAIN COPENHAGEN) 1-67 102-143 199-236 350-388 544-581 PVF12.sub.-- VARV PROTEIN F12 VACCINIA VIRUS (STRAIN L-IVP) 1-67 102-143 199-236 350-388 544-581 PVF16.sub.-- VACCC PROTEIN F12 VARIOLA VIRUS 1-67 199-236 350-388 547-581 PVF16.sub.-- VACCP PROTEIN F16 VACCINIA VIRUS (STRAIN COPENHAGEN) 155-194 PVF16.sub.-- VARV PROTEIN F16 VACCINIA VIRUS (STRAIN L-1VP) 155-194 PVFP3.sub.-- FOWPV PROTEIN F16 VARIOLA VIRUS 155-194 PVFP4.sub.-- FOWPV PROTEIN FP3 FOWLPOX VIRUS 1-43 PVFP7.sub.-- FOWPV PROTEIN FP4 FOWLPOX VIRUS 139-173 239-273 PVFPL.sub.-- FOWP1 PROTEIN FP7 FOWLPOX VIRUS 23-57 PVFUS.sub.-- VACCC FPLEFT PROTEIN (FRAGMENT) FOWLPOX VIRUS (STRAIN FP-1) 77-111 PVFUS.sub.-- VACCV 14 KD FUSION PROTEIN VACCINIA VIRUS (STRAIN COPENHAGEN) 30-64 PVG01.sub.-- HSVII 14 KD FUSION PROTEIN VACCINIA VIRUS (STRAIN WR) 30-64 PVG01.sub.-- VACCC HYPOTHETICAL GENE 1 PROTEIN ICTALURID HERPESVIRUS (CHANNEL CATFISH 271-306 512-563 591-647 730-764 VIRUS) (CCV) PVG01.sub.-- VACCV PROTEIN G1 VACCINIA VIRUS (STRAIN COPENHAGEN) 301-339 PVG01.sub.-- VARV PROTEIN G1 (FRAGMENT) VACCINIA VIRUS (STRAIN WR) 240-278 PVG03.sub.-- HSVEB PROTEIN G1 VARIOLA VIRUS 301-339 PVG03.sub.-- HSVEK GENE 3 PROTEIN EQUINE HERPESVIRUS TYPE 1 (STRAIN AS14P) 143-177 (EHV-1) PVG03.sub.-- VARV GENE 3 PROTEIN (ORF L1) EQUINE HERPESVIRUS TYPE 1 (STRAIN 143-177 KENTUCKY A) (EHV-1) PVG05.sub.-- VACCC PROTEIN G3 VARIOLA VIRUS 64-98 PVG05.sub.-- VARV PROTEIN G5 VACCINIA VIRUS (STRAIN COPENHAGEN) 117-158 255-289 355-389 PVG06.sub.-- HSVII PROTEIN G5 VARIOLA VIRUS 117-158 255-289 355-359 PVG07.sub.-- HSVII HYPOTHETICAL GENE 6 MEMBRANE ICTALURID HERPESVIRUS 1 (CHANNEL CATFISH 61-109 PROTEIN VIRUS) (CCV) PVG07.sub.-- VACCC HYPOTHETICAL GENE 7 MEMBRANE ICTALURID HERPESVIRUS 1 (CHANNEL CATFISH 69-103 PROTEIN VIRUS) (CCV) PVG07.sub.-- VARV PROTEIN G7 VACCINIA VIRUS (STRAIN COPENHAGEN) 114-175 324-358 PVG09.sub.-- VACCC PROTEIN G7 VARIOLA VIRUS 114-175 324-358 PVG09.sub.-- VACCV PROTEIN F1 (PROTEIN G9) VACCINIA VIRUS (STRAIN COPENHAGEN) 304-338 PVG09.sub.-- VARV PROTEIN F1 (PROTEIN G9) VACCINIA VIRUS (STRAIN WR) 304-338 (FRAGMENT) PVG10.sub.-- HSVII PROTEIN F1 (PROTEIN 09) VARIOLA VIRUS 304-338 PVG12.sub.-- SPVIR HYPOTHETICAL GENE 10 MEMBRANE ICTALURID HERPESVIRUS 1 (CHANNEL CATFISH 63-97 PROTEIN VIRUS) (CCV) PVG16.sub.-- HSVSA GENE 12 PROTEIN SPIOPLASMA VIRUS SPV1-R8A2 B 11-45 PVG17.sub.-- HSVII HYPOTHETICAL GENE 16 PROTEIN HERPESVIRUS SAIMIRI (STRAIN 11) 58-95 PVG18.sub.-- HSVII HYPOTHETICAL GENE 17 PROTEIN ICTALURID HERPESVIRUS 1 (CHANNEL CATFISH 92-129 177-211 VIRUS) (CCV) PVGIL.sub.-- AMEPV HYPOTHETICAL GENE 18 PROTEIN ICTALURID HERPESVIRUS 1 (CHANNEL CATFISH 174-208 215-256 VIRUS) (CCV) PVG1.sub.-- SPVIR GIL PROTEIN AMSACTA MOOREI ENTOMOPOXVIRUS (AMEPV) 407-441 PVG1.sub.-- SPV4 CAPSID PROTEIN SPIROPLASMA VIRUS SPV1-R8A2 B 136-170 256-297 320-357 PVG22.sub.-- HSVII CAPSID PROTEIN SPIROPLASMA VIRUS 4 (SPV4) 287-321 PVG24.sub.-- HSVII HYPOTHETICAL GENE 22 PROTEIN ICTALURID HERPESVIRUS 1 (CHANNEL CATFISH 117-158 437-629 660-892 899-1055 VIRUS) (CCV) PVG27.sub.-- HSVII HYPOTHETICAL GENE 24 PROTEIN ICTALURID HERPESVIRUS 1 (CHANNEL CATFISH 7-72 74-108 VIRUS) (CCV) PVG28.sub.-- HSVII HYPOTHETICAL GENE 27 PROTEIN ICTALURID HERPESVIRUS 1 (CHANNEL CATFISH 164-219 VIRUS) (CCV) PVG2R.sub.-- AMEPV HYPOTHETICAL GENE 28 PROTEIN ICTALURID HERPESVIRUS 1 (CHANNEL CATFISH 253-290 VIRUS) (CCV) PVG2.sub.-- SPVIR HYPOTHETICAL G2R PROTEIN AMSACTA MOOREI ENTOMOPOXVIRUS (AMPEV) 29-63 184-218 PVG2.sub.-- SPV4 GENE 2 PROTEIN SPIROPLASMA VIRUS SPV1-R8A2 B 222-256 285-326 PVG33.sub.-- HSVII GENE 2 PROTEIN SPIROPLASMA VIRUS 4 (SPV4) 255-310 PVG34.sub.-- HSVII HYPOTHETICAL GENE 33 PROTEIN ICTALURID HERPESVIRUS 1 (CHANNEL CATFISH 149-183 VIRUS) (CCV) PVG35.sub.-- HSVII HYPOTHETICAL GENE 34 PROTEIN ICTALURID HERPESVIRUS 1 (CHANNEL CATFISH 345-379 VIRUS) (CCV) PVG37.sub.-- HSVII HYPOTHETICAL GENE 35 PROTEIN ICTALURID HERPESVIRUS 1 (CHANNEL CATFISH 17-90 VIRUS) (CCV) PVG38.sub.-- HSVII HYPOTHETICAL GENE 37 PROTEIN ICTALURID HERPESVIRUS 1 (CHANNEL CATFISH 435-472 VIRUS) (CCV) PVG39.sub.-- HSVII HYPOTHETICAL GENE 38 PROTEIN ICTALURID HERPESVIRUS 1 (CHANNEL CATFISH 84-118 VIRUS) (CCV) PVG3.sub.-- SPVIR HYPOTHETICAL GENE 39 PROTEIN ICTALURID HERPESVIRUS 1 (CHANNEL CATFISH 124-158 266-300 VIRUS) (CCV) PVG3.sub.-- SPV4 GENE 3 PROTEIN SPIROPLASMA VIRUS SPV1-R8A2 B 8-49 162-196 203-244 PVG43.sub.-- HSVII GENE 3 PROTEIN SPIROPLASMA VIRUS 4 (SPV4) 6-54 87-121 PVG45.sub.-- HSVSA HYPOTHETICAL GENE 43 PROTEIN ICTALURID HERPESVIRUS 1 (CHANNEL CATFISH 116-150 262-296 324-361 643-677 VIRUS) (CCV) PVG46.sub.-- HSVII HYPOTHETICAL GENE 45 PROTEIN HERPESVIRUS SAIMIRI (STRAIN 11) 121-162 PVG48.sub.-- HSVII PROBABLE MAJOR GLYCOPROTEIN ICTALURID HERPESVIRUS 1 (CHANNEL CATFISH 45-86 939- 1251- VIRUS) (CCV) 1078 1321 PVG48.sub.-- HSVSA HYPOTHETICAL GENE 48 PROTEIN ICTALURID HERPESVIRUS 1 (CHANNEL CATFISH 169-207 VIRUS) (CCV) PVG49.sub.-- HSVSA HYPOTHETICAL GENE 48 PROTEIN HERPESVIRUS SAIMIRI (STRAIN 11) 360-417 611-666 733-767 PVG4R.sub.-- AMEPV HYPOTHETICAL GENE 49 PROTEIN HERPESVIRUS SAIMIRI (STRAIN 11) 68-102 PVG4.sub.-- SPV4 G4R PROTEIN AMSACTA MOOREI ENTOMOPOXVIRUS (AMPEV) 4-38 PVG51.sub.-- HSVII GENE 4 PROTEIN SPIROPLASMA VIRUS 4 (SPV4) 89-130 PVG51.sub.-- HSVSA HYPOTHETICAL GENE 51 MEMBRANE ICTALURID HERPESVIRUS 1 (CHANNEL CATFISH 34-73 890-123 PROTEIN VIRUS) (CCV) PVG53.sub.-- HSVII GENE 51 GLYCOPROTEIN HERPESVIRUS SAIMIRI (STRAIN 11) 29-70 123-157 162-196 PVG54.sub.-- HSVII HYPOTHETICAL GENE 53 PROTEIN ICTALURID HERPESVIRUS 1 (CHANNEL CATFISH 67-127 VIRUS) (CCV) PVG55.sub.-- HSVII HYPOTHETICAL GENE 54 PROTEIN ICTALURID HERPESVIRUS 1 (CHANNEL CATFISH 355-396 VIRUS) (CCV) PVG55.sub.-- HSVSA HYPOTHETICAL GENE 55 PROTEIN ICTALURID HERPESVIRUS 1 (CHANNEL CATFISH 101-135 VIRUS) (CCV) PVG56.sub.-- HSVII HYPOTHETICAL GENE 55 PROTEIN HERPESVIRUS SAIMIRI (STRAIN 11) 126-178 PVG59.sub.-- HSVII HYPOTHETICAL GENE 56 PROTEIN ICTALURID HERPESVIRUS 1 (CHANNEL CATFISH 151-192 578-612 644-678 750-784 846-880 1111- VIRUS) (CCV) 1145 PVG59.sub.-- HSVSA HYPOTHETICAL GENE 59 MEMBRANE ICTALURID HERPESVIRUS 1 (CHANNEL CATFISH 10-72 89-123 PROTEIN VIRUS) (CCV) PVG5.sub.-- SPVIR GENE 59 PROTEIN HERPESVIRUS SAIMIRI (STRAIN 11) 169-209 PVG61.sub.-- HSVII GENE 5 PROTEIN SPIROPLASMA VIRUS SPV1-R8A2 B 65-103 PVG63.sub.-- HSVII HYPOTHETICAL GENE 61 PROTEIN ICTALURID HERPESVIRUS 1 (CHANNEL CATFISH 265-299 VIRUS) (CCV) PVG65.sub.-- HSVII HYPOTHETICAL GENE 63 PROTEIN ICTALURID HERPESVIRUS 1 (CHANNEL CATFISH 546-584 VIRUS) (CCV) PVG66.sub.-- HSVII HYPOTHETICAL GENE 65 PROTEIN ICTALURID HERPESVIRUS 1 (CHANNEL CATFISH 805-839 1213- VIRUS) (CCV) 1254 PVG67.sub.-- HSVII HYPOTHETICAL GENE 66 PROTEIN ICTALURID HERPESVIRUS 1 (CHANNEL CATFISH 154-188 328-410 VIRUS) (CCV) PVG68.sub.-- HSVII HYPOTHETICAL GENE 67 PROTEIN ICTALURID HERPESVIRUS 1 (CHANNEL CATFISH 379-413 501-546 1321- 1478- VIRUS) (CCV) 1369 1541 PVG72.sub.-- HSVII HYPOTHETICAL GENE 68 PROTEIN ICTALURID HERPESVIRUS 1 (CHANNEL CATFISH 245-288 VIRUS) (CCV) PVG75.sub.-- HSVII HYPOTHETICAL GENE 72 PROTEIN ICTALURID HERPESVIRUS 1 (CHANNEL CATFISH 447-484 723-757 912-949 VIRUS) (CCV) PVG8.sub.-- SPVIR HYPOTHETICAL GENE 75 PROTEIN ICTALURID HERPESVIRUS 1 (CHANNEL CATFISH 271-305 388-422 VIRUS) (CCV) PVGF1.sub.-- IBVB GENE 8 PROTEIN SPIROPLASMA VIRUS SPV1-R8A2 B 5-51 PVGH3.sub.-- HCMVA F1 PROTEIN AVIAN INFECTIOUS BRONCHITIS VIRUS 142-179 1233- 2119- 3388- 3475- 3517- 3761- (STRAIN BEAUDETTE) (1 1267 2156 3424 3513 3556 3795 PVGL1.sub.-- CVPR8 GLYCOPROTEIN H301 PRECURSOR HUMAN CYTOMEGALOVIRUS (STRAIN AD169) PVGL2.sub.-- CVBF E1 GLYCOPROTEIN PRECURSOR PORCINE RESPIRATORY CORONAVIRUS 212-257 (MATRIX GLYCOP (STRAIN 86/137004/BRI PVGL2.sub.-- CVBL9 E2 GLYCOPROTEIN PRECURSOR BOVINE CORONAVIRUS (STRAIN F15 642-676 850-885 993- 1263- (SPIKE GLYCOPRO 1088 1305 PVGL2.sub.-- CVBLY E2 GLYCOPROTEIN PRECURSOR BOVINE CORONAVIRUS (STRAIN L9) 850-885 993- 1263- (SPIKE GLYCOPRO 1109 1305 PVGL2.sub.-- CVBM E2 GLYCOPROTEIN PRECURSOR BOVINE CORONAVIRUS (STRAIN LY-138) 642-676 850-885 993- 1263- (SPIKE GLYCOPRO 1109 1305 PVGL2.sub.-- CVBQ E2 GLYCOPROTEIN PRECURSOR BOVINE CORONAVIRUS (STRAIN MEBUS 642-676 850-885 993- 1263- (SPIKE GLYCOPRO 1109 1305 PVGL2.sub.-- CVBV E2 GLYCOPROTEIN PRECURSOR BOVINE CORONAVIRUS (STRAIN QUEBEC) 642-676 850-885 993- 1263- (SPIKE GLYCOPRO 1109 1305 PVGL2.sub.-- CVH22 E2 GLYCOPROTEIN PRECURSOR BOVINE CORONAVIRUS (STRAIN VACCINE) 642-676 850-885 993- 1263- (SPIKE GLYCOPRO 1109 1305 PVGL2.sub.-- CVM4 E2 GLYCOPROTEIN PRECURSOR HUMAN CORONAVIRUS (STRAIN 229E) 770-916 1055- (SPIKE GLYCOPRO 1112 PVGL2.sub.-- CVMA5 E2 GLYCOPROTEIN PRECURSOR MURINE CORONAVIRUS MHV (STRAIN WILD 643-684 1001- 1270- (SPIKE GLYCOPRO TYPE 4)(MHV-4) 1117 1315 PVGL2.sub.-- CVMJC E2 GLYCOPROTEIN PRECURSOR MURINE CORONAVIRUS MHV (STRAIN A59) 591-632 949- 1218- (SPIKE GLYCOPRO 1079 1263 PVGL2.sub.-- CVMJH E2 GLYCOPROTEIN PRECURSOR MURINE CORONAVIRUS MHV (STRAIN 643-684 1001- 1270- (SPIKE GLYCOPRO JHMV/VARIANT CL-2) 1117 1315 PVGL2.sub.-- CVPFS E2 GLYCOPROTEIN PRECURSOR MURINE CORONAVIRUS MHV (STRAIN JHM) 503-543 860-976 1129- (SPIKE GLYCOPRO 1174 PVGL2.sub.-- CVPMI E2 GLYCOPROTEIN PRECURSOR PROCINE TRANSMISSIBLE GASTROENTERITIS 69-110 448-482 692-733 889-923 1040- 1352- (SPIKE GLYCOPRO CORONAVIRUS (S 1186 1389 PVGL2.sub.-- CVPPR E2 GLYCOPROTEIN PRECURSOR PROCINE TRANSMISSIBLE GASTROENTERITIS 69-110 448-482 692-733 889-923 1040- 1352- (SPIKE GLYCOPRO CORONAVIRUS (S 1186 1389 PVGL2.sub.-- CVPPU E2 GLYCOPROTEIN PRECURSOR PROCINE TRANSMISSIBLE GASTROENTERITIS 70-110 446-480 690-731 887-921 1038- 1350- (SPIKE GLYCOPRO CORONAVIRUS (S 1184 1387 PVGL2.sub.-- CVPR8 E2 GLYCOPROTEIN PRECURSOR PROCINE TRANSMISSIBLE GASTROENTERITIS 69-110 446-480 690-731 887-921 1038- 1350- (SPIKE GLYCOPRO CORONAVIRUS (S 1184 1387 PVGL2.sub.-- CVPRM E2 GLYCOPROTEIN PRECURSOR PROCINE RESPIRATORY CORONAVIRUS (STRAIN 224-258 468-509 665-699 816-962 1128- (SPIKE GLYCOPRO 86/137004/BRIT 1165 PVGL2.sub.-- CVPRT E2 GLYCOPROTEIN PRECURSOR PROCINE RESPIRATORY CORONAVIRUS (STRAIN 224-258 468-509 665-699 816-962 1128- (SPIKE GLYCOPRO RM4)(PRCV) 1165 PVGL2.sub.-- EBV E2 GLYCOPROTEIN PRECURSOR PROCINE TRANSMISSIBLE GASTROENTERITIS 69-110 446-480 690-731 887-921 1038- 1350- (SPIKE GLYCOPRO CORONAVIRUS (S 1184 1387 PVGL2.sub.-- FIPV PROBABLE MEMBRANE 68-102 GLYCOPROTEIN PVGL2.sub.-- IBV6 E2 GLYCOPROTEIN PRECURSOR FELINE INFECTIOUS PERITONITIS VIRUS 189-245 451-485 695-736 892-926 1043- 1355- (STRAIN 79-1146) 1189 1392 PVGL2.sub.-- IBVB E2 GLYCOPROTEIN PRECURSOR AVIAN INFECTIOUS BRONCHITIS VIRUS 791-905 1057- (STRAIN 6/82) 1091 PVGL2.sub.-- IBVD2 E2 GLYCOPROTEIN PRECURSOR AVIAN INFECTIOUS BRONCHITIS VIRUS 437-78 772-904 1056- (STRAIN BEAUDETTE) 1090 PVGL2.sub.-- IBVK E2 GLYCOPROTEIN PRECURSOR AVIAN INFECTIOUS BRONCHITIS VIRUS 773-905 1057- (STRAIN D274) 1091 PVGL2.sub.-- IBVM E2 GLYCOPROTEIN PRECURSOR AVIAN INFECTIOUS BRONCHITIS VIRUS (STRAIN 437-478 722-904 1056- KB8523) 1090 PVGLB.sub.-- HCMVA E2 GLYCOPROTEIN PRECURSOR AVIAN INFECTIOUS BRONCHITIS VIRUS 437-478 722-904 1056- (STRAIN M41) 1090 PVGLB.sub.-- HCMVT GLYCOPROTEIN B PRECURSOR HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 43-88 128-162 436-484 844-878 PVGLB.sub.-- HSVII GLYCOPROTEIN B PRECURSOR HUMAN CYTOMEGALOVIRUS (STRAIN TOWNE) 22-88 128-162 437-478 451-485 845-879 PVGLB.sub.-- HSV1F GLYCOPROTEIN B PRECURSOR HERPES SIMPLEX VIRUS (TYPE 1/STRAIN 17) 828-890 PVGLB.sub.-- HSV1K GLYCOPROTEIN B PRECURSOR HERPES SIMPLEX VIRUS (TYPE 1/STRAIN F)] 827-889 PVGLB.sub.-- HSV1P GLYCOPROTEIN B PRECURSOR HERPES SIMPLEX VIRUS (TYPE 1/STRAIN KOS) 827-889 PVGLB.sub.-- HSV23 GLYCOPROTEIN B PRECURSOR HERPES SIMPLEX VIRUS (TYPE 1/STRAIN PATTON) 828-890 PVGLB.sub.-- HSV2H GLYCOPROTEIN B PRECURSOR HERPES SIMPLEX VIRUS (TYPE 2/STRAIN 333) 828-890 PVGLB.sub.-- HSV2S GLYCOPROTEIN B PRECURSOR HERPES SIMPLEX VIRUS (TYPE 2/STRAIN HG52) 828-890 PVGLB.sub.-- HSV6U GLYCOPROTEIN B PRECURSOR HERPES SIMPLEX VIRUS (TYPE 2/STRAIN SA8) 817-871 PVGLB.sub.-- HSVB1 GLYCOPROTEIN B HERPES SIMPLEX VIRUS (TYPE 6/STRAIN 37-71 185-223 UGANDA-1102) PVGLB.sub.-- HSVB2 GLYCOPROTEIN I PRECURSOR BOVINE HERPESVIRUS TYPE 1 859-913 PVGLB.sub.-- HSVBC GLYCOPROTEIN B-1 PRECURSOR BOVINE HERPESVIRUS TYPE 2 (STRAIN BMV) 440-474 848-902 PVGLB.sub.-- HSVE1 GLYCOPROTEIN I PRECURSOR BOVINE HERPESVIRUS TYPE 1 (STRAIN COOPER) 863-900 PVGLB.sub.-- HSVE4 GLYCOPROTEIN B PRECURSOR EQUINE HERPESVIRUS TYPE 1 (ISOLATE HVS25A) 542-576 911-961 PVGLB.sub.-- HSVEA GLYCOPROTEIN B PRECURSOR EQUINE HERPESVIRUS TYPE 4 (STRAIN 1942) 474-515 847-900 PVGLB.sub.-- HSVEB GLYCOPROTEIN B PRECURSOR EQUINE HERPESVIRUS TYPE 1 (STRAIN AB1) 542-576 911-961 PVGLB.sub.-- HSVEL GLYCOPROTEIN B PRECURSOR EQUINE HERPESVIRUS TYPE 1 (STRAIN AB4P) 542-576 911-961 PVGLB.sub.-- HSVMD GLYCOPROTEIN B PRECURSOR EQUINE HERPESVIRUS TYPE 1 (STRAIN 542-576 910-960 KENTUCKY D) PVGLB.sub.-- HSVSA GLYCOPROTEIN B PRECURSOR MAREK'S DISEASE HERPESVIRUS 390-435 649-683 787-845 (STRAIN RB-1B) PVGLB.sub.-- MCMVS GLYCOPROTEIN B PRECURSOR HERPESVIRUS SAIMIRI (STRAIN 11) 240-288 406-447 PVGLB.sub.-- PRV1F GLYCOPROTEIN B PRECURSOR MURINE CYTOMEGALOVIRUS (STRAIN SMITH) 206-260 427-475 693-734 744-778 860-894 PVGLB.sub.-- VZVD GLYCOPROTEIN GII PRECURSOR PSEUDORABIES VIRUS (STRAIN 847-881 INDIANA-FUNKHAUSER/BECKE PVGLC.sub.-- HSVII GLYCOPROTEIN B PRECURSOR VARICELLA-ZOSTER VIRUS (STRAIN DUMAS) 92-133 596-630 809-867 PVGLC.sub.-- HSV1K GLYCOPROTEIN C PRECURSOR HERPES SIMPLEX VIRUS (TYPE 1/STRAIN 17) 469-510 PVGLC.sub.-- HSV2 GLYCOPROTEIN C PRECURSOR HERPES SIMPLEX VIRUS (TYPE 1/STRAIN KOS) 469-510 PVGLC.sub.-- HSV23 GLYCOPROTEIN C PRECURSOR HERPES SIMPLEX VIRUS (TYPE 2) 442-476 PVGLC.sub.-- HSVBC GLYCOPROTEIN C PRECURSOR HERPES SIMPLEX VIRUS (TYPE 2/STRAIN 333) 443-477 PVGLC.sub.-- HSVEB GLYCOPROTEIN GIII PRECURSOR BOVINE HERPESVIRUS TYPE 1 (STRAIN COOPER) 235-269 PVGLC.sub.-- HSVMB GLYCOPROTEIN C PRECURSOR EQUINE HERPESVIRUS TYPE 1 (STRAIN AB4P) AND 182-218 (STRAIN KEN PVGLC.sub.-- HSVMD SECRETORY GLYCOPROTEIN GP57-65 MAREK'S DISEASE HERPESVIRUS (STRAIN BC-1) 63-97 PRECURSOR PVGLC.sub.-- HSVMG SECRETORY GLYCOPROTEIN GP57-65 MAREK'S DISEASE HERPESVIRUS (STRAIN RB-1B 63-97 PRECURSOR PVGLC.sub.-- HSVMM SECRETORY GLYCOPROTEIN GP57-65 MAREK'S DISEASE HERPESVIRUS (STRAIN GA) 62-96 PRECURSOR PVGLC.sub.-- PRV1F SECRETORY GLYCOPROTEIN GP57-65 MAREK'S DISEASE HERPESVIRUS (STRAIN MD5) 63-97 PRECURSOR PVGLC.sub.-- VZVD GLYCOPROTEIN GIII PRECURSOR PSEUDORABIES VIRUS (STRAIN 183-235 INDIANA-FUNKHAUSER/BECKE PVGLC.sub.-- VZVS GLYCOPROTEIN GPV VARICELLA-ZOSTER VIRUS (STRAIN DUMAS) 280-321 PVGLD.sub.-- HSVEA GLYCOPROTEIN GPV VARICELLA-ZOSTER VIRUS (STRAIN SCOTT) 280-321 PVGLD.sub.-- HSVEB GLYCOPROTEIN D PRECURSOR EQUINE HERPESVIRUS TYPE 1 (STRAIN AB1) 89-123 PVGLD.sub.-- HSVEK GLYCOPROTEIN D PRECURSOR EQUINE HERPESVIRUS TYPE 1 (STRAIN AB4P) AND 139-173 (STRAIN KEN PVGLE.sub.-- HSVII GLYCOPROTEIN D PRECURSOR EQUINE HERPESVIRUS TYPE 1 (STRAIN 139-173 KENTUCKY A) PVGLE.sub.-- HSV2 GLYCOPROTEIN E PRECURSOR HERPES SIMPLEX VIRUS (TYPE 1/STRAIN 17) 111-145 PVGLF.sub.-- BRSVA GLYCOPROTEIN E PRECURSOR HERPES SIMPLEX VIRUS (TYPE 2) 111-159 PVGLF.sub.-- BRSVC FUSION GLYCOPROTEIN PRECURSOR BOVINE RESPIRATORY SYNCYTIAL VIRUS 146-202 504-545 (STRAIN A51908) PVGLF.sub.-- BRSVR FUSION GLYCOPROTEIN PRECURSOR BOVINE RESPIRATORY SYNCYTIAL VIRUS 146-202 267-302 506-554 (STRAIN COPENHAGE PVGLF.sub.-- CDV0 FUSION GLYCOPROTEIN PRECURSOR BOVINE RESPIRATORY SYNCYTIAL VIRUS (STRAIN 228-297 340-381 568-602 RB94) PVGLF.sub.-- HRSV1 FUSION GLYCOPROTEIN PRECURSOR CANINE DISTEMPER VIRUS (STRAIN 116-203 267-302 506-549 ONDERSTEPOORT) PVGLF.sub.-- HRSVA FUSION GLYCOPROTEIN PRECURSOR HUMAN RESPIRATORY SYNCYTIAL VIRUS (STRAIN 116-202 267-302 506-549 SUBGROUP B/STRAI PVGLF.sub.-- HRSVL FUSION GLYCOPROTEIN PRECURSOR HUMAN RESPIRATORY SYNCYTIAL VIRUS (STRAIN A 116-202 267-302 506-547 PVGLF.sub.-- HRSVR FUSION GLYCOPROTEIN PRECURSOR HUMAN RESPIRATORY SYNCYTIAL VIRUS (STRAIN 116-202 267-302 506-549 SUBGROUP A/STRAI PVGLF.sub.-- MEASE FUSION GLYCOPROTEIN PRECURSOR HUMAN RESPIRATORY SYNCYTIAL VIRUS 116-184 228-269 452-500 (STRAIN 55-2 PVGLF.sub.-- MEASI FUSION GLYCOPROTEIN PRECURSOR MEASLES VIRUS (STRAIN EDMONSTON) AND 119-187 231-272 455-503 STRAIN HALLE) PVGLF.sub.-- MEASY FUSION GLYCOPROTEIN PRECURSOR MEASLES VIRUS (STRAIN IP-3-CA) 116-184 228-269 452-500 PVGLF.sub.-- MUMPI FUSION GLYCOPROTEIN PRECURSOR MEASLES VIRUS (STRAIN YAMAGATA-1) 20-54 103-179 235-272 447-502 PVGLF.sub.-- MUMPM FUSION GLYCOPROTEIN PRECURSOR MUMPS VIRUS (STRAIN SBL-1) 20-54 103-179 235-272 447-502 PVGLF.sub.-- MUMPR FUSION GLYCOPROTEIN PRECURSOR MUMPS VIRUS (STRAIN MIYAHARA VACCINE) 20-54 103-179 235-272 447-502 PVGLF.sub.-- MUMPS FUSION GLYCOPROTEIN PRECURSOR MUMPS VIRUS (STRAIN RW) 20-54 103-179 235-272 447-502 PVGLF.sub.-- NDVA FUSION GLYCOPROTEIN PRECURSOR MUMPS VIRUS (STRAIN SBL) 117-182 231-272 426-512 PVGLF.sub.-- NDVB FUSION GLYCOPROTEIN PRECURSOR NEWCASTLE DISEASE VIRUS (STRAIN 122-182 231-272 426-517 AUSTRALIA-VICTORIA/32) PVGLF.sub.-- NDVH3 FUSION GLYCOPROTEIN PRECURSOR NEWCASTLE DISEASE VIRUS (STRAIN 117-182 231-272 426-517 BEAUDETTE C/45) PVGLF.sub.-- NDVH4 FUSION GLYCOPROTEIN PRECURSOR NEWCASTLE DISEASE VIRUS (STRAIN 122-182 231-272 426-517 HER/33) PVGLF.sub.-- NDVI FUSION GLYCOPROTEIN PRECURSOR NEWCASTLE DISEASE VIRUS (STRAIN 133-182 238-272 426-517 B1-HITCHNER/47) PVGLF.sub.-- NDVL FUSION GLYCOPROTEIN PRECURSOR NEWCASTLE DISEASE VIRUS (STRAINITALIEN/45) 133-182 231-272 426-517 PVGLF.sub.-- NDVM FUSION GLYCOPROTEIN PRECURSOR NEWCASTLE DISEASE VIRUS (STRAINLAS/46) 117-182 231-272 426-512 PVGLF.sub.-- NDVQ FUSION GLYCOPROTEIN PRECURSOR NEWCASTLE DISEASE VIRUS (STRAINMIYADERA/51) 122-182 231-272 433-512 PVGLF.sub.-- NDVT FUSION GLYCOPROTEIN PRECURSOR NEWCASTLE DISEASE VIRUS (STRAIN 117-182 231-272 426-517 QUEENSLAND/66) PVGLF.sub.-- NDVTG FUSION GLYCOPROTEIN PRECURSOR NEWCASTLE DISEASE VIRUS (STRAINTEXAS) 122-182 231-272 433-517 PVGLF.sub.-- NDVU FUSION GLYCOPROTEIN PRECURSOR NEWCASTLE DISEASE VIRUS (STRAINTEXAS G.B./48) 122-182 231-272 433-512 PVGLF.sub.-- PHODV FUSION GLYCOPROTEIN PRECURSOR NEWCASTLE DISEASE VIRUS (STRAINULSTER/67) 29-63 197-266 309-350 533-581 PVGLF.sub.-- PI1HC FUSION GLYCOPROTEIN PRECURSOR PHOCINE DISTEMPER VIRUS 123-174 207-267 459-503 PVGLF.sub.-- PI2H FUSION GLYCOPROTEIN PRECURSOR HUMAN PARAINFLUENZA 1 VIRUS (STRAIN C39) 93-183 477-528 PVGLF.sub.-- PI2HG FUSION GLYCOPROTEIN PRECURSOR HUMAN PARAINFLUENZA 2 VIRUS 93-183 477-528 PVGLF.sub.-- PI2HT FUSION GLYCOPROTEIN PRECURSOR HUMAN PARAINFLUENZA 2 VIRUS (STRAIN GREER) 93-183 477-528 PVGLF.sub.-- PI3B FUSION GLYCOPROTEIN PRECURSOR HUMAN PARAINFLUENZA 2 VIRUS (STRAIN 117-182 207-241 456-518 TOSHIBA) PVGLF.sub.-- PI3H4 FUSION GLYCOPROTEIN PRECURSOR BOVINE PARAINFLUENZA 3 VIRUS 117-182 207-241 462-532 PVGLF.sub.-- RINDK FUSION GLYCOPROTEIN PRECURSOR HUMAN PARAINFLUENZA 1 VIRUS (STRAIN 112-180 224-265 448-493 NIH 47885) PVGLF.sub.-- RINDL FUSION GLYCOPROTEIN PRECURSOR RINDERPEST VIRUS (STRAIN KABETE O) 112-180 224-265 448-506 PVGLF.sub.-- SEND5 FUSION GLYCOPROTEIN PRECURSOR RINDERPEST VIRUS (STRAIN L) 127-188 211-271 463-533 PVGLF.sub.-- SENDF FUSION GLYCOPROTEIN PRECURSOR SENDAI VIRUS (STRAIN Z/HOST MUTANTS) 127-188 211-271 463-533 PVGLF.sub.-- SENDH FUSION GLYCOPROTEIN PRECURSOR SENDAI VIRUS (STRAIN FUSHIMI) 127-188 211-271 463-533 PVGLF.sub.-- SENDJ FUSION GLYCOPROTEIN PRECURSOR SENDAI VIRUS (STRAIN HARRIS) 127-188 218-271 463-533 PVGLF.sub.-- SENDZ FUSION GLYCOPROTEIN PRECURSOR SENDAI VIRUS (STRAIN HVJ) 127-188 211-271 463-533 PVGLF.sub.-- SV41 FUSION GLYCOPROTEIN PRECURSOR SENDAI VIRUS (STRAIN Z) 127-188 211-271 463-533 PVGLF.sub.-- SV5 FUSION GLYCOPROTEIN PRECURSOR SIMIAN VIRUS 41 96-186 454-508 PVGLF.sub.-- TRTV FUSION GLYCOPROTEIN PRECURSOR SIMIAN VIRUS 5 (STRAIN W3) 103-171 241-275 451-487 PVGLG.sub.-- BEFV FUSION GLYCOPROTEIN PRECURSOR TURKEY PHINOTRACHEITIS VIRUS 105-161 190-224 457-498 PVGLG.sub.-- BRSVC SPIKE GLYCOPROTEIN PRECURSOR BOVINE EPHEMERAL FEVER VIRUS 506-612 PVGLG.sub.-- HRSV1 MAJOR SURFACE GLYCOPROTEIN G BOVINE RESPIRATORY SYNCYTIAL VIRUS (STRAIN 30-70 104-138 COPENHAGE PVGLG.sub.-- HRSV2 MAJOR SURFACE GLYCOPROTEIN G HUMAN RESPIRATORY SYNCYTIAL VIRUS 30-81 (SUBGROUP B/STRAI PVGLG.sub.-- HRSV3 MAJOR SURFACE GLYCOPROTEIN G HUMAN RESPIRATORY SYNCYTIAL VIRUS (STRAIN 30-85 RSB642 PVGLG.sub.-- HRSV4 MAJOR SURFACE GLYCOPROTEIN G HUMAN RESPIRATORY SYNCYTIAL VIRUS (STRAIN 30-85 RSB1734 PVGLG.sub.-- HRSV5 MAJOR SURFACE GLYCOPROTEIN G HUMAN RESPIRATORY SYNCYTIAL VIRUS (STRAIN 30-107 RSB5857) PVGLG.sub.-- HRSV6 MAJOR SURFACE GLYCOPROTEIN G HUMAN RESPIRATORY SYNCYTIAL VIRUS (STRAIN 30-85 RSB6190) PVGLG.sub.-- HRSV7 MAJOR SURFACE GLYCOPROTEIN G HUMAN RESPIRATORY SYNCYTIAL VIRUS (STRAIN 30-85 RSB6256) PVGLG.sub.-- HRSV8 MAJOR SURFACE GLYCOPROTEIN G HUMAN RESPIRATORY SYNCYTIAL VIRUS (STRAIN 30-85 RSB6614) PVGLG.sub.-- HRSVA MAJOR SURFACE GLYCOPROTEIN G HUMAN RESPIRATORY SYNCYTIAL VIRUS 30-81 (SUBGROUP B/STRAI PVGLG.sub.-- HRSVL MAJOR SURFACE GLYCOPROTEIN G HUMAN RESPIRATORY SYNCYTIAL VIRUS (STRAIN 30-67 A2) PVGLG.sub.-- HRVE4 MAJOR SURFACE GLYCOPROTEIN G HUMAN RESPIRATORY SYNCYTIAL VIRUS 25-85 (SUBGROUP A/STRAI PVGLG.sub.-- SIGMA GLYCOPROTEIN G PRECURSOR EQUINE HERPESVIRUS TYPE 4 (STRAIN 1942) 271-305 PVGLG.sub.-- SYNV SPIKE GLYCOPROTEIN PRECURSOR SIGMA VIRUS 344-381 464-498 PVGLG.sub.-- VHSV0 SPIKE GLYCOPROTEIN PRECURSOR SONCHUS YELLOW NET VIRUS 488-523 PVGLG.sub.-- VSVIG SPIKE GLYCOPROTEIN PRECURSOR VIRAL HEMORRHAGIC SEPTICEMIA VIRUS 363-397 (STRAIN 07-71) PVGLH.sub.-- EBV SPIKE GLYCOPROTEIN PRECURSOR VESICULAR STOMATITIS VIRUS (SEROTYPE 476-510 INDIANA/STRAIN G PVGLH.sub.-- HCMVA GLYCOPROTEIN GP85 PRECURSOR EPSTEIN-BARR VIRUS (STRAIN B95-8) 53-87 160-201 336-380 653-694 PVGLH.sub.-- HCMVT GLYCOPROTEIN H PRECURSOR HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 103-137 270-311 693-741 PVGLH.sub.-- HSVII GLYCOPROTEIN H PRECURSOR HUMAN CYTOMEGALOVIRUS (STRAIN TOWNE) 102-136 692-740 PVGLH.sub.-- HSVIE GLYCOPROTEIN H PRECURSOR HERPES SIMPLEX VIRUS (TYPE 1/STRAIN 17) 447-481 PVGLH.sub.-- HSV6G GLYCOPROTEIN H PRECURSOR HERPES SIMPLEX VIRUS (TYPE 1/STRAIN HFEM) 447-481 PVGLH.sub.-- HSVBC GLYCOPROTEIN H PRECURSOR HERPES SIMPLEX VIRUS (TYPE 6/STRAIN GS) 357-406 PVGLH.sub.-- HSVE4 GLYCOPROTEIN H PRECURSOR BOVINE HERPESVIRUS TYPE 1 (STRAIN COOPER) 364-416 PVGLH.sub.-- HSV3B GLYCOPROTEIN H PRECURSOR EQUINE HERPESVIRUS TYPE 4 (STRAIN 1942) 334-379 414-455 PVGLH.sub.-- HSVSA GLYCOPROTEIN H PRECURSOR EQUINE HERPESVIRUS TYPE 1 (STRAIN AB4P) AND 327-372 407-448 ISOLATE HV PVGLH.sub.-- MCMVS GLYCOPROTEIN H PRECURSOR HERPESVIRUS SAIMIRI (STRAIN 11) 32-66 374-453 664-712 PVGLH.sub.-- PRVKA GLYCOPROTEIN H PRECURSOR MURINE CYTOMEGALOVIRUS (STRAIN SMITH 440-474 PVGLH.sub.-- PRVN3 GLYCOPROTEIN H PRECURSOR PSEUDORABIES VIRUS (STRAIN KAPLAN) 226-260 PVGLH.sub.-- PRVRI GLYCOPROTEIN H PRECURSOR PSEUDORABIES VIRUS (STRAIN NIA-3) 226-260 PVGLH.sub.-- VZVD GLYCOPROTEIN H PRECURSOR PSEUDORABIES VIRUS (STRAIN RICE) 226-260 PVGLI.sub.-- HCMVA PROBABLE GLYCOPROTEIN H VARICELLA-ZOSTER VIRUS (STRAIN DUMAS) 455-506 PRECURSOR PVGLM.sub.-- BUNGE IMMEDIATE EARLY GLYCOPROTEIN HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 47-111 323-359 PRECURSOR PVGLM.sub.-- BUNL7 M POLYPROTEIN PRECURSOR BUNYAVIRUS GERMISTON 512-567 685-737 1228- 1262 PVGLM.sub.-- BUNSH M POLYPROTEIN PRECURSOR BUNYAVIRUS LA CROSSE (ISOLATE L74) 643-677 916-950 PVGLM.sub.-- BUNYW M POLYPROTEIN PRECURSOR BUNYAVIRUS SNOWSHOE HARE 643-677 PVGLM.sub.-- DUGBV M POLYPROTEIN PRECURSOR BUNYAMWERA VIRUS 340-374 504-563 905-939 PVGLM.sub.-- HANTB M POLYPROTEIN PRECURSOR DUGBE VIRUS 937-989 1239- 1300 PVGLM.sub.-- HANTH M POLYPROTEIN PRECURSOR HANTAAN VIRUS (STRAIN B-1) 693-727 PVGLM.sub.-- HANTL M POLYPROTEIN PRECURSOR HANTAAN VIRUS (STRAIN HOJO) 72-106 PVGLM.sub.-- HANTV M POLYPROTEIN PRECURSOR HANTAAN VIRUS (STRAIN LEE) 72-106 PVGLM.sub.-- INSV M POLYPROTEIN PRECURSOR HANTAAN VIRUS (STRAIN 76-118) 72-106 PVGLM.sub.-- PHV M POLYPROTEIN PRECURSOR IMPATIENS NECROTIC SPOT VIRUS 1067- 1101 PVGLM.sub.-- PTPV M POLYPROTEIN PRECURSOR PROSPECT HILL VIRUS 73-111 PVGLM.sub.-- SEOU8 M POLYPROTEIN PRECURSOR PUNTA TORO PHLEBOVIRUS 149-251 PVGLM.sub.-- SEOUR M POLYPROTEIN PRECURSOR SEOUL VIRUS (STRAIN 30-39) 693-727 PVGLM.sub.-- SEOUS M POLYPROTEIN PRECURSOR SEOUL VIRUS (STRAIN R22) 694-728 PVGLN.sub.-- BEFV M POLYPROTEIN PRECURSOR SEOUL VIRUS (STRAIN SR-11) 693-730 PVGLP.sub.-- BEV NONSTRUCTURAL GLYCOPROTEIN BOVINE EPHEMERAL FEVER VIRUS 377-414 513-569 GNS PRECURSO PVGLX.sub.-- PRVRI PEPLOMER GLYCOPROTEIN BERNE VIRUS 43-82 90-124 622-656 1128- PRECURSOR 1236 PVGLY.sub.-- JUNIN SECRETED GLYCOPROTEIN GX PSEUDORABIES VIRUS (STRAIN RICE) 420-461 PVGLY.sub.-- LASSG GLYCOPROTEIN POLYPROTEIN JUNIN ARENAVIRUS 301-349 PRECURSOR PVGLY.sub.-- LASSJ GLYCOPROTEIN POLYPROTEIN LASSA VIRUS (STRAIN GA391) 317-360 388-422 PRECURSOR PVGLY.sub.-- LYCVA GLYCOPROTEIN POLYPROTEIN LASSA VIRUS (STRAIN JOSIAH) 318-361 389-423 PRECURSOR PVGLY.sub.-- LYCVW GLYCOPROTEIN POLYPROTEIN LYMPHOCYTIC CHORIOMENINGITIS VIRUS (STRAIN 333-367 395-432 PRECURSOR ARMSTON) PVGLY.sub.-- MOPEI GLYCOPROTEIN POLYPROTEIN LYMPHOCYTIC CHORIOMENINGITIS VIRUS (STRAIN 124-158 333-367 395-432 PRECURSOR WE) PVGLY.sub.-- PIARV GLYCOPROTEIN POLYPROTEIN MOPEIA VIRUS 316-359 PRECURSOR PVGLY.sub.-- TACV GLYCOPROTEIN POLYPROTEIN PICHINDE ARENA VIRUS 334-375 PRECURSOR PVGLY.sub.-- TACV5 GLYCOPROTEIN POLYPROTEIN TACARIBE VIRUS 315-363 PRECURSOR PVGLY.sub.-- TACV7 GLYCOPROTEIN POLYPROTEIN TACARIBE VIRUS (STRAIN V5) 303-351 382-416 PRECURSOR PVGLY.sub.-- TACVT GLYCOPROTEIN POLYPROTEIN TACARIBE VIRUS (STRAIN V7) 302-350 381-415 PRECURSOR PVGNB.sub.-- CPMV GLYCOPROTEIN POLYPROTEIN TACARIBE VIRUS (STRAIN TRVL 11598) 303-351 382-416 PRECURSOR PVGNM.sub.-- CPMV GENOME POLYPROTEIN B COWPEA MOSAIC VIRUS 835`869 PVGNM.sub.-- CPSMV GENOME POLYPROTEIN M COWPEA MOSAIC VIRUS 160-201 PVGNM.sub.-- RCMV GENOME POLYPROTEIN M COWPEA SEVERE MOSAIC VIRUS (STRAIN DG) 192-226 758-792 874-915 PVGP8.sub.-- EBV GENOME POLYPROTEIN M RED CLOVER MOTTLE VIRUS 837-871 912-946 PVGP.sub.-- EBOV PROBABLE MEMBRANE ANTIGEN EPSTEIN-BARR VIRUS (STRAIN B95-8) 94-149 GP85 PVGP.sub.-- MABVM STRUCTURAL GLYCOPROTEIN EBOLA VIRUS 280-31 334-368 469-503 PRECURSOR PVGP.sub.-- MABVP STRUCTURAL GLYCOPROTEIN MARBURG VIRUS (STRAIN MUSOKE) 562-596 PRECURSOR PVH02.sub.-- VACCC STRUCTURAL GLYCOPROTEIN MARBURG VIRUS (STRAIN POPP) 562-596 PRECURSOR PVH02.sub.-- VACCV LATE PROTEIN H2 VACCINIA VIRUS (STRAIN COPEHAGEN) 58-92 PVH02.sub.-- VARV LATE PROTEIN H2 VACCINIA VIRUS (STRAIN WR) 58-94 PVH05.sub.-- VACCC LATE PROTEIN H2 VARIOLA VIRUS 58-92 PVH05.sub.-- VACCV PROTEIN H5 VACCINIA VIRUS (STRAIN COPEHAGEN) 118-185 PVH05.sub.-- VARV PROTEIN H5 VACCINIA VIRUS (STRAIN WR) 118-185 PVHEL.sub.-- LSV PROTEIN H5 VARIOLA VIRUS 136-203 PVHRP.sub.-- VACCC PROBABLE HELICASE LILY SYMPTOMLESS VIRUS 126-160 PVHRP.sub.-- VACCV HOST RANGE PROTEIN VACCINIA VIRUS (STRAIN COPEHAGEN) 216-279 PVI03.sub.-- VACCC HOST RANGE PROTEIN VACCINIA VIRUS (STRAIN WR) 216-279 PVI03.sub.-- VACCV PROTEIN I3 VACCINIA VIRUS (STRAIN COPEHAGEN) 150-193 210-244 PVI03.sub.-- VARV PROTEIN I3 VACCINIA VIRUS (STRAIN WR) 150-193 210-244 PVI06.sub.-- VACCV PROTEIN I3 VARIOLA VIRUS 150-193 210-244 PVI06.sub.-- VARV PROTEIN I6 VACCINIA VIRUS (STRAIN WR) 58-92 PVI07.sub.-- VARV PROTEIN I6 VARIOLA VIRUS 58-92 PVI08.sub.-- VACCC PROTEIN I7 VARIOLA VIRUS 373-407 PVI08.sub.-- VACCV PUTATIVE RNA HELICASE I8 VACCINIA VIRUS (STRAIN COPEHAGEN) 548-589 PVI08.sub.-- VARV PUTATIVE RNA HELICASE I8 VACCINIA VIRUS (STRAIN WR) 548-589 PVIE1.sub.-- HCMVA PUTATIVE RNA HELICASE I8 VARIOLA VIRUS 548-589 PVIE1.sub.-- HCMVT 55 KD IMMEDIATE-EARLY PROTEIN 1 HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 78-112 171-205 368-402 416-450 PVIE1.sub.-- MCMVS 55 KD IMMEDIATE-EARLY PROTEIN 1 HUMAN CYTOMEGALOVIRUS (STRAIN TOWNE) 78-112 171-205 368-402 416-450 PVIE2.sub.-- NPVOP IMMEDIATE-EARLY PROTEIN 1 MURINE CYTOMEGALOVIRUS (STRAIN SMITH) 244-297 PVIEN.sub.-- NPVAC IMMEDIATE-EARLY PROTEIN IE-2 ORGYIA PSEUDOTSUGATA MULTICAPSID 94-128 305-395 POLYHEDRO SIS VIRUS PVIF.sub.-- CAEVC IMMEDIATE-EARLY REGULATORY AUTOGRAPHA CALIFORNICA NUCLEAR 277-407 PROTEIN IE-N POLYHEDROSIS VIRUS PVIF.sub.-- FIVPE VIRION INFECTIVITY FACTOR CAPRINE ARTHRITIS ENCEPHALITIS VIRUS 23-92 (STRAIN CORK) PVIF.sub.-- FIVSD VIRION INFECTIVITY FACTOR FELINE IMMUNODEFICIENCY VIRUS (ISOLATE 53-94 PETALUMA) PVIF.sub.-- HVIA2 VIRION INFECTIVITY FACTOR FELINE IMMUNODEFICIENCY VIRUS (ISOLATE 32-80 SAN DIEGO) PVIF.sub.-- HVIB1 VIRION INFECTIVITY FACTOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 1-42 62-96 (ARV2/SF2 ISOLATE PVIF.sub.-- HVIB5 VIRION INFECTIVITY FACTOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (BH10, 1-42 62-96 BRU, HXB, PV PVIF.sub.-- HVIEL VIRION INFECTIVITY FACTOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (BHS 1-42 62-96 ISOLATE) PVIF.sub.-- HVIJR VIRION INFECTIVITY FACTOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (ELI 1-42 62-96 ISOLATE) PVIF.sub.-- HVIMA VIRION INFECTIVITY FACTOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (JRCSF 1-42 62-96 ISOLATE) PVIF.sub.-- HVIMN VIRION INFECTIVITY FACTOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (MAL 2-36 ISOLATE) PVIF.sub.-- HVIN5 VIRION INFECTIVITY FACTOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (MN 1-42 62-96 ISOLATE) PVIF.sub.-- HVINA VIRION INFECTIVITY FACTOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (NEW 1-42 62-96 YORK-5 ISOL PVIF.sub.-- HV1ND VIRION INFECTIVITY FACTOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 1-42 62-96 (ISOLATE NIT-A) PVIF.sub.-- HV1OY VIRION INFECTIVITY FACTOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 1-42 62-96 (NDK ISOLATE) PVIF.sub.-- HV1RH VIRION INFECTIVITY FACTOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 1-42 62-96 (OYI ISOLATE) PVIF.sub.-- HV1U4 VIRION INFECTIVITY FACTOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 1-42 62-96 (RF/HAT ISOLATE) PVIF.sub.-- HV1Z2 VIRION INFECTIVITY FACTOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (STRAIN 1-42 UGANDAN PVIF.sub.-- HV1Z6 VIRION INFECTIVITY FACTOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 1-42 62-96 (Z2/CDC-Z3 4 ISOLAT PVIF.sub.-- HV2D2 VIRION INFECTIVITY FACTOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 1-42 62-96 (ZAIRE 6 ISOLATE PVIF.sub.-- HV2NZ VIRION INFECTIVITY FACTOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 147-195 (ISOLATE D205.7) PVIF.sub.-- HV2RO VIRION INFECTIVITY FACTOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 152-193 (ISOLATE NIH-Z) PVIF.sub.-- OMVVS VIRION INFECTIVITY FACTOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 163-197 (ISOLATE ROD) PVIF.sub.-- SIVAI VIRION INFECTIVITY FACTOR OVINE LENTIVIRUS (STRAIN SA-OMVV) 44-114 PVIF.sub.-- SIVAG VIRION INFECTIVITY FACTOR SIMIAN IMMUNODEFICIENCY VIRUS (AGM155 2-58 150-202 ISOLATE) PVIF.sub.-- SIVAI VIRION INFECTIVITY FACTOR SIMIAN IMMUNODEFICIENCY VIRUS (AGM3 17-58 ISOLATE) PVIF.sub.-- SIVAT VIRION INFECTIVITY FACTOR SIMIAN IMMUNODEFICIENCY VIRUS (ISOLATE 2-36 143-187 AGM/CLONE GRI PVIF.sub.-- SIVCZ VIRION INFECTIVITY FACTOR SIMIAN IMMUNODEFICIENCY VIRUS (TYO-1 20-58 150-195 ISOLATE) PVIF.sub.-- SIVGB VIRION INFECTIVITY FACTOR CHIMPANZEE IMMUNODEFICIENCY VIRUS 1-42 PVIMP.sub.-- HSV11 VIRION INFECTIVITY FACTOR SIMIAN IMMUNODEFICIENCY VIRUS (ISOLATE GB1) 1-39 PVIMP.sub.-- HSVEB PROBABLE INTEGRAL MEMBRANE HERPES SIMPLEX VIRUS (TYPE 1/STRAIN 17) 85-134 PROTEIN PVIMP.sub.-- HSVSA PROBABLE INTEGRAL MEMBRANE EQUINE HERPESVIRUS TYPE 1 (STRAIN AB4P) 148-182 335-369 PROTEIN PVIMP.sub.-- VZVD INTEGRAL MEMBRANE PROTEIN HERPESVIRUS SAIMIRI (STRAIN 11) 80-129 PVINT.sub.- - SSV1 PROBABLE INTEGRAL MEMBRANE VARICELLA-ZOSTER VIRUS (STRAIN DUMAS) 107-151 155-189 267-301 PROTEIN PVJ01.sub.-- VACCC PROBABLE INTEGRASE SULFOLOBUS VIRUS-LIKE PARTICLE SSV1 85-130 138-172 PVJ01.sub.-- VACCV PROTEIN J1 VACCINIA VIRUS (STRAIN COPENHAGEN) 22-56 PVJ01.sub.-- VARV PROTEIN J1 VACCINIA VIRUS (STRAIN WR) 22-56 PVK03.sub.-- VACCC PROTEIN J1 VARIOLA VIRUS 22-56 PVK03.sub.-- VACCV PROTEIN K3 VACCINIA VIRUS (STRAIN COPENHAGEN) 38-82 PVK07.sub.-- VACCV PROTEIN K3 VACCINIA VIRUS (STRAIN WR) 38-82 PVL02.sub.-- VACCC PROTEIN K7 VACCINIA VIRUS (STRAIN WR), AND (STRAIN 115-149 COPENHAGEN) PVL02.sub.-- VACCV PROTEIN L2 VACCINIA VIRUS (STRAIN COPENHAGEN) 47-81 PVL02.sub.-- VARV PROTEIN L2 VACCINIA VIRUS (STRAIN WR) 47-92 PVL1.sub.-- CRPVK PROTEIN L2 VARIOLA VIRUS 47-81 PVL1.sub.-- FPVL PROBABLE L1 PROTEIN COTTONTAIL RABBIT (SHOPE) PAPILLOMAVIRUS 261-295 331-383 (STRAIN KANS PVL1.sub.-- HPV05 PROBABLE L1 PROTEIN AVIAN PAPILLOMAVIRUS FPV-L 38-90 PVL1.sub.-- HPV08 PROBABLE L1 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 5 355-393 PVL1.sub.-- HPV1A PROBABLE L1 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 8 354-392 PVL1.sub.-- HPV47 PROBABLE L1 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 1A 345-379 PVL1.sub.-- PAPVD PROBABLE L1 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 47 353-391 PVL2.sub.-- REOVD PROBABLE L1 PROTEIN DEER PAPILLOMAVIRUS 23-57 PVL2.sub.-- HPV05 MAJOR CORE PROTEIN LAMBDA 1 REOVIRUS (TYPE 3/STRAIN DEARING) 94-142 437-471 PVL2.sub.-- HPV08 PROBABLE L2 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 341-375 PVL2.sub.-- HPV16 PROBABLE L2 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 8 354-392 PVL2.sub.-- HPV1A PROBABLE L2 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 16 295-333 PVL2.sub.-- HPV31 PROBABLE L1 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 1A 345-379 PVL2.sub.-- HPV35 PROBABLE L2 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 31 228-326 PVL2.sub.-- HPV47 PROBABLE L2 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 35 292-333 PVL2.sub.-- HPV58 PROBABLE L1 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 47 341-375 PVL2.sub.-- HPV5B PROBABLE L2 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 58 293-327 PVL3.sub.-- REOVD PROBABLE L2 PROTEIN HUMAN PAPILLOMAVIRUS TYPE 5B 341-375 PVL3.sub.-- REOVJ MINOR CORE PROTEIN LAMBDA 3 REOVIRUS (TYPE 3/STRAIN DEARING) 107-148 1112- 1178 PVL3.sub.-- REOVL MINOR CORE PROTEIN LAMBDA 3 REOVIRUS (TYPE 2/STRAIN D5/JONES) 1112- 1178 PVL96.sub.-- IRV1 MINOR CORE PROTEIN LAMBDA 3 REOVIRUS (TYPE 1/STRAIN LANG) 107-148 331-365 1112- 1178 PVM01.sub.-- VACCC L96 PROTEIN TIPULA IRIDESCENT VIRUS 146-180 198-236 PVM1.sub.-- REOVL PROTEIN MI VACCINIA VIRUS (STRAIN COPEHAGEN) 5-56 PVM21.sub.-- REOVD MINOR VIRION STRUCTURAL REOVIRUS (TYPE 1/STRAIN LANG) 287-321 PROTEIN MU-2 PVM22.sub.-- REOVD MAJOR VIRION STRUCTURAL REOVIRUS (TYPE 3/STRAINDEARING) 416-450 619-663 PROTEIN MU-1/MU-1C PVM2.sub.-- REOVJ MAJOR VIRION STRUCTURAL REOVIRUS (TYPE 3/STRAINDEARING) 416-450 619-662 PROTEIN MU-1/MU-1C PVM2.sub.-- REOVL MAJOR VIRION STRUCTURAL REOVIRUS (TYPE 2/STRAIND5/JONES) 416-450 619-662 PROTEIN MU-1/MU-1C PVM3.sub.-- REOVD MAJOR VIRION STRUCTURAL REOVIRUS (TYPE 1/STRAINLANG) 416-450 619-662 PROTEIN MU-1/MU-1C PVMA2.sub.-- BRSVA MAJOR NONSTRUCTURAL PROTEIN REOVIRUS (TYPE 3/STRAINDEARING) 135-190 337-371 523-558 618-690 MU-NS PVMA2.sub.-- HRSVA MATRIX GLYCOPROTEIN M2 BOVINE RESPIRATORY SYNCYTIAL VIRUS 42-90 (STRAIN A51908) PVMA2.sub.-- TRTV MATRIX GLYCOPROTEIN M2 HUMAN RESPIRATORY SYNCYTIAL VIRUS 42-90 (STRAIN A2) PVMAT.sub.-- CDVO MATRIX GLYCOPROTEIN M2 TURKEY RHINOTRACHEITIS VIRUS 36-70 PVMAT.sub.-- INCJJ MATRIX PROTEIN CANINE DISTEMPER VIRUS (STRAIN 193-234 ONDERSTEPOORT) PVMAT.sub.-- NDVA MATRIX (M) PROTEIN INFLUENZA C VIRUS (STRAIN C/JJ/50) 73-114 151-208 PVMAT.sub.-- NDVB MATRIX PROTEIN NEWCASTLE DISEASE VIRUS (STRAIN 310-358 AUSTRALIA-VICTORIA/32) PVMAT.sub.-- PI3B MATRIX PROTEIN NEWCASTLE DISEASE VIRUS (STRAIN 324-358 BEAUDETTE C/45) PVMAT.sub.-- PI3H4 MATRIX PROTEIN BOVINE PARAINFLUENZA 3 VIRUS 99-133 204-252 PVMAT.sub.-- RABVA MATRIX PROTEIN HUMAN PARAINFLUENZA 3 VIRUS (STRAIN 99-133 204-252 N111 47885) PVMAT.sub.-- RABVC MATRIX PROTEIN RABIES VIRUS (STRAIN AVO1) 69-103 PVMAT.sub.-- RABVE MATRIX PROTEIN RABIES VIRUS (STRAIN CVS-11) 69-103 PVMAT.sub.-- RABVN MATRIX PROTEIN RABIES VIRUS (STRAIN ERA) 69-103 PVMAT.sub.-- RABVP MATRIX PROTEIN RABIES VIRUS (STRAIN NISHIGAHARA 69-103 RCEH) PVMAT.sub.-- RABVS MATRIX PROTEIN RABIES VIRUS (STRAIN PV) 69-103 PVMAT.sub.-- SYNV MATRIX PROTEIN RABIES VIRUS (STRAIN SAD B19) 69-103 PVMAT.sub.-- VSVIG MATRIX PROTEIN SONCHUS YELLOW NET VIRUS 246-280 PVMEI.sub.-- CVBM MATRIX PROTEIN VESICULAR STOMATITIS VIRUS (SEROTYPE 198-232 INDIANA/STRAIN G PVMEI.sub.-- CVPFS E1 GLYCOPROTEIN BOVINE CORONAVIRUS (STRAIN MEBUS) 175-209 PVMEI.sub.-- CVPPU E1 GLYCOPROTEIN PRECURSOR PORCINE TRANSMISSIBLE GASTROENTERITIS 98-146 212-257 CORONAVIRUS (S PVMEI.sub.-- CVPRM E1 GLYCOPROTEIN PRECURSOR PORCINE TRANSMISSIBLE GASTROENTERITIS 212-257 CORONAVIRUS (S PVMEI.sub.-- CVTKE E1 GLYCOPROTEIN PRECURSOR PORCINE RESPIRATORY CORONAVIRUS (STRAIN 212-257 RM4) PVMEI.sub.-- FIPV E1 GLYCOPROTEIN TURKEY ENTERIC CORONAVIRUS 28-62 175-209 PVMEI.sub.-- IBV6 E1 GLYCOPROTEIN PRECURSOR FELINE INFECTIOUS PERITONITIS VIRUS 212-257 (STRAIN 79-1146) PVMEI.sub.-- IBVB E1 GLYCOPROTEIN AVIAN INFECTIOUS BRONCHITIS VIRUS (STRAIN 21-55 177-218 6/82) PVMEI.sub.-- IBVB2 E1 GLYCOPROTEIN AVIAN INFECTIOUS BRONCHITIS VIRUS (STRAIN 21-55 177-218 BEAUDETTE) PVMEI.sub.-- IBVK E1 GLYCOPROTEIN AVIAN INFECTIOUS BRONCHITIS VIRUS (STRAIN 21-55 177-218 BEAUDETTE M4 PVMEM.sub.-- EBV E1 GLYCOPROTEIN AVIAN INFECTIOUS BRONCHITIS VIRUS (STRAIN 177-218 KB8522) PVMP.sub.-- CAMVC PROBABLE MEMBRANE PROTEIN EPSTEIN-BARR VARIOUS (STRAIN B95-8) 36-94 PVMP.sub.-- CAMVD MOVEMENT PROTEIN CAULIFLOWER MOSAIC VIRUS (STRAIN CM-1841) 187-254 270-324 PVMP.sub.-- CAMVE MOVEMENT PROTEIN CAULIFLOWER MOSAIC VIRUS (STRAIN D/H) 187-254 270-324 PVMP.sub.-- CAMVN MOVEMENT PROTEIN CAULIFLOWER MOSAIC VIRUS (STRAIN BBC) 187-254 270-324 PVMP.sub.-- CAMVS MOVEMENT PROTEIN CAULIFLOWER MOSAIC VIRUS (STRAIN NY8153) 187-254 270-324 PVMP.sub.-- CAMVW MOVEMENT PROTEIN CAULIFLOWER MOSAIC VIRUS (STRAIN 187-254 270-324 STRASBOURG) PVMP.sub.-- CERV MOVEMENT PROTEIN CAULIFLOWER MOSAIC VIRUS (STRAIN W260) 187-254 270-324 PVMP.sub.-- FMVD MOVEMENT PROTEIN CARNATION ETCHED RING VIRUS 212-246 PVMP.sub.-- SOCMV MOVEMENT PROTEIN FIGWORT MOSAIC VIRUS (STRAIN DXS) 217-251 PVMSA.sub.-- HPBDB MOVEMENT PROTEIN SOYBEAN CHLOROTIC MOTTLE VIRUS 76-118 PVMSA.sub.-- HPBDC MAJOR SURFACE ANTIGEN DUCK HEPATITIS B VIRUS (BROWN SHANGHAI 272-313 324-361 PRECURSOR DUCK ISOLATE S PVMSA.sub.-- HPBDU MAJOR SURFACE ANTIGEN DUCK HEPATITIS B VIRUS (STRAIN CHINA) 271-312 323-360 PRECURSOR PVMSA.sub.-- HPBDW MAJOR SURFACE ANTIGEN DUCK HEPATITIS B VIRUS 234-275 289-323 PRECURSOR PVMSA.sub.-- HPBGS MAJOR SURFACE ANTIGEN DUCK HEPATITIS B VIRUS (WHITE SHANGHAI 272-313 324-361 PRECURSOR DUCK ISOLATE S3 PVMSA.sub.-- HPBHE MAJOR SURFACE ANTIGEN GROUND SQUIRREL HEPATITIS VIRUS 210-244 PRECURSOR PVMSA.sub.-- WHV1 MAJOR SURFACE ANTIGEN HERON HEPATITIS B VIRUS 294-328 PRECURSOR PVMSA.sub.-- WHV59 MAJOR SURFACE ANTIGEN WOODCHUCK HEPATITIS VIRUS 1 208-242 PRECURSOR PVMSA.sub.-- WHV7 MAJOR SURFACE ANTIGEN WOODCHUCK HEPATITIS VIRUS 59 213-247 PRECURSOR PVMSA.sub.-- WHV81 MAJOR SURFACE ANTIGEN WOODCHUCK HEPATITIS VIRUS 7 213-247 PRECURSOR PVMT1.sub.-- DHV11 PROBABLE MAJOR SURFACE ANTIGEN WOODCHUCK HEPATITIS VIRUS 8 (INFECTIOUS 213-247 PRECURSOR CLONE) PVMT1.sub.-- IAANN MATRIX PROTEIN 1 DHORI VIRUS (STRAIN INDIAN/1313/61) 201-235 PVMT1.sub.-- IABAN MATRIX (M1) PROTEIN INFLUENZA A VIURS (STRAIN A/ANN ARBOR/6/60) 92-126 174-222 PVMT1.sub.-- IACAO MATRIX (M1) PROTEIN INFLUENZA A VIURS (STRAIN A/BANGKOK/1/79) 92-126 174-222 PVMT1.sub.-- IAFOW MATRIX (M1) PROTEIN INFLUENZA A VIURS (STRAIN A/CAMEL/ 31-79 MONGOLIA/82) PVMT1.sub.-- IAFPR MATRIX (M1) PROTEIN INFLUENZA A VIURS (STRAIN A/FORT WARREN/1/50), 92-126 174-222 AND (STR PVMT1.sub.-- IAFPW MATRIX (M1) PROTEIN INFLUENZA A VIURS (STRAIN A/FOWL PLAGUE 92-126 174-222 VIRUS/ROSTO CK PVMT1.sub.-- IALE1 MATRIX (M1) PROTEIN INFLUENZA A VIURS (STRAIN A/FOWL PLAGUE 92-126 174-222 VIRUS/WEYBR ID PVMT1.sub.-- IALE2 MATRIX (M1) PROTEIN INFLUENZA A VIURS (STRAIN A/LENINGRAD/134/57) 92-126 174-222 PVMT1.sub.-- IAMAN MATRIX (M1) PROTEIN INFLUENZA A VIURS (STRAIN A/LENINGRAD/134/ 92-126 174-222 17/57) PVMT1.sub.-- IAPOC MATRIX (M1) PROTEIN INFLUENZA A VIURS (STRAIN A/MALLARD/NEW 92-126 174-222 YORK/6750/7 8) PVMT1.sub.-- IAPUE MATRIX (M1) PROTEIN INFLUENZA A VIURS (STRAIN A/PORT CHALMERS/ 92-126 174-222 1/73) PVMT1.sub.-- IAUDO MATRIX (M1) PROTEIN INFLUENZA A VIURS (STRAIN A/PUERTO RICO/8/34) 92-126 174-222 PVMT1.sub.-- IAWIL MATRIX (M1) PROTEIN INFLUENZA A VIURS (STRAIN A/UDORN/307/7) 92-126 174-222 PVMT1.sub.-- IAZ11 MATRIX (M1) PROTEIN INFLUENZA A VIURS (STRAIN A/WILSON-SMITH/33 92-126 174-222 PVMT1.sub.-- INBAC MATRIX (M1) PROTEIN INFLUENZA A VIURS (STRAIN A/SWINE/IOWA/15/30 92-126 174-222 PVMT1.sub.-- INBAD MATRIX (M1) PROTEIN INFLUENZA A VIURS (STRAIN B/ANN ARBOR/1/66 175-209 [COLD-ADATE PVMT1.sub.-- INBLE MATRIX (M1) PROTEIN INFLUENZA A VIURS (STRAIN B/ANN ARBOR/1/66 175-209 [WILD-TYPE]) PVMT1.sub.-- INBSI MATRIX (M1) PROTEIN INFLUENZA A VIURS (STRAIN B/LEE/40) 175-209 PVMT2.sub.-- INBAC MATRIX (M1) PROTEIN INFLUENZA A VIURS (STRAIN B/SINGAPORE/222/79) 175-209 PVMT2.sub.-- INBAD PROBABLE MATRIX (M2) PROTEIN INFLUENZA A VIURS (STRAIN B/ANN ARBOR/1/66 132-184 [COLD-ADAPTE PVMT2.sub.-- INBLE PROBABLE MATRIX (M2) PROTEIN INFLUENZA A VIURS (STRAIN B/ANN ARBOR/1/66 132-184 [WILD-TYPE]) PVMT2.sub.-- INBSI PROBABLE MATRIX (M2) PROTEIN INFLUENZA A VIURS (STRAIN B/LEE/40) 132-184 PVMT8.sub.-- MYXVL PROBABLE MATRIX (M2) PROTEIN INFLUENZA A VIURS (STRAIN B/SINGAPORE/222/79) 132-184 PVN01.sub.-- VACCC M-T8 PROTEIN MYXOMA VIRUS (STRAIN LAUSANNE) 46-80 145-197 PVN01.sub.-- VACCV PROTEIN N1 VACCINIA VIRUS (STRAIN COPENHAGEN) 64-112 PVN34.sub.-- ROTBS PROTEIN N1 VACCINIA VIRUS (STRAIN WR) 64-112 PVN34.sub.-- ROTPC NONSTRUCTURAL PROTEIN NS34 BOVINE ROTAVIRUS (GROUP C/STRAIN SHINTOKU) 64-169 PVNCA.sub.-- AAV2 NONSTRUCTURAL PROTEIN NS34 PORCINE ROTAVIRUS (GROUP C/STRAIN COWDEN) 64-117 121-169 PVNCA.sub.-- RSV DNA REPLICATION PROTEIN ADENO-ASSOCIATED VIRUS 2 91-125 217-251 PVNCN.sub.-- PAVBO MAJOR NONCAPSID PROTEIN RICE STRIPE VIRUS 129-163 PVNCS.sub.-- ADVG PROBABLE NONCAPSID PROTEIN NP1 BOVINE PARVOVIRUS 221-255 PVNCS.sub.-- AEDEV NONCAPSID PROTEIN NS-1 ALEUTIAN MINK DISEASE PARVOVIRUS (STRAIN G) 19-60 270-304 PVNCS.sub.-- FPV19 NONCAPSID PROTEIN NS-1 AEDES DENSONUCLEOSIS VIRUS (STRAIN 276-339 521-571 585-640 715-760 780-849 GKV 002 002) PVNCS.sub.-- MEVA NONCAPSID PROTEIN NS-1 FELINE PANLEUKOPENIA VIRUS (STRAIN 193) 53-98 PVNCS.sub.-- MUMIM NONCAPSID PROTEIN NS-1 MINK ENTERITIS VIRUS (STRAIN ABASHIRI) 53-98 PVNCS.sub.-- MUMIV NONCAPSID PROTEIN NS-1 MURINE MINUTE VIRUS (STRAIN MVMI) 35-91 261-297 PVNCS.sub.-- PAVBO NONCAPSID PROTEIN NS-1 MURINE MINUTE VIRUS 35-87 259-297 PVNCS.sub.-- PAVCN PROBABLE NONCAPSID PROTEIN NS1 BOVINE PARVOVIRUS 181-222 PVNCS.sub.-- PAVHB NONCAPSID PROTEIN NS-1 CANINE PARVOVIRUS (STRAIN N) 53-98 PVNCS.sub.-- PAVHH NONCAPSID PROTEIN NS-1 HUMAN PARVOVIRUS B19 236-270 PVNCS.sub.-- PAVPN NONCAPSID PROTEIN NS-1 HAMSTER PARVOVIRUS H1 35-76 259-297 PVNC1.sub.-- BTVI0 NONCAPSID PROTEIN NS-1 PORCINE PARVOVIRUS (STRAIN NADL-2) 24-77 169-210 309-346 PVNC1.sub.-- BTVI7 NONSTRUCTURAL PROTEIN NS1 BLUETONGUE VIRUS (SEROTYPE 10/ISOLATE USA) 107-141 PVNC1.sub.-- BTVIA NONSTRUCTURAL PROTEIN NS1 BLUETONGUE VIRUS (SEROTYPE 17/ISOLATE USA) 107-141 PVNC1.sub.-- BTVIS NONSTRUCTURAL PROTEIN NS1 BLUETONGUE VIRUS (SEROTYPE 1/ISOLATE 107-141 AUSTRALIA) PVNC1.sub.-- BTV20 NONSTRUCTURAL PROTEIN NS1 BLUETONGUE VIRUS (SEROTYPE 1/ISOLATE 107-141 SOUTH AFRICA) PVNC1.sub.-- EHDV2 NONSTRUCTURAL PROTEIN NS1 BLUETONGUE VIRUS (SEROTYPE 20/ISOLATE 107-141 AUSTRALIA) PVNC1.sub.-- IAANN NONSTRUCTURAL PROTEIN NS1 EPIZOOTIC HEMORRHAGIC DISEASE VIRUS 401-454 (SEROTYPE 2/STRAI PVNC1.sub.-- IACAO NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN A/ANN ARBOR/6/60) 49-83 PVNC1.sub.-- IACKG NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN A/CAMEL/ 37-71 MONGOLIA/82 PVNS1.sub.-- IACKJ NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN A/CHICKEN/ 49-83 GERMANY/N/49) PVNS1.sub.-- IADA2 NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN A/CHICKEN/JAPAN/24) 46-80 PVNS1.sub.-- IADE1 NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN A/DUCK/ALBERTA/ 49-83 60/76) PVNS1.sub.-- IADU3 NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN A/DUCK/ENGLAND/ 46-80 1/56) PVNS1.sub.-- IAFOM NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN A/DUCK/UKRAINE/1/63) 46-80 PVNS1.sub.-- IAFOW NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN A/FORT MONMOUTH/ 49-83 1/47) PVNS1.sub.-- IAFPR NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN A/FORT WARREN/1/50), 49-83 AND STRA PVNS1.sub.-- IALEI NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN A/FOWL PLAGUE 49-83 VIRUS/ROSTOCK PVNS1.sub.-- IALEN NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN A/LENINGRAD/ 49-83 134/57) PVNS1.sub.-- IAMA6 NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN A/ 49-83 LENINGRAD/54/1) PVNS1.sub.-- IAMAN NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN A/ 49-83 MALLARD/ALBERTA/88/76 PVNS1.sub.-- IAMAO NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN A/MALLARD/NEW 49-83 YORK/6750/78) PVNS1.sub.-- IAMYN NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN A/MALLARD/NEW 49-83 YORK/687/78 PVNS1.sub.-- IAP10 NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN A/MYNAH/ 46-80 HANEDA-THAI/76) PVNS1.sub.-- IAP11 NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN A/PINTAIL/ 49-83 ALBERTA/119/79 PVNS1.sub.-- IAP12 NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN A/PINTAIL/ 49-83 ALBERTA/121/79) PVNS1.sub.-- IAP13 NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN A/PINTAIL/ 49-83 ALBERTA/268/78 PVNS1.sub.-- IAPUE NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN A/PINTAIL/ 49-83 ALBERTA/358/79) PVNS1.sub.-- IATKB NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN A/PUERTO 49-83 RICO/8/34) PVNS1.sub.-- IATKC NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN A/TURKEY/ 49-83 BETHLEHEM-GLILIT/14 PVNS1.sub.-- IATKR NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN A/TURKEY/ 49-83 CANADA/63) PVNS1.sub.-- IATRS NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN A/TURKEY/ 49-83 OREGON/71) PVNS1.sub.-- IATRT NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN A/TERN/ 46-80 SOUTH AFRICA/61 PVNS1.sub.-- IAZII NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN A/TERN/ 49-83 TURKMENIA/18/72) PVNS1.sub.-- INBAC NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN A/SWINE/IOWA/15/30) 49-83 PVNS1.sub.-- INBGA NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN B/ANN ARBOR/ 143-177 1/66 [COLD-ADAPTE PVNS1.sub.-- INGHK NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN B/GA/86) 143-177 PVNS1.sub.-- INBHT NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN B/HONG KONG/ 143-177 8/73), AND (STRAIN PVNS1.sub.-- INBID NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN B/HT/84) 143-177 PVNS1.sub.-- INBLE NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN B/ID/86) 143-177 PVNS1.sub.-- INBMD NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN B/LEE/40) 143-177 PVNS1.sub.-- INBPA NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN B/MARYLAND/59) 143-177 PVNS1.sub.-- INBRU NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN B/PA/79) 143-177 277-337 PVNS1.sub.-- INBSI NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN B/RU/69) 139-173 PVNS1.sub.-- INBSJ NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN B/ 143-177 SINGAPORE/222/79) PVNS1.sub.-- INBVJ NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN B/ 143-177 SINGAPORE/64) PVNS1.sub.-- INVYA NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN B/ 143-177 VICTORIA/87) PVNS2.sub.-- AHSV9 NONSTRUCTURAL PROTEIN NS1 INFLUENZA A VIRUS (STRAIN B/ 143-177 YAMAGATA/1/73) PVNS2.sub.-- BTV17 NONSTRUCTURAL PROTEIN NS2 AFRICAN HORSE SICKNESS VIRUS 67-101 (SEROTYPE 9) PVNS2.sub.-- BTV1X NONSTRUCTURAL PROTEIN NS2 BLUETONGUE VIRUS (SEROTYPE 17/ 203-237 ISOLATE USA) PVNS2.sub.-- CVMJH NONSTRUCTURAL PROTEIN NS2 BLUETONGUE VIRUS (SEROTYPE 10) 203-237 PVNS2.sub.-- EHDV2 NONSTRUCTURAL PROTEIN NS2 MURINE CORONAVIRUS MHV (STRAIN JHM) 71-105 PVNS2.sub.-- IAALA NONSTRUCTURAL PROTEIN NS2 EPIZOOTIC HEMORRHAGIC DISEASE 206-272 276-311 VIRUS (SEROTYPE 2/STRAI PVNS2.sub.-- IAANA NONSTRUCTURAL PROTEIN NS2 INFLUENZA A VIRUS (STRAIN A/ALASKA/6/77), 14-93 AND (STRAIN A/U PVNS2.sub.-- IAANN NONSTRUCTURAL PROTEIN NS2 INFLUENZA A VIRUS (STRAIN A/ANAS ACUTA/ 14-93 PRIMORJE/695/76) PVNS2.sub.-- IACHI NONSTRUCTURAL PROTEIN NS2 INFLUENZA A VIRUS (STRAIN A/ANN ARBOR/6/60), 14-93 AND STRAIN PVNS2.sub.-- IACKG NONSTRUCTURAL PROTEIN NS2 INFLUENZA A VIRUS (STRAIN A/CHILE/1/83) 14-93 PVNS2.sub.-- IACKJ NONSTRUCTURAL PROTEIN NS2 INFLUENZA A VIRUS (STRAIN A/CHICKEN/ 14-93 GERMANY/N/49) PVNS2.sub.-- IADA2 NONSTRUCTURAL PROTEIN NS2 INFLUENZA A VIRUS (STRAIN A/CHICKEN/ 11-90 JAPAN/24) PVNS2.sub.-- IADE1 NONSTRUCTURAL PROTEIN NS2 INFLUENZA A VIRUS (STRAIN A/DUCK/ 14-79 ALBERTA/60/76) PVNS2.sub.-- IADU3 NONSTRUCTURAL PROTEIN NS2 INFLUENZA A VIRUS (STRAIN A/DUCK/ 11-90 ENGLAND/1/56) PVNS2.sub.-- IAFOM NONSTRUCTURAL PROTEIN NS2 INFLUENZA A VIRUS (STRAIN A/DUCK/ 11-90 UKRAINE/1/63) PVNS2.sub.-- IAFOW NONSTRUCTURAL PROTEIN NS2 INFLUENZA A VIRUS (STRAIN A/FORT 14-93 MONMOUTH/1/47) PVNS2.sub.-- IAFPR NONSTRUCTURAL PROTEIN NS2 INFLUENZA A VIRUS (STRAIN A/FORT 14-93 WARREN/1/50) PVNS2.sub.-- IALE2 NONSTRUCTURAL PROTEIN NS2 INFLUENZA A VIRUS (STRAIN A/FOWL PLAGUE 14-93 VIRUS/ROSTOCK PVNS2.sub.-- IALEN NONSTRUCTURAL PROTEIN NS2 INFLUENZA A VIRUS (STRAIN A/LENINGRAD/ 14-93 134/17/57) PVNS2.sub.-- IAMA6 NONSTRUCTURAL PROTEIN NS2 INFLUENZA A VIRUS (STRAIN A/LENINGRAD/ 14-93 54/1) PVNS2.sub.-- IAMA8 NONSTRUCTURAL PROTEIN NS2 INFLUENZA A VIRUS (STRAIN A/MALLARD/ 14-79 ALBERTA/88/76) PVNS2.sub.-- IAMAN NONSTRUCTURAL PROTEIN NS2 INFLUENZA A VIRUS (STRAIN A/MALLARD/ 14-79 ALBERTA/827/78) PVNS2.sub.-- IAMAO NONSTRUCTURAL PROTEIN NS2 INFLUENZA A VIRUS (STRAIN A/MALLARD/NEW 14-93 YORK/6750/78) PVNS2.sub.-- IAMYN NONSTRUCTURAL PROTEIN NS2 INFLUENZA A VIRUS (STRAIN A/MALLARD/NEW 14-93 YORK/6874/78) PVNS2.sub.-- IAPI0 NONSTRUCTURAL PROTEIN NS2 INFLUENZA A VIRUS (STRAIN A/MYNAH/ 11-90 HANEDA-THAI/76) PVNS2.sub.-- IAPI1 NONSTRUCTURAL PROTEIN NS2 INFLUENZA A VIRUS (STRAIN A/PINTAIL/ 14-93 ALBERTA/119/79) PVNS2.sub.-- IAPI2 NONSTRUCTURAL PROTEIN NS2 INFLUENZA A VIRUS (STRAIN A/PINTAIL/ 14-79 ALBERTA/121/79) PVNS2.sub.-- IAPUE NONSTRUCTURAL PROTEIN NS2 INFLUENZA A VIRUS (STRAIN A/PINTAIL/ 14-93 ALBERTA/268/78) PVNS2.sub.-- IATKB NONSTRUCTURAL PROTEIN NS2 INFLUENZA A VIRUS (STRAIN A/PUERTO 14-93 RICO/8/34) PVNS2.sub.-- IATKR NONSTRUCTURAL PROTEIN NS2 INFLUENZA A VIRUS (STRAIN A/TURKEY/ 14-79 BETHLEHEM-GLILIT/14 PVNS2.sub.-- IATRS NONSTRUCTURAL PROTEIN NS2 INFLUENZA A VIRUS (STRAIN A/TURKEY/ 14-79 OREGON/71 PVNS2.sub.-- IAUSS NONSTRUCTURAL PROTEIN NS2 INFLUENZA A VIRUS (STRAIN A/TERN/SOUTH 11-52 AFRICA/61) PVNS2.sub.-- INBLE NONSTRUCTURAL PROTEIN NS2 INFLUENZA A VIRUS (STRAIN A/USSR/90/77) 14-93 PVNS2.sub.-- INBYA NONSTRUCTURAL PROTEIN NS2 INFLUENZA A VIRUS (STRAIN B/LEE/40) 2-43 59-119 PVNS2.sub.-- INCJJ NONSTRUCTURAL PROTEIN NS2 INFLUENZA A VIRUS (STRAIN B/YAMAGATA/1/73 ) 2-43 59-119 PVNS2.sub.-- PVM NONSTRUCTURAL PROTEIN NS2 INFLUENZA A VIRUS (STRAIN C/JJ/50 57-98 PVNS3.sub.-- AHSV3 NONSTRUCTURAL PROTEIN 2 PNEUMONIA VIRUS OF MICE 70-104 PVNS3.sub.-- AHSV9 NONSTRUCTURAL PROTEIN NS3 AFRICAN HORSE SICKNESS VIRUS (SEROTYPE 3) 44-78 166-215 PVNS3.sub.-- BRD NONSTRUCTURAL PROTEIN NS3 AFRICAN HORSE SICKNESS VIRUS (SEROTYPE 9) 37-78 88-122 166-215 PVNS3.sub.-- CVPFS NONSTRUCTURAL PROTEIN NS3 BROADHAVEN VIRUS 26-98 102-147 PVNS4.sub.-- CVH22 NONSTRUCTURAL PROTEIN 3-1 PORCINE TRANSMISSIBLE GASTROENTERITIS 13-51 CORONAVIRUS S) PVNS4.sub.-- RSV NONSTRUCTURAL PROTEIN 4 HUMAN CORONAVIRUS (STRAIN 229E) 11-52 PVNS7.sub.-- CVCAE NONSTRUCTURAL PROTEIN NS4 RICE STRIPE VIRUS 2-40 PVNS7.sub.-- CVFE3 NONSTRUCTURAL PROTEIN 7 CANINE ENTERIC CORONAVIRUS (STRAIN K378) 11-47 PVNS7.sub.-- FIPV NONSTRUCTURAL PROTEIN 7 FELINE ENTERIC CORONAVIRUS (STRAIN 79-1683) 1-42 PVNSC.sub.-- CDVO NONSTRUCTURAL PROTEIN 7 FELINE INFECTIOUS PERITONITIS VIRUS 1-42 (STRAIN 79-1146) PVNSC.sub.-- MEASE NONSTRUCTURAL PROTEIN C CANINE DISTEMPER VIRUS (STRAIN 50-84 95-152 ONDERSTEPOO RT) PVNSC.sub.-- MEASI NONSTRUCTURAL PROTEIN C MEASLES VIRUS (STRAIN EDMONSTON) 43-84 PVNSC.sub.-- MEASY NONSTRUCTURAL PROTEIN C MEASLES VIRUS (STRAIN IP-3-CA) 43-84 PVNSC.sub.-- PIIHB NONSTRUCTURAL PROTEIN C MEASLES VIRUS (STRAIN YAMAGATA-1) 43-84 PVNSC.sub.-- PIIHC NONSTRUCTURAL PROTEIN C HUMAN PARAINFLUENZA 1 VIRUS (STRAIN C35) 133-167 PVNSC.sub.-- PIIHD NONSTRUCTURAL PROTEIN C HUMAN PARAINFLUENZA 1 VIRUS (STRAIN C39) 133-167 PVNSC.sub.-- PIIHE NONSTRUCTURAL PROTEIN C HUMAN PARAINFLUENZA 1 VIRUS (STRAIN C1-5/73) 133-167 PVNSC.sub.-- PI3H4 NONSTRUCTURAL PROTEIN C HUMAN PARAINFLUENZA 1 VIRUS (STRAIN C1-14/83) 40-75 133-167 PVNSC.sub.-- SEND6 NONSTRUCTURAL PROTEIN C HUMAN PARAINFLUENZA 3 VIRUS (STRAIN NIH 58-133 161-199 47885) PVNSC.sub.-- SENDH NONSTRUCTURAL PROTEIN C SENDAI VIRUS (STRAIN 6/94) 133-167 PVNSC.sub.-- SENDZ NONSTRUCTURAL PROTEIN C SENDAI VIRUS (STRAIN HARRIS) 133-167 PVNSM.sub.-- INSV NONSTRUCTURAL PROTEIN C SENDAI VIRUS (STRAIN Z) 133-167 PVNST.sub.-- BUNGE NONSTRUCTURAL PROTEIN NS-M IMPATIENS NECROTIC SPOT VIRUS (INSV) 44-102 262-296 PVNST.sub.-- BUNLY NONSTRUCTURAL PROTEIN NS-S BUNYAVIRUS GERMISTON 34-75 PVNST.sub.-- BUNLC NONSTRUCTURAL PROTEIN NS-S BUNYAVIRUS LA CROSSE (ISOLATE L74) 5-39 PVNST.sub.-- MAGV NONSTRUCTURAL PROTEIN NS-S BUNYAVIRUS LA CROSSE 5-39 PVNST.sub.-- TOSV NONSTRUCTURAL PROTEIN NS-S MAGUARI VIRUS 35-69 PVNST.sub.-- UUK NONSTRUCTURAL PROTEIN NS-S TOSCANA VIRUS (TOS) 144-183 PVNUA.sub.-- PRVKA NONSTRUCTURAL PROTEIN NS-S UUKUNIEMI VIRUS (UUK) 139-173 PVNUC.sub.-- DHVI1 PROBABLE NUCLEAR ANTIGEN PSEUDORABIES VIRUS (STRAIN KAPLAN)(PRV) 1134- 1175 PVNUC.sub.-- EBOV NUCLEOPROTEIN DHORI VIRUS (STRAIN INDIAN/1313/61)(DHO) 209-243 PVNUC.sub.-- IAANA NUCLEOPROTEIN EBOLA VIRUS 191-225 227-261 329-369 PVNUC.sub.-- IAANN NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/ANAS ACUTA/ 1-42 96-154 357-408 PRIMORJE/6 95/76) PVNUC.sub.-- IABRA NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/ANN ARBOR/6/60) 1-42 357-408 PVNUC.sub.- - IABUD NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/BRAZIL/11/78) 1-42 357-408 PVNUC.sub.-- IACAL NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/BUDGERIGAR/ 1-42 96-154 357-408 HOKKAIDO/1/77) PVNUC.sub.-- IACKG NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/CALIFORNIA/10/78) 1-42 357-409 PVNUC.sub.-- IACKP NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/CHICKEN/ 1-42 96-154 357-408 GERMANY/N/49) PVNUC.sub.-- IADAU NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/CHICKEN/ 1-42 96-154 357-408 PENNSYLVANIA/1/83) PVNUC.sub.-- IADBE NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/DUCK/AUSTRALIA/ 1-42 96-154 357-408 749/80) PVNUC.sub.-- IADCZ NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/DUCK/BEIJING/1/78) 1-42 96-154 357-408 PVNUC.sub.-- IADE1 NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/DUCK/ 1-42 96-154 360-408 CZECHOSLOVAKIA/56) PVNUC.sub.-- IADE2 NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/DUCK/ENGLAND/ 1-42 96-154 357-408 1/56) PVNUC.sub.-- IADHK NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/DUCK/ 1-42 96-154 357-408 ENGLAND/1/62) PVNUC.sub.-- IADM2 NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/DUCK/ 1-42 96-154 357-408 HONG KONG/7/75) PVNUC.sub.-- IADMA NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/DUCK/ 1-42 96-154 357-408 MEMPHIS/928/74 PVNUC.sub.-- IADNZ NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/DUCK/ 1-42 96-154 357-408 MANITOBA/1/53) PVNUC.sub.-- IADU2 NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/DUCK/NEW 1-42 96-154 357-408 ZEALAND/31/76) PVNUC.sub.-- IAEN5 NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/DUCK/ 96-154 357-408 UKRAINE/2/60) PVNUC.sub.-- IAFOM NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/ENGLAND/ 1-42 357-409 19/55) PVNUC.sub.-- IAFOW NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/FORT 1-42 357-409 MONMOUTH/1/47) PVNUC.sub.-- IAFPD NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/FORT 357-408 WARREN/1/50) PVNUC.sub.-- IAFPR NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/FOWL PLAGUE 1-42 96-154 357-408 VIRUS/DOBS ON/ PVNUC.sub.-- IAGRE NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/FOWL PLAGUE 1-42 96-154 360-408 VIRUS/ROST OCK PVNUC.sub.-- IAGU1 NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/GREY TEAL/ 1-42 113-154 357-408 AUSTRALIA/2/79) PVNUC.sub.-- IAGU2 NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/GULL/MARYLAND/ 1-42 357-408 5/77) PVNUC.sub.-- IAGU3 NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/GULL/MARYLAND/ 96-154 357-409 704/77) PVNUC.sub.-- IAGU4 NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/GULL/MARYLAND/ 1-42 96-154 357-409 1824/78) PVNUC.sub.-- IAGUA NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/GULL/MARYLAND/ 1-42 96-154 357-409 1815/79) PVNUC.sub.-- IAGUM NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/GULL/ASTRAKHAN/ 1-42 96-154 357-409 2227/84) PVNUC.sub.-- IAGUN NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/GULL/ 1-42 96-154 357-409 MASSACHUSETTS/26/80) PVNUC.sub.-- IAHIC NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/GULL/MINNESOTA/ 1-42 96-154 357-409 945/80) PVNUC.sub.-- IAHJI NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/HICKOX/40) 1-42 357-409 PVNUC.sub.-- IAHLO NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/EQUINE/ 1-42 96-154 357-408 JILLIN/1/89) PVNUC.sub.-- IAHMI NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/EQUINE/LONDON/ 1-42 96-154 357-408 1416/73) PVNUC.sub.-- IAHO1 NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/EQUINE/MIAMI/1/63) 1-42 96-154 PVNUC.sub.-- IAHO2 NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/HONG KONG/1/68) 1-42 357-409 PVNUC.sub. -- IAHPR NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/HONG KONG/5/83) 1-42 357-409 PVNUC.sub.-- IAHTE NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/EQUINE/PRAGUE/ 96-154 357-408 1/56) PVNUC.sub.-- IAKIE NUCLEOPROTEIN INFLUENZA A VIRUS 1-42 96-154 357-408 PVNUC.sub.-- IALEN NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/KIEV/59/79) 1-42 357-409 PVNUC.sub.-- IAMAA NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/LENINGRAD/54/1) 1-42 357-409 PVNUC.sub.-- IAMAN NUCLEOPROTEIN INFLUENZA A VIRUS 1-42 96-154 357-408 PVNUC.sub.-- IAMIN NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/MALLARD/NEW 1-42 96-154 357-408 YORK/6750/78) PVNUC.sub.-- IANEI NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/MINK/SWEDEN/84) 1-42 96-154 357-408 PVNUC.sub.-- IANT6 NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/NEW JERSEY/8/76) 1-42 96-154 357-408 PVNUC.sub.-- IAOHI NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/NT/60/68) 1-42 357-409 PVNUC.sub.-- IAPAR NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/OHIO/4/83) 1-42 357-409 PVNUC.sub.-- IAPUE NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/PARROT/ULSTER/ 1-42 96-154 357-408 73) PVNUC.sub.-- IARUD NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/PUERTO RICO/ 1-42 357-409 8/34) PVNUC.sub.-- IASE0 NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/RUDDY 1-42 96-154 357-408 TURNSTONE/NEW JERSE PVNUC.sub.-- IASH2 NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/SEAL/ 1-42 96-154 357-408 MASSACHUSETTS/1/80) PVNUC.sub.-- IASIN NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/SHEARWATER/ 1-42 357-408 AUSTRALIA/72) PVNUC.sub.-- IATEI NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/SINGAPORE/1/57) 1-42 357-409 PVNUC.sub.-- IATKN NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/TEAL/ 1-42 96-154 357-408 ICELAND/29/80) PVNUC.sub.-- IATKO NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/TURKEY/ 1-42 96-154 357-408 MINNESOTA/1661/81) PVNUC.sub.-- IATRS NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/TURKEY/ 1-42 96-154 357-408 ONTARIO/7732/66) PVNUC.sub.-- IATRT NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/TERN/SOUTH 1-42 96-154 360-408 AFRICA/61) PVNUC.sub.-- IATX7 NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/TERN/ 1-42 96-154 357-405 TURKMENIA/18/72) PVNUC.sub.-- IAUDO NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/TEXAS/1/77) 1-42 357-409 PVNUC.sub.-- IAUSS NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/UDORN/307/72) 1-42 357-409 PVNUC.sub.-- IAVI6 NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/USSR/90/77) 1-42 357-408 PVNUC.sub.-- IAWHN NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/VICTORIA/5/68) 357-408 PVNUC.sub.-- IAWHP NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/WHALE/ 1-42 96-154 357-409 MAINE/328/84) PVNUC.sub.-- IAWIL NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/WHALE/PACIFIC 1-42 96-154 357-408 OCEAN/19/76) PVNUC.sub.-- IAWIS NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/WILSON-SMITH/33) 1-42 357-409 PVNUC.sub.-- IAZ29 NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/WISCONSIN/3523/88) 1-42 96-154 357-408 PVNUC.sub.-- IAZ41 NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/SWINE/29/37) 1-42 96-154 357-408 PVNUC.sub.-- IAZCA NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/SWINE/41/49) 1-42 96-154 357-408 PVNUC.sub.-- IAZDA NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/SWINE/ 1-42 357-409 CAMBRIDGE/1/35) PVNUC.sub.-- IAZGE NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/SWINE/DANDONG/ 1-42 357-409 9/83) PVNUC.sub.-- IAZH1 NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/SWINE/GERMANY/ 1-42 96-154 357-408 2/81) PVNUC.sub.-- IAZH3 NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/SWINE/HONG KONG/ 1-42 357-409 6/76) PVNUC.sub.-- IAZH4 NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/SWINE/HONG KONG/ 1-42 96-154 357-408 126/82) PVNUC.sub.-- IAZI1 NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/SWINE/HONG 1-42 96-154 357-408 KONG/127/82) PVNUC.sub.-- IAZI2 NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/SWINE/IOWA/ 1-42 96-154 357-408 15/30) PVNUC.sub.-- IAZI3 NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/SWINE/IOWA/ 1-42 96-154 357-408 1976/31) PVNUC.sub.-- IAZJ1 NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/SWINE/46) 1-42 96-154 357-408 PVNUC.sub.-- IAZJ2 NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/SWINE/ITALY/ 1-42 96-154 357-408 437/76) PVNUC.sub.-- IAZJ3 NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/SWINE/ITALY/ 1-42 96-154 357-408 2/79) PVNUC.sub.-- IAZJ4 NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/SWINE/ITALY/ 1-42 96-154 357-408 141/81) PVNUC.sub.-- IAZJA NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/SWINE/ITALY/ 1-42 96-154 357-408 839/89) PVNUC.sub.-- IAZMA NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/SWINE/JAMESBURG/ 1-42 96-154 357-408 42) PVNUC.sub.-- IAZNE NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/SWINE/MAY/54) 1-42 96-154 357-408 PVNUC.sub.-- IAZOH NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/SWINE/ 1-42 96-154 357-408 NETHERLANDS/12/85) PVNUC.sub.-- IAZON NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/SWINE/OHIO/23/35) 1-42 96-154 357-408 PVNUC.sub.-- IAZTE NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/SWINE/ONTARIO/ 1-42 96-154 357-408 2/81) PVNUC.sub.-- IAZW1 NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/SWINE/ 1-42 96-154 357-408 TENNESSEE/24/77) PVNUC.sub.-- IAZW2 NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/SWINE/ 1-42 96-154 357-408 WISCONSIN/1/57) PVNUC.sub.-- INBAA NUCLEOPROTEIN INFLUENZA A VIRUS (STRAIN A/SWINE/ 1-42 96-154 357-408 WISCONSIN/1/61) PVNUC.sub.-- INBAC NUCLEOPROTEIN INFLUENZA B VIRUS (STRAIN B/ANN ARBOR/1/86) 75-142 480-514 PVNUC.sub.- - INBAD NUCLEOPROTEIN INFLUENZA B VIRUS (STRAIN B/ANN ARBOR/1/66 75-142 480-514 [COLD-ADAPTE PVNUC.sub.-- INBLE NUCLEOPROTEIN INFLUENZA B VIRUS (STRAIN B/ANN ARBOR/1/66 75-145 480-514 [WILD-TYPE]) PVNUC.sub.-- INBSI NUCLEOPROTEIN INFLUENZA B VIRUS (STRAIN B/LEE/40 75-146 480-514 PVNUC.sub.-- INCCA NUCLEOPROTEIN INFLUENZA B VIRUS (STRAIN B/SINGAPORE/222/ 75-142 480-514 79) PVNUC.sub.-- MABVM NUCLEOPROTEIN INFLUENZA C VIRUS (STRAIN C/CALIFORNIA/78) 92-203 406-447 PVNUC.sub.-- MABVP NUCLEOPROTEIN MARBURG VIRUS (STRAIN MUSOKE) 173-207 322-407 PVO01.sub.-- VACCC NUCLEOPROTEIN MARBURG VIRUS (STRAIN POPP) 173-207 322-407 PVO01.sub.-- VARV PROTEIN O1 VACCINIA VIRUS (STRAIN COPEHAGEN) 102-145 245-279 341-382 581-615 PVOR1.sub.-- FXMV PROTEIN O1 VARIOLA VIRUS 102-145 245-279 341-382 581-615 PVOR1.sub.-- NMV 152 KD PROTEIN FOXTAIL MOSAIC VIRUS 293-327 PVOR1.sub.-- PMV 186 KD PROTEIN NARCISSUS MOSAIC VIRUS (NMV) 1519- 1575 PVOR1.sub.-- PVMR 176 KD PROTEIN PAPAYA MOSAIC POTEXIVIRUS (PMV) 1-39 299-337 1474- 1532 PVOR1.sub.-- PVX 223 KD PROTEIN POTATO VIRUS M (STRAIN RUSSIAN) (PVM) 597-638 682-759 PVOR1.sub.-- PVXCP 165 KD PROTEIN POTATO VIRUS X (PVX) 516-550 PVOR1.sub.-- SMYEA 165 KD PROTEIN POTATO VIRUS X (STRAIN CP) (PVX) 510-547 PVOR1.sub.-- WCMVM 150 KD PROTEIN STRAWBERRY MILD YELLOW EDGE-ASSOCIATED 308-342 931-965 VIRUS (SMYE PVOR1.sub.-- WCMVO 147 KD PROTEIN WHITE CLOVER MOSAIC VIRUS (STRAIN M) (WCMV) 1240- 1289 PVO10.sub.-- NPVAC 147 KD PROTEIN WHITE CLOVER MOSAIC VIRUS (STRAIN O) (WCMV) 1240- 1289 PVO10.sub.-- NPVOP P10 PROTEIN AUTOGRAPHA CALIFORNICA NUCLEAR 7-41 POLYHEDROSIS VIRUS( PVO10.sub.-- RBSDV P10 PROTEIN ORGYIA PSEUDOTSUGATA MULTICAPSID 7-50 POLYHEDROSIS VIRUS PVO10.sub.-- RGDV PROTEIN S10 RICE BLACK STREAKED DWARF VIRUS (RBSDV) 339-382 395-429 506-556 PVO10.sub.-- WTV NONSTRUCTURAL PROTEIN PNS10 RICE GALL DWARF VIRUS (RGDV) 186-273 PVO11.sub.-- RDV NONSTRUCTURAL PROTEIN PNS10 WOUND TUMOR VIRUS (WTV) 220-254 PVO11.sub.-- WTV NONSTRUCTURAL PROTEIN PNS11 RICE DWARF (RDV) 25-80 273-314 PVO12.sub.-- RDV NONSTRUCTURAL PROTEIN PNS11 WOUND TUMOR VIRUS (WTV) 16-74 PVO12.sub.-- WTV NONSTRUCTURAL PROTEIN P11 RICE DWARF VIRUS (RDV)) 140-181 PVO18.sub.-- WTVNJ NONSTRUCTURAL PROTEIN PNS12 WOUND TUMOR VIRUS (WTV) 68-108 PVO19.sub.-- HSVEB NONSTRUCTURAL PROTEIN PNS12 WOUND TUMOR VIRUS (STRAIN NJ) 68-108 (WTV) PVO23.sub.-- HCMVA CAPSID ASSEMBLY AND DNA EQUINE HERPESVIRUS TYPE 1 (STRAIN AB4P)(EHV-1) 189-231 MATURATION PROTE PVO23.sub.-- HSV6U PROBABLE CAPSID PROTEIN VP23 HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 41-82 146-180 PVO24.sub.-- EBOV PROBABLE CAPSID PROTEIN VP23 HERPES SIMPLEX VIRUS (TYPE 6/STRAIN 47-81 UGANDA-1102) PVO26.sub.-- HSVEB MEMBRANE-ASSOCIATED EBOLA VIRUS 166-200 STRUCTURAL PROTEIN V PVO26.sub.-- HSVSA CAPSID PROTEIN VP26 EQUINE HERPESVIRUS TYPE 1 (STRAIN AB4P) (EHV-1) 36-77 PVO26.sub.-- NPVOP CAPSID PROTEIN VP26 HERPESVIRUS SAIMIRI (STRAIN 11) 41-78 PVO26.sub.-- VZVD P26 PROTEIN ORGYIA PSEUDOTSUGATA MULTICAPSID 118-159 POLYHEDROSIS VIRUS PVP2.sub.-- AHSV4 CAPSID PROTEIN VP26 VARICELLA-ZOSTER VIRUS (STRAIN DUMAS)(VZV) 47-81 PVP2.sub.-- BTV10 OUTER CAPSID PROTEIN VP2 AFRICAN HORSE SICKNESS VIRUS (SEROTYPE 136-188 270-304 410-465 614-662 684-720 976- 4/STRAIN VACCI 1056 PVP2.sub.-- BTV11 OUTER CAPSID PROTEIN VP2 BLUETONGUE VIRUS (SEROTYPE 10/ISOLATE USA) 168-225 PVP2.sub.-- BTV17 OUTER CAPSID PROTEIN VP2 BLUETONGUE VIRUS (SEROTYPE 11/ISOLATE USA) 77-111 559-593 PVP2.sub.-- BTV1S OUTER CAPSID PROTEIN VP2 BLUETONGUE VIRUS (SEROTYPE 17/ISOLATE USA) 77-111 168-209 PVP2.sub.-- EHDV1 OUTER CAPSID PROTEIN VP2 BLUETONGUE VIRUS (SEROTYPE 1/ISOLATE SOUTH 119-153 576-610 668-702 AFRICA) PVP2.sub.-- ROTBR OUTER CAPSID PROTEIN VP2 EPIZOOTIC HEMORRHAGIC DISEASE VIRUS 72-106 247-301 405-453 461-495 895-929 (SEROTYPE 1)(EHDV PVP2.sub.-- ROTBU RNA-BINDING PROTEIN VP2 BOVINE ROTAVIRUS (STRAIN RF) 2-94 482-516 523-557 607-655 675-754 PVP2.sub.-- ROTHW RNA-BINDING PROTEIN VP2 BOVINE ROTAVIRUS (STRAIN UK) 2-94 483-517 524-558 608-656 676-755 PVP2.sub.-- ROTPC RNA-BINDING PROTEIN VP2 HUMAN ROTAVIRUS (SEROTYPE 1/STRAIN WA) 17-97 492-526 533-567 617-658 685-764 PVP2.sub.-- ROTSI RNA-BINDING PROTEIN VP2 PORCINE ROTAVIRUS (GROUP C/STRAIN COWDEN) 1-50 52-99 194-228 515-551 599-643 705-746 PVP30.sub.-- ASFE7 RNA-BINDING PROTEIN VP2 SIMIAN II ROTAVIRUS (STRAIN SA11) 36-96 483-517 608-656 680-755 PVP31.sub.-- FRG3V PHOSPHOPROTEIN P30 AFRICAN SWINE FEVER VIRUS (STRAIN 29-89 E-75)(ASFV) PVP32.sub.-- ASFB7 EARLY 31 KD PROTEIN FROG VIRUS 3 (FV3) 227-261 PVP35.sub.-- EBOV PHOSPHOPROTEIN P32 AFRICAN SWINE FEVER VIRUS (STRAIN 29-89 BA71V)(ASFV) PVP35.sub.-- NPVAC POLYMERSASE COMPLEX PROTEIN EBOLA VIRUS 80-119 VP35 PVP35.sub.-- NPVBM EARLY 35 KD PROTEIN AUTOGRAPHA CALIFORNICA NUCLEAR 54-102 POLYHEDROSIS VIRUS( PVP35.sub.-- VACCC EARLY 35 KD PROTEIN BOMBYX MORI NUCLEAR POLYHEDROSIS 54-102 224-258 VIRUS (BMNPV) PVP35.sub.-- VACCP IMMUNODOMINANT ENVELOPE VACCINIA VIRUS (STRAIN COPEHAGEN) 140-181 PROTEIN P35 PVP35.sub.-- VACCV IMMUNODOMINANT ENVELOPE VACCINIA VIRUS (STRAIN L-IVP) 17-51 PROTEIN P35 PVP35.sub.-- VARV IMMUNODOMINANT ENVELOPE VACCINIA VIRUS (STRAIN WR) 140-181 PROTEIN P35 PVP3.sub.-- AHSV4 IMMUNODOMINANT ENVELOPE VARIOLA VIRUS 141-182 PROTEIN P35 PVP3.sub.-- BTV10 VP3 CORE PROTEIN AFRICAN HORSE SICKNESS VIRUS (SEROTYPE 4/ 173-214 240-274 667-704 STRAIN VACCI PVP3.sub.-- BTV17 VP3 CORE PROTEIN BLUETONGUE VIRUS (SEROTYPE 10/ISOLATE USA) 214-255 853-894 PVP3.sub.-- BTV1A VP3 CORE PROTEIN BLUETONGUE VIRUS (SEROTYPE 17/ISOLATE USA) 214-255 853-894 PVP3.sub.-- EHDV1 VP3 CORE PROTEIN BLUETONGUE VIRUS (SEROTYPE 1/ISOLATE 214-255 853-894 AUSTRALIA PVP3.sub.-- EHDVA VP3 CORE PROTEIN EPIZOOTIC HEMORRHAGIC DISEASE VIRUS 208-246 798-832 851-892 (SEROTYPE 1)(EHDV PVP3.sub.-- GFLV VP3 CORE PROTEIN EPIZOOTIC HEMORRHAGIC DISEASE VIRUS 208-246 735-770 798-832 851-892 PVP3.sub.-- RDV P3 PROTEIN GRAPEVINE FANLEAF VIRUS (GFLV) 96-133 PVP3.sub.-- ROTPC MAJOR 114 KD STRUCTURAL PROTEIN RICE DWARF VIRUS (RDV) 299-337 817-872 PVP3.sub.-- ROTSI INNER CORE PROTEIN VP3 PORCINE ROTAVIRUS (GROUP C/STRAIN COWDEN) 24-58 229-263 329-395 406-446 640-688 PVP40.sub.-- EBV INNER CORE PROTEIN VP3 SIMIAN II ROTAVIRUS(STRAIN SAII) 26-76 244-278 331-365 451-492 662-696 PVP40.sub.-- HSVII INNER CORE PROTEIN VP3 EPSTEIN-BARR VIRUS (STRAIN B95-8)(HUMAN 433-467 HERPESVIRUS 4) PVP40.sub.-- HSVEB CAPSID PROTEIN P40 HERPES SIMPLEX VIRUS (TYPE 1/STRAIN 17) 206-257 599-633 PVP40.sub.-- ILTVT CAPSID PROTEIN P40 EQUINE HERPESVIRUS TYPE 1 (STRAIN AB4P)(EHV-1) 180-245 PVP40.sub.-- SCMVC CAPSID PROTEIN P40 INFECTIOUS LARYNGOTRACHEITIS VIRUS (STRAIN 1-35 509-557 THORNE V88 PVP40.sub.-- VZVD CAPSID PROTEIN P40 SIMIAN CYTOMEGALOVIRUS (STRAIN COLBURN) 457-498 PVP41.sub.-- NPVAC CAPSID PROTEIN P40 VARICELLA-ZOSTER VIRUS (STRAIN DUMAS)(VZV) 167-246 486-522 PVP41.sub.-- ROTSI CAPSID PROTEIN P40 AUTOGRAPHA CALIFORNICA NUCLEAR 132-166 POLYHEDROSIS VIRUS ( PVP42.sub.-- ROTSI STRUCTURAL GLYCOPROTEIN GP41 SIMIAN II ROTAVIRUS (STRAIN SAII) 1-35 484-518 528-630 PVP4A.sub.-- VACCC OUTER CAPSID PROTEIN VP4 SIMIAN II ROTAVIRUS (STRAIN SAII) 1-35 237-518 531-646 PVP4A.sub.-- VACCV OUTER CAPSID PROTEIN VP4 VACCINIA VIRUS (STRAIN COPEHAGEN) 355-359 718-763 794-828 857-891 PVP4A.sub.-- VARV MAJOR CORE PROTEIN P4A VACCINIA VIRUS (STRAIN WR) 262-296 355-359 718-763 794-828 857-891 PRECURSOR PVP4B.sub.-- FOWPV MAJOR CORE PROTEIN P4A VARIOLA VIRUS 355-389 719-764 795-829 858-892 PRECURSOR PVP4B.sub.-- VACCC MAJOR CORE PROTEIN P4A FOWLPOX VIRUS 131-172 296-330 PRECURSOR PVP4B.sub.-- VACCV MAJOR CORE PROTEIN P4B VACCINIA VIRUS (STRAIN COPEHAGEN) 3-37 125-163 249-283 PRECURSOR PVP4B.sub.-- VARV MAJOR CORE PROTEIN P4B VACCINIA VIRUS (STRAIN WR) 3-37 125-163 249-283 PRECURSOR PVP4.sub.-- BTV10 MAJOR CORE PROTEIN P4B VARIOLA VIRUS 3-37 125-163 249-283 PRECURSOR PVP4.sub.-- BTV11 MAJOR CORE PROTEIN P4B BLUETONGUE VIRUS (SEROTYPE 10/ISOLATE USA) 579-617 619-643 PRECURSOR PVP4.sub.-- BTV13 VP4 CORE PROTEIN BLUETONGUE VIRUS (SEROTYPE 11/ISOLATE USA) 569-607 609-643 PVP4.sub.-- BTV2A VP4 CORE PROTEIN BLUETONGUE VIRUS (SEROTYPE 13/ISOLATE USA) 569-607 609-643 PVP4.sub.-- NCDV VP4 CORE PROTEIN BLUETONGUE VIRUS (SEROTYPE 2/ISOLATE USA) 569-607 609-643 PVP4.sub.-- RDV OUTER CAPSID PROTEIN VP4 NEBRASKA CALF DIARRHEA VIRUS (STRAIN 484-518 528-630 NCDV-LINCOLN) PVP4.sub.-- ROTB4 NONSTRUCTURAL PROTEIN PNS4 RICE DWARF VIRUS (RDV) 388-437 444-478 627-679 PVP4.sub.-- ROTBC OUTER CAPSID PROTEIN VP4 BOVINE ROTAVIRUS (SEROTYPE 6/STRAIN C486) 1-35 112-146 338-379 484-518 528-653 PVP4.sub.-- ROTBU OUTER CAPSID PROTEIN VP4 BOVINE ROTAVIRUS (STRAIN C486) 1-35 484-518 528-630 PVP4.sub.-- ROTEH OUTER CAPSID PROTEIN VP4 BOVINE ROTAVIRUS (STRAIN UK) 1-35 112-146 338-379 484-518 538-653 PVP4.sub.-- ROTGI OUTER CAPSID PROTEIN VP4 EQUINE ROTAVIRUS (STRAIN H-2) 1-35 112-146 227-274 345-379 484-518 528-653 PVP4.sub.-- ROTHI OUTER CAPSID PROTEIN VP4 ROTAVIRUS (GROUP B/STRAIN IDIR) 117-151 476-519 PVP4.sub.-- ROTHS OUTER CAPSID PROTEIN VP4 HUMAN ROTAVIRUS (SEROTYPE 1/STRAIN 1076 1-35 236-273 337-378 483-517 530-645 PVP4.sub.-- ROTH6 OUTER CAPSID PROTEIN VP4 HUMAN ROTAVIRUS (SEROTYPE 2/STRAIN RV-5) 1-35 236-273 337-378 483-517 527-652 PVP4.sub.-- ROTHD OUTER CAPSID PROTEIN VP4 HUMAN ROTAVIRUS (SEROTYPE 1/STRAIN 69M) 1-35 112-146 237-274 338-379 484-518 531-646 PVP4.sub.-- ROTHJ OUTER CAPSID PROTEIN VP4 HUMAN ROTAVIRUS (SEROTYPE 2/STRAIN DS1) 1-35 236-273 337-378 483-517 527-652 PVP4.sub.-- ROTHK OUTER CAPSID PROTEIN VP4 HUMAN ROTAVIRUS (STRAIN K8) 1-35 237-274 345-379 484-518 528-588 PVP4.sub.-- ROTHL OUTER CAPSID PROTEIN VP4 HUMAN ROTAVIRUS (STRAIN KU) 1-35 337-378 483-517 527-652 PVP4.sub.-- ROTHM OUTER CAPSID PROTEIN VP4 HUMAN ROTAVIRUS (STRAIN L26) 1-35 236-273 337-378 483-517 527-652 PVP4.sub.-- ROTHN OUTER CAPSID PROTEIN VP4 HUMAN ROTAVIRUS (SEROTYPE 1/STRAIN M37) 1-35 337-378 483-517 530-645 PVP4.sub.-- ROTHP OUTER CAPSID PROTEIN VP4 HUMAN ROTAVIRUS (SEROTYPE 3/STRAIN MCN13) 1-35 237-274 338-379 484-518 531-645 PVP4.sub.-- ROTHR OUTER CAPSID PROTEIN VP4 HUMAN ROTAVIRUS (SEROTYPE 3/STRAIN P) 1-35 236-273 337-378 483-517 527-652 PVP4.sub.-- ROTHT OUTER CAPSID PROTEIN VP4 HUMAN ROTAVIRUS (SEROTYPE 3/STRAIN RRV) 1-38 91-146 227-274 PVP4.sub.-- ROTHV OUTER CAPSID PROTEIN VP4 HUMAN ROTAVIRUS (SEROTYPE 4/STRAIN 1-35 236-273 337-378 483-517 530-644 ST. THOMAS 3) PVP4.sub.-- ROTHW OUTER CAPSID PROTEIN VP4 HUMAN ROTAVIRUS (SEROTYPE 4/STRAIN VA70 1-35 237-273 337-378 483-517 527-652 PVP4.sub.-- ROTP5 OUTER CAPSID PROTEIN VP4 HUMAN ROTAVIRUS (SEROTYPE 1/STRAIN WA) 1-35 237-273 344-378 483-517 527-652 PVP4.sub.-- ROTPC OUTER CAPSID PROTEIN VP4 PORCINE ROTAVIRUS (SEROTYPE 5/STRAIN OSU) 112-146 484-518 528-629 PVP4.sub.-- ROTPG OUTER CAPSID PROTEIN VP4 PORCINE ROTAVIRUS (GROUP C/STRAIN COWDEN) 6-40 127-161 241-278 293-334 580-614 PVP4.sub.-- ROTPY OUTER CAPSID PROTEIN VP4 PORCINE ROTAVIRUS (STRAIN GOTTFRIED) 1-35 236-273 337-378 483-517 530-564 569-639 PVP4.sub.-- ROTRH OUTER CAPSID PROTEIN VP4 PORCINE ROTAVIRUS (STRAIN YM) 1-35 112-146 237-274 484-518 528-629 PVP4.sub.-- ROTSF OUTER CAPSID PROTEIN VP4 RHESUS ROTAVIRUS 1-38 112-146 237-274 338-379 484-522 531-646 PVP4.sub.-- ROTSS OUTER CAPSID PROTEIN VP4 SIMIAN II ROTAVIRUS (STRAIN SA11-FEM) 1-35 484-518 528-630 PVP4.sub.-- WTV DE OUTER CAPSID PROTEIN VP4 SIMIAN II ROTAVIRUS (STRAIN SA11-SEM) 1-35 237-274 345-379 484-518 531-646 PVP5.sub.-- ASHV4 NONSTRUCTURAL PROTEIN PNS4 WOUND TUMOR VIRUS (WTV) 28-62 565-621 PVP5.sub.-- BRD OUTER CAPSID PROTEIN VP4 AFRICAN HORSE SICKNESS VIRUS 7-58 113-229 (SEROTYPE 4/STRAIN VACCI PVP5.sub.-- BTV10 OUTER CAPSID PROTEIN VP4 BROADHAVEN VIRUS (BRD) 45-86 98-226 PVP5.sub.-- BTV11 OUTER CAPSID PROTEIN VP5 BLUETONGUE VIRUS (SEROTYPE 10/ISOLATE USA) 14-58 92-150 154-222 404-438 PVP5.sub.-- BTV13 OUTER CAPSID PROTEIN VP5 BLUETONGUE VIRUS (SEROTYPE 11/ISOLATE USA) 14-58 92-150 154-222 404-445 PVP5.sub.-- BTV1A OUTER CAPSID PROTEIN VP5 BLUETONGUE VIRUS (SEROTYPE 13/ISOLATE USA) 14-58 154-222 404-438 PVP5.sub.-- BTV1S OUTER CAPSID PROTEIN VP5 BLUETONGUE VIRUS (SEROTYPE 11/ISOLATE 14-58 92-143 148-222 404-448 AUSTRALIA) PVP5.sub.-- BTV2A OUTER CAPSID PROTEIN VP5 BLUETONGUE VIRUS (SEROTYPE 11/ISOLATE 14-58 92-143 148-222 404-438 SOUTH AFRICA) PVP5.sub.-- EHDV1 OUTER CAPSID PROTEIN VP5 BLUETONGUE VIRUS (SEROTYPE 2/ISOLATE USA) 14-58 92-222 404-438 PVP5.sub.-- RDV OUTER CAPSID PROTEIN VP5 EPIZOOTIC HEMORRHAGIC DISEASE VIRUS 24-58 92-126 163-233 291-325 399-433 (SEROTYPE 1)(EHDV PVP5.sub.-- WTV OUTER COAT PROTEIN P5 RICE DWARF VIRUS (RDV) 38-86 95-136 550-594 PVP5.sub.-- BTV10 OUTER COAT PROTEIN P5 WOUND TUMOR VIRUS (WTV) 434-503 4547-581 751-798 PVP61.sub.-- MRDV VP6 PROTEIN BLUETONGUE VIRUS (SEROTYPE 10/ISOLATE USA) 163-215 PVP61.sub.-- NPVAC PROBABLE NONSTRUCTURAL 41.0 KD MAIZE ROUGH DWARF VIRUS (MRDV) 128-202 PROTEIN PVP62.sub.-- BTV10 61 KD PROTEIN AUTOGRAPHA CALIFORNICA NUCLEAR 29-96 351-386 POLYHEDROSIS VIRUS ( PVP64.sub.-- NPVOP VP6 PROTEIN BLUETONGUE VIRUS (SEROTYPE 10/ISOLATE USA) 47-88 159-207 214-251 PVP67.sub.-- NPVAC MAJOR ENVELOPE GLYCOPROTEIN ORGYIA PSEUDOTSUGATA MULTICAPSID 396-361 431-479 PRECURSOR POLYHEDROSIS VIRUS PVP67.sub.-- NPVGM MAJOR ENVELOPE GLYCOPROTEIN AUTOGRAPHA CALIFORNICA NUCLEAR 44-78 289-364 443-477 PRECURSOR POLYHEDROSIS VIRUS ( PVP6.sub.-- BTV11 MAJOR ENVELOPE GLYCOPROTEIN GALLERIA MELLONELLA NUCLEAR 206-281 POLYHEDROSIS VIRUS (CMN PVP6.sub.-- BTV13 VP6 PROTEIN BLUETONGUE VIRUS (SEROTYPE 11/ISOLATE USA) 159-211 PVP6.sub.-- BTV17 VP6 PROTEIN BLUETONGUE VIRUS (SEROTYPE 13/ISOLATE USA) 159-211 PVP6.sub.-- BTV15 VP6 PROTEIN BLUETONGUE VIRUS (SEROTYPE 17/ISOLATE USA) 68-102 159-211 PVP6.sub.-- BTV2A VP6 PROTEIN BLUETONGUE VIRUS (SEROTYPE 1/ISOLATE 12-78 163-211 SOUTH AFRICA) PVP6.sub.-- RDV VP6 PROTEIN BLUETONGUE VIRUS (SEROTYPE 2/ISOLATE USA) 44-78 135-187 PVP6.sub.-- WTV STRUCTURAL PROTEIN P6 RICE DWARF VIRUS (RDV) 150-191 296-344 360-401 PVP6.sub.-- WTVNH STRUCTURAL PROTEIN P6 WOUND TUMOR VIRUS (WTV) 144-78 286-334 400-434 PVP74.sub.-- NPVAC STRUCTURAL PROTEIN P6 WOUND TUMOR VIRUS (STRAIN NJ)(WTV) 144-178 286-334 PVP74.sub.-- NPVCF P74 PROTEIN AUTOGRAPHA CALIFORNICA NUCLEAR 387-456 POLYHEDROSIS VIRUS ( PVP75.sub.-- HSVSA P74 PROTEIN CHORISTONEURA FUMIFERANA NUCLEAR 385-453 POLYHEDROSIS VIRU PVP79.sub.-- NPVAC PROBABLE MEMBRANE ANTIGEN 75 HERPESVIRUS SAIMIRI (STRAIN 11) 50-99 163-211 931-984 PVP7.sub.-- BTV10 79 KD PROTEIN AUTOGRAPHA CALIFORNICA NUCLEAR 44-78 363-397 406-440 POLYHEDROSIS VIRUS ( PVP7.sub.-- BTV13 VP7 CORE PROTEIN BLUETONGUE VIRUS (SEROTYPE 10/ISOLATE USA) 184-228 PVP7.sub.-- BTV17 VP7 CORE PROTEIN BLUETONGUE VIRUS (SEROTYPE 11/ISOLATE USA) 201-235 PVP7.sub.-- BTV1A VP7 CORE PROTEIN BLUETONGUE VIRUS (SEROTYPE 13/ISOLATE USA) 184-228 PVP7.sub.-- BTV1S VP7 CORE PROTEIN BLUETONGUE VIRUS (SEROTYPE 17/ISOLATE 184-235 AUSTRALIA) PVP7.sub.-- BTV2A VP7 CORE PROTEIN BLUETONGUE VIRUS (SEROTYPE 1/ISOLATE 184-228 SOUTH AFRICA) PVP7.sub.-- EHDV1 VP7 CORE PROTEIN BLUETONGUE VIRUS (SEROTYPE 2/ISOLATE USA) 184-228 PVP7.sub.-- RDV VP7 CORE PROTEIN EPIZOOTIC HEMORRHAGIC DISEASE VIRUS 16-50 134-178 (SEROTYPE 1)(EHDV PVP7.sub.-- WTV NONSTRUCTURAL PROTEIN PN57 RICE DWARF VIRUS (RDV) 47-95 172-255 PVP80.sub.-- NPVAC NONSTRUCTURAL PROTEIN PN57 WOUND TUMOR VIRUS (WTV) 47-84 195-243 458-495 PVP87.sub.-- NPVOP CAPSID PROTEIN P80 AUTOGRAPHA CALIFORNICA NUCLEAR 7-51 99-142 156-204 221-298 POLYHEDROSIS VIRUS ( PVP8.sub.-- BTV10 CAPSID PROTEIN P87 ORGYIA PSEUDOTSUGATA MULTICAPSID 80-162 410-451 POLYHEDROSIS VIRUS PVP8.sub.-- BTV11 NONSTRUCTURAL PROTEIN P8 BLUETONGUE VIRUS (SEROTYPE 10/ISOLATE USA) 54-102 185-219 PVP8.sub.-- BTV13 NONSTRUCTURAL PROTEIN P8 BLUETONGUE VIRUS (SEROTYPE 11/ISOLATE USA) 54-102 185-219 PVP8.sub.-- BTV17 NONSTRUCTURAL PROTEIN P8 BLUETONGUE VIRUS (SEROTYPE 13/ISOLATE USA) 54-102 185-219 PVP8.sub.-- BTV1A NONSTRUCTURAL PROTEIN P8 BLUETONGUE VIRUS (SEROTYPE 17/ISOLATE USA) 54-102 185-219 PVP8.sub.-- BTV1S NONSTRUCTURAL PROTEIN P8 BLUETONGUE VIRUS (SEROTYPE 1/ISOLATE 54-102 185-219 AUSTRALIA) PVP8.sub.-- BTV2A NONSTRUCTURAL PROTEIN P8 BLUETONGUE VIRUS (SEROTYPE 1/ISOLATE 54-102 185-219 SOUTH AFRICA) PVP8.sub.-- FOWPV NONSTRUCTURAL PROTEIN P8 BLUETONGUE VIRUS (SEROTYPE 2/ISOLATE USA) 54-102 185-219 PVP9.sub.-- RDV STRUCTURAL PROTEIN VP8 FOWLPOX VIRUS 193-245 PRECURSOR PVP9.sub.-- WTV NONSTRUCTURAL PROTEIN PN59 RICE DWARF VIRUS (RDV) 13-47 186-226 PVP9.sub.-- WTVNJ STRUCTURAL PROTEIN P9 WOUND TUMOR VIRUS (WTV) 140-212 PVPG.sub.-- BYDV1 STRUCTURAL PROTEIN P9 WOUND TUMOR VIRUS (STRAIN NJ)(WTV) 140-212 PVPHE.sub.-- NPVAC PUTATIVE GENOME-LINKED BARLEY YELLOW DWARF VIRUS (ISOLATE 25-59 PROTEIN PRECURSOR MAV-PSI)(BYDV) PVPHE.sub.-- NPVOP 29 KD POLYHEDRAL ENVELOPE AUTOGRAPHA CALIFORNICA NUCLEAR 146-223 PROTEIN POLYHEDROSIS VIRUS ( PVPR.sub.-- SIVML 32 KD POLYHEDRAL ENVELOPE ORGYIA PSEUDOTSUGATA MULTICAPSID 131-201 206-265 PROTEIN POLYHEDROSIS VIRUS PVPU.sub.-- HVIA2 VPR PROTEIN SIMIAN IMMUNODEFICIENCY VIRUS (K78 ISOLATE) 78-115 (SIV-MAC) PVPU.sub.-- HVIB1 VPR PROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE I 1-38 (ARV2/SF2 ISOLATE PVPU.sub.-- HVIB8 VPR PROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE I 4-72 (BH10 ISOLATE)(H) PVPU.sub.-- HVIBN VPR PROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE I 5-72 (BH8 ISOLATE)(HIV PVPU.sub.-- HVIBR VPR PROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE I 4-59 (BRAIN ISOLATE)(H PVPU.sub.-- HVIC4 VPR PROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE I 4-72 (BRU ISOLATE)(HIV PVPU.sub.-- HVIEL VPR PROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE I 3-40 (CDC-451 ISOLATE) PVPU.sub.-- HVIH2 VPR PROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE I 6-40 (ELI ISOLATE)(HIV- PVPU.sub.-- HVIJ3 VPR PROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE I 5-72 (HXB2 ISOLATE)(HI PVPU.sub.-- HVIJR VPR PROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE I 2-50 (JH3 ISOLATE)(HIV- PVPU.sub.-- HVIMA VPR PROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE I 4-59 (JRCSF ISOLATE)(H PVPU.sub.-- HVIND VPR PROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE I 5-50 (MAL ISOLATE)(HI PVPU.sub.-- HVIPV VPR PROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE I 4-40 (NKD ISOLATE)(HI PVPU.sub.-- HVIRH VPR PROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE I 4-72 (PV22 ISOLATE)(HI PVPU.sub.-- HVIS1 VPR PROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE I 1-39 (RF/HAT ISOLATE)( PVPU.sub.-- HVIZ2 VPR PROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE I 4-59 (SF162 ISOLATE)(HI PVPU.sub.-- SIVCZ VPR PROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE I 6-40 (Z2/CSC-Z34 ISOLAT PVPX.sub.-- HV2D2 VPR PROTEIN CHIMPANZEE IMMUNODEFICIENCY VIRUS 21-78 (SIV(CPZ)) (CIV) PVRNA.sub.-- BSMV VPR PROTEIN HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 42-85 (ISOLATE D205.7)(H PVS05.sub.-- ROTSI ALPHA-A PROTEIN BARELY STRIPE MOSAIC VIRUS (BSMV) 40-74 857-989 PVS06.sub.-- ROTBS NONSTRUCTURAL PROTEIN NCVP2 SIMIAN II ROTAVIRUS (STRAIN SA11) 248-287 PVS06.sub.-- ROTGA VP6 PROTEIN BOVINE ROTAVIRUS (GROUP C/STRAIN SHINTOKU) 6-44 PVS06.sub .-- ROTGI VP6 PROTEIN ROTAVIRUS (GROUP B/STRAIN ADRV)(ADULT 69-144 DIARRHEA ROT PVS06.sub.-- ROTHC VP6 PROTEIN ROTAVIRUS (GROUP B/STRAIN IDIR) 24-58 64-103 PVS06.sub.-- ROTPC VP6 PROTEIN HUMAN ROTAVIRUS (GROUP C/STRAIN BRISTOL) 9-43 PVS07.sub.-- ROTBJ VP6 PROTEIN PORCINE ROTAVIRUS (GROUP C/STRAIN COWDEN) 9-43 PVS07.sub.-- ROTBU GLYCOPROTEIN VP7 BOVINE ROTAVIRUS (STRAIN KN-4) 2-36 282-320 PVS07.sub.-- ROTP5 NONSTRUCTURAL PROTEIN NCVP3 BOVINE ROTAVIRUS (STRAIN UK) 88-153 199-236 PVS07.sub.- - ROTSI NONSTRUCTURAL PROTEIN NCVP3 PORCINE ROTAVIRUS (SEROTYPE 5/STRAIN OSU) 88-162 202-236 PVS08.sub.-- ROTBU NONSTRUCTURAL PROTEIN NCVP3 SIMIAN II ROTAVIRUS (STRAIN SA11) 88-153 199-236 PVS08.sub.-- ROTSI NONSTRUCTURAL PROTEIN NS2/VP9 BOVINE ROTAVIRUS (STRAIN UK 2-70 75-119 160-226 PVS09.sub.-- ROTB4 NONSTRUCTURAL PROTEIN NCVP4 SIMIAN II ROTAVIRUS (STRAIN SA11) 2-46 144-212 217-255 PVS09.sub.-- ROTB5 GLYCOPROTEIN VP7 BOVINE ROTAVIRUS (SEROTYPE 6/STRAIN B641) 2-54 282-320 PVS09.sub.-- ROTB6 GLYCOPROTEIN VP7 BOVINE ROTAVIRUS (STRAIN A5) 2-43 282-320 PVS09.sub.-- ROTBA GLYCOPROTEIN VP7 BOVINE ROTAVIRUS (SEROTYPE 6/STRAIN 61A) 2-54 282-320 PVS09.sub.-- ROTBB GLYCOPROTEIN VP7 BOVINE ROTAVIRUS (STRAIN A44) 2-54 282-320 PVS09.sub.-- ROTBK GLYCOPROTEIN VP7 BOVINE ROTAVIRUS (SEROTYPE 10/STRAIN B223) 2-54 282-320 PVS09.sub.-- ROTBN GLYCOPROTEIN VP7 BOVINE ROTAVIRUS (STRAIN KK3 2-54 282-320 PVS09.sub.-- ROTBT GLYCOPROTEIN VP7 BOVINE ROTAVIRUS (STRAIN NCDV) 2-54 282-320 PVS09.sub.-- ROTBU GLYCOPROTEIN VP7 BOVINE ROTAVIRUS (STRAIN (SEROTYPE 1/ 2-43 282-320 STRAIN T449) PVS09.sub.-- ROTC7 GLYCOPROTEIN VP7 BOVINE ROTAVIRUS (STRAIN (STRAIN UK) 2-54 282-320 PVS09.sub.-- ROTEL GLYCOPROTEIN VP7 CHICKEN ROTAVIRUS A (SEROTYPE 7/STRAIN CH2) 285-326 PVS09.sub.-- ROTGA GLYCOPROTEIN VP7 EQUINE ROTAVIRUS (STRAIN L338) 282-320 PVS09.sub.-- ROTG1 GLYCOPROTEIN VP7 PRECURSOR ROTAVIRUS (GROUP B/STRAIN ADRV)(ADULT 43-77 DIARRHEA ROTA PVS09.sub.-- ROTH4 GLYCOPROTEIN VP7 PRECURSOR ROTAVIRUS (GROUP B/STRAIN IDIR) 45-79 PVS09.sub.-- ROTH9 GLYCOPROTEIN VP7 HUMAN ROTAVIRUS (SEROTYPE 4/STRAIN RV-4) 2-43 282-320 PVS09.sub.-- ROTHA GLYCOPROTEIN VP7 HUMAN ROTAVIRUS (SEROTYPE G/STRAIN RK9) 282-320 PVS09.sub.-- ROTHB GLYCOPROTEIN VP7 HUMAN ROTAVIRUS (SEROTYPE 2/STRAIN HU5) 282-320 PVS09.sub.-- ROTHD GLYCOPROTEIN VP7 HUMAN ROTAVIRUS (SEROTYPE G/STRAIN B37) 2-43 282-320 PVS09.sub.-- ROTHH GLYCOPROTEIN VP7 HUMAN ROTAVIRUS (SEROTYPE 2/STRAIN DS1) 282-320 PVS09.sub.-- ROTHL GLYCOPROTEIN VP7 HUMAN ROTAVIRUS (SEROTYPE 2/STRAIN HN126) 282-320 PVS09.sub.-- ROTHM GLYCOPROTEIN VP7 HUMAN ROTAVIRUS (STRAIN L26) 1-35 282-320 PVS09.sub.-- ROTHO GLYCOPROTEIN VP7 HUMAN ROTAVIRUS (SEROTYPE 1/STRAIN M37) 2-43 282-320 PVS09.sub.-- ROTHP GLYCOPROTEIN VP7 HUMAN ROTAVIRUS (SEROTYPE 1/STRAIN MO 2-43 282-320 AND STRAIN D) PVS09.sub.-- ROTHR GLYCOPROTEIN VP7 HUMAN ROTAVIRUS (SEROTYPE 3/STRAIN P) 282-320 PVS09.sub.-- ROTHS GLYCOPROTEIN VP7 HUMAN ROTAVIRUS (SEROTYPE 3/STRAIN RRV) 282-320 PVS09.sub.-- ROTHT GLYCOPROTEIN VP7 HUMAN ROTAVIRUS (SEROTYPE 2/STRAIN S2) 282-320 PVS09.sub.-- ROTHV GLYCOPROTEIN VP7 HUMAN ROTAVIRUS (SEROTYPE 4/STRAIN 18-56 208-242 282-320 ST. THOMAS 3) PVS09.sub.-- ROTHW GLYCOPROTEIN VP7 HUMAN ROTAVIRUS (SEROTYPE 4/STRAIN VA70) 18-56 208-242 282-320 PVS09.sub.-- ROTP2 GLYCOPROTEIN VP7 HUMAN ROTAVIRUS (SEROTYPE 1/STRAIN WA) 2-43 282-320 PVS09.sub.-- ROTP3 GLYCOPROTEIN VP7 PORCINE ROTAVIRUS (SEROTYPE 3/STRAIN AT/76) 282-320 PVS09.sub.-- ROTP4 GLYCOPROTEIN VP7 PORCINE ROTAVIRUS (SEROTYPE 3/STRAIN CRW-8) 282-320 PVS09.sub.-- ROTP5 GLYCOPROTEIN VP7 PORCINE ROTAVIRUS (SEROTYPE 4/STRAIN OSU) 2-56 208-242 282-320 PVS09.sub.-- ROTP6 GLYCOPROTEIN VP7 PORCINE ROTAVIRUS (SEROTYPE 5/STRAIN OSU) 282-320 PVS09.sub.-- ROTPB GLYCOPROTEIN VP7 PORCINE ROTAVIRUS (SEROTYPE 5/STRAIN TFR-41) 282-320 PVS09.sub.-- ROTPK GLYCOPROTEIN VP7 PORCINE ROTAVIRUS (SEROTYPE 4/STRAIN BEN-144) 18-56 208-242 282-320 PVS09.sub.-- ROTPM GLYCOPROTEIN VP7 PORCINE ROTAVIRUS (STRAIN K) 18-56 282-320 PVS09.sub.-- ROTPY GLYCOPROTEIN VP7 PORCINE ROTAVIRUS (SEROTYPE 4/STRAIN BMI-I) 18-56 208-242 282-320 PVS09.sub.-- ROTRH GLYCOPROTEIN VP7 PORCINE ROTAVIRUS (STRAIN YM) 1-35 282-320 PVS09.sub.-- ROTSI GLYCOPROTEIN VP7 RHESUS ROTAVIRUS 282-320 PVS10.sub.-- ROTBN GLYCOPROTEIN VP7 SIMIAN II ROTAVIRUS (STRAIN SA11) 282-320 PVS10.sub.-- ROTBS NONSTRUCTURAL GLYCOPROTEIN BOVINE ROTAVIRUS (STRAIN NCDV) 73-161 NCVP5 PVS10.sub.-- ROTBU MINOR OUTER CAPSID PROTEIN BOVINE ROTAVIRUS (STRAIN GROUP C/STRAIN 17-58 SHINTOKU) PVS10.sub.-- ROTH2 NONSTRUCTURAL GLYCOPROTEIN BOVINE ROTAVIRUS (STRAIN UK) 73-161 NCVP5 PVS10.sub.-- ROTH7 NONSTRUCTURAL GLYCOPROTEIN HUMAN ROTAVIRUS (STRAIN A28) 73-162 NCVP5 PVS10.sub.-- ROTH8 NONSTRUCTURAL GLYCOPROTEIN HUMAN ROTAVIRUS (STRAIN A64/CLONE 2) 73-162 NCVP5 PVS10.sub.-- ROTHC NONSTRUCTURAL GLYCOPROTEIN HUMAN ROTAVIRUS (STRAIN A64/CLONE 6) 73-162 NCVP5 PVS10.sub.-- ROTHW MINOR OUTER CAPSID PROTEIN HUMAN ROTAVIRUS (STRAIN GROUP C/ 121-158 STRAIN BRISTOL) PVS10.sub.-- ROTSI NONSTRUCTURAL GLYCOPROTEIN HUMAN ROTAVIRUS (SEROTYPE 1/STRAIN WA) 73-136 NCVP5 PVS11.sub.-- ROTGA NONSTRUCTURAL GLYCOPROTEIN SIMIAN II ROTAVIRUS (STRAIN SA11) 73-162 NCVP5 PVS11.sub.-- ROTGI NONSTRUCTURAL PROTEIN ROTAVIRUS (GROUP B/STRAIN ADRV)(ADULT 24-65 96-130 DIARRHEA ROTA PVS11.sub.-- ROTH5 NONSTRUCTURAL PROTEIN ROTAVIRUS (GROUP B/STRAIN IDIR) 9-68 PVS11.sub.-- ROTH6 MINOR OUTER CAPSID PROTEIN HUMAN ROTAVIRUS (SEROTYPE 2/STRAIN RV-5) 100-145 PVS11.sub.-- ROTHB MINOR OUTER CAPSID PROTEIN HUMAN ROTAVIRUS (SEROTYPE 1/STRAIN 69M) 107-144 PVS11.sub.-- ROTHD MINOR OUTER CAPSID PROTEIN HUMAN ROTAVIRUS (SEROTYPE G/STRAIN B37) 107-144 PVS11.sub.-- ROTHW MINOR OUTER CAPSID PROTEIN HUMAN ROTAVIRUS (SEROTYPE 2/STRAIN DSI) 111-145 PVS11.sub.-- ROTSI MINOR OUTER CAPSID PROTEIN HUMAN ROTAVIRUS (SEROTYPE 1/STRAIN WA) 111-145 PVS48.sub.-- TBRVC MINOR OUTER CAPSID PROTEIN SIMIAN II ROTAVIRUS (STRAIN SA11) 111-145 PVSH.sub.-- MUMP1 SATELLITE RNA 48 KD PROTEIN TOMATO BLACK RING VIRUS (STRAIN C)(TBV) 217-165 PVSH.sub.-- MUMP2 SMALL HYDROPHOBIC PROTEIN MUMPS VIRUS (STRAIN SBL-1), AND MUMPS 9-46 VIRUS (STRAIN SBL PVSH.sub.-- MUMP4 SMALL HYDROPHOBIC PROTEIN MUMPS VIRUS (STRAIN EDINGBURGH 2), AND 13-47 STRAIN EDINGB PVSH.sub.-- MUMPA SMALL HYDROPHOBIC PROTEIN MUMPS VIRUS (STRAIN EDINGBURGH 4) 13-47 PVSH.sub.-- MUMPB SMALL HYDROPHOBIC PROTEIN MUMPS VIRUS (STRAIN MATSUYAMA) 13-51 PVSH.sub.-- MUMPE SMALL HYDROPHOBIC PROTEIN MUMPS VIRUS (STRAIN BELFAST) 13-52 PVSH.sub.-- MUMPJ SMALL HYDROPHOBIC PROTEIN MUMPS VIRUS (STRAIN ENDERS) 9-46 PVSH.sub.-- MUMPK SMALL HYDROPHOBIC PROTEIN MUMPS VIRUS (STRAIN JERYL-LYNN) 9-46 PVSH.sub.-- MUMPL SMALL HYDROPHOBIC PROTEIN MUMPS VIRUS (STRAIN KILHAM) 9-51 PVSH.sub.-- MUMPM SMALL HYDROPHOBIC PROTEIN MUMPS VIRUS (STRAIN BRISTOL I) 13-55 PVSH.sub.-- MUMPT SMALL HYDROPHOBIC PROTEIN MUMPS VIRUS (STRAIN MIYAHARA VACCINE) 17-51 PVSH.sub.-- MUMPU SMALL HYDROPHOBIC PROTEIN MUMPS VIRUS (STRAIN TAKAHASHI) 13-47 PVSH.sub.-- REOVD SMALL HYDROPHOBIC PROTEIN MUMPS VIRUS (STRAIN URABE VACCINE AM9) 13-47 PVSH.sub.-- REOVJ SIGMA I PROTEIN PRECURSOR REOVIRUS (TYPE 3/STRAIN DEARING) 8-122 127-175 222-259 PVSH.sub.-- REOVL SIGMA I PROTEIN PRECURSOR REOVIRUS (TYPE 2/STRAIN D5/JONES) 1-178 PVSI2.sub .-- REOVD SIGMA 1 PROTEIN PRECURSOR REOVIRUS (TYPE 1/STRAIN LANG) 3-107 112-198 PVSI2.sub.-- REOVL SIGMA 2 PROTEIN REOVIRUS (TYPE 3/STRAIN DEARING) 350-384 PVSIS.sub.-- REOVD SIGMA 2 PROTEIN REOVIRUS (TYPE 1/STRAIN LANG) 350-384 PVSIS.sub.-- REOVJ SIGMA 1-S PROTEIN REOVIRUS (TYPE 3/STRAIN DEARING) 85-119 PVST2.sub.-- HEVBU SIGMA 1-S PROTEIN REOVIRUS (TYPE 2/STRAIN D5/JONES) 7-45 PVST2.sub.-- HEVME STRUCTURAL PROTEIN 2 PRECURSOR HEPATITIS E VIRUS (STRAIN BURMA)(HEV) 318-352 PVST2.sub.-- HEVMY STRUCTURAL PROTEIN 2 PRECURSOR HEPATITIS E VIRUS (STRAIN MEXICO)(HEV) 317-351 PVST2.sub.-- HEVPA STRUCTURAL PROTEIN 2 PRECURSOR HEPATITIS E VIRUS (STRAIN MYANMAR)(HEV) 318-352 PVST2.sub.-- HEVRH STRUCTURAL PROTEIN 2 PRECURSOR HEPATITIS E VIRUS (STRAIN PAKISTAN)(HEV) 318-352 PVT3A.sub.-- CAPVI STRUCTURAL PROTEIN 2 HEPATITIS E VIRUS (ISOLATE RHESUS)(HEV) 186-220 PVT4.sub.-- CAPVI PROTEIN T3A CAPRIPOXVIRUS (STRAIN INS-1) 120-158 PVT4.sub.-- CAPVK T4 PROTEIN CAPRIPOXVIRUS (STRAIN INS-1) 86-120 PVTER.sub.-- EBV T4 PROTEIN CAPRIPOXVIRUS (STRAIN KS-1) 86-120 PVTER.sub.-- HCMVA PROBABLE DNA PACKAGING PROTEIN EPSTEIN-BARR VIRUS (STRAIN B95-8)(HUMAN 235-290 595-629 HERPESVIRUS 4) PVTER.sub.-- HSV6U PROBABLE DNA PACKAGING PROTEIN HUMAN CYTOMEGALOVIRUS (STRAIN AD169) 417-451 617-658 PVTER.sub.-- HSVEB PROBABLE DNA PACKAGING PROTEIN HERPES SIMPLEX VIRUS (TYPE 6/STRAIN 468-502 UGANDA-1102) PVTER.sub.-- HSVI1 PROBABLE DNA PACKAGING PROTEIN EQUINE HERPESVIRUS TYPE 1(STRAIN AB4P) 11-45 (EHV-10 PVTER.sub.-- HSVSA PROBABLE DNA PACKAGING PROTEIN ICTALURID HERPESVIRUS I (CHANNEL CATFISH 98-136 698-744 VIRUS)(CCV) PVTER.sub.-- VZVD PROBABLE DNA PACKAGING PROTEIN HERPESVIRUS SAIMIRI (STRAIN 11) 226-267 PVV.sub.-- PI4HA PROBABLE DNA PACKAGING PROTEIN VARICELLA-ZOSTER VIRUS (STRAIN DUMAS)(VZV) 588-622 PVYI.sub.-- SEND6 V PROTEIN HUMAN PARAINFLUENZA 4A VIRUS (STRAIN 4-38 TOSHIBA)(PIV-4A) PY101.sub.-- SSVI YI PROTEIN SENDAI VIRUS (STRAIN 6/94) 104-138 PY108.sub.-- SSVI HYPOTHETICAL 10.1 KD PROTEIN SULFOLOBUS VIRUS-LIKE PARTICLE SSVI 16-80 PY110.sub.-- SSVI HYPOTHETICAL 10.8 KD PROTEIN SULFOLOBUS VIRUS-LIKE PARTICLE SSVI 4-65 PY119.sub.-- SSVI HYPOTHETICAL 11.0 KD PROTEIN SULFOLOBUS VIRUS-LIKE PARTICLE SSVI 55-59 PY11K.sub.-- TYDVA HYPOTHETICAL 11.9 KD PROTEIN SULFOLOBUS VIRUS-LIKE PARTICLE SSVI 30-96 PY12K.sub.-- FCVC6 HYPOTHETICAL 11.2 KD PROTEIN TOBACCO YELLOW DWARF VIRUS (STRAIN 53-87 AUSTRALIA)(TYDV) PY12K.sub.-- FCVF9 HYPOTHETICAL 12.2 KD PROTEIN FELINE CALICIVIRUS (STRAIN CF1/68 FIV)(FCV) 4-38 IN COAT PROTEIN PY12K.sub.-- RHDV HYPOTHETICAL 12.1 KD PROTEIN FELINE CALICIVIRUS (STRAIN F9)(FCV) 4-38 IN COAT PROTEIN PY12K.sub.-- RHDV3 HYPOTHETICAL 12.7 KD PROTEIN RABBIT HEMORRHAGIC DISEASE VIRUS (RHDV) 13-50 IN COAT PROTEI PY13K.sub.-- CLVK HYPOTHETICAL 12.7 KD PROTEIN RABBIT HEMORRHAGIC DISEASE VIRUS (STRAIN 13-50 IN COAT PROTEIN V-351)(RHDV) PY13K.sub.-- CLVN HYPOTHETICAL 13.1 KD PROTEIN CASSAVA LATENT VIRUS (STRAIN WEST KENYAN 40-77 844) PY13K.sub.-- NPVOP HYPOTHETICAL 13.1 KD PROTEIN CASSAVA LATENT VIRUS (STRAIN NIGERIAN) 43-77 PY13K.sub.-- SSVI HYPOTHETICAL 14.5 KD PROTEIN ORGYIA PSEUDOTSUGATA MULTICAPSID 16-67 IN 39 KD PROTEIN POLYHEDROSIS VIRUS PY14K.sub.-- SSVI HYPOTHETICAL 13.2 KD PROTEIN SULFOLOBUS VIRUS-LIKE PARTICLE SSVI 2-36 62-96 PY168.sub.-- ADE02 HYPOTHETICAL 13.7 KD PROTEIN SULFOLOBUS VIRUS-LIKE PARTICLE SSVI 5-39 PY16K.sub.-- SSVI HYPOTHETICAL PROTEIN C-168 HUMAN ADENOVIRUS TYPE 2 119-166 PY17K.sub.-- SSVI HYPOTHETICAL 15.6 KD PROTEIN SULFOLOBUS VIRUS-LIKE PARTICLE SSVI 1-35 77-111 PY18K.sub.-- SSVI HYPOTHETICAL 17.8 KD PROTEIN SULFOLOBUS VIRUS-LIKE PARTICLE SSVI 1-45 119-153 PY20K.sub.-- SSVI HYPOTHETICAL 18.0 KD PROTEIN SULFOLOBUS VIRUS-LIKE PARTICLE SSVI 102-136 PY28K.sub.-- SSVI HYPOTHETICAL 20.4 KD PROTEIN SULFOLOBUS VIRUS-LIKE PARTICLE SSVI 73-107 PY2.sub.-- SOCMV HYPOTHETICAL 28.5 KD PROTEIN SULFOLOBUS VIRUS-LIKE PARTICLE SSVI 127-180 PY31K.sub.-- SSVI HYPOTHETICAL PROTEIN 2 SOYBEAN CHLOROTIC MOTTLE VIRUS 117-154 PY32K.sub.-- SSVI HYPOTHETICAL 31.5 KD PROTEIN SULFOLOBUS VIRUS-LIKE PARTICLE SSVI 7-97 100-141 PY38K.sub.-- NPVAC HYPOTHETICAL 31.7 KD PROTEIN SULFOLOBUS VIRUS-LIKE PARTICLE SSVI 230-278 PY3.sub.-- SCOMV HYPOTHETICAL 37.7 KD PROTEIN AUTOGRAPHA CALIFORNIC NUCLEAR 133-241 POLYHEDROSIS VIRUS ( PY5K9.sub.-- SSVI HYPOTHETICAL PROTEIN 3 SOYBEAN CHLOROTIC MOTTLE VIRUS 115-149 PY7.sub.-- SOCMV HYPOTHETICAL 5.9 KD PROTEIN SULFOLOBUS VIRUS-LIKE PARTICLE SSVI 1-51 PY85K.sub.-- SSVI HYPOTHETICAL PROTEIN 7 SOYBEAN CHLOROTIC MOTTLE VIRUS 56-94 PY8.sub.-- SOCMV HYPOTHETICAL 85.7 KD PROTEIN SULFOLOBUS VIRUS-LIKE PARTICLE SSVI 81-125 503-537 546-587 658-700 PYB01.sub.-- FOWPM HYPOTHETICAL PROTEIN 8 SOYBEAN CHLOROTIC MOTTLE VIRUS 46-83 PYB04.sub.-- FOWPM HYPOTHETICAL BAMHI-ORF1 FOWLPOX VIRUS (ISOLATE HP-438[MUNICH]) 74-115 184-221 PROTEIN PYB05.sub.-- FOWPM HYPOTHETICAL BAMHI-ORF4 FOWLPOX VIRUS (ISOLATE HP-438[MUNICH]) 29-70 PROTEIN PYB06.sub.-- FOWPM HYPOTHETICAL BAMHI-ORF5 FOWLPOX VIRUS (ISOLATE HP-438[MUNICH]) 3-37 61-95 PROTEIN PYB07.sub.-- FOWPM HYPOTHETICAL BAMHI-ORF6 FOWLPOX VIRUS (ISOLATE HP-438[MUNICH]) 115-149 PROTEIN PYB10.sub.-- FOWPM HYPOTHETICAL BAMHI-ORF7 FOWLPOX VIRUS (ISOLATE HP-438[MUNICH]) 344-378 PROTEIN PYB12.sub.-- FOWPM HYPOTHETICAL BAMHI-ORF10 FOWLPOX VIRUS (ISOLATE HP-438[MUNICH]) 162-253 PROTEIN PYB13.sub.-- FOWPM HYPOTHETICAL BAMHI-ORF12 FOWLPOX VIRUS (ISOLATE HP-438[MUNICH]) 4-47 117-153 PROTEIN PYBL2.sub.-- EBV HYPOTHETICAL BAMHI-ORF13 FOWLPOX VIRUS (ISOLATE HP-438[MUNICH]) 122-163 PROTEIN PYDH1.sub.-- HSVS7 HYPOTHETICAL BBLF2 PROTEIN EPSTEIN-BARR VIRUS (STRAIN B95-8)(HUMAN 458-506 HERPESVIRUS 4) PYF30.sub.-- FOWPI HYPOTHETICAL 24.1 KD PROTEIN HERPESVIRUS SAIMIRI (STRAIN 484-77) 147-188 IN DHFR 3'REGION PYGAI.sub.-- HSVMB HYPOTHETICAL 30.9 KD PROTEIN FOWLPOX VIRUS (STRAIN FP-1) 160-204 PYGAI.sub.-- HSVMM HYPOTHETICAL 23.6 KD PROTEIN IN MAREK'S DISEASE HERPESVIRUS (STRAIN BC-1) 176-211 GLYCOPROTEI (MDHV) PYH22.sub.-- VACCV HYPOTHETICAL 23.6 KD PROTEIN IN MAREK'S DISEASE HERPESVIRUS (STRAIN BC-1) 176-211 GLYCOPROTEI (MDHV) PYHR3.sub.-- VACCV HYPOTHETICAL 21.7 KD VACCINIA VIRUS (STRAIN WR) 34-78 95-139 HINDIII-C PROTEIN PYKR4.sub.-- EBV HYPOTHETICAL HOST RANGE 27.4 VACCINIA VIRUS (STRAIN WR) 24-58 181-222 KD PROTEIN PYL15.sub.-- ADE41 HYPOTHETICAL BKRF4 PROTEIN EPSTEIN-BARR VIRUS (STRAIN B95-8)(HUMAN 16-58 HERPESVIRUS 4) PYLR2.sub.-- EBV HYPOTHETICAL 12.4 KD PROTEIN HUMAN ADENOVIRUS TYPE 41 39-81 IN 33 KD PROTEIN PYOR1.sub.-- COYMV HYPOTHETICAL BLRF2 PROTEIN EPSTEIN-BARR VIRUS (STRAIN B95-8)(HUMAN 64-125 HERPESVIRUS 4) PYOR2.sub.-- COYMV HYPOTHETICAL 23 KD PROTEIN COMMELINA YELLOW MOTTLE VIRUS (COYMV) 94-147 PYOR2.sub.-- LELV HYPOTHETICAL 15 KD PROTEIN COMMELINA YELLOW MOTTLE VIRUS (COYMV) 33-77 PYOR3.sub.-- TTVI HYPOTHETICAL 28.4 KD PROTEIN LELYSTAD VIRUS (LV) 100-134 PYOR5.sub.-- ADEGI HYPOTHETICAL 6.9 KD PROTEIN THERMOPROTEUS TENAX VIRUS 1 (STRAIN 14-54 KRAI)(TTV1) PYORA.sub.-- TTVI HYPOTHETICAL 31.5 KD PROTEIN AVIAN ADENOVIRUS GALI (STRAIN PHELPS)(FOWL 70-127 ADENOVIRU PYORD.sub.-- TTVI HYPOTHETICAL 8.1 KD PROTEIN THERMOPROTEUS TENAX VIRUS I (STRAIN KRA1) 21-67 (TTV1) PYORE.sub.-- TTVI HYPOTHETICAL 15.4 KD PROTEIN THERMOPROTEUS TENAX VIRUS I (STRAIN KRA1) 6-51 89-130 (TTV1) PYORL.sub.-- TTVI HYPOTHETICAL 15.3 KD PROTEIN THERMOPROTEUS TENAX VIRUS I (STRAIN KRA1) 78-122 (TTV1) PYORQ.sub.-- TTVI HYPOTHETICAL 26.8 KD PROTEIN THERMOPROTEUS TENAX VIRUS I (STRAIN KRA1) 1-45 (TTV1) PYORT.sub.-- TTVI HYPOTHETICAL 7.3 KD PROTEIN THERMOPROTEUS TENAX VIRUS I (STRAIN KRA1) 1-43 (TTV1) PYORW.sub.-- TTVI HYPOTHETICAL 38.7 KD PROTEIN THERMOPROTEUS TENAX VIRUS I (STRAIN KRA1) 4-38 281-315 (TTV1) PYP12.sub.-- RTBV HYPOTHETICAL 12.1 KD PROTEIN THERMOPROTEUS TENAX VIRUS I (STRAIN KRA1) 4-89 (TTV1) PYP12.sub.-- RTBVP HYPOTHETICAL P12 PROTEIN RICE TUNGRO BACILLIFORM VIRUS (RTBV) 33-72 PYP24.sub.-- RTBV HYPOTHETICAL P12 PROTEIN RICE TUNGRO BACILLIFORM VIRUS (ISOLATE 33-72 PHILIPPINES)(RTE PYP24.sub.-- RTBVP HYPOTHETICAL P24 PROTEIN RICE TUNGRO BACILLIFORM VIRUS (RTBV) 51-101 106-157 PYP46.sub.-- RTBV HYPOTHETICAL P24 PROTEIN RICE TUNGRO BACILLIFORM VIRUS (ISOLATE 51-101 106-157 PHILIPPINES)(RTE PYP46.sub.-- RTBVP HYPOTHETICAL P46 PROTEIN RICE TUNGRO BACILLIFORM VIRUS (RTBV) 49-111 197-231 PYP63.sub.-- NPVAC HYPOTHETICAL P46 PROTEIN RICE TUNGRO BACILLIFORM VIRUS (ISOLATE 49-111 197-231 PHILIPPINES)(RTE PYP7A.sub.-- TNVA HYPOTHETICAL PROTEIN IN AUTOGRAPHA CALIFORNICA NUCLEAR 32-73 P6.5 5'REGION POLYHEDROSIS VIRUS ( PYPOH.sub.-- NPVAC HYPOTHETICAL P7A PROTEIN TOBACCO NECROSIS VIRUS (STRAIN A)(TNV) 1-65 PYPOL.sub.-- IPNVJ HYPOTHETICAL 23.6 KD PROTEIN AUTOGRAPHA CALIFORNICA NUCLEAR 116-153 IN POLYHEDRIN 5 POLYHEDROSIS VIRUS ( PYQ1.sub.-- AMEPV HYPOTHETICAL 17.3 KD PROTEIN INFECTIOUS PANCREATIC NECROSIS 25-66 VIRUS (SEROTYPE JASPER) PYQ3.sub.-- AMEPV HYPOTHETICAL 7.6 KD PROTEIN AMSACTA MOOREI ENTOMOPOXVIRUS (AMEPV) 9-61 IN TK 5'REGION PYRF2.sub.-- HSV6G HYPOTHETICAL PROTEIN IN AMSACTA MOOREI ENTOMOPOXVIRUS (AMEPV) 1-57 62-96 149-183 TK 3'REGION PYRF3.sub.-- HSV6G HYPOTHETICAL PROTEIN RF2 HERPES SIMPLEX VIRUS (TYPE 6/STRAIN GS) 193-264 PYRF4.sub.-- HSV6G HYPOTHETICAL PROTEIN RF3 HERPES SIMPLEX VIRUS (TYPE 6/STRAIN GS) 134-175 PYRP2.sub.-- IRV6 HYPOTHETICAL PROTEIN RF4 HERPES SIMPLEX VIRUS (TYPE 6/STRAIN GS) 252-286 404-442 PYRR1.sub.-- EBV REPETITIVE PROTEIN ORF2 CHILO IRIDESCENT VIRUS (CIV)(INSECT 1-45 IRIDESCENT VIRUS TYP PYSR1.sub.-- EBV HYPOTHETICAL BRRF1 PROTEIN EPSTEIN-BARR VIRUS (STRAIN B95-8)(HUMAN 96-130 HERPES VIRUS 4) PYTR1.sub.-- EBV HYPOTHETICAL BSRF1 PROTEIN EPSTEIN-BARR VIRUS (STRAIN B95-8)(HUMAN 98-177 HERPES VIRUS 4) PYUB2.sub.-- NPVOP HYPOTHETICAL BTRF1 PROTEIN EPSTEIN-BARR VIRUS (STRAIN B95-8)(HUMAN 390-424 HERPES VIRUS 4) PYVAC.sub.-- VACCC HYPOTHETICAL 24.0 KD PROTEIN ORGYIA PSEUDOTSUGATA MULTICAPSID 25-69 170-204 IN UBIQUITIN 3'RE POLYHEDROSIS VIRUS PYVAG.sub.-- VACCC HYPOTHETICAL 14.4 KD PROTEIN VACCINIA VIRUS (STRAIN COPENHAGEN) 29-63 PYVAH.sub.-- VACCC HYPOTHETICAL 9.3 KD PROTEIN VACCINIA VIRUS (STRAIN COPENHAGEN) 3-37 PYVAN.sub.- - VACCC HYPOTHETICAL 14.5 KD PROTEIN VACCINIA VIRUS (STRAIN COPENHAGEN) 78-112 PYVBH.sub.-- VACCC HYPOTHETICAL 7.9 KD PROTEIN VACCINIA VIRUS (STRAIN COPENHAGEN) 23-57 PYVCC.sub.-- VACCC HYPOTHETICAL 7.4 KD PROTEIN VACCINIA VIRUS (STRAIN COPENHAGEN) 5-39 PYVDB.sub.- - VACCC HYPOTHETICAL 9.2 KD PROTEIN VACCINIA VIRUS (STRAIN COPENHAGEN) 11-48 PYVDB.sub.-- VACCC HYPOTHETICAL 8.5 KD PROTEIN VACCINIA VIRUS (STRAIN COPENHAGEN) 29-80 PYVDC.sub.-- VACCC HYPOTHETICAL 8.5 KD PROTEIN VACCINIA VIRUS (WR) 46-80 PYVGB.sub.-- VACCC HYPOTHETICAL 7.3 KD PROTEIN VACCINIA VIRUS (WR) 7-41 PYVHA.sub.-- VACCC HYPOTHETICAL 8.4 KD PROTEIN VACCINIA VIRUS (STRAIN COPENHAGEN) 10-51 HYPOTHETICAL 8.1 KD PROTEIN VACCINIA VIRUS (STRAIN COPENHAGEN) 9-53

The peptides of the invention may be synthesized or prepared by techniques well known in the art. See, for example, Creighton, 1983, Proteins: Structures and Molecular Principles, W. H. Freeman and Co., New York, which is incorporated herein by reference in its entirety. Short peptides, for example, can be synthesized on a solid support or in solution. Longer peptides may be made using recombinant DNA techniques. Here, the nucleotide sequences encoding the peptides of the invention may be synthesized, and/or cloned, and expressed according to techniques well known to those of ordinary skill in the art. See, for example, Sambrook, et al., 1989, Molecular Cloning, A is Laboratory Manual, Vols. 1-3, Cold Spring Harbor Press, New York.

The peptides of the invention may alternatively be synthesized such that one or more of the bonds which link the amino acid residues of the peptides are non-peptide bonds. These alternative non-peptide bonds may be formed by utilizing reactions well known to those in the art, and may include, but are not limited to imino, ester, hydrazide, semicarbazide, and azo bonds, to name but a few. In yet another embodiment of the invention, peptides comprising the sequences described above may be synthesized with additional chemical groups present at their amino and/or carboxy termini, such that, for example, the stability, bioavailability, and/or inhibitory activity of the peptides is enhanced. For example, hydrophobic groups such as carbobenzoxyl, dansyl, or t-butyloxycarbonyl groups, may be added to the peptides' amino termini. Likewise, an acetyl group or a 9-fluorenylmethoxy-carbonyl group may be placed at the peptides' amino termini. (See "X" in Tables I to IV, above.) Additionally, the hydrophobic group, t-butyloxycarbonyl, or an amido group may be added to the peptides' carboxy termini. (See "Z" in Tables I to IV, above.)

Further, the peptides of the invention may be synthesized such that their steric configuration is altered. For example, the D-isomer of one or more of the amino acid residues of the peptide may be used, rather than the usual L-isomer.

Still further, at least one of the amino acid residues of the peptides of the invention may be substituted by one of the well known non-naturally occurring amino acid residues. Alterations such as these may serve to increase the stability, bioavailability and/or inhibitory action of the peptides of the invention.

Any of the peptides described above may, additionally, have a macromolecular carrier group covalently attached to their amino and/or carboxy termini. Such macromolecular carrier groups may include, for example, lipid-fatty acid conjugates, polyethylene glycol, carbohydrates or additional peptides. "X", in Tables I to IV, above, may therefore additionally represent any of the above macromolecular carrier groups covalently attached to the amino terminus of a peptide, with an additional peptide group being preferred. Likewise, "Z", in Tables I to IV, may additionally represent any of the macromolecular carrier groups described above.

Described herein, are methods for ability of a compound, such as the peptides of the invention, to inhibit membrane fusion events. Specifically, assays for cell fusion events are described in Section 5.5.1, below, and assays for antiviral activity are described in Section 5.5.2, below.

Assays for cell fusion events are well known to those of skill in the art, and may be used in conjunction, for example, with the peptides of the invention to test the peptides' antifusogenic capabilities.

Cell fusion assays are generally performed in vitro. Such an assay may comprise culturing cells which, in the absence of any treatment would undergo an observable level of syncytial formation. For example, uninfected cells may be incubated in the presence of cells chronically infected with a virus that induces cell fusion. Such viruses may include, but are not limited to, HIV, SIV, or respiratory syncytial virus.

For the assay, cells are incubated in the presence of a peptide to be assayed. For each peptide, a range of peptide concentrations may be tested. This range should include a control culture wherein no peptide has been added.

Standard conditions for culturing cells, well known to those of ordinary skill in the art, are used. After incubation for an appropriate period (24 hours at 37.degree. C., for example) the culture is examined microscopically for the presence of multinucleated giant cells, which are indicative of cell fusion and syncytial formation. Well known stains, such as crystal violet stain, may be used to facilitate the visualization of syncytial formation.

The antiviral activity exhibited by the peptides of the invention may be measured, for example, by easily performed in vitro assays, such as those described below, which can test the peptides' ability to inhibit syncytia formation, or their ability to inhibit infection by cell-free virus. Using these assays, such parameters as the relative antiviral activity of the peptides, exhibit against a given strain of virus and/or the strain specific inhibitory activity of the peptide can be determined.

A cell fusion assay may be utilized to test the peptides' ability to inhibit viral-induced, such as HIV-induced, syncytia formation in vitro. Such an assay may comprise culturing uninfected cells in the presence of cells chronically infected with a syncytial-inducing virus and a peptide to be assayed. For each peptide, a range of peptide concentrations may be tested. This range should include a control culture wherein no peptide has been added. Standard conditions for culturing, well known to those of ordinary skill in the art, are used. After incubation for an appropriate period (24 hours at 37.degree. C., for example) the culture is examined microscopically for the presence of multinucleated giant cells, which are indicative of cell fusion and syncytia formation. Well known stains, such as crystal violet stain, may be used to facilitate syncytial visualization. Taking HIV as an example, such an assay would comprise CD-4.sup.+ cells (such as Molt or CEM cells, for example) cultured in the presence of chronically HIV-infected cells and a peptide to be assayed.

Other well known characteristics of viral infection may also be assayed to test a peptide's antiviral capabilities. Once again taking HIV as an example, a reverse transcriptase (RT) assay may be utilized to test the peptides' ability to inhibit infection of CD-4.sup.+ cells by cell-free HIV. Such an assay may comprise culturing an appropriate concentration (i.e., TCID.sub.50) of virus and CD-4.sup.+ cells in the presence of the peptide to be tested. Culture conditions well known to those in the art are used. As above, a range of peptide concentrations may be used, in addition to a control culture wherein no peptide has been added. After incubation for an appropriate period (e.g., 7 days) of culturing, a cell-free supernatant is prepared, using standard procedures, and tested for the present of RT activity as a measure of successful infection. The RT activity may be tested using standard techniques such as those described by, for example, Goff et al. (Goff, S. et al., 1981, J. Virol. 38:239-248) and/or Willey et al. (Willey, R. et al., 1988, J. Virol. 62:139-147). These references are incorporated herein by reference in their entirety.

Standard methods which are well-known to those of skill in the art may be utilized for assaying non-retroviral activity. See, for example, Pringle et al. (Pringle, C. R. et al., 1985, J. Medical Virology 17:377-386) for a discussion of respiratory syncytial virus and parainfluenza virus activity assay techniques. Further, see, for example, "Zinsser Microbiology", 1988, Joklik, W. K. et al., eds., Appleton & Lange, Norwalk, Conn., 19th ed., for a general review of such techniques. These references are incorporated by reference herein in their entirety. In addition, the Examples presented below, in Sections 17, 18, 26 and 27 each provide additional assays for the testing of a compound's antiviral capability.

In vivo assays may also be utilized to test, for example, the antiviral activity of the peptides of the invention. To test for anti-HIV activity, for example, the in vivo model described in Barnett et al. (Barnett, S. W. et al., 1994, Science 266:642-646) may be used.

Additionally, anti-RSV activity can be assayed in vivo via well known mouse models. For example, RSV can be administered intranasally to mice of various inbred strains. Virus replicates in lungs of all strains, but the highest titers are obtained in P/N, C57L/N and DBA/2N mice. Infection of BALB/c mice produces an asymptomatic bronchiolitis characterized by lymphocytic infiltrates and pulmonary virus titers of 10.sup.4 to 10.sup.5 pfu/g of lung tissue (Taylor, G. et al., 1984, Infect. Immun. 43:649-655).

Cotton rat models of RSV are also well known. Virus replicates to high titer in the nose and lungs of the cotton rat but produces few if any signs of inflammation.

The peptides of the invention may be utilized as antifusogenic or antiviral compounds, or as compounds which modulate intracellular processes involving coiled coil peptide structures. Further, such peptides may be used to identify agents which exhibit antifusogenic, antiviral or intracellular modulatory activity. Still further, the peptides of the invention may be utilized as organism or viral type/subtype-specific diagnostic tools.

The antifusogenic capability of the peptides of the invention may additionally be utilized to inhibit or treat/ameliorate symptoms caused by processes involving membrane fusion events. Such events may include, for example, virus transmission via cell-cell fusion, abnormal neurotransmitter exchange via cell-fusion, and sperm-egg fusion. Further, the peptides of the invention may be used to inhibit free viral, such as retroviral, particularly HIV, transmission to uninfected cells wherein such viral infection involves membrane fusion events or involves fusion of a viral structure with a cell membrane. Among the intracellular disorders involving coiled coil peptides structures which may be ameliorated by the peptides of the invention are disorders involving, for example, bacterial toxins.

With respect to antiviral activity, the viruses whose transmission may be inhibited by the peptides of the invention include, but are not limited to all strains of the viruses listed above, in Tables V through VII, and IX through XIV.

These viruses include, for example, human retroviruses, particularly HIV-1 and HIV-2 and the human T-lymphocyte viruses (HTLV-I and II). The non-human retroviruses whose transmission may be inhibited by the peptides of the invention include, but are not limited to bovine leukosis virus, feline sarcoma and leukemia viruses, simian immunodeficiency, sarcoma and leukemia viruses, and sheep progress pneumonia viruses.

Non retroviral viruses whose transmission may be inhibited by the peptides of the invention include, but are not limited to human respiratory syncytial virus, canine distemper virus, newcastle disease virus, human parainfluenza virus, influenza viruses, measles viruses, Epstein-Barr viruses, hepatitis B viruses, and simian Mason-Pfizer viruses.

Non enveloped viruses whose transmission may be inhibited by the peptides of the invention include, but are not limited to picornaviruses such as polio viruses, hepatitis A virus, enterovirus, echoviruses and coxsackie viruses, papovaviruses such as papilloma virus, parvoviruses, adenoviruses and reoviruses.

As discussed more fully, below, in Section 5.5.1 and in the Example presented, below, in Section 8, DP107, DP178, DP107 analog and DP178 analog peptides form non-covalent protein-protein interactions which are required for normal activity of the virus. Thus, the peptides of the invention may also be utilized as components in assays for the identification of compounds that interfere with such protein-protein interactions and may, therefore, act as antiviral agents. These assays are discussed, below, in Section 5.5.1.

As demonstrated in the Example presented below in Section 6, the antiviral activity of the peptides of the invention may show a pronounced type and subtype specificity, i.e., specific peptides may be effective in inhibiting the activity of only specific viruses. This feature of the invention presents many advantages. One such advantage, for example, lies in the field of diagnostics, wherein one can use the antiviral specificity of the peptide of the invention to ascertain the identity of a viral isolate. With respect to HIV, one may easily determine whether a viral isolate consists of an HIV-1 or HIV-2 strain. For example, uninfected CD-4.sup.+ cells may be co-infected with an isolate which has been identified as containing HIV the DP178 (SEQ ID:1) peptide, after which the retroviral activity of cell supernatants may be assayed, using, for example, the techniques described above in Section 5.2. Those isolates whose retroviral activity is completely or nearly completely inhibited contain HIV-1. Those isolates whose viral activity is unchanged or only reduced by a small amount, may be considered to not contain HIV-1. Such an isolate may then be treated with one or more of the other DP178 peptides of the invention, and subsequently be tested for its viral activity in order to determine the identify of the viral isolate. The DP107 and DP178 analogs of the invention may also be utilized in a diagnostic capacity specific to the type and subtype of virus or organism in which the specific peptide sequence is found. A diagnostic procedure as described, above, for DP178, may be used in conjunction with the DP107/DP178 analog of interest.

As demonstrated in the Example presented in Section 8, below, DP107 and DP178 portions of the TM protein gp41 form non-covalent protein-protein interactions. As is also demonstrated, the maintenance of such interactions is necessary for normal viral infectivity. Thus, compounds which bind DP107, bind DP178, and/or act to disrupt normal DP107/DP178 protein-protein interactions may act as antifusogenic, antiviral or cellular modulatory agents. Described below are assays for the identification of such compounds. Note that, while, for ease and clarity of discussion, DP107 and DP178 peptides will be used as components of the assays described, but it is to be understood that any of the DP107 analog or DP178 analog peptides described, above, in Sections 5.1 through 5.3 may also be utilized as part of these screens for compounds.

Compounds which may be tested for an ability to bind DP107, DP178, and/or disrupt DP107/DP178 interactions, and which therefore, potentially represent antifusogenic, antiviral or intracellular modulatory compounds, include, but are not limited to, peptides made of D- and/or L-configuration amino acids (in, for example, the form of random peptide libraries; see Lam, K. S. et al., 1991, Nature 354:8284), phosphopeptides (in, for example, the form of random or partially degenerate, directed phosphopeptide libraries; see, for example, Songyang, Z. et al., 1993, Cell 72:767-778), antibodies, and small organic or inorganic molecules. Synthetic compounds, natural products, and other sources of potentially effective materials may be screened in a variety of ways, as described in this Section.

The compounds, antibodies, or other molecules identified may be tested, for example, for an ability to inhibit cell fusion or viral activity, utilizing, for example, assays such as those described, above, in Section 5.5.

Among the peptides which may be tested are soluble peptides comprising DP107 and/or DP178 domains, and peptides comprising DP107 and/or DP178 domains having one or more mutations within one or both of the domains, such as the M41-P peptide described, below, in the Example presented in Section 8, which contains a isoleucine to proline mutation within the DP178 sequence.

In one embodiment of such screening methods is a method for identifying a compound to be tested for antiviral ability comprising:

(a) exposing at least one compound to a peptide comprising a DP107 peptide for a time sufficient to allow binding of the compound to the DP107 peptide;

(b) removing non-bound compounds; and

(c) determining the presence of the compound bound to the DP107 peptide, thereby identifying an agent to be tested for antiviral ability.

In a second embodiment of such screening methods is a method for identifying a compound to be tested for antiviral ability comprising:

(a) exposing at least one compound to a peptide comprising a DP178 peptide for a time sufficient to allow binding of the compound to the DP178 peptide;

(b) removing non-bound compounds; and

(c) determining the presence of the compound bound to the DP178 peptide, thereby identifying an agent to be tested for antiviral ability.

One method utilizing these types of approaches that may be pursued in the isolation of such DP107-binding or DP178-binding compounds is an assay which would include the attachment of either the DP107 or the DP178 peptide to a solid matrix, such as, for example, agarose or plastic beads, microtiter plate wells, petri dishes, or membranes composed of, for example, nylon or nitrocellulose. In such an assay system, either the DP107 or DP178 protein may be anchored onto a solid surface, and the compound, or test substance, which is not anchored, is labeled, either directly or indirectly. In practice, microtiter plates are conveniently utilized. The anchored component may be immobilized by non-covalent or covalent attachments. Non-covalent attachment may be accomplished simply by coating the solid surface with a solution of the protein and drying.

Alternatively, an immobilized antibody, preferably a monoclonal antibody, specific for the protein may be used to anchor the protein to the solid surface. The surfaces may be prepared in advance and stored.

In order to conduct the assay, the labeled compound is added to the coated surface containing the anchored DP107 or DP178 peptide. After the reaction is complete, unreacted components are removed (e.g., by washing) under conditions such that any complexes formed will remain immobilized on the solid surface. The detection of complexes anchored on the solid surface can be accomplished in a number of ways. Where the compound is pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed. Where the labeled component is not pre-labeled, an indirect label can be used to detect complexes anchored on the surface; e.g., using a labeled antibody specific for the compound (the antibody, in turn, may be directly labeled or indirectly labeled with a labeled anti-Ig antibody).

Alternatively, such an assay can be conducted in a liquid phase, the reaction products separated from unreacted components, and complexes detected; e.g., using an immobilized antibody specific for DP107 or DP178, whichever is appropriate for the given assay, or ab antibody specific for the compound, i.e., the test substance, in order to anchor any complexes formed in solution, and a labeled antibody specific for the other member of the complex to detect anchored is complexes.

By utilizing procedures such as this, large numbers of types of molecules may be simultaneously screened for DP107 or DP178-binding capability, and thus potential antiviral activity.

Further, compounds may be screened for an ability to inhibit the formation of or, alternatively, disrupt DP107/DP178 complexes. Such compounds may then be tested for antifusogenic, antiviral or intercellular modulatory capability. For ease of description, DP107 and DP178 will be referred to as "binding partners." Compounds that disrupt such interactions may exhibit antiviral activity. Such compounds may include, but are not limited to molecules such as antibodies, peptides, and the like described above.

The basic principle of the assay systems used to identify compounds that interfere with the interaction between the DP107 and DP178 peptides involves preparing a reaction mixture containing peptides under conditions and for a time sufficient to allow the two peptides to interact and bind, thus forming a complex. In order to test a compound for disruptive activity, the reaction is conducted in the presence and absence of the test compound, i.e., the test compound may be initially included in the reaction mixture, or added at a time subsequent to the addition of one of the binding partners; controls are incubated without the test compound or with a placebo. The formation of any complexes between the binding partners is then detected. The formation of a complex in the control reaction, but not in the reaction mixture containing the test compound indicates that the compound interferes with the interaction of the DP107 and DP178 peptides.

The assay for compounds that interfere with the interaction of the binding partners can be conducted in a heterogeneous or homogeneous format. Heterogeneous assays involve anchoring one of the binding partners onto a solid phase and detecting complexes anchored on the solid phase at the end of the reaction. In homogeneous assays, the entire reaction is carried out in a liquid phase. In either approach, the order of addition of reactants can be varied to obtain different information about the compounds being tested. For example, test compounds that interfere with the interaction between the binding partners, e.g., by competition, can be identified by conducting the reaction in the presence of the test substance; i.e., by adding the test substance to the reaction mixture prior to or simultaneously with the binding partners. On the other hand, test compounds that disrupt preformed complexes, e.g. compounds with higher binding constants that displace one of the binding partners from the complex, can be tested by adding the test compound to the reaction mixture after complexes have been formed. The various formats are described briefly below.

In a heterogeneous assay system, one binding partner, e.g., either the DP107 or DP178 peptide, is anchored onto a solid surface, and its binding partner, which is not anchored, is labeled, either directly or indirectly. In practice, microtiter plates are conveniently utilized. The anchored species may be immobilized by non-covalent or covalent attachments. Non-covalent attachment may be accomplished simply by coating the solid surface with a solution of the protein and drying. Alternatively, an immobilized antibody specific for the protein may be used to anchor the protein to the solid surface. The surfaces may be prepared in advance and stored.

In order to conduct the assay, the binding partner of the immobilized species is added to the coated surface with or without the test compound. After the reaction is complete, unreacted components are removed (e.g., by washing) and any complexes formed will remain immobilized on the solid surface. The detection of complexes anchored on the solid surface can be accomplished in a number of ways. Where the binding partner was pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed. Where the binding partner is not pre-labeled, an indirect label can be used to detect complexes anchored on the surface; e.g., using a labeled antibody specific for the binding partner (the antibody, in turn, may be directly labeled or indirectly labeled with a labeled anti-Ig antibody). Depending upon the order of addition of reaction components, test compounds which inhibit complex formation or which disrupt preformed complexes can be detected.

Alternatively, the reaction can be conducted in a liquid phase in the presence or absence of the test compound, the reaction products separated from unreacted components, and complexes detected; e.g., using an immobilized antibody specific for one binding partner to anchor any complexes formed in solution, and a labeled antibody specific for the other binding partner to detect anchored complexes. Again, depending upon the order of addition of reactants to the liquid phase, test compounds which inhibit complex or which disrupt preformed complexes can be identified.

In an alternate embodiment of the invention, a homogeneous assay can be used. In this approach, a preformed complex of the DP107 and DP178 peptides is prepared in which one of the binding partners is labeled, but the signal generated by the label is quenched due to complex formation (see, e.g., U.S. Pat. No. 4,109,496 by Rubenstein which utilizes this approach for immunoassays). The addition of a test substance that competes with and displaces one of the binding partners from the preformed complex will result in the generation of a signal above background. In this way, test substances which disrupt DP-107/DP-178 protein-protein interaction can be identified.

In an alternative screening assay, test compounds may be assayed for the their ability to disrupt a DP178/DP107 interaction, as measured immunometrically using an antibody specifically reactive to a DP107/DP178 complex (i.e., an antibody that recognizes neither DP107 nor DP178 individually). Such an assay acts as a competition assay, and is based on techniques well known to those of skill in the art.

The above competition assay may be described, by way of example, and not by way of limitation, by using the DP178 and M41.DELTA.178 peptides and by assaying test compounds for the disruption of the complexes formed by these two peptides by immunometrically visualizing DP178/M41.DELTA.178 complexes via the human recombinant Fab, Fab-d, as described, below, in the Example presented in Section 8. M41.DELTA.178 is a maltose binding fusion protein containing a gp41 region having its DP178 domain deleted, and is described, below, in the Example presented in Section 8.

Utilizing such an assay, M41.DELTA.178 may be immobilized onto solid supports such as microtiter wells. A series of dilutions of a test compound may then be added to each M41.DELTA.178-containing well in the presence of a constant concentration of DP-178 peptide. After incubation, at, for example, room temperature for one hour, unbound DP-178 and test compound are removed from the wells and wells are then incubated with the DP178/M41.DELTA.178-specific Fab-d antibody. After incubation and washing, unbound Fab-d is removed from the plates and bound Fab-d is quantitated. A no-inhibitor control should also be conducted. Test compounds showing an ability to disrupt DP178/M41.DELTA.178 complex formation are identified by their concentration-dependent decrease in the level of Fab-d binding.

A variation of such an assay may be utilized to perform a rapid, high-throughput binding assay which is capable of directly measuring DP178 binding to M41.DELTA.178 for the determination of binding constants of the ligand of inhibitory constants for competitors of DP178 binding.

Such an assay takes advantage of accepted radioligand and receptor binding principles. (See, for example, Yamamura, H. I. et al., 1985, "Neurotransmitter Receptor Binding", 2nd ed., Raven Press, New York.) As above, M41.DELTA.178 is immobilized onto a solid support such as a microtiter well. DP178 binding to M41.DELTA.178 is then quantitated by measuring the fraction of DP178 that is bound as .sup.125 I-DP178 and calculating the total amount bound using a value for specific activity (dpm/.mu.g peptide) determined for each labeled DP178 preparation. Specific binding to M41.DELTA.178 is defined as the difference of the binding of the labeled DP178 preparation in the microtiter wells (totals) and the binding in identical wells containing, in addition, excess unlabeled DP178 (nonspecifics).

The peptides of the invention may be administered using techniques well known to those in the art. Preferably, agents are formulated and administered systemically. Techniques for formulation and administration may be found in "Remington's Pharmaceutical Sciences", 18th ed., 1990, Mack Publishing Co., Easton, Pa. Suitable routes may include oral, rectal, transmucosal, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intramedullary injections, as well as, intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections, just to name a few. For injection, the agents of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiological saline buffer. For such transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

In instances wherein intracellular administration of the peptides of the invention or other inhibitory agents is preferred, techniques well known to those of ordinary skill in the art may be utilized. For example, such agents may be encapsulated into liposomes, then administered as described above. Liposomes are spherical lipid bilayers with aqueous interiors. All molecules present in an aqueous solution at the time of liposome formation are incorporated into the aqueous interior. The liposomal contents are both protected from the external microenvironment and, because liposomes fuse with cell membranes, are effectively delivered into the cell cytoplasm. Additionally, due to their hydrophobicity, when small molecules are to be administered, direct intracellular administration may be achieved.

Nucleotide sequences encoding the peptides of the invention which are to be intracellularly administered may be expressed in cells of interest, using techniques well known to those of skill in the art. For example, expression vectors derived from viruses such as retroviruses, vaccinia viruses, adeno-associated viruses, herpes viruses, or bovine papilloma viruses, may be used for delivery and expression of such nucleotide sequences into the targeted cell population. Methods for the construction of such vectors and expression constructs are well known. See, for example, Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor N.Y., and Ausubel et al., 1989, Current Protocols in Molecular Biology, Greene Publishing Associates and Wiley Interscience, New York.

With respect to HIV, peptides of the invention, particularly DP107 and DP178, may be used as therapeutics in the treatment of AIDS. In addition, the peptides may be used as prophylactic measures in previously uninfected individuals after acute exposure to an HIV virus. Examples of such prophylactic use of the peptides may include, but are not limited to, prevention of virus transmission from mother to infant and other settings where the likelihood of HIV transmission exists, such as, for example, accidents in health care settings wherein workers are exposed to HIV-containing blood products. The successful use of such treatments do not rely upon the generation of a host immune response directed against such peptides.

Effective dosages of the peptides of the invention to be administered may be determined through procedures well known to those in the art which address such parameters as biological half-life, bioavailability, and toxicity. Given the data presented below in Section 6, DP178, for example, may is prove efficacious in vivo at doses required to achieve circulating levels of about 1 to about 10 ng per ml of peptide.

A therapeutically effective dose refers to that amount of the compound sufficient to result in amelioration of symptoms or a prolongation of survival in a patient. Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD.sub.50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD.sub.50 /ED.sub.50. Compounds which exhibit large therapeutic indices are preferred. The data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC.sub.50 (e.g., the concentration of the test compound which achieves a half-maximal inhibition of the fusogenic event, such as a half-maximal inhibition of viral infection relative to the amount of the event in the absence of the test compound) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography (HPLC).

The peptides of the invention may, further, serve the role of a prophylactic vaccine, wherein the host raises antibodies against the peptides of the invention, which then serve to neutralize HIV viruses by, for example, inhibiting further HIV infection.

Administration of the peptides of the invention as a prophylactic vaccine, therefore, would comprise administering to a host a concentration of peptides effective in raising an immune response which is sufficient to neutralize HIV, by, for example, inhibiting HIV ability to infect cells. The exact concentration will depend upon the specific peptide to be administered, but may be determined by using standard techniques for assaying the development of an immune response which are well known to those of ordinary skill in the art. The peptides to be used as vaccines are usually administered intramuscularly.

The peptides may be formulated with a suitable adjuvant in order to enhance the immunological response. Such adjuvants may include, but are not limited to mineral gels such as aluminum hydroxide; surface active substances such as lysolecithin, pluronic polyols, polyanions; other peptides; oil emulsions; and potentially useful human adjuvants such as BCG and Corynebacterium parvum. Many methods may be used to introduce the vaccine formulations described here. These methods include but are not limited to oral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, and intranasal routes.

Alternatively, an effective concentration of polyclonal or monoclonal antibodies raised against the peptides of the invention may be administered to a host so that no uninfected cells become infected by HIV. The exact concentration of such antibodies will vary according to each specific antibody preparation, but may be determined using standard techniques well known to those of ordinary skill in the art. Administration of the antibodies may be accomplished using a variety of techniques, including, but not limited to those described in this section.

For all such treatments described above, the exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g. Fingl et al., 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 p1).

It should be noted that the attending physician would know how to and when to terminate, interrupt, or adjust administration due to toxicity, or to organ dysfunctions. Conversely, the attending physician would also know to adjust treatment to higher levels if the clinical response were not adequate (precluding toxicity). The magnitude of an administrated dose in the management of the oncogenic disorder of interest will vary with the severity of the condition to be treated and the route of administration. The dose and perhaps dose frequency, will also vary according to the age, body weight, and response of the individual patient. A program comparable to that discussed above may be used in veterinary medicine.

Use of pharmaceutically acceptable carriers to formulate the compounds herein disclosed for the practice of the invention into dosages suitable for systemic administration is within the scope of the invention. With proper choice of carrier and suitable manufacturing practice, the compositions of the present invention, in particular, those formulated as solutions, may be administered parenterally, such as by intravenous injection. The compounds can be formulated readily using pharmaceutically acceptable carriers well known in the art into dosages suitable for oral administration. Such carriers enable the compounds of the invention to be formulated as tablets, pills, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated.

Pharmaceutical compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an effective amount to achieve its intended purpose. Determination of the effective amounts is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. The preparations formulated for oral administration may be in the form of tablets, dragees, capsules, or solutions.

The pharmaceutical compositions of the present invention may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.

Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

Pharmaceutical preparations for oral use can be obtained by combining the active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.

Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added.

In this example, DP178 (SEQ ID:1) is shown to be a potent inhibitor of HIV-1 mediated CD-4.sup.+ cell-cell fusion and infection by cell free virus. In the fusion assay, this peptide completely blocks virus induced syncytia formation at concentrations of from 1-10 ng/ml. In the infectivity assay the inhibitory concentration is somewhat higher, blocking infection at 90 ng/ml. It is further shown that DP178 (SEQ ID:1) shows that the antiviral activity of DP178 (SEQ ID:1) is highly specific for HIV-1. Additionally, a synthetic peptide, DP-185 (SEQ ID:3), representing a HIV-1-derived DP178 homolog is also found to block HIV-1-mediated syncytia formation.

Peptides were synthesized using Fast Moc chemistry on an Applied Biosystems Model 431A peptide synthesizer. Generally, unless otherwise noted, the peptides contained amidated carboxy termini and acetylated amino termini. Amidated peptides were prepared using Rink resin (Advanced Chemtech) while peptides containing free carboxy termini were synthesized on Wang (p-alkoxy-benzyl-alcohol) resin (Bachem). First residues were double coupled to the appropriate resin and subsequent residues were single coupled. Each coupling step was followed by acetic anhydride capping. Peptides were cleaved from the resin by treatment with trifluoracetic acid (TFA) (10 ml), H.sub.2 O (0.5 ml), thioanisole (0.5 ml), ethanedithiol (0.25 ml), and crystalline phenol (0.75 g). Purification was carried out by reverse phase HPLC. Approximately 50 mg samples of crude peptide were chromatographed on a Waters Delta Pak C18 column (19 mm .times.30 cm, 15.mu. spherical) with a linear gradient; H.sub.2 O/acetonitrile 0.1% TFA. Lyophilized peptides were stored desiccated and peptide solutions were made in water at about 1 mg/ml. Electrospray mass spectrometry yielded the following results: DP178 (SEQ ID:1):4491.87 (calculated 4491.94); DP-180 (SEQ ID:2):4491.45 (calculated 4491.94); DP-185 (SEQ ID:3):not done (calculated 4546.97).

The HIV-1.sub.LAI virus was obtained from R. Gallo (Popovic, M. et al., 1984, Science 224:497-508) and propagated in CEM cells cultured in RPMI 1640 containing 10% fetal calf serum. Supernatant from the infected CEM cells was passed through a 0.2 .mu.m filter and the infectious titer estimated in a microinfectivity assay using the AA5 cell line to support virus replication. For this purpose, 25 .mu.l of serial diluted virus was added to 75 .mu.l AA5 cells at a concentration of 2.times.10.sup.5 /ml in a 96-well microtitre plate. Each virus dilution was tested in triplicate. Cells were cultured for eight days by addition of fresh medium every other day. On day 8 post infection, supernatant samples were tested for virus replication as evidenced by reverse transcriptase activity released to the supernatant. The TCID.sub.50 was calculated according to the Reed and Muench formula (Reed, L. J. et al., 1938, Am. J. Hyg. 27:493-497). The titer of the HIV-1.sub.LAI, and HIV-1.sub.MN stocks used for these studies, as measured on the AA5 cell line, was approximately 1.4.times.10.sup.6 and 3.8.times.10.sup.4 TCID.sub.50 /ml, respectively.

Approximately 7.times.10.sup.4 Molt cells were incubated with 1.times.10.sup.4 CEM cells chronically infected with the HIV-1.sub.LAI virus in 96-well plates (one-half area cluster plates; Costar, Cambridge, Mass.) in a final volume of 100 .mu.l culture medium as previously described (Matthews, T. J. et al., 1987, Proc. Natl. Acad. Sci. U.S.A. 84: 5424-5428). Peptide inhibitors were added in a volume of 10 .mu.l and the cell mixtures were incubated for 24 hr. at 37.degree. C. At that time, multinucleated giant cells were estimated by microscopic examination at a 40.times. magnification which allowed visualization of the entire well in a single field.

Synthetic peptides were incubated at 37.degree. C. with either 247 TCID.sub.50 (for experiment depicted in FIG. 2), or 62 TCID.sub.50 (for experiment depicted in FIG. 3) units of HIV-1.sub.LAI virus or 25 TCID.sub.50 units of HIV-2.sub.NIHZ and CEM CD4.sup.+ cells at peptide concentrations of 0, 0.04, 0.4, 4.0, and 40 .mu.g/ml for 7 days. The resulting reverse transcriptase (RT) activity in counts per minute was determined using the assay described, below, in Section 6.1.5. See, Reed, L. J. et al., 1938, Am. J. Hyg. 27: 493-497 for an explanation of TCID.sub.50 calculations.

The micro-reverse transcriptase (RT) assay was adapted from Goff et al. (Goff, S. et al., 1981, J. Virol. 38:239-248) and Willey et al. (Willey, R. et 20al., 1988, J. Virol. 62:139-147). Supernatants from virus/cell cultures are adjusted to 1% Triton-X100. A 10 .mu.l sample of supernatant was added to 50 .mu.l of RT cocktail in a 96-well U-bottom microtitre plate and the samples incubated at 37.degree. C. for 90 min. The RT cocktail contained 75 mM KCl, 2 mM dithiothreitol, 5 mM MgCl.sub.2, 5 .mu.g/ml poly A (Pharmacia, cat. No. 27-4110-01), 0.25 unit s/ml oligo dT (Pharmacia, cat . No. 27-7858-01), 0.05% NP40, 50 mM Tris-HCl, pH 7.8, 0.5 .mu.M non-radioactive dTTP, and 10 .mu.Ci/Ml .sup.32 P-dTTP (Amersham, cat. No. PB.10167).

After the incubation period, 40 .mu.l of reaction mixture was applied to a Schleicher and Schuell (S+S) NA45 membrane (or DE81 paper) saturated in 2.times.SSC buffer (0.3M NaCl and 0.003M sodium citrate) held in a S+S Minifold over one sheet of GB003 (S+S) filter paper, with partial vacuum applied. Each well of the minifold was washed four times with 200 .mu.l 2.times.SSC, under full vacuum. The membrane was removed from the minifold and washed 2 more times in a pyrex dish with an excess of 2.times.SSC. Finally, the membrane was drained on absorbent paper, placed on Whatman #3 paper, covered with Saran wrap, and exposed to film overnight at -70.degree. C.

The initial screen for antiviral activity assayed peptides' ability to block syncytium formation induced by overnight co-cultivation of uninfected Molt4 cells with chronically HIV-1 infected CEM cells. The results of several such experiments are presented herein. In the first of these experiments, serial DP178 (SEQ ID:1) peptide concentrations between 10 .mu.g/ml and 12.5 ng/ml were tested for blockade of the cell fusion process. For these experiments, CEM cells chronically infected with either HIV-1.sub.LAI, HIV-1.sub.MN, HIV-1.sub.RF, or HIV-1.sub.SF2 virus were cocultivated overnight with uninfected Molt 4 cells. The results (FIG. 4) show that DP178 (SEQ ID:1) afforded complete protection against each of the HIV-1 isolates down to the lowest concentration of DP178 (SEQ ID:1) used. For HIV.sub.LAI inhibition, the lowest concentration tested was 12.5 ng/ml; for all other HIV-1 viruses, the lowest concentration of DP178 (SEQ ID:1) used in this study was 1000 ng/ml. A second peptide, DP-180 (SEQ ID:2), containing the same amino acid residues as DP178 (SEQ ID:1) but arranged in a random order exhibited no evidence of anti-fusogenic activity even at the high concentration of 40 .mu.g/ml (FIG. 4). These observations indicate that the inhibitory effect of DP178 (SEQ ID:1) is primary sequence-specific and not related to non-specific peptide/protein interactions. The actual endpoint (i.e., the lowest effective inhibitory concentration) of DP178 inhibitory action is within the range of 1-10 ng/ml.

The next series of experiments involved the preparation and testing of a DP178 (SEQ ID:1) homolog for its ability to inhibit HIV-1-induced syncytia formation. As shown in FIG. 1, the sequence of DP-185 (SEQ ID:3) is slightly different from DP178 (SEQ ID:1) in that its primary sequence is taken from the HIV-1.sub.SF2 isolate and contains several amino acid differences relative to DP178 (SEQ ID:1) near the N terminus. As shown in FIG. 4, DP-185 (SEQ ID:3), exhibits inhibitory activity even at 312.5 ng/ml, the lowest is concentration tested.

The next series of experiments involved a comparison of DP178 (SEQ ID:1) HIV-1 and HIV-2 inhibitory activity. As shown in FIG. 5, DP178 (SEQ ID:1) blocked HIV-1-mediated syncytia formation at peptide concentrations below 1 ng/ml. DP178 (SEQ ID:1) failed, however, to block HIV-2 mediated syncytia formation at concentrations as high as 10 .mu.g/ml. This striking 4 log selectivity of DP178 (SEQ ID:1) as an inhibitor of HIV-1-mediated cell fusion demonstrates an unexpected HIV-1 specificity in the action of DP178 (SEQ ID:1). DP178 (SEQ ID:1) inhibition of HIV-1-mediated cell fusion, but the peptide's inability to inhibit HIV-2 medicated cell fusion in the same cell type at the concentrations tested provides further evidence for the high degree of selectivity associated with the antiviral action of DP178 (SEQ ID:1).

DP178 (SEQ ID:1) was next tested for its ability to block CD-4.sup.+ CEM cell infection by cell free HIV-1 virus. The results, shown in FIG. 2, are from an experiment in which DP178 (SEQ ID:1) was assayed for its ability to block infection of CEM cells by an HIV-1.sub.LAI isolate. Included in the experiment were three control peptides, DP-116 (SEQ ID:9), DP-125 (SEQ ID:8), and DP-118 (SEQ ID:10). DP-116 (SEQ ID:9) represents a peptide previously shown to be inactive using this assay, and DP-125 (SEQ ID:8; Wild, C. et al., 1992, Proc. Natl. Acad, Sci. U.S.A. 89:10,537) and DP-118 (SEQ ID:10) are peptides which have previously been shown to be active in this assay. Each concentration (0, 0.04, 0.4, 4, and 40 .mu.g/ml) of peptide was incubated with 247 TCID.sub.50 units of HIV-1.sub.LAI virus and CEM cells. After 7 days of culture, cell-free supernatant was tested for the presence of RT activity as a measure of successful infection. The results, shown in FIG. 2, demonstrate that DP178 (SEQ ID:1) inhibited the de novo infection process mediated by the HIV-1 viral isolate at concentrations as low as 90 ng/ml (IC50=90 ng/ml). In contrast, the two positive control peptides, DP-125 (SEQ: ID:8) and DP-118 (SEQ ID:10), had over 60-fold higher IC50 concentrations of approximately 5 .mu.g/ml.

In a separate experiment, the HIV-1 and HIV-2 inhibitory action of DP178 (SEQ ID:1) was tested with CEM cells and either HIV-1.sub.LAI or HIV-2.sub.NIHZ. 62 TCID.sub.50 HIV-1.sub.LAI or 25 GCID.sub.50 HIV-2.sub.NIHZ were used in these experiments, and were incubated for 7 days. As may be seen in FIG. 3, DP178 (SEQ ID:1) inhibited HIV-1 infection with an IC50 of about 31 ng/ml. In contrast, DP178 (SEQ ID:1) exhibited a much higher IC50 for HIV-2.sub.NIHZ, thus making DP178 (SEQ ID:1) two logs more potent as a HIV-1 inhibitor than a HIV-2 inhibitor. This finding is consistent with the results of the fusion inhibition assays described, above, in Section 6.2.1, and further supports a significant level of selectivity (i.e., for HIV-1 over HIV-2).

In this Example, the 36 amino acid synthetic peptide inhibitor DP178 (SEQ ID:1) is shown to be non-cytotoxic to cells in culture, even at the highest peptide concentrations (40.mu./ml) tested.

Cell proliferation and toxicity assay: Approximately 3.8.times.10.sup.5 CEM cells for each peptide concentration were incubated for 3 days at 37.degree. C. in T25 flasks. Peptides tested were DP178 (SEQ ID:1) and DP-116 (SEQ ID:9), as described in FIG. 1. Peptides were synthesized as described, above, in Section 6.1. The concentrations of each peptide used were 0, 2.5, 10, and 40 .mu.g/ml. Cell counts were taken at incubation times of 0, 24, 48, and 72 hours.

Whether the potent HIV-1 inhibitor DP178 (SEQ ID:1) exhibited any cytotoxic effects was assessed by assaying the peptide's effects on the proliferation and viability of cells in culture. CEM cells were incubated in the presence of varying concentrations of DP178 (SEQ ID:1), and DP-116 (SEQ ID:9), a peptide previously shown to be ineffective as a HIV inhibitor (Wild, C. et al., 1992, Proc. Natl. Acad. Sci. U.S.A. 89:10,537-10,541). Additionally, cells were incubated in the absence of either peptide.

The results of the cytotoxicity study demonstrate that DP178 (SEQ ID:1) exhibits no cytotoxic effects on cells in culture. As can be seen, below, in Table XXIV, even the proliferation and viability characteristics of cells cultured for 3 days in the presence of the highest concentration of DP178 (SEQ ID:1) tested (40 .mu.g/ml) do not significantly differ from the DP-116 (SEQ ID:9) or the no-peptide controls. The cell proliferation data is also represented in graphic form in FIG. 6. As was demonstrated in the Working Example presented above in Section 6, DP178 (SEQ ID:1) completely inhibits HIV-1 mediated syncytia formation at peptide concentrations between 1 and 10 ng/ml, and completely inhibits cell-free viral infection at concentrations of at least 90 ng/ml. Thus, this study demonstrates that even at peptide concentrations greater than 3 log higher than the HIV inhibitory dose, DP178 (SEQ ID:1) exhibits no cytotoxic effects.

Soluble recombinant forms of gp41 used in the example described below provide evidence that the DP178 peptide associates with a distal site on gp41 whose interactive structure is influenced by the DP107 leucine zipper motif. A single mutation disrupting the coiled-coil structure of the leucine zipper domain transformed the soluble recombinant gp41 protein from an inactive to an active inhibitor of HIV-1 fusion. This transformation may result from liberation of the potent DP178 domain from a molecular clasp with the leucine zipper, DP107, determinant. The results also indicate that the anti-HIV activity of various gp41 derivatives (peptides and recombinant proteins) may be due to their ability to form complexes with viral gp41 and interfere with its fusogenic process.

Construction of fusion proteins and mutants shown in FIG. 7 was accomplished as follows: the DNA sequence corresponding to the extracellular domain of gp41 (540-686) was cloned into the Xmn I site of the expression vector pMal-p2 (New England Biolab) to give M41. The gp41 sequence was amplified from pgtat (Malim et al., 1988, Nature 355: 181-183) by using polymerase chain reaction (PCR) with upstream primer 5'-ATGACGCTGACGGTACAGGCC-3' (primer A) (SEQ ID NO:11) and downstream primer 5'-TGACTAAGCTTAATACCACAGCCAATTTGTTAT-3' (SEQ ID NO:12) (primer B). M41-P was constructed by using the T7-Gen in vitro mutagenesis kit from United States Biochemicals (USB) following the supplier's instructions. The mutagenic primer (5'-GGAGCTGCTTGGGGCCCCAGAC-3') (SEQ ID NO:13) introduces an Ile to Pro mutation in M41 at position 578. M41.DELTA.107, from which the DP-107 region has been deleted, was made using a deletion mutagenic primer 5'-CCAAATCCCCAGGAGCTGCTCGAGCTGCACTATACCAGAC-3' (SEQ ID NO:14) (primer C) following the USB T7-Gen mutagenesis protocol. M41.DELTA.178, from which the DP-178 region has been deleted, was made by cloning the DNA fragment corresponding to gp41 amino acids 540-642 into the Xmn I site of pMal-p2. Primer A and 5'-ATAGCTTCTAGATTAATTGTTAATTTCTCTGTCCC-3' (SEQ ID NO:15) (primer D) were used in the PCR with the template pgtat to generate the inserted DNA fragments. M41-P was used as the template with primer A and D in PCR to generate M41-P.DELTA.178. All inserted sequences and mutated residues were checked by restriction enzyme analysis and confirmed by DNA sequencing.

The fusion proteins were purified according to the protocol described in the manufacturer's brochure of protein fusion and purification systems from New England Biolabs (NEB). Fusion proteins (10 ng) were analyzed by electrophoresis on 8% SDS polyacrylamide gels. Western blotting analysis was performed as described by Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, 2d Ed, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., Ch. 18, pp. 64-75. An HIV-1 positive serum diluted 1000-fold, or a human Fab derived from repertoire cloning was used to react with the fusion proteins. The second antibody was HRP-conjugated goat antihuman Fab. An ECL Western blotting detection system (Amersham) was used to detect the bound antibody. A detailed protocol for this detection system was provided by the manufacturer. Rainbow molecular weight markers (Amersham) were used to estimate the size of fusion proteins.

Cell fusion assays were performed as previously described (Matthews et al., 1987, Proc. Natl. Acad. Sci. U.S.A. 84: 5424-5481). CEM cells (7.times.10.sup.4) were incubated with HIV-1.sub.IIIB chronically infected CEM cells (10.sup.4) in 96-well flat-bottomed half-area plates (Costar) in 100 .mu.l culture medium. Peptide and fusion proteins at various concentrations in 10 .mu.l culture medium were incubated with the cell mixtures at 37.degree. C. for 24 hours. Multinucleated syncytia were estimated with microscopic examination. Both M41 and M41-P did not show cytotoxicity at the concentrations tested and shown in FIG. 8.

Inhibition of HIV-1 induced cell-cell fusion activity was carried out in the presence of 10 nM DP178 and various concentrations of M41.DELTA.178 or M41-P.DELTA.178 as indicated in FIG. 9. There was no observable syncytia in the presence of 10 nM DP178. No peptide or fusion protein was added in the control samples.

The amino acid sequence of DP178 used is: YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF. For enzyme linked immunoassay (ELISA), M41.DELTA.178 or M41-P.DELTA.178 (5 .mu.g/ml) in 0.1M NaHCO.sub.3, pH 8.6, were coated on 96 wells Linbro ELISA plates (Flow Lab, Inc.) overnight. Each well was washed three times with distilled water then blocked with 3% bovine serum albumin (BSA) for 2 hours. After blocking, peptides with 0.5% BSA in TBST (40 mM Tris-HCl pH7.5, 150 mM NaCl, 0.05% Tween 20) were added to the ELISA plates and incubated at room temperature for 1 hour. After washing three times with TBST, Fab-d was added at a concentration of 10 ng/ml with 0.5% BSA in TBST. The plates were washed three times with TBST after incubation at room temperature for 1 hour. Horse radish peroxidase (HRP) conjugated goat antihuman Fab antiserum at a 2000 fold dilution in TBST with 0.5% BSA was added to each well and incubated at room temperature for 45 minutes. The plates were then washed four times with TBST. The peroxidase substrate o-phenylene diamine (2.5 mg/ml) and 0.15% H.sub.2 O.sub.2 were added to develop the color. The reaction was stopped with an equal volume of 4.5 N H.sub.2 SO.sub.4 after incubation at room temperature for 10 minutes. The optical density of the stopped reaction mixture was measured with a micro plate reader (Molecular Design) at 490 nm. Results are shown in FIG. 10.

As a step toward understanding the roles of the two helical regions in gp41 structure and function, the ectodomain of gp41 was expressed as a maltose binding fusion protein (M41) (FIG. 7). The fusogenic peptide sequence at the N-terminal of gp41 was omitted from this recombinant protein and its derivatives to improve solubility. The maltose binding protein facilitated purification of the fusion proteins under relatively mild, non-denaturing conditions. Because the M41 soluble recombinant gp41 was not glycosylated, lacked several regions of the transmembrane protein (i.e., the fusion peptide, the membrane spanning, and the cytoplasmic domains), and was expressed in the absence of gp120, it was not expected to precisely reflect the structure of native gp41 on HIV-1 virions. Nevertheless, purified M41 folded in a manner that preserved certain discontinuous epitopes as evidenced by reactivity with human monoclonal antibodies, 98-6, 126-6, and 50-69, previously shown to bind conformational epitopes on native gp41 expressed in eukaryotic cells (Xu et al., 1991, J. Virol. 65: 4832-4838; Chen, 1994, J. Virol. 68:2002-2010). Thus, at least certain regions of native gp41 defined by these antibodies appear to be reproduced in the recombinant fusion protein M41. Furthermore, M41 reacted with a human recombinant Fab (Fab-d) that recognizes a conformational epitope on gp41 and binds HIV-1 virions as well as HIV-1 infected cells but not uninfected cells as analyzed by FACS. Deletion of either helix motif, i.e., DP107 or DP178, of the M41 fusion protein eliminated reactivity with Fab-d. These results indicate that both helical regions, separated by 60 amino acids in the primary sequence, are required to maintain the Fab-d epitope.

The wild type M41 fusion protein was tested for anti-HIV-1 activity. As explained, supra, synthetic peptides corresponding to the leucine zipper (DP107) and the C-terminal putative helix (DP178) show potent anti-HIV activity. Despite inclusion of both these regions, the recombinant M41 protein did not affect HIV-1 induced membrane fusion at concentrations as high as 50 .mu.M (Table XXV, below).

Surprisingly, a single amino acid substitution, proline in place of isoleucine in the middle of the leucine zipper motif, yielded a fusion protein (M41-P) which did exhibit antiviral activity (Table XXV and FIG. 8). As seen in Table XXV, M41-P blocked syncytia formation by 90% at approximately 85 nM and neutralized HIV-1.sub.IIIB infection by 90% at approximately 70 nM concentrations. The anti-HIV-1 activity of M41-P appeared to be mediated by the C-terminal helical sequence since deletion of that region from M41-P yielded an inactive fusion protein, M41-P.DELTA.178 (Table XXV). This interpretation was reinforced by experiments demonstrating that a truncated fusion protein lacking the DP178 sequence, M41.DELTA.178, abrogated the potent anti-fusion activity of the DP178 peptide in a concentration-dependent manner (FIG. 9). The same truncated fusion protein containing the proline mutation disrupting the leucine zipper, M41-P.DELTA.178, was not active in similar competition experiments (FIG. 9). The results indicate that the DP178 peptide associates with a second site on gp41 whose interactive structure is dependent on a wild type leucine zipper sequence. A similar interaction may occur within the wild type fusion protein, M41, and act to form an intramolecular clasp which sequesters the DP178 region, making it unavailable for anti-viral activity.

A specific association between these two domains is also indicated by other human monoclonal Fab-d studies. For example, Fab-d failed to bind either the DP178 peptide or the fusion protein M41.DELTA.178, but its epitope was reconstituted by simply mixing these two reagents together (FIG. 10). Again, the proline mutation in the leucine zipper domain of the fusion protein, M41-P.DELTA.178, failed to reconstitute the epitope in similar mixing experiments.

A number of known coiled-coil sequences have been well described in the literature and contain heptad repeat positioning for each amino acid. Coiled-coil nomenclature labels each of seven amino acids of a heptad repeat A through G, with amino acids A and D tending to be hydrophobic positions. Amino acids E and G tend to be charged. These four positions (A, D, E, and G) form the amphipathic backbone structure of a monomeric alpha-helix. The backbones of two or more amphipathic helices interact with each other to form di-, tri-, tetrameric, etc., coiled-coil structures. In order to begin to design computer search motifs, a series of well characterized coiled coils were chosen including yeast transcription factor GCN4, Influenza Virus hemagglutinin loop 36, and human proto-oncogenes c-Myc, c-Fos, and c-Jun. For each peptide sequence, a strict homology for the A and D positions, and a list of the amino acids which could be excluded for the B, C, E, F, and G positions (because they are not observed in these positions) was determined. Motifs were tailored to the DP107 and DP178 sequences by deducing the most likely possibilities for heptad positioning of the amino acids of HIV-1 Bru DP-107, which is known to have coiled-coil structure, and HIV1 Bru DP178, which is still structurally undefined. The analysis of each of the sequences is contained in FIG. 12. For example, the motif for GCN4 was designed as follows:

1. The only amino acids (using standard single letter amino acid codes) found in the A or D positions of GCN4 were [LMNV].

2. All amino acids were found at B, C, E, F, and G positions except {CFGIMPTW}.

3. The PESEARCH motif would, therefore, be written as follows: [LMNV]-{CFGIMPTW} (2)-[LMNV]-{CFGIMPTW} (3)-[LMNV]-{CFGIMPTW} (2)-[LMNV]-{CFGIMPTW} (3)-[LMNV]-{CFGIMPTW} (2)-[LMNV]-{CFGIMPTW} (3)-[LMNV]-{CFGIMPTW} (2)-[LMNV]-{CFGIMPTW} (3)

Translating or reading the motif: "at the first A position either L, M, N, or V must occur; at positions B and C (the next two positions) accept everything except C, F, G, I, M, P, T, or W; at the D position either L, M, N, or V must occur; at positions E, F, and G (the next 3 positions) accept everything except C, F, G, I, M, P, T, or W." This statement is contained four times in a 28-mer motif and five times in a 35-mer motif. The basic motif key then would be: [LMNV]-{CFGIMPTW}. The motif keys for the remaining well described coiled-coil sequences are summarized in FIG. 12.

The motif design for DP107 and DP178 was slightly different than the 28-mer model sequences described above due to the fact that heptad repeat positions are not defined and the peptides are both longer than 28 residues. FIG. 13 illustrates several possible sequence alignments for both DP107 and DP178 and also includes motif designs based on 28-mer, 35-mer, and full-length peptides. Notice that only slight differences occur in the motifs as the peptides are lengthened. Generally, lengthening the base peptide results in a less stringent motif. This is very useful in broadening the possibilities for identifying DP107-or DP-178 -like primary amino acid sequences referred to in this document as "hits".

In addition to making highly specific motifs for each type peptide sequence to be searched, it is also possible to make "hybrid" motifs. These motifs are made by "crossing" two or more very stringent motifs to make a new search algorithm which will find not only both "parent" motif sequences but also any peptide sequences which have similarities to one, the other, or both "parents". For example, in FIG. 14 the "parent" sequence of GCN4 is crossed with each of the possible "parent" motifs of DP-107. Now the hybrid motif must contain all of the amino acids found in the A and D positions of both parents, and exclude all of the amino acids not found in either parent at the other positions. The resulting hybrid from crossing GCN4 or [LMNV]{CFGIMPTW} and DP107 (28-mer with the first L in the D position) or [ILQT]{CDFIMPST}, is [ILMNQTV]{CFIMPT}. Notice that now only two basic hybrid motifs exist which cover both framing possibilities, as well as all peptide lengths of the parent DP-107 molecule. FIG. 15 represents the "hybridizations" of GCN4 with DP-178. FIG. 16 represents the "hybridizations" of DP107 and DP178. It is important to keep in mind that the represented motifs, both parent and hybrid, are motif keys and not the depiction of the full-length motif needed to actually do the computer search.

Hybridizations can be performed on any combination of two or more motifs. FIG. 17 summarizes several three-motif hybridizations including GCN4, DP107 (both frames), and DP178 (also both frames). Notice that the resulting motifs are now becoming much more similar to each other. In fact, the first and third hybrid motifs are actually subsets of the second and fourth hybrid motifs respectively. This means that the first and third hybrid motifs are slightly more stringent than the second and fourth. It should also be noted that with only minor changes in these four motifs, or by hybridizing them, a single motif could be obtained which would find all of the sequences. However, it should be remembered that stringency is also reduced. Finally, the most broad-spectrum and least-stringent hybrid motif is described in FIG. 18 which summarizes the hybridization of GCN4, DP107 (both frames), DP178 (both frames), c-Fos, c-Jun, c-Myc, and Flu loop 36.

A special set of motifs was designed based on the fact that DP-178 is located only approximately ten amino acids upstream of the transmembrane spanning region of gp41 and just C-terminal to a proline which separates DP107 and DP178. It has been postulated that DP178 may be an amphipathic helix when membrane associated, and that the proline might aid in the initiation of the helix formation. The same arrangement was observed in Respiratory Syncytial Virus; however, the DP178-like region in this virus also had a leucine zipper just C-terminal to the proline. Therefore, N-terminal proline-leucine zipper motifs were designed to analyze whether any other viruses might contain this same pattern. The motifs are summarized in FIG. 19.

The PC/Gene protein database contains 5879 viral amino acid sequences (library file PVIRUSES; CD-ROM release 11.0). Of these, 1092 are viral enveloped or glycoprotein sequences (library file PVIRUSE1). Tables V through XIV contain lists of protein sequence names and motif hit locations for all the motifs searched.

FIG. 20 represents search results for HIV-1 BRU isolate gp41 (PC/Gene protein sequence PENV.sub.-- HV1BR). Notice that the hybrid motif which crosses DP-107 and DP-178 (named 107.times.178.times.4; the same motif as found in FIG. 16 found three hits including amino acids 550-599, 636-688, and 796-823. These areas include DP-107 plus eight N-terminal and four C-terminal amino acids; DP178 plus seven N-terminal and ten C-terminal amino acids; and an area inside the transmembrane region (cytoplasmic). FIG. 20 also contains the results obtained from searching with the motif named ALLMOTI5, for which the key is found in FIG. 17 ({CDGHP} {CFP}.times.5). This motif also found three hits including DP107 (amino acids 510-599), DP178 (615-717), and a cytoplasmic region (772-841). These hits overlap the hits found by the motif 107.times.178.times.4 with considerable additional sequences on both the amino and carboxy termini. This is not surprising in that 107.times.178.times.4 is a subset of the ALLMOTI5 hybrid motif. Importantly, even though the stringency of ALLMOTI5 is considerably less than 107.times.178.times.4, it still selectively identifies the DP107 and DP178 regions of gp41 shown to contain sequences for inhibitory peptides of HIV-1. The results of these two motif searches are summarized in Table V under the PC/Gene protein sequence name PENV HV1BR. The proline-leucine zipper motifs also gave several hits in HIV-1 BRU including 503-525 which is at the very C-terminus of gp120, just upstream of the cleavage site (P7LZIPC and P12LZIPC); and 735-768 in the cytoplasmic domain of gp41 (P23LZIPC). These results are found in Tables VIII, IX, and X under the same sequence name as mentioned above. Notice that the only area of HIV-1 BRU which is predicted by the Lupas algorithm to contain a coiled-coil region, is from amino acids 635-670. This begins eight amino acids N-terminal to the start and ends eight amino acids N-terminal to the end of DP178. DP107, despite the fact that it is a known coiled coil, is not predicted to contain a coiled-coil region using the Lupas method.

FIG. 21 represents search results for Human Respiratory Syncytial Virus (RSV; Strain A2) fusion glycoprotein F1 (PC/Gene protein sequence name PVGLF.sub.-- HRSVA). Motif 107.times.178.times.4 finds three hits including amino acids 152-202, 213-243, and 488-515. The arrangement of these hits is similar to what is found in HIV-1 except that the motif finds two regions with similarities to DP-178, one just downstream of what would be called the DP107 region or amino acids 213-243, and one just upstream of the transmembrane region (also similar to DP178) or amino acids 488-515. Motif ALLMOTI5 also finds three areas including amino acids 116-202, 267-302, and 506-549. The proline-leucine zipper motifs also gave several hits including amino acids 205-221 and 265-287 (PLLZIPC 265-280, P12LZIPC), and 484-513 (P7LZIPC and P12LZIPC 484-506, P23LZIPC). Notice that the PLZIP motifs also identify regions which share location similarities with DP-178 of HIV-1.

Motif hits for Simian immunodeficiency Virus gp41 (AGM3 isolate; PC/Gene protein sequence name PENV.sub.-- SIVAG) are shown in FIG. 22. Motif 107.times.178.times.4 finds three hits including amino acids 566-593, 597-624,and 703-730. The first two hits only have three amino acids between them and could probably be combined into one hit from 566-624 which would represent a DP107-like hit. Amino acids 703 to 730 would then represent a DP178-like hit. ALLMOTI5 also finds three hits including amino acids 556-628 (DP107 like), 651-699 (DP178-like), and 808-852 which represents the transmembrane spanning region. SIV also has one region from 655-692 with a high propensity to form a coiled coil as predicted by the Lupas algorithm. Both 107.times.178.times.4 and ALLMOTI5 motifs find the same region. SIV does not have any PLZIP motif hits in gp41.

The identification of DP178/DP107 analogs for a second SIV isolate (MM251) is demonstrated in the Example presented, below, in Section 19.

Canine Distemper Virus (strain Onderstepoort) fusion glycoprotein F1 (PC/Gene Protein sequence name PVGLF.sub.-- CDVO) has regions similar to Human RSV which are predicted to be DP107-like and DP178-like (FIG. 23). Motif 107.times.178.times.4 highlights one area just C-terminal to the fusion peptide at amino acids 252-293. Amino acids 252-286 are also predicted to be coiled coil using the Lupas algorithm. Almost 100 amino acids C-terminal to the first region is a DP178-like area at residues 340-367. ALLMOTI5 highlights three areas of interest including: amino acids 228-297, which completely overlaps both the Lupas prediction and the DP107-like 107.times.178.times.4 hit; residues 340-381, which overlaps the second 107.times.178.times.4 hit; and amino acids 568-602, which is DP178-like in that it is located just N-terminal to the transmembrane region. It also overlaps another region (residues 570-602) predicted by the Lupas method to have a high propensity to form a coiled coil. Several PLZIP motifs successfully identified areas of interest including P6 and P12LZIPC which highlight residues 336-357 and 336-361 respectively; P1 and P12LZIPC which find residues 398-414; and P12and P23LZIPC which find residues 562-589 and 562-592 respectively.

FIG. 24 shows the motif hits found in Newcastle Disease Virus (strain Australia-Victoria/32; PC Gene protein sequence name PVGLF.sub.-- NDVA). Motif 107.times.178.times.4 finds two areas including a DP107-like hit at amino acids 151-178 and a DP178-like hit at residues 426-512. ALLMOTI5 finds three areas including residues 117-182, 231-272, and 426-512. The hits from 426-512 include a region which is predicted by the Lupas method to have a high coiled-coil propensity (460-503). The PLZIP motifs identify only one region of interest at amino acids 273-289 (P1 and 12LZIPC).

Both motifs 107.times.178.times.4 and ALLMOTI5 exhibit DP107-like hits in the same region, 115-182 and 117-182 respectively, of Human Parainfluenza Virus (strain NIH 47885; PC/Gene protein sequence name PVGLF.sub.-- p13H4; (FIG. 25). In addition, the two motifs have a DP178 like hit just slightly C-terminal at amino acids 207-241. Both motifs also have DP178-like hits nearer the transmembrane region including amino acids 457-497 and 462-512 respectively. Several PLZIP motif hits are also observed including 283-303 (P5LZIPC), 283-310 (P12LZIPC), 453-474 (P6LZIPC), and 453-481 (P23LZIPC). The Lupas algorithm predicts that amino acids 122-176 may have a propensity to form a coiled-coil.

FIG. 26 illustrates the Lupas prediction for a coiled coil in Influenza A Virus (strain A/Aichi/2/68) at residues 379-436, as well as the motif hits for 107.times.178.times.4 at amino acids 387-453, and for ALLMOTI5 at residues 380-456. Residues 383-471 (38-125 of HA2) were shown by Carr and Kim to be an extended coiled coil when under acidic pH (Carr and Kim, 1993, Cell 73: 823-832). The Lupas algorithm predicts a coiled-coil at residues 379-436. All three methods successfully predicted the region shown to actually have coiled-coil structure; however, ALLMOTI5 predicted the greatest portion of the 88 residue stretch.

In the Example presented herein, respiratory syncytial virus (RSV) peptides identified by utilizing the computer-assisted search motifs described in the Examples presented in Sections 9 and 11, above, were tested for anti-RSV activity. Additionally, circular dichroism (CD) structural analyses were conducted on the peptides, as discussed below. It is demonstrated that several of the identified peptides exhibit potent antiviral capability. Additionally, it is shown that several of these peptides exhibit a substantial helical character.

Structural analyses: The CD spectra were measured in a 10 mM sodium phosphate, 150 mM sodium chloride, pH 7.0, buffer at approximately 10 mM concentrations, using a 1 cm pathlength cell on a Jobin/Yvon Autodichrograph Mark V CD spectrophotometer. Peptides were synthesized according to the methods described, above, in Section 6.1. Peptide concentrations were determined from A.sub.280 using Edlehoch's method (1967, Biochemistry 6:1948).

Anti-RSV antiviral activity assays: The assay utilized herein tested the ability of the peptides to disrupt the ability of HEp2 cells acutely infected with RSV (i.e., cells which are infected with a multiplicity of infection of greater than 2) to fuse and cause syncytial formation on a monolayer of uninfected an uninfected line of Hep-2 cells. The lower the observed level of fusion, the greater the antiviral activity of the peptide was determined to be.

Uninfected confluent monolayers of Hep-2 cells were grown in microtiter wells in 3% EMEM (Eagle Minimum Essential Medium w/o L-glutamine [Bio Whittaker Cat. No. 12-125F], with fetal bovine serum [FBS; which had been heat inactivated for 30 minutes at 56.degree. C.; Bio Whittaker Cat. No. 14-501F) supplemented at 3%, antibiotics (penicillin/streptomycin; Bio Whittaker Cat. No. 17-602E) added at 1%, and glutamine added at 1%.

To prepare Hep2 cells for addition to uninfected cells, cultures of acutely infected Hep2 cells were washed with DPBS (Dulbecco's Phosphate Buffered Saline w/o calcium or magnesium; Bio Whittaker Cat. No. 17-512F) and cell monolayers were removed with Versene (1:5000; Gibco Life Technologies Cat. No. 15040-017). The cells were spun 10 minutes and resuspended in 3% FBS. Cell counts were performed using a hemacytometer. Persistent cells were added to the uninfected Hep-2 cells.

The antiviral assay was conducted by, first, removing all media from the wells containing uninfected Hep-2 cells, then adding peptides (at the dilutions described below) in 3% EMEM, and 100 acutely RSV-infected Hep2 cells per well. Wells were then incubated at 37.degree. C. for 48 hours.

After incubation, cells in control wells were is checked for fusion centers, media was removed from the wells, followed by addition, to each well, of either Crystal Violet stain or XTT. With respect to Crystal Violet, approximately 50 .mu.l 0.25% Crystal Violet stain in methanol were added to each well. The wells were rinsed immediately, to remove excess stain, and were allowed to dry. The number of syncytia per well were then counted, using a dissecting microscope.

With respect to XTT (2,3-bis[2-Methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxyanilide inner salt), 50 .mu.l XTT (1 mg/ml in RPMI buffered with 100 mM HEPES, pH 7.2-7.4, plus 5% DMSO) were added to each well. The OD.sub.450/690 was measured (after blanking against growth medium without cells or reagents, and against reagents) according to standard procedures.

Peptides: The peptides characterized in the study presented herein were:

1) peptides T-142 to T-155 and T-575, as shown in FIGS. 27A-C, and peptides T-22 to T-27, T-68, T-334 and T-371 to T-375 and T-575, as shown in FIG. 27C;

2) peptides T-120 to T-141 and T-576, as shown in FIGS. 27D-F, and peptides T-12, T-13, T-15, T-19, T-28 to T-30, T-66, T-69, T-70 and T-576, as shown in FIG. 27F; and

3) peptides T-67 and T-104 to T-119 and T-384, as shown in FIGS. 28A-C, and peptides T-71, T-613 to T-617, T-662 to T-676 and T-730, as shown in FIG. 28C.

The peptides of group 1 represent portions of the RSV F2 protein DP178/107-like region. The peptides of group 2 represent portions of the RSV F1 protein DP107-like region. The peptides of groups 3 represent portions of the RSV F1 protein DP178-like region.

Each peptide was tested at 2-fold serial dilutions ranging from 10 .mu.g/ml to approximately 100 ng/ml. For each of the assays, a well containing is no peptide was also used. The IC.sub.50 data for each peptide represents the average of several experiments conducted utilizing that peptide.

The data summarized in FIGS. 27A-C and 28A-C represent antiviral and structural information obtained from peptides derived from the RSV F2 DP178/DP107-like F2 region (FIGS. 27A-C), the RSV F1 DP-107-like region (FIGS. 27D-F) and the RSV DP178-like F2 region (FIGS. 28A-C).

As shown in FIGS. 27A-F, a number of the RSV DP178/DP107-like peptides exhibited a detectable level of antiviral activity. Peptides from the RSV DP178/DP107-like F2 region (FIGS. 27A-C), for example, T-142 to T-145 and T-334 purfied peptides, exhibited detectable levels of antiviral activity, as evidenced by their IC.sub.50 values. Further, a number of RSV F1 DP107-like peptides (FIGS. 27D-F) exhibited a sizable level of antiviral activity as purified peptides, including, for example, peptides T-124 to T-127, T-131, T-135 and T-137 to T-139, as demonstrated by their low IC.sub.50 values. In addition, CD analysis FIGS. 27A-B, 27D-F) reveals that many of the peptides exhibit some detectable level of helical structure.

The results summarized in FIGS. 28A-C demonstrate that a number of DP178-like purified peptides exhibit a range of potent anti-viral activity. These peptides include, for example, T-67, T-104, T-105 and T-107 to T-119, as listed in FIG. 28A, and T-665 to T-669 and T-671 to T-673, as listed in FIG. 28C. In addition, some of the DP178-like peptides exhibited some level of helicity.

Thus, the computer assisted searches described, hereinabove, successfully identified viral peptide domains that represent highly promising anti-RSV antiviral compounds.

In the Example presented herein, human parainfluenza virus type 3 (HPIV3) peptides identified by utilizing the computer-assisted search motifs described in the Examples presented in Sections 9 and 15, above, were tested for anti-HPIV3 activity. Additionally, circular dichroism (CD) structural analyses were conducted on the peptides, as discussed below. It is demonstrated that several of the identified peptides exhibit potent antiviral capability. Additionally, it is shown that several of these peptides exhibit a substantial helical character.

Structural analyses: Structural analyses consisted of circular dichroism (CD) studies. The CD spectra were measured in a 10 mM sodium phosphate, 150 mM sodium chloride, pH 7.0, buffer at approximately 10 mm concentrations, using a 1 cm pathlength cell on a Jobin/Yvon Autodichrograph Mark V CD spectrophotometer. Peptide concentrations were determined from A.sub.280 using Edlehoch's method (1967, Biochemistry 6:1948).

Anti-HPIV3 antiviral activity assays: The assay utilized herein tested the ability of the peptides to disrupt the ability of Hep2 cells chronically infected with HPIV3 to fuse and cause syncytial formation on a monolayer of an uninfected line of CV-1W cells. The more potent the lower the observed level of fusion, the greater the antiviral activity of the peptide.

Uninfected confluent monolayers of CV-1W cells were grown in microtiter wells in 3% EMEM (Eagle Minimum Essential Medium w/o L-glutamine [Bio Whittaker Cat. No. 12-125F], with fetal bovine serum [FBS; which had been heat inactivated for 30 minutes at 56.degree. C.; Bio Whittaker Cat. No. 14-501F) supplemented at 3%, antibiotics/antimycotics (Gibco BRL Life Technologies Cat. No. 15040-017) added at 1%, and glutamine added at 1%.

To prepare Hep2 cells for addition to uninfected cells, cultures of chronically infected Hep2 cells were washed with DPBS (Dulbecco's Phosphate Buffered Saline w/o calcium or magnesium; Bio Whittaker Cat. No. 17-512F) and cell monolayers were removed with Versene (1:5000; Gibco Life Technologies Cat. No. 15040-017). The cells were spun 10 minutes and resuspended in 3% FBS. Cell counts were performed using a hemacytometer. Persistent cells were added to the uninfected CV-1W cells.

The antiviral assay was conducted by, first, removing all media from the wells containing uninfected CV-1W cells, then adding peptides (at the dilutions described below) in 3% EMEM, and 500 chronically HPIV3-infected Hep2 cells per well. Wells were then incubated at 37.degree. C. for 24 hours.

On day 2, after cells in control wells were checked for fusion centers, media was removed from the wells, followed by addition, to each well, of approximately 50 .mu.l 0.25% Crystal Violet stain in methanol. Wells were rinsed immediately, to remove excess stain and were then allowed to dry. The number of syncytia per well were then counted, using a dissecting microscope.

Alternatively, instead of Crystal Violet analysis, cells were assayed with XTT, as described, avove, in Section 17.1.

Peptides: The peptides characterized in the study presented herein were:

1) Peptides 157 to 188, as shown in FIGS. 29A-C, and peptides T-38 to T-40, T-42 to T-46 and T-582, as shown in FIGS. 29D-E. These peptides are derived from the DP107 region of the HPIV3 F1 fusion protein (represented by HPF3 107, as shown in FIGS. 29A-C); and

2) Peptides 189 to 210, as shown in FIGS. 30A-B, and T-269, T-626, T-383 and T-577 to T-579, as shown in FIG. 30C. These peptides are primarily derived from the DP178 region of the HPIV3 F1 fusion protein (represented by HPF3 178, as shown in FIGS. 30A-C). Peptide T-626 contains two mutated amino acid resides (represented by a shaded background). Additionally, peptide T-577 represents F1 amino acids 65-100, T-578 represents F1 amino acids 207-242 and T-579 represents F1 amino acids 273-309.

Each peptide was tested at 2-fold serial dilutions ranging from 500 .mu.g/ml to approximately 500 ng/ml. For each of the assays, a well containing no peptide was also used.

The data summarized in FIGS. 29A-E and 30A-C represent antiviral and structural information obtained from peptides derived from the HPIV3 fusion protein DP107-like region (FIGS. 29A-E) and the HPIV3 fusion protein DP178-like region (FIGS. 30A-C).

As shown in FIGS. 29A-E, a number of the HPIV3 DP107-like peptides exhibited potent levels of antiviral activity. These peptides include, for example, peptides T-40, T-172 to T-175, T-178, T-184 and T-185.

CD analysis reveals that a number of the peptides exhibit detectable to substantial level of helical structure.

The results summarized in FIGS. 30A-C demonstrate that a number of the DP178-like peptides tested exhibit a range of anti-viral activity. These peptides include, for example, peptides 194 to 211, as evidenced by their low IC.sub.50 values. In fact, peptides 201 to 205 exhibit IC.sub.50 values in the nanogram/ml range. In addition, many of the DP178-like peptides exhibited some level of helicity.

Thus, the computer assisted searches described, hereinabove, have successfully identified viral peptide domains that represent highly promising anti-HPIV3 antiviral compounds.

FIG. 31 represents search results for SIV isolate MM251 (PC/Genes.RTM. protein sequence PENV.sub.-- SIVM2). Both 107.times.178.times.4 and ALLMOTI5 search motifs identified two regions with similarities to DP107 and/or DP178.

The peptide regions found by 107.times.178.times.4 were located at amino acid residues 156-215 and 277-289. The peptide regions found by ALLMOTI5 were located at amino acid residues 156-219 and 245-286. Both motifs, therefore, identify similar regions.

Interestingly, the first SIV peptide region (i.e., from amino acid residue 156 to approximately amino acid residue 219) correlates with a DP107 region, while the second region identified (i.e., from approximately amino acid residue 245 to approximately amino acid residue 289) correlates with the DP178 region of HIV. In fact, an alignment of SIV isolate MM251 and HIV isolate BRU, followed by a selection of the best peptide matches for HIV DP107 and DP178, reveals that the best matches are found within the peptide regions identified by the 107.times.178.times.4 and ALLMOTI5 search motifs.

It should be noted that a potential coiled-coil region at amino acid residues 242-282 is predicted by the Lupas program. This is similar to the observation in HIV in which the coiled-coil is predicted by the Lupas program to be in the DP178 rather than in the DP107 region. It is possible, therefore, that SIV may be similar to HIV in that it may contain a coiled-coil structure in the DP107 region, despite such a structure being missed by the Lupas algorithm. Likewise, it may be that the region corresponding to a DP178 analog in SIV may exhibit an undefined structure, despite the Lupas program's prediction of a coiled-coil structure.

The results presented herein describe the identification of DP178/DP107 analogs within two different Epstein-Barr Virus proteins. Epstein-Barr is a human herpes virus which is the causative agent of, for example, infectious mononucleosis (IM), and is also associated with nasopharyngeal carcinomas (NPC), Burkitt's lymphoma and other diseases. The virus predominantly exists in the latent form and is activated by a variety of stimuli.

FIG. 32 depicts the search motif results for the Epstein-Barr Virus (Strain B95-8; PC/Gene.RTM. protein sequence PVGLB.sub.-- EBV) glycoprotein gpllo precursor (gp115). The 107.times.178.times.4 motif identified two regions of interest, namely the regions covered by amino acid residues 95-122 and 631-658. One PZIP region was identified at amino acid residue 732-752 which is most likely a cytoplasmic region of the protein. The Lupas algorithm predicts a coiled-coil structure for amino acids 657-684. No ALLMOTI5 regions were identified.

FIG. 33 depicts the search motif results for the Zebra (or EB1) trans-activator protein (BZLF1) of the above-identified Epstein-Barr virus. This protein is a transcription factor which represents the primary mediator of viral reactivation. It is a member of the b-ZIP family of transcription factors and shares significant homology with the basic DNA-binding and dimerization domains of the cellular oncogenes c-fos and C/EBP. The Zebra protein functions as a homodimer.

Search results demonstrate that the Zebra protein exhibits a single region which is predicted to be either of DP107 or DP178 similarity, and is found between the known DNA binding and dimerization regions of the protein. Specifically, this region is located at amino acid residues 193-220, as shown in FIG. 33. The Lupas program predicted no coiled-coil regions.

FIG. 34 illustrates the motif search results for the fusion protein F1 of measles virus, strain Edmonston (PC Gene.RTM. protein sequence PVGLF.sub.-- MEASE), successfully identifying DP178/DP107 analogs.

The 107.times.178.times.4 motif identifies a single region at amino acid residues 228-262. The ALLMOTI5 search motif identifies three regions, including amino acid residues 116-184, 228-269 and 452-500. Three regions containing proline residues followed by a leucine zipper-like sequence were found beginning at proline residues 214, 286 and 451.

The Lupas program identified two regions it predicted had potential for coiled-coil structure, which include amino acid residues 141-172 and 444-483.

FIG. 35 depicts the results of a PZIP motif search conducted on the Hepatitis B virus subtype AYW. Two regions of interest within the major surface antigen precursor S protein were identified. The first lies just C-terminal to the proposed fusion peptide of the major surface antigen (Hbs) which is found at amino acid residues 174-191. The second region is located at amino acid residues 233-267. The Lupas program predicts no coiled-coil repeat regions.

In order to test the potential anti-HBV antiviral activity of these D178/DP107 analog regions, peptides derived from area around the analog regions are synthesized, as shown in FIGS. 52A-B. These peptides represent one amino acid peptide "walks" through the putative DP178/DP107 analog regions. The peptides are synthesized according to standard Fmoc chemistry on Rinkamide MBHA resins to provide for carboxy terminal blockade (Chang, C. D. and Meinhofer, J., 1978, Int. J. Pept. Protein Res. 11:246-249; Fields, G. B. and Noble, R. L., 1990, Int. J. Pept. Protein Res. 35:161-214). Following complete synthesis, the peptide amino-terminus is blocked through automated acetylation and the peptide is cleaved with trifluoroacetic acid (TFA) and the appropriate scavengers (King, D. S. et al., 1990, Int. J. Pept. Res. 36:255-266). After cleavage, the peptide is precipitated with ether and dried under vacuum for 24 hours.

The anti-HBV activity of the peptides is tested by utilizing standard assays to determine the test peptide concentration required to cause an acceptable (e.g., 90%) decrease in the amount of viral progeny formed by cells exposed to an HBV viral inoculum. Candidate antivial peptides are further characterized in model systems such as wood chuck tissue culture and animal systems, prior to testing on humans.

The results depicted herein illustrate the results of search motifs conducted on the Simian Mason-Pfizer monkey virus. The motifs reveal DP178/DP107 analogs within the enveloped (TM) protein GP20, as shown in FIG. 36.

The 107.times.178.times.4 motifs identifies a region at amino acid residues 422-470. The ALLMOTI5 finds a region at amino acid residues 408-474. The Lupas program predicted a coiled-coil structure a amino acids 424-459.

The results presented herein demonstrate the identification of DP178/DP107 analogs corresponding to sequences present in proteins of a variety of bacterial species.

FIG. 37 depicts the search motif results for the Pseudomonas aeruginosa fimbrial protein (Pilin). Two regions were identified by motifs 107.times.178.times.4 and ALLMOTI5. The regions located at amino acid residues 30-67 and 80-144 were identified by the 107.times.178.times.4 motif. The regions at amino acid residues 30-68 and 80-125 were identified by the ALLMOTI5.

FIG. 38 depicts the search motif results for the Pseudomonas gonorrhoeae fimbrial protein (Pilin). A single region was identified by both the 107.times.178.times.4 and the ALLMOTI5 motifs. The region located at amino acid residues 66-97 was identified by the 107.times.178.times.4 motif. The region located at amino acid residues 66-125 were identified by the ALLMOTI5 search motif. No coiled-coil regions were predicted by the Lupas program.

FIG. 39 depicts the search motif results for the Hemophilus Influenza fimbrial protein (Pilin). A single region was identified by both the 107.times.178.times.4 and the ALLMOTI5 motifs. The region located at amino acid residues 102-129 was identified by the 107.times.178.times.4 motif. The region located at amino acid residues 102-148 were identified by the ALLMOTI5 search motif. No coiled-coil regions were predicted by the Lupas program.

FIG. 40 depicts the search motif results for the Staphylococcus aureus toxic shock syndrome Hemophilus Influenza fimbrial protein (Pilin). A single region was identified by both the 107.times.178.times.4 and the ALLMOTI5 motifs. The region located at amino acid residues 102-129 was identified by the 107.times.178.times.4 motif. The region located at amino acid residues 102-148 were identified by the ALLMOTI5 search motif. No coiled-coil regions were predicted by the Lupas program.

FIG. 41 summarizes the motif search results conducted on the Staphylococcus aureus enterotoxin Type E protein. These results demonstrate the successful identification of DP178/DP107 analogs corresponding to peptide sequences within this protein, as described below.

The ALLMOTI5 motif identified a region at amino acid residues 22-27. The 107.times.178.times.4 motif identified two regions, with the first at amino acid residues 26-69 and the second at 88-115. A P12LZIPC motif search identified two regions, at amino acid residues 163-181 and 230-250.

The Lupas program predicted a region with a high propensity for coiling at amino acid residues 25-54. This sequence is completely contained within the first region identified by both ALLMOTI5 and 107.times.178.times.4 motifs.

FIG. 42 depicts the search motif results conducted on a second Staphylococcus aureus toxin, enterotoxin A. Two regions were identified by the ALLMOTI5 motif, at amino acid residues 22-70 and amino acid residues 164-205. The 107.times.178.times.4 motif found two regions, the first at amino acid residues 26-69 and the second at amino acid residues 165-192. A P23LZIPC motif search revealed a region at amino acid residues 216-250. No coiled-coil regions were predicted by the Lupas program.

FIG. 43 shows the motif search results conducted on the E. coli heat labile enterotoxin A protein, demonstrating that identification of DP178/DP107 analogs corresponding to peptides located within this protein. Two regions were identified by the ALLMOTI5 motif, with the first residing at amino acid residues 55-115, and the second residing at amino acid residues 216-254. The 107.times.178.times.4 motif identified a single region at amino acid residues 78-105. No coiled-coil regions were predicted by the Lupas program.

The results presented herein demonstrate the identification of DP178/DP107 analogs corresponding to peptide sequences present within several different human proteins.

FIG. 44 illustrates the search motif results conducted on the human c-fos oncoprotein. The ALLMOTI5 motif identified a single region at amino acid residues 155-193. The 107.times.178.times.4 motif identified one region at amino acid residues 162-193. The Lupas program predicted a region at amino acid residues 148-201 to have coiled-coil structure.

FIG. 45 illustrates the search motif results conducted on the human lupus KU autoantigen protein P70. The ALLMOTI5 motif identified a single region at amino acid residues 229-280. The 107.times.178.times.4 motif identified one region at amino acid residues 235-292. The Lupas program predicted a region at amino acid residues 232-267 to have coiled-coil structure.

FIG. 46 illustrates the search motif results conducted on the human zinc finger protein 10. The ALLMOTI5 motif identified a single region at amino acid residues 29-81. The 107.times.178.times.4 motif identified one region at amino acid residues 29-56. A P23LZIPC motif search found a single region at amino acid residues 420-457. The Lupas program predicted no coiled-coil regions.

In the Example presented herein, measles (MeV) virus DP178-like peptides identified by utilizing the computer-assisted search motifs described in the Examples presented in Sections 9 and 21, above, are tested for anti-MeV activity. Additionally, circular dichroism (CD) structural analyses are conducted on the peptides, as discussed below. It is demonstrated that several of the identified peptides exhibit potent antiviral capability. Additionally, it is shown that none of the these peptides exhibit a substantial helical character.

Structural analyses: The CD spectra were measured in a 10 mM sodium phosphate, 150 mM sodium chloride, pH 7.0, buffer at approximately 10 mM concentrations, using a 1 cm pathlength cell on a Jobin/Yvon Autodichrograph Mark V CD spectrophotometer. Peptide concentrations were determined from A.sub.280 using Edlehoch's method (1967, Biochemistry 6:1948).

Anti-MeV antiviral activity syncytial reduction assay: The assay utilized herein tested the ability of the peptides to disrupt the ability of Vero cells acutely infected with MeV (i.e., cells which are infected with a multiplicity of infection of 2-3) to fuse and cause syncytial formation on a monolayer of an uninfected line of Vero cells. The more potent the peptide, the lower the observed level of fusion, the greater the antiviral activity of the peptide.

Uninfected confluent monolayers of Vero cells were grown in microtiter wells in 10% FBS EMEM (Eagle Minimum Essential Medium w/o L-glutamine [Bio Whittaker Cat. No. 12-125F], with fetal bovine serum [FBS; which had been heat inactivated for 30 minutes at 56.degree. C.; Bio Whittaker Cat. No. 14-SOF) supplemented at 10%, antibiotics/antimycotics (Bio Whittaker Cat. No. 17-602E) added at 1%, and glutamine added at 1%.

To prepare acutely infected Vero cells for addition to the uninfected cells, cultures of acutely infected Vero cells were washed twice with HBSS (Bio Whittaker Cat. No. 10-543F) and cell monolayers were removed with trypsin (Bio Whittaker Cat. No. 17-161E). Once cells detached, media was added, any remaining clumps of cells were dispersed, and hemacytometer cell counts were performed.

The antiviral assay was conducted by, first, removing all media from the wells containing uninfected Vero cells, then adding peptides (at the is dilutions described below) in 10% FBS EMEM, and 50-100 acutely MeV-infected Vero cells per well. Wells were then incubated at 37.degree. C. for a maximum of 18 hours.

On day 2, after cells in control wells were checked for fusion centers, media was removed from the wells, followed by addition, to each well, of approximately 50 .mu.l 0.25% Crystal Violet stain in methanol. Wells were rinsed twice with water immediately, to remove excess stain and were then allowed to dry. The number of syncytia per well were then counted, using a dissecting microscope.

Anti-MeV antiviral activity plaque reduction assay: The assay utilized herein tested the ability of the peptides to disrupt the ability of MeV to infect permissive, uninfected Vero cells, leading to the infected cells' fusing with uninfected cells to produce syncytia. The lower the observed level of syncytial formation, the greater the antiviral activity of the peptide.

Monolayers of uninfected Vero cells are grown as described above.

The antiviral assay was conducted by, first, removing all media from the wells containing uninfected Vero cells, then adding peptides (at the dilutions described below) in 10% FBS EMEM, and MeV stock virus at a final concentration of 30 plaque forming units (PFU) per well. Wells were then incubated at 37.degree. C. for a minimum of 36 hours and a maximum of 48 hours.

On day 2, after cells in control wells were checked for fusion centers, media was removed from the wells, followed by addition, to each well, of approximately 50 .mu.l 0.25% Crystal Violet stain in methanol. Wells were rinsed twice with water immediately, to remove excess stain and were then allowed to dry. The number of syncytia per well were then counted, using a dissecting microscope.

Peptides: The peptides characterized in the study presented herein were peptides T-252A0 to T-256A0, T-257B1/C1, and T-258B1 to T-265B0, and T-266A0 to T-268A0, as shown in FIGS. 47A-B. These peptides represent a walk through the DP178-like region of the MeV fusion protein.

Each peptide was tested at 2-fold serial dilutions ranging from 100 .mu.g/ml to approximately 100 ng/ml. For each of the assays, a well containing no peptide was also used.

The data summarized in FIGS. 47A-B represents antiviral and structural information obtained via "peptide walks" through the DP178-like region of the MeV fusion protein.

As shown in FIGS. 47A-B, the MeV DP178-like peptides exhibited a range of antiviral activity as crude peptides. Several of these peptides were chosen for purification and further antiviral characterization. The IC.sub.50 values for such peptides were determined, as shown in FIGS. 47A-B, and ranged from 1.35 .mu.g/ml (T-257B1/C1) to 0.072 .mu.g/ml (T-265B1). None of the DP178 like peptides showed, by CD analysis, a detectable level of helicity.

Thus, the computer assisted searches described, hereinabove, as in for example, the Example presented in Section 9, for example, successfully identified viral peptide domains that represent highly promising anti-MeV antiviral compounds.

In the Example presented herein, simian immunodeficiency virus (SIV) DP178-like peptides identified by utilizing the computer-assisted search motifs described in the Examples presented in Sections 9, 12 and 19, above, were tested for anti-SIV activity. It is demonstrated that several of the identified peptides exhibit potent antiviral capability.

Anti-SIV antiviral assays: The assay utilized herein were as reported in Langolis et al. (Langolis, A. J. et al., 1991, AIDS Research and Human Retroviruses 7:713-720).

Peptides: The peptides characterized in the study presented herein were peptides T-391 to T-400, as shown in FIGS. 48A-B. These peptides represent a walk through the DP178-like region of the SIV TM protein.

Each peptide was tested at 2-fold serial dilutions ranging from 100 .mu.g/ml to approximately 100 ng/ml. For each of the assays, a well containing no peptide was also used.

The data summarized in FIGS. 48A-B represents antiviral information obtained via "peptide walks" through the DP178-like region of the SIV TM protein.

As shown in FIGS. 48A-B, peptides T-391 to T-400 were tested and exhibited a potent antiviral activity as crude peptides.

Thus, the computer assisted searches described, hereinabove, as in for example, the Example presented in Section 9, for example, successfully identified viral peptide domains that represent highly promising anti-SIV antiviral compounds.

The Example presented in this Section represents a study of the antiviral activity of DP107 and DP178 truncations and mutations. It is demonstrated that several of these DP107 and DP178 modified peptides exhibit substantial antiviral activity.

Anti-HIV assays: The antiviral assays performed were as those described, above, in Section 6.1. Assays utilized HIV-1/IIIb and/or HIV-2 NIHZ isolates. Purified peptides were used, unless otherwise noted in FIGS. 49A-L.

Peptides: The peptides characterized in the study presented herein were:

1) FIGS. 49A-L present peptides derived from the region around and containing the DP178 region of the HIV-1 BRU isolate. Specifically, this region spanned from gp41 amino acid residue 615 to amino acid residue 717. The peptides listed contain truncations of this region and/or mutations which vary from the DP178 sequence amino acid sequence. Further, certain of the peptides have had amino- and/or carboxyterminal groups either added or removed, as indicated in the figures; and

2) FIGS. 50A-B. presents peptides which represent truncations of DP107 and/or the gp41 region surrounding the DP107 amino acid sequence of HIV-1 BRU isolate. Certain of the peptides are unblocked or biotinylated, as indicated in the figure.

Blocked peptides contained an acyl N-terminus and an amido C-terminus.

Anti-HIV antiviral data was obtained with the group 1 DP178-derived peptides listed in FIGS. 49A-L. The full-length, non-mutant DP178 peptide (referred to in FIGS. 49A-L as T20) results shown are for 4 ng/ml.

In FIGS. 49A-D, a number of the DP178 truncations exhibited a high level of antiviral activity, as evidenced by their low IC.sub.50 values. These include, for example, test peptides T-50, T-624, T-636 to T-641, T-645 to T-650, T-652 to T-654 and T-656. T-50 represents a test peptide which contains a point mutation, as indicated by the residue's shaded background. The HIV-1-derived test peptides exhibited a distinct strain-specific antiviral activity, in that none of the peptides tested on the HIV-2 NIHZ isolate demonstrated appreciable anti-HIV-2 antiviral activity.

Among the peptides listed in FIGS. 49E-H, are test peptides representing the amino (T-4) and carboxy (T-3) terminal halves of DP178 were tested. The amino terminal peptide was not active (IC.sub.50 >400 .mu.g/ml) whereas the carboxy terminal peptide showed potent antiviral activity (IC.sub.50 =3 .mu.g/ml). A number of additional test peptides also exhibited a high level of antiviral activity. These included, for example, T-61/T-102, T-217 to T-221, T-235, T-381, T-677, T-377, T-590, T-378, T-591, T-271 to T-272, T-611, T-222 to T-223 and T-60/T-224. Certain of the antiviral peptides contain point mutations and/or amino acid residue additions which vary from the DP178 amino acid sequence.

In FIGS. 4I-L, point mutations and/or amino and/or carboxy-terminal modifications are introduced into the DP178 amino acid sequence itself. As shown in the figure, the majority of the test peptides listed exhibit potent antiviral activity.

Truncations of the DP107 peptide (referred to in FIGS. 50A-B as T21) were also produced and tested, as shown in FIGS. 50A-B. FIGS. 50A-B also presents data concerning blocked and unblocked peptides which contain additional amino acid residues from the gp41 region in which the DP107 sequence resides. Most of these peptides showed antiviral activity, as evidenced by their low IC.sub.50 values.

Thus, the results presented in this Section demonstrate that not only do the full length DP107 and DP178 peptides exhibit potent antiviral activity, but truncations and/or mutant versions of these peptides can also possess substantial antiviral character.

In the Example presented herein, peptides derived from the Epstein-Barr (EBV) DP-178/DP107 analog region of the Zebra protein identified, above, in the Example presented in Section 20 are described and tested for anti-EBV activity. It is demonstrated that among these peptides are ones which exhibit potential antiviral activity.

ElectroPhoretic Mobility Shift Assays (EMSA): Briefly, an EBV Zebra protein was synthesized utilizing SP6 RNA polymerase in vitro transcription and wheat germ in vitro translation systems (Promega Corporation recommendations; Butler, E. T. and Chamberlain, M. J., 1984, J. Biol. Chem. 257:5772; Pelham, H. R. B. and Jackson, R. J., 1976, Eur. J. Biochem. 67:247). The in vitro translated Zebra protein was then preincubated with increasing amounts of peptide up to 250 ng/ml prior to the addition of 10,000 to 20,000 c.p.m. of a .sup.32 P-labeled Zebra response element DNA fragment. After a 20 minute incubation in the presence of the response element, the reaction was analyzed on a 4% non-denaturing polyacrylamide gel, followed by autoradiography, utilizing standard gelshift procedures. The ability of a test peptide to prevent Zebra homodimer DNA binding was assayed by the peptide's ability to abolish the response element gel migration retardation characteristic of a protein-bound nucleic acid molecule.

Peptides: The peptides characterized in this study represent peptide walks through the region containing, and flanked on both sides by, the DP178/DP107 analog region identified in the Example presented in Section 20, above, and shown as shown in FIG. 33. Specifically, the peptide walks covered the region from amino acid residue 173 to amino acid residue 246 of the EBV Zebra protein.

Each of the tested peptides were analyzed at a range of concentrations, with 150 ng/ml being the lowest concentration at which any of the peptides exerted an inhibitory effect.

The EBV Zebra protein transcription factor contains a DP178/DP107 analog region, as demonstrated in the Example presented, above, in Section 20. This protein appears to be the primary factor responsible for the reactivation capability of the virus. A method by which the DNA-binding function of the Zebra virus may be abolished may, therefore, represent an effective antiviral technique. In order to identify potential anti-EBV DP178/DP107 peptides, therefore, peptides derived from the region identified in Section 20, above, were tested for their ability to inhibit Zebra protein DNA binding.

The test peptides' ability to inhibit Zebra protein DNA binding was assayed via the EMSA assays described, above, in Section 28.1. The data summarized in FIGS. 51A-C presents the results of EMSA assays of the listed EBV test peptides. These peptides represent one amino acid "walks" through the region containing, and flanked on both sides by, the DP178/DP107 analog region identified in the Example presented in Section 20, above, and shown as shown in FIG. 33. As shown in FIGS. 51A-C, the region from which these peptides are derived lies from EBV Zebra protein amino acid residue 173 to 246. A number of the test peptides which were assayed exhibited an ability to inhibit Zebra protein homodimer DNA binding, including 439, 441, 444 and 445.

Those peptides which exhibit an ability to inhibit Zebra protein DNA binding represent potential anti-EBV antiviral compounds whose ability to inhibit EBV infection can be further characterized.

The present invention is not to be limited in scope by the specific embodiments described which are intended as single illustrations of individual aspects of the invention, and functionally equivalent methods and components are within the scope of the invention. Indeed, various modifications of the invention, in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.